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Abstract 
 
This is an investigation into lipodystrophy syndrome (LS), defined as specific body fat 
alterations (BFA) and/or metabolic abnormality (MA), in HIV-infected children. Antiretroviral 
therapy (ART) has resulted in improved disease-free survival in HIV-infected individuals, but is 
an established risk factor for LS. The metabolic profile seen in LS patients is similar to that seen 
in the early stages of cardiovascular disease. As ART coverage improves, and because 
treatment is life-long, the importance of LS will become more relevant, especially as treated 
children survive into adulthood, and accumulate longer durations of exposure to multiple drugs. 
 
Data from a prospective European multi-centre cohort of 426 HIV-infected subjects aged 2-18, 
has been analysed. The manifestation of LS using clearly-defined phenotypes is described, with 
estimates of prevalence and incidence. Risk factors for LS were identified in logistic, and 
proportional hazards regression models. The temporal relationship between BFA and MA was 
explored, and the impact of LS on serum lipids modelled using a multi-level approach. Finally 
interventions used to manage symptoms of LS were described.    
 
The prevalence of LS at recruitment (median age 12.2 years) was 56.5% (95% CI: 51.7, 61.3): 
half had BFA alone, one-quarter had MA alone, and one-quarter had both. Over follow-up 
(median: 4.2 years) the incidence of BFA was 8.0 per 100 person-years (95% CI: 6.0, 10.7) and 
that of MA was 4.1 per 100 person-years (95% CI: 2.8, 5.9). Significant, independent risk 
factors associated with increased risk of LS outcomes included protease inhibitor (PI) or non-
nucleoside reverse transcriptase inhibitor (NNRTI) use, age, clinical status, and White ethnicity. 
Decreased risk was associated with immunosuppression and detectable viral load. Several 
factors were associated with increased pro-atherosclerotic lipid concentrations over follow-up: 
however, NNRTI use and female sex were significantly associated with increased anti-
atherosclerotic HDL-cholesterol. This thesis used data from a unique large prospective cohort to 
underline the increasing significance of LS in HIV-infected children and adolescents.  
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1. Human immunodeficiency virus and lipodystrophy 
syndrome 
 
 
1.1 Epidemiology of HIV 
 
The number of people estimated to be living with HIV in 2010 was 34 million (95% CI: 31.6, 
35.2), of whom 3.4 million (95% CI: 3.0, 3.8) were children aged less than 15 years1. This 
marked an increase in prevalence from the previous year (total prevalence: 33.3 million 95% CI: 
31.4-35.3 million, and paediatric prevalence: 2.5 million, 95% CI: 1.6-3.42) reflecting improved 
prognosis following treatment (as opposed to an increase in incidence)3. The global incidence of 
HIV in children (i.e. aged <15 years) peaked in 2002-2002 (Figure 1-1) due to the stabilization of 
HIV prevalence amongst women and the prevention of vertical transmissiona4 (mother-to-child-
transmission: MTCT), with paediatric prevalence increasing steadily over the past twenty years 
(Figure 1-1)5.  
  
The highest prevalence of HIV infection in children aged less than 15 years in 2010 was seen in 
Africa, with an estimate more than 150 times greater than the prevalence estimated in Europe 
(Table 1-1).  
 
 
 
 
 
 
  
                                                 
a
 An estimated 90% of newly infected cases of paediatric HIV in Sub-Saharan Africa per annum 
occur as a result of vertical transmission during or after pregnancy   
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Figure 1-1 Global (a) incidence and (b) prevalence of HIV infections among children aged 
<15 years between 1990 and 20075  
 
 
Estimates provided by the Joint United Nations Programme on HIV/AIDS (UNAIDS): bars indicate lowest and 
highest estimates from model.  
 
(a) 
(b) 
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Table 1-1: Estimated prevalence and incidence of HIV in children aged less than 15 years 
in 2010  
 
Prevalence Incidence 
 Estimate (95% CI) Estimate (95% CI) 
Africa 3100000 (2800000, 
3500000) 
350000 (300000, 
410000) 
South East Asia 140000 (92000, 
190000) 
17000 (11000, 
25000) 
Americas 58000 (44000, 
74000) 
5000 (3200, 6900) 
Eastern Mediterranean 42000 (28000, 
57000) 
7400 (5200, 9800) 
Western Pacific 39000 (33000, 
46000) 
5000 (3800, 6200) 
Europe 19000 (15000, 
25000) 
2400 (1900, 2900) 
Data provided by the World Health Organization (WHO)/United Nations Children’s Fund (UNICEF)/the Joint 
United Nations Programme on HIV/AIDS (UNAIDS)1 
 
In 2010 the greatest incidence occurred in Africa followed by Southeast Asia, whilst the smallest 
incidence was seen in Europe1. Despite prevalence and incidence amongst children aged <15 
years being greatest in Africa, access to antiretroviral therapy (ART) was consistently lower 
here compared to other World Health Organization (WHO) regions (Figure 1-2).The Joint United 
Nations Programme on HIV/AIDS (UNAIDS) estimated HIV prevalence was calculated using the 
Estimates and Projection Package, and also the Spectrum Projection Package. While the ability 
to investigate underlying assumptions and explore key indicators and trends are strengths of 
these models, the resultant projections must be treated with caution: some assumptions used  
in the calculation may be based on a small number of studies, patterns of prevalence by age 
and sex being assumed to be constant over time, and limited data on patterns of HIV infection 
in key high-risk groups e.g. age distribution among injecting drug users6.  
 
In 2001, member states of the United Nations Organization (UN) committed themselves to 
taking “extraordinary action to move towards universal access to HIV prevention, treatment and 
support” by 2010 as part of the Political declaration on HIV/AIDS 7.  Percentage coverage of 
ART increased in both children and adults between 2005 and 20088, through initiatives 
prompted by the sixth Millennium Development Goal (MDG)  including the aim of achieving, by 
2010, the universal access to treatment for HIV/AIDS for all those who need it9,10. UNAIDS 
estimate that 14.6 million (range; 13.2, 13.5) people were in need of ART in 2009, up from 14.3 
million (range; 13.2, 15.4 million) in 2008, in low and middle income countries (using WHO 2010 
guidelines regarding treatment11,12b). Only 5.2 million of these people received ART in 2009 
                                                 
b
 Eligibility for ART defined as either CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms, or WHO clinical 
stage 3 (moderate unexplained malnutrition/unexplained persistent diarrhoea/unexplained persistent fever/oral 
candidiasis/oral hairy leukoplakia/acute necrotizing ulcerative ginigivitis or periodontitis/pulmonary tuberculosis/ bacterial 
pneumonia/HIV-associated lung disease/lymphoid interstitial pneumonitis/ unexplained anaemia (<80d/L) and/or 
neutropenia (<1000/µL)/thrombocytopmenia (<50 000/µL)) or stage 4 (unexplained severe wasting or 
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compared to 4.0 million in 2008, although this represented an increase in the percentage 
coverage of ART from 28% (range; 26, 31) to 36% (range; 33, 39) between these two years. In 
2009, 1.3 million (range; 0.8, 1.7) children aged less than 15 years were estimated to need 
ART, of whom 356 400 received therapy resulting in 28% (range; 21, 43) coverage13,14.  
 
Figure 1-2: Estimated proportion of HIV-infected adults and children (age <15 years) who 
received antiretroviral therapy in 2010, by region of residence 
 
Data provided by World Health Organization (WHO)/United Nations Children’s Fund (UNICEF)/the Joint United 
Nations Programme on HIV/AIDS (UNAIDS)1. 2008 WHO recommendation for ART in HIV-infected adults and 
adolescents in resource-limited settings: confirmation of infection, and either clinical signs of advanced 
disease or laboratory evidence of severe immunosuppression11. 2010 WHO recommendations for ART in HIV-
infected adults and adolescents in resource-limited settings: CD4 count <350 cells/mm3 regardless of presence 
or absence of clinical symptoms12 
 
Most regions ART access is lower in children compared with adults. Europe is the only region 
where the converse was true in 20101, despite this being the region with the lowest estimates of 
HIV infection in children: this highlights the disparities between low-income with middle and 
high-income countries. Sub Saharan Africa is estimated to account for 89% of paediatric need 
for ART. Furthermore, rates of coverage in Latin America and the Caribbean, East, South/ 
South-East Asia, and, Europe and Central Asia are lower in children than in adults13.  
 
However, such comparisons over time are difficult to validate. Estimates of coverage in regions 
where numbers are low (such as Europe) are inaccurate, and furthermore, as recommendations 
for treatment have changed, comparisons over time may be inappropriate. Indeed, 
                                                                                                                                               
malnutrition/pneumocystis pneumonia/recurrent bacterial infections/chronic herpes simplex/extrapulmonary 
tuberculosis/Kaposi’s sarcoma/oesophageal candidiasis/central nervous system toxoplasmosis/HIV 
encephalopathy/cytomegalovirus infection/extrapulmonary cryptococcosis/disseminated endemic 
mycosis/cryptosporidiosis/isosporiasis/disseminated non-tuberculous mycobacteria infection/Candida infection/visceral 
herpes simplex/rectal fistula/cerebral or B cell non-Hodgkin lymphoma/progressive multifocal 
leukoencephalopathy/cardiomyopathy or nephropathy) disease irrespective of CD4 count  
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recommendations regarding eligibility criteria to commence ART have become broader over 
time. While this may be expected to increase uptake, in practice as eligibility criteria broaden, 
the number of entitled people who do not have access to treatment increase in resource poor 
settings. Thus, considering this caveat in tandem with advances in ART coverage, the goal of 
universal access remains elusive, particularly regarding levels of access among infected 
children.  
 
 1.2 HIV and AIDS 
 
The disease which would later be known as Acquired Immune Deficiency Syndrome  (AIDS) 
was first reported in 1981 as a set of case reports of Pneumocystis jiroveci pneumonia (PCP) 
(formerly known as Pneumocystis carinii) in gay men occurring in Los Angeles15. In addition to 
this rare form of fungal pneumonia, other opportunistic infections and cancers associated with 
AIDS were identified (e.g. mycobacterium infections, toxoplasmosis, invasive fungal infections, 
Kaposi’s sarcoma and non-Hodgkin’s lymphoma etc.).   
 
Concurrently with these reports from Las Angeles in the early 1980s, reports of 
immunodeficiency in haemophiliac  patients which was similar to the immunodeficiency seen in 
AIDS patients contributed to the theory of a blood-borne infection as the causative agent16,17. 
The occurrence of AIDS in heterosexual Africans who were not injecting drug users added to 
the growing evidence that there was also a heterosexual mode of transmission18,19. In 1983, a 
distinct retrovirus which had been seen in patients prior to the development of AIDS was first 
isolated20.  Although a number of theories regarding the cause of AIDS were postulated21, by 
1984 evidence was growing linking infection by the retrovirus HIVc with the development of 
AIDS22-24. By 1986 the Centres for Disease Control (CDC) had developed a working definition 
for AIDS25, which was revised in 199326. Two strains of HIV were eventually isolated; HIV-1 and 
HIV-2. HIV-1 is more virulent, responsible for the majority of global HIV infections, while HIV-2 is 
mainly restricted to West Africa and may result in less aggressive disease27. 
  
  
                                                 
c
 Previously known as Lymphadenopathy-Associated Retrovirus (LAV) in isolates taken from patients in France, and 
Human-T-cell Leukaemia Virus (HTLV-III) in isolates taken from patients in the USA.  
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1.3 Infection with HIV 
 
HIV is a lentivirus composed of a protein capsid containing a lipid membrane enclosing two 
copies of single stranded ribonucleic acid (RNA) and the enzymes reverse transcriptase and 
integrase. The virus preferentially binds to host T-helper lymphocytes28 (CD4 cells). CD4 cells 
have an essential function in the immune system, having roles in determining B-cell antibody 
class switching, activation of cytotoxic T-cells and activity of phagocytes. It is the HIV-mediated 
depletion of CD4 cells that leads to compromise of the host immune system and vulnerability to 
opportunistic infection27,29-31. The clinical endpoint of HIV infection is AIDS: while HIV infection 
may initially be symptomless, the transition to AIDS may (but not always) initially manifest as 
opportunistic infections, and cancers associated with the immune system20.  
 
1.3.1 Natural history of HIV infection 
Following primary infection with HIV, there is a period of rapid replication of the virus32-34 which 
is accompanied by a sharp decrease in CD4 lymphocyte cells35-37. This stage may be 
symptomatic, as seroconversion occurs, and last several weeks. The initial period of infection is 
known as the acute phase and culminates in wide dissemination of the virus and its seeding in 
lymphoid organs38,39.  This is followed by a period of clinical latency where HIV level (viral load) 
remains low, and CD4 cell numbers recover, although HIV continues to be expressed by 
infected CD4 cells40. The asymptomatic latent period may last several years as viral load and 
CD4 cells levels stabilize. However, the value of the plateau in HIV-infected children is higher 
than in adults, and is accompanied by a slow sustained increase in CD4 cells41. Following a 
gradual rise in viral load and decrease in CD4 cells, constitutional symptoms, opportunistic 
disease, AIDS-related clinical illness, and ultimately death occur42-46. Viral load is closely 
associated with prognosis47,48, while counts of CD4 cells are an indicator of the degree of 
immunosuppression: as viral load increases, there is a resultant reduction in CD4 cells which 
may culminate in a poorer prognosis. The estimated median interval between seroconversion 
and the onset of AIDS-related clinical disease in treatment–naïve adult patients is 11 years49,50.  
 
Around 20% of vertically-infected children progress to AIDS within the first year of life in the 
absence of treatment51, a substantially higher proportion than seen in adults52. However, 
analysis of 990 children enrolled in the European Collaborative Study (ECS) suggested that the 
rate of progression in those children who do not rapidly progress may be slower than in adults, 
with less than 10% of HIV-infected children showing HIV-related symptoms before AIDS onset 
and after the first year of life, and less than 50% being symptomatic after AIDS diagnosis53. 
Furthermore, the HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS) conducted 
a meta-analysis of longitudinal data collected for 3941 children which indicated that there were 
non-linear associations between risk of disease and both CD4% (the percentages of total 
lymphocytes that are expressing CD4 antigens) and viral load, with older children having lower 
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short-term risk of clinical progression than younger children at a given CD4%54. Further analysis 
of HPPMCS and comparison with data collected from adults suggested that, following 
adjustment for CD4 count, the effect of age on disease progression while not significant in 
children aged five year or older, was significantly associated with increases in AIDS-related 
disease or death in adults55. Indeed, these findings and the finding from a clinical trial reporting 
decreased hazard of AIDS-related outcomes in infants treated immediately with ART compared 
to infants with deferred treatment56, has  been important in updating paediatric treatment 
guidelines.  Stage of maternal infection, maternal survival, background mortality rates and 
timing of infection (for example whether infection occurred in utero, intrapartum, or postnatal) 
have been identified as important predictors of paediatric survival times, especially in resource-
poor settings57,58. 
 
1.3.2 Cellular mechanism of infection with HIV 
Figure 1-3 illustrates the process of infection of a CD4 cell by HIV and highlights stages which 
are targets for therapeutic intervention.  
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Figure 1-3: Mechanism of infection of CD4 expressing cells by HIV (adapted from Levy 
199342)  
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therapeutic action 
HIV and lipodystrophy   Chapter 1
  
   
 
27
HIV binds to the CD4 epitope of the host T-lymphocyte28 initiating confirmation changes in the 
viral envelope and allowing for fusion between the virus and the cell. The HIV capsid enters the 
host cell cytoplasm where the viral reverse transcriptase enzyme transcribes the viral RNA to 
double stranded deoxyribonucleic acid (DNA). The newly produced HIV DNA then enters the 
CD4 cell nucleus where it becomes integrated into the host DNA by the viral integrase enzyme. 
Transcription of the host/viral DNA is catalysed by the host cellular RNA polymerase generating 
new HIV RNA. The host cellular apparatus are then used to construct and assemble new viral 
capsids which are released from the initial infected CD4 cell and can go on to infect further host 
CD4 cells30. 
 
1.3.3 Antiretroviral therapy 
The aim of ART is to prevent increases in viral load by targeting specific steps in either the 
replication of HIV virions, or the infection of new cells, e.g. assembly of new virion particles, 
transcription of viral RNA, integration of nascent viral DNA into host cell DNA, or entry of virions 
into uninfected cells (Figure 1-3). The first antiretroviral drug, zidovudine, was found to be 
effective against HIV-1 in 1984, and licensed as an anti-HIV therapy in 198759.  
 
Increasing coverage60 of ART has resulted in considerably improved survival, better health and 
reduced need for hospitalization in both adults61-63 and children64-66.  Several studies have 
reported mortality to be significantly reduced in adults who are treated with ART67-69. An 
estimated 4-6 year survival benefit associated with specific ART regimens was calculated in a 
model using data from US life tables and from the Collaboration in HIV Outcomes US 
(CHORUS) cohort of 4791 individuals70. Indeed, a second mathematical model using CDC and 
other published surveillance data estimated that at least 3 million years of life have been saved 
in the United States as a result of treatment71. Analyses from the ART Cohort Collaboration 
(ART-CC), a collaboration of 14 cohorts of HIV-infected subjects in Europe and North America, 
have estimated that a HIV-infected individual living in a high-income country who is on ART and 
aged twenty years, may expect a lifespan two-thirds smaller than the average in their country of 
residence i.e. a life expectancy of 44.7 years72.  Furthermore, a UK model predicted that median 
age of death for a man who becomes HIV-infected in 2010 via homosexual sex at age at 30 
years, to be 75 years with an average of 7 years of life lost compared to an uninfected man73. 
As survival has improved and the HIV-infected population ages, the importance of co-
morbidities including cardiovascular disease (CVD), diabetes, non-AIDS-defining malignancy, 
viral hepatitis and osteoporosis has been increasingly recognised 74.   
 
Increased survival rates associated with ART in children have been reported in both the 
developing and developed world.  The 5-year survival rate, from the initiation of ART, in 1752 
children enrolled in the multi-country TREAT Asia Pediatric HIV Observation Database 
(TAPHOD) project was 91.7% (95% CI: 90.0, 93.2), with mortality being highest in the first three 
months after start of treatment75. Similarly, the 2-year survival rate was 93.1% (95% CI: 94.1, 
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98.9) in 1058 children enrolled across 8 cohorts participating in the Kids’ Antiretroviral 
Treatment in Lower-Income Countries (KIDS-ART-LINC) Collaboration across Sub-Saharan 
Africa76.  Furthermore, rates of survival of HIV-infected children improved in the 1997-2001 birth 
cohort relative to the 1994-1996 birth cohort, and in the 1994-1996 birth cohort relative to the 
1989-1993 birth cohort, in analysis of almost 3000 HIV-infected children enrolled in the US-
based Pediatric Spectrum of HIV Disease Study (PSD): this was attributed to the increased 
availability of triple-drug ART regimens77. 
 
Several classes of ART are now available, each of which targets specific steps in the HIV 
lifecycle (Figure 1-3). Table 1-2 summarizes some drugs in use today, and the class to which 
each belongs.  
 
Table 1-2 : Commonly used antiretroviral drugs, by class   
ART Class Drugs 
Nucleoside/Nucleotide 
reverse transcriptase 
inhibitors (NRTI) 
Abacavir, Adefovir, Apricitabine, Didanosine, Emtricitabine, 
Lamivudine, Stavudine, Tenofovir, Zalcitabine, Zidovudine 
Non-nucleoside 
reverse transcriptase 
inhibitors (NNRTI) 
Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine 
Protease inhibitors 
(PI) 
Amprenavir, Atazanavir, Darunavir, Fosamprenavir, Indinavir, 
Lopinavir, Nelfinavir, Ritonavir, Saquinavir, Tipranavir  
Integrase inhibitors (II) Raltegravir, Elvitegravir  
Fusion inhibitors (FI) Enfuviritide 
Chemokine co-
receptor antagonists 
(CRA) 
Maraviroc 
 
Nucleoside reverse transcriptase inhibitors (NRTI) incorporate themselves into the nascent HIV-
RNA, produced from the HIV-DNA that entered the host cell from the invading capsid (Figure 1-
3), preventing further elongation of the HIV-RNA and prohibiting production of new HIV virions78-
80
. NRTIs are amongst the most widely used antiretroviral drugs, since they were the first 
available class of drug 81, and also form the “backbone” of many combination regimens82. 
 
The second class of ART to be developed were the protease inhibitors (PI), which target the 
viral protease enzyme thus preventing cleavage of precursor virion proteins and so inhibiting 
formation of new virus particles83.  
 
Non-nucleoside reverse transcriptase inhibitors (NNRTI) directly inhibit the viral reverse 
transcriptase enzyme responsible for producing the HIV-DNA from the invader HIV-RNA: 
NNRTI binds directly to the enzyme and prevents the necessary conformational changes 
needed to catalyse reverse transcription, ultimately preventing the production of any HIV-
DNA80,84. The inhibitory effects of NNRTI on HIV were first reported in 199085, with the first drug, 
nevirapine, available in the early 1990s. 
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Integrase inhibitors (II) target HIV enzyme integrase which is responsible for processing of the 
nascent HIV-DNA strand produced by viral reverse transcriptase, and integrating it into the host 
DNA, thus preventing production of new virus particles86. Raltegravir was the first II to be 
approved, in 200787.  
 
Fusion inhibitors (FI)88 and chemokine receptor antagonists (CRA)89 inhibit binding and entry of 
HIV into the host cell.  The only FI currently available is enfuviritide which must be injected 
parenterally, making long-term use difficult, especially for children. The first CRA (maraviroc) 
was licenced in 200790.  
 
1.3.4 Combination antiretroviral therapy  
Although NRTI mono-therapy was seen to suppress viral load, use of two NRTIs (dual therapy) 
was more effective81,91,92. However, a major breakthrough with respect to HIV treatment came in 
1996, with the discovery that a combination of more than two ART drugs was highly effective in 
preventing disease progression93-95. Highly active antiretroviral therapy (HAART) is often used 
synonymously with the term combination ART (cART). Using more than one drug, or class of 
drug, results in multiple sites in the HIV replication cycle being targeted, and thus there is a 
greater likelihood of its interruption. Furthermore, as viral load is suppressed, the chances of 
treatment failure and emerging drug resistance decrease96-99.  
 
The International AIDS Society USA Panel guidelines recommend that HAART should consist 
of two NRTIs with either one NNRTI or two PIs (i.e. one PI, plus a booster PI)100. The success of 
HAART in suppressing HIV replication and associated immunosuppression, leading to 
increased survival, improved quality of life, and reduced morbidity, has been widely reported. In 
a 1998 investigation, both mono-therapy and non-PI containing regimens were found to be 
associated with an independent increased risk of morbidity or mortality compared to PI-
containing regimens in 1255 patients enrolled in the US-based HIV-Outpatient Study (HOPS): 
indeed, mortality decreased from 29.4 per 100 person-years in 1995 (the pre-HAART era) to 8.8 
per 100 person-years in 1997 (after the introduction of HAART)62. Prospective follow-up of 2674 
adults enrolled in the Swiss HIV Cohort Study showed that clinical progression was substantially 
decreased following treatment with HAART compared to the pre-HAART treatment period. This 
was attributed to increased CD4 cell counts, with a significant increase in hazard of 
undetectable viral load seen between pre-HAART and post-HAART time periods, i.e. 1995/96 
vs. 1997/98 (HR: 1.31, 95% CI: 1.17, 1.48m p < 0.0001)101. Similarly, in a comparison of two 
prospective multi-cohort studies, the pre-HAART era Multicentre AIDS Cohort Study (MACS) of 
1604 homosexual men first enrolled in the 1980s102 and the ART-CC study of over 12 000 
adults commencing HAART in 1997/8, ART-CC participants had a reduced 3-year probability of 
AIDS regardless of viral load or CD4+ lymphocyte count103. 
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HAART has been shown to be effective in reducing viral load and increasing CD4 cell count in 
children in both resource-rich104,105 and resource-poor settings106,107, although adherence is an 
important issue108. Good adherence has been associated with controlled viraemia in both adults 
and children. During six month follow-up of 99 adult HIV-infected US-resident patients receiving 
medication in controlled environments (jail or nursing home), adherence was significantly 
associated with successful virological outcome (p < 0.001), and increase in CD4 lymphocyte 
count p = 0.006) 109. Poor adherence was significantly associated with virological failure (HIV-
RNA ≥ 1000copies/mL) in multivariable analyses of ≤277 HIV-infected adults living in Uganda 
who were followed up for up to 24 months110, with poor adherence also reported as a significant 
and independent risk factor in 4541 subjects enrolled in the Swiss HIV Cohort Study111.  Thus 
imperfect adherence is one of the main risk factors for uncontrolled viraemia in treated 
people112, with viraemia itself being associated with the emergence of drug resistant strains of 
HIV113.  
 
1.3.5 Antiretroviral therapy in children 
Specific considerations with respect to treating HIV-infected children include those relating to 
toxicity, tolerability and formulation. Increasing numbers of drugs are being licenced for use in 
children114, but concerns still remain regarding dosage and specific regimen.  
 
Analysis of 1441 children enrolled in the UK National Study of HIV in Pregnancy and Childhood 
(NSHPC) and Collaborative HIV Paediatric Study (CHIPS) showed not only substantial and 
sustained decreases in AIDS-associated clinical events since the introduction of HAART, but 
also increases in CD4% greater than 10%, in children initiating HAART at younger ages and 
with a lower CD4% at baseline115. Longitudinal data from 1142 children enrolled within the 
Italian Register for HIV infection suggested that triple class therapy was associated with a 
significant 61% decreased relative hazard of mortality compared to no ART in adjusted models: 
mono-therapy and dual cART were associated with non-significant hazards of 23% and 30% 
respectively95,116.  Moreover, a significant reduced risk of mortality was associated with use of 
HAART compared to non-HAART regimens (hazard ratio: 0.24, 95% CI: 0.11, 0.51) in a model, 
adjusted for severity of disease at initiation, using ten-year longitudinal data collected from 1236 
children enrolled in a US-based multicentre study117. 
 
The Paediatric European Network for the Treatment of AIDS (PENTA) guidelines118 explicitly 
state  that treatment in children and adolescents should; 
• Achieve and sustain full HIV-RNA suppression with minimization of short term and long 
term ART drug toxicity.  
• Prevent drug resistance. 
• Promote normal immune function, thus preventing opportunistic infection. 
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The United States National Institutes of Health (NIH) guidelines share these aims but with the 
added proviso that ART should improve the quality of life of paediatric patients119. Table 1-3 
summarizes the current treatment guidelines published by PENTA, comparing them to the NIH 
and WHO guidelines.  
 
Commencement of treatment 
The Children with Early Antiretroviral Therapy (CHER) trial of 377 South African infants 
compared immediate ART with deferred treatment (until specific CD4 cell counts or HIV-RNA 
levels were reached): immediate treatment was associated with a 76% reduction in mortality at 
age seven months56. Furthermore, several observational studies have investigated the optimal 
time at which to begin ART in HIV-infected infants and children. A significant reduced number of 
AIDS-related clinical outcomes in children who started ART before three months of age was 
seen when compared with children who were first treated after three months amongst 210 
children in a multicentre European study120.  Analysis of 131 children enrolled in the ECS 
showed that both commencement of therapy before 5 months of age, and initiation with HAART 
were significantly associated with improvements in CD4 cell counts121. This is reflected in the 
recent update to paediatric guidelines12,122,123, (Table 1-3). Previous guidelines specified clinical, 
immunological or virological thresholds for starting ART124. The durability of first-line HAART 
commenced before 12 months of age in suppressing viral load and maintaining CD4 counts has 
been shown during 5 year follow-up of more than 400 children enrolled within the European 
Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC)125. However, the long-term 
outcomes resulting from ART being initiated at different CD4 counts is unknown. 
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Table 1-3: Comparison of paediatric treatment guidelines by the Paediatric European 
Network for the Treatment of AIDS122, US National Institute of Health 119 and the World 
Health Organization 126.  
 
PENTA 2009 US NIH 2010 WHO 2010 
0-11 months 
   
Clinical Treat all Treat all Treat all 
Immunological    
Virological    
12-35 months 
   
Clinical Treat CDC Stage B or 
C/WHO stage 3/4 
Treat CDC Stage B/C Treat WHO Stage 3/4 
Immunological (CD4%/ 
count) 
Treat<25% or 
<1000cells/µL 
Treat<25% Treat <25% or <750 
cells/µL 
Virological Consider>100 000 
copies/mL 
Consider>100 000 
copies/mL 
 
12-59 months 
   
Clinical Treat CDC Stage B or 
C/WHO stage 3/4 
Treat CDC Stage 
N/A/specific B conditions 
Treat WHO Stage 3/4 
Immunological (CD4%/ 
count) 
Treat<20% or 
<500cells/µL 
Treat<25% Treat<20% or 
≤350cells/µL 
Virological Consider>100 000 
copies/mL 
Consider>100 000 
copies/mL 
 
5+ years 
   
Clinical Treat CDC Stage B or 
C/WHO stage 3/4 
Treat CDC Stage 
N/A/specific B conditions 
Treat WHO Stage 3/4 
Immunological (CD4% 
/count) 
Treat<350cells/µL Treat<350cells/µL Treat<15% or 200cells/µL 
Virological Consider>100 000 
copies/mL 
Consider>100 000 
copies/mL 
 
 
PENTA recommend that children aged over 12 years be treated with ART according to 
specified thresholds (Table 1-3). There is considerable debate regarding whether it is more 
appropriate to defer treatment in children (i.e. those aged >12 months) as opposed to adults127. 
It has been argued that due to the absence of randomized clinical trials in this age group, the 
evidence supporting early treatment with ART is incomplete. Furthermore, as treatment in 
children is likely to be life-long, children are more likely to accumulate decades of ART, and the 
effects of this are unknown: in this scenario, a potential approach to minimize cumulative 
exposure is to defer treatment. However, childhood mortality correlates with poor clinical status 
(including increased viral load) at the commencement of treatment in infancy and early 
childhood128: once HIV-infected children survive to 1 year of age, the rate of disease 
progression is relatively slow indicating the importance of maintaining health a young ages.   
 
The economic implications of ART have been highlighted129,130, and may be a consideration in 
deciding on timing of treatment. In certain contexts, for example low-income countries, 
decisions may therefore be made to “ration”131  treatment until clinical symptoms appear or 
acceptable CD4 levels reached, rather than adopting the recommendation of early treatment.  
 
Adherence  
The availability of ART formulations which are palatable to children are still comparatively rare, 
which has contributed to lower rates of adherence in children132,133.  Both the tolerability and 
toxicity of specific ART in children and adolescents has been well documented134,135: this may 
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influence patient adherence to treatment. The desire to avoid both the direct effect of toxicity in 
paediatric patients, and also the indirect effects (such as poor adherence leading to viral 
rebound, AIDS-related clinical symptoms, and the emergence of drug-resistant HIV strains136-
138) may also contribute to the argument against early treatment.  
 
The relationship between adherence to ART and the emergence of drug resistance is in itself 
complex139,140, with evidence suggesting that resistant strains can occur at high levels of 
adherence to non-ritonavir boosted PI-based ART, but at poor-to-moderate levels of adherence 
to NNRTI-based ART141,142, reflecting the long half-life of NNRTI143. Relatively high levels of 
suboptimal adherence to HAART can occur before clinical effects are seen: during 12-month 
follow-up of 195 adult patients with initial undetectable viral load, HAART adherence of 70-89% 
was associated with viral rebound with clinically significant resistance144.  
 
Poor adherence is associated with viral rebound in children145,146, but few studies have 
investigated associations between adherence and clinical outcome in childhood. Good 
adherence in younger children requires their co-operation in the administration of medication, 
but is also complicated by the important role of the care giver or parent. This individual must 
have an understanding of the treatment, a commitment to the health of the child, organized to 
give the drugs at the appropriate time, and (in some cases), the economic ability to provide 
medication147. Furthermore, late adolescence where management of treatment moves from 
adult carers to the teenager can be a difficult time in terms of the maintenance of adequate drug 
adherence. In addition attitudes in the society may be important. For example disclosure of HIV 
status may be an issue in most communities where there is prejudice against HIV: adherence 
may be associated with a risk of disclosure in adolescents, especially where drugs need to be 
taken during the working day148. The factors involved in paediatric ART adherence are 
illustrated in Figure 1-4.  
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Figure 1-4: Factors associated with paediatric and adolescent adherence to antiretroviral 
therapy (adapted from Haberer and Mellins (2009)146) 
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A systematic review of 17 paediatric studies found that rates of adherence ranged from 49% to 
100%, with over three-quarters of studies reporting rates of over 75%149.  Furthermore meta-
analysis estimates of adult adherence were 55% in North America and 77% in Africa150. A direct 
comparison of adolescents (aged 11-19 years) and adults in a South African population showed 
that adolescents were less adherent, with lower rates of virological suppression and 
immunological recovery (p < 0.01)151.  
 
Switching ART regimen 
Change in ART regimens to maintain HIV viral suppression has been examined in large 
prospective studies152, in part prompted by the observation that  the rate of virological rebound 
in adults treated with either PI-based ART or HAART was as high as 40% in the late 
1990s101,153. In a recent Ugandan-based prospective study of 124 children initiating HAART, 
14% ( n = 17) displayed virological failure (HIV-DNA ≥400 copies/mL) after 48 weeks of 
treatment, 3 of whom were infants aged <1 year154. In a Cambodian study following 212 children 
commencing HAART, 19% had virological failure following at least one year of treatment155. 
Other paediatric studies have reported similar results156,157. Thus it is likely that children and 
adolescents may be subject to increasing ART switching between drugs and regimens through 
their lifetimes in order to maintain viral suppression.  
 
Age at initiation of ART is an important factor in HIV-suppression, and thus also an important 
factor in switching of regimens. In analysis of 324 ART-naïve HIV-infected children enrolled in 
CHIPS, CD4 cell increases were more likely in younger children, but viral load suppression was 
more likely in older children (p < 0.001 for both). Furthermore, long term increases in CD4% 
occurred faster, and decreases in viral load slower in younger children (follow-up of 6 months 
versus 24 months): these results were all independent of pre-treatment CD4 and viral load 
status158. The poorer virological outcome with increasing age may result in switching of 
regimens to maintain suppression. Concurrently, the durability of first-line regimens has 
improved over calendar time. EPPICC reported an increased proportion of subjects with viral 
suppression between 1996-1999 and 2004-2008: rates of switching to second-line regimens 
were lower among children starting four-drug NNRTI-based and boosted-PI regimens, and two-
thirds of subjects remained on first-line regimens for over five years  (analysis of 426 children 
followed up for a median of 5.9 years after the commencement of ART)125. Thus switching to 
second and third line regimens may be deferred due to success in maintaining HIV suppression 
on current treatment.  
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The aim of the PENPACT-1d clinical trial of 266 children was to compare strategies of starting 
and changing ART on long-term virological suppression in ART-naïve children. Results 
suggested that switching may have consequences in terms of resistance, dependent on 
regimen and indicators for switching. The trial investigated the effectiveness of PI-based and 
NNRTI-based HAART, and switching to second-line ART of these regimens at high and low viral 
load thresholds by randomizing participants to four arms:  switching at higher viral load resulted 
in accumulation of more NRTI resistance mutations compared to the lower threshold in the 
NNRTI arms, while there was no difference in NRTI or PI mutations in the PI arms regardless of 
the viral load at switching159. Thus despite the recent studies looking at switching paediatric 
populations the long-term effects of switching treatments in children are still unknown. 
Nevertheless, PENPACT-1 reported that over 70% of children remained on first-line regimens at 
5 years following initiation of treatment, reiterating the increased stability of these drugs in 
recent years. 
 
Results from the PLATO II (Pursuing Later Treatment Options II) study of 1007 HIV-infected 
children demonstrated the rate of triple class (ART regimen containing at least one each of PI, 
NNRTI and NRTI) failure and associated factors over an average follow-up of 4 years: while the 
observed rate of 12% was relatively low, it was twice that of adults160.  Thus, there are still 
substantial challenges in maintaining durable viral suppression in children which is exacerbated 
by both the limited number of ART formulations available for children, and the need to provide 
life-long treatment.   
 
Vertical transmission of HIV and perinatal antiretroviral treatment 
Most infections occur in children as a result of vertical transmission (MTCT), which may occur 
before, during or following birth161-163. Combined analysis of data from three Africa-based 
studies and one Australia-based studies estimated a 29% risk of transmission of HIV-1 from 
postnatally infected mothers to their children through breast milk164. In a Kenyan-based 24-
month prospective clinical trial, transmission rates were significantly higher in breast-fed versus 
formula-fed infants165.   However, the risk of transmission associated with exclusive breast 
feeding compared to non-exclusive breast feeding is controversial166  
 
Effective options for preventing vertical transmission other than avoiding breastfeeding include 
avoidance of infant exposure to contaminated maternal secretions by elective caesarean 
section delivery167. Indeed, rates of caesarean sections in HIV-infected pregnant women 
enrolled in the multicentre ECS have been seen to increase steadily168 since early reports that 
vaginal mode of delivery was associated with a (non-significant) increase in vertical 
transmission169.   
 
                                                 
d
 Paediatric European Network for Treatment of AIDS (PENTA) and Pediatric AIDS Clinical 
Trials Group (PACTG/IMPAACT) 
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Analysis of 19, 494 HIV-infected women resident in South Africa and who had recently given 
birth showed significant protective effects against vertical transmission associated with ART use 
in pregnancy, or lifelong maternal ART use170. Specific ART during pregnancy was shown to 
have a significant protective effect against vertical transmission (compared to zidovudine mono-
therapy) in a Brazilian study of 452 women171. Postpartum ART in babies born to HIV-infected 
mothers who have either received no treatment during pregnancy172 or presented for delivery 
late with unknown HIV-status173 has been shown to result in reduced rates of infection in the 
weeks following birth. Other studies have found reduced rates of vertical transmission following 
intrapartum and/or postpartum ART in infants who were/were not breastfed174-176.  Furthermore, 
ART treatment during late pregnancy followed by postpartum treatment in the infant has been 
shown to reduce the risk of postnatal infection at 24 months177. A Cochrane review has 
concluded that reductions in vertical transmission can be made by avoidance of breast feeding 
by HIV-infected mothers, or in the case of breast feeding occurring: exclusive breast feeding 
during the first few months of life, and/or chronic antiretroviral prophylaxis in the infant178 Indeed 
rates of vertical transmission have decreased over time since the introduction of HAART 
treatment179.  
 
Social and economic pressures may limit the uptake of initiatives aimed at reducing vertical 
transmission through reduced rates of breast feeding and/or prophylactic treatment during 
pregnancy180-182. This may explain why the percentage of HIV-infected pregnant women 
receiving prophylactic ART is higher in Europe and Central Asia compared to Sub-Saharan 
Africa13. Indeed, the mother-to-child transmission rate in the UK has been reported as being 
less than 2%, being reduced further in women who have received at least 14 days of ART183. 
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1.4 Lipodystrophy syndrome  
1.4.1 Phenotype 
Lipodystrophy syndrome (LS) can be defined as a body fat alteration which is usually 
accompanied by metabolic abnormality. The body fat alteration may manifest as lipoatrophy (fat 
loss occurring in at least one of the following: face, limbs or buttocks) and/or as lipohypertrophy 
(fat gain occurring in at least one of the following: back of neck, breasts or abdomen). The 
metabolic abnormality can take the form of hypercholesterolemia, fasting hypertriglyceridemia or 
glucose intolerance. Figure 1-5 illustrates this definition.  
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Figure 1-5: Definition of lipodystrophy syndrome incorporates body fat alterations at 
distinct body locations, and specific metabolic abnormalities  
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The body fat alterations can take the form of either lipoatrophy in the face, arms, buttocks or 
limbs, or lipohypertrophy in the back/neck (‘buffalo hump’), breasts or abdomen, as illustrated 
schematically in Figure1-6, and photographically in  adult (Figure1-7) and paediatric (Figure 1-8) 
patients.  
 
Figure 1-6: Body fat alterations seen in lipodystrophy syndrome (LS) by location.  
 
 
Areas susceptible to lipoatrophy are shown in red and locations of lipohypertrophy are shown in blue.  
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Figure 1-7: Manifestation of body fat alterations seen in male adults with lipodystrophy 
syndrome.  
 
 
 
Top left; dorso-cervical lipohypertrophy (buffalo hump), bottom left; abdominal lipohypertrophy, top/bottom 
right; face lipoatrophy, and middle left; buttock lipoatrophy. Retrieved from http://survivinghiv.blogspot.com  
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Figure 1-8: Manifestation of body fat alterations seen in paediatric patients with 
lipodystrophy syndrome.  
 
  
Left; 20 year old male with breast lipohypertrophy, and right; 15 year old female with dorso-cervical 
lipohypertrophy (buffalo hump). Reproduced courtesy of Dr. Alex Peltier. 
 
 
LS may occur as either fat alteration without metabolic abnormality, or metabolic abnormality 
without fat alteration. With different combinations of fat disorder and metabolic components, the 
phenotype becomes more heterogeneous. This has led to the argument that LS can be divided 
into three, possibly overlapping, conditions184: 
1. Lipoatrophy: subcutaneous fat loss (especially affecting the limbs, face and buttocks), 
and deep fat loss (visible at the level of “Bichat”, pre-auricular or orbital fat pads, and 
manifesting in pain triggered by mastication, sunken eyeballs and retro-orbital pain). 
This may be associated with an increase in triglyceride levels and insulin levels, but 
remaining in the normal range. 
2. Mixed syndrome: peripheral fat loss (limbs, buttocks, face), and fat gain, but no deep fat 
loss. This may be associated with metabolic changes similar to those seen in insulin 
resistance, i.e. raised insulin, C-peptide, and free fatty acid. 
3. Subcutaneous adiposity: this may manifest with fat accumulation in the dorso-cervical 
and breast region, but not seen to the same extent as seen in obesity. Furthermore, 
there is no increase in visceral adipose tissue area, nor any insulin resistance.  
 
However, this may be an over simplification as other phenotypes not easily categorized within 
this classification have been observed Furthermore,  the described categories above were 
proposed from cross-sectional analysis of 154 male adults. In a US study comparing 30 HIV-
infected adults to non-infected controls, significant differences in mean triglycerides and high 
density lipoprotein (HDL) cholesterol were seen between patients with lipohypertrophy and 
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those with both lipohypertrophy and lipoatrophy: thus demonstrating a syndrome of insulin 
resistance characterized by hyperinsulinaemia, hypercholesterolemia, low HDL, and truncal 
lipohypertrophy185.  Moreover, prospective follow-up of patients who started on different ART in 
a US study (n = 41) found PI use to be significantly associated with increases in insulin, 
glucose, triglyceride, low density lipoprotein (LDL) cholesterol and total cholesterol, but these 
changes were independent of fat alterations186.  
 
The problematic phenotype characterization of LS is compounded by an incomplete 
understanding of the relationship between metabolic abnormality and fat alterations, particularly 
with respect to temporality. The relationship between lipoatrophy and lipohypertrophy is 
complex. It is thought that the inflammatory sequelae of both HIV infection and ART reduce the 
capacity of adipose cells to store lipid, and also cause the release of free fatty acid through 
increased lipolysis and adipocyte apoptosis, ultimately resulting in lipoatrophy187.  Indeed, it has 
been argued that distinct adipocyte depots within the body react to PIs differently, with 
subcutaneous adipocytes more predisposed to becoming insulin resistant and lipoatrophy 
processes188,189.  In contrast, the pathogenesis of lipohypertrophy is less well understood, 
possibly occurring secondary to lipoatrophy as a consequence of fat no longer being able to be 
stored in subcutaneous tissue187. However, this proposed pathogenesis does not address the 
situation where lipohypertrophy occurs in the absence of lipoatrophy. 
 
 
1.4.2 Prevalence  
LS was first described in HIV-infected adults undergoing ART in 1997190, but has also been 
described in treatment naïve patients191. The timing of the recognition of ART-associated LS 
reflects the accumulating exposure to ART in the treated population and the emerging use of 
HAART8. Prevalence in HIV-infected adults of fat alterations and/or metabolic abnormality was 
50% in a 1999 Canadian population receiving ART192, and of fat alterations of 70% in a 2006 
Rwandan population receiving HAART193.  
 
Fewer studies have concentrated on the epidemiology of LS in children and adolescents than in 
adults. The syndrome was first described in children in a French study in 2000; 13 individuals 
from a sample of 33 HIV-infected children (mean age 9 years) showed evidence of body fat 
changes and also exhibited non-significant hypertriglyceridemia compared with children with no 
body fat changes194. In another early, cross–sectional, study of 40 HIV-infected children (mean 
age of 9.1 years), the prevalence of fat alterations was 18%, and of hypertriglyceridemia and/or 
hypercholesterolemia was 73%. Although no significant associations between postulated risk 
factors and LS were found, children receiving paediatric dosing regimens were less likely to 
develop LS in comparison to children on adult regimens (p = 0.0003)195; however, this 
association may have been confounded with age and pubertal stage of participants. Both the 
largest paediatric studies into LS, with 1812 and 2122 participants were nested within the same 
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prospective cohort, the Paediatric AIDS Clinical Trials Group 219c (PACT 219C): they reported 
a prevalence of hypercholesterolemia (defined by age, race and gender cut-offs) of 13% (95% 
CI: 11.1, 14.3 among 229 HIV-infected children)196,  with an incidence of 13% (defined as 
cholesterol >220mg/dL)  in 2122 susceptible subjects over a median follow-up of 50.4 months 
(incidence rate; 3.4 cases per 100 person-years, 95% CI: 3.0, 3.9)197 
 
The lack of consensus regarding the definition of the LS phenotype makes it difficult to establish 
valid comparisons between reported prevalence and incidence from different studies. 
Furthermore, there are comparatively few prospective studies with follow-up of large numbers of 
participants. In a 24 month prospective study of 84 HIV-infected adults treated with HAART 
enrolled in a French cohort, LS was defined as at least one of the following; abdominal 
lipohypertrophy, fat lipoatrophy, limb wasting, breast lipohypertrophy, pleomegalia, or alopecia: 
the incidence of LS was reported as 5% at 6 months following treatment initiation, increasing to 
26% at 9 months and remaining at his level at 12 and 24 months post initiation198. A similar 
Spanish study of 496 ART-naïve adult patients commencing HAART and followed-up over 24 
months defined LS as central obesity and/or subcutaneous lipoatrophy: the incidence was 
reported as being 11.7 per 100 person/years (95% CI; 9.2, 14.2), i.e. 17% of the cohort199.   
 
Similar problems regarding herterogeneity of outcome are seen in published paediatric 
research: some studies looked at fat alterations as a whole195,200-208, while others specifically 
examined lipoatrophy or lipohypertrophy194,209,210. While most studies in children investigated 
clinically-assessed changes in body shape, others also used measures such as skin fold 
thickness211 or estimation of percentage body fat212,213.  The most recent study to investigate 
body fat alterations in HIV-infected children reported a prevalence of 25.0% (95% CI: 14.8, 
34.6): this was a cross-sectional study of 57 children (median age 9.5 years) living in Spain with 
alterations assessed by the treating clinician207. In contrast, a French cross-sectional study of 39 
children (median age: 9.1 years) reported a prevalence of body fat alterations of 33.3%: 
peripheral fat wasting was defined as face/buttock/limb atrophy with arm skinfold thickness <3rd 
percentile of reference values for sex and age in a French population, and trunk adiposity 
defined as breast enlargement/back of neck/abdominal enlargement with trunk:arm skinfold 
ratio >2 standard deviations from the mean194. As with adults most paediatric studies follow a 
cross-sectional design which precludes the estimation of incidence. Furthermore, excluding the 
PACTG 219C study, the largest of the longitudinal studies contained 178 
participants200,201,203,204,210,211. Although valuable prevalence and descriptive data has been 
collected in cross sectional studies, advances in understanding the pathogenesis of LS in 
children and adolescents require longitudinal analyses of both existing and incident cases. 
Ideally these studies should be prospective in nature as retrospective studies are hampered by 
data collection from secondary sources, such as patient notes, rather than utilizing standardized 
and focused tools 
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A review of adult studies estimating the prevalence of LS, defined as any sign of fat alterations, 
reported a range of prevalence between 2% and 84%. The heterogeneity in these estimates 
was attributed not only to varied definitions of the syndrome, but also a mixture of self-reported 
and clinical methods of assessment214. HOPS, a cohort which enrolled HIV-infected adults in 
eight US studies, reported a prevalence of fat alterations of 49% among 1080 patients215, while 
the prevalence of fat alterations was 38% and of metabolic abnormality was 49% amongst the 
581 patients from five hospitals enrolled in the Aquitaine Cohort216. The largest cross-sectional 
study in paediatric LS, the European Paediatric Lipodystrophy Cohort multi-centre investigation 
including 477 children of median age 9.8 years, reported a prevalence of body fat alterations of 
26%, of hypercholesterolemia of 21% and of hypertriglyceridemia of 27%209. 
 
There is evidence that body fat disorders occurring in HIV infected children can progress over 
time. Body fat mass was measured using dual energy x-ray absorptiometry (DEXA) in a 
prospective observational study of 28 pre-pubertal HIV-infected children aged 4 -13 years with 
an average of 1.2 years follow-up. Eight children were assessed to have limb lipoatrophy and 
truncal lipohypertrophy at baseline, and there was significant decrease in body fat percentage 
during follow-up in these children (p < 0.05). In addition, non-significantly decreased limb fat 
over time was seen in children with initial fat disorder, but a significant increase in limb fat was 
seen in children without initial fat disorder (p ≤ 0.01)200. However, this study had low statistical 
power and thus independent associations with risk factors, such as ART use, could not be 
assessed. 
 
1.4.3 Pathogenesis  
Both HIV- and ART-dependent pathways of LS pathogenesis have been proposed. 
 
HIV and lipodystrophy syndrome 
An ART-independent mechanism of pathogenesis of LS remains controversial. Although studies 
have found independent associations of LS with duration of HIV infection (patients with LS 
having longer durations of infection compared to patient without217), CD4 cell count (patients 
with LS being shown to have lower CD4 cell counts than patients without200), and viral load 
(patients with LS having lower viral load compared to patients without218), the role of these 
factors in pathogenesis is unclear. Alterations in adipose gene expression have been observed 
in treatment naïve HIV-infected patients219, providing evidence of  ART-independent pathways 
of lipodystrophy pathogenesis. A relationship between HIV-RNA and resting energy expenditure 
has been reported220, suggesting that the host immune response may play a role in lipoatrophy 
by increasing energy demand when activated, and ultimately resulting in the breakdown of 
energy stores such as adipose tissue. Tumour necrosis factor alpha (TNF) 221 and interleukin 
(IL)-6 222 levels are increased in subcutaneous adipocytes from lipoatrophic patients and it is 
thought that the infection-stimulated pro-inflammatory cytokines TNF, IL-1, and IL-2 have a role 
in stimulating hyper-metabolism and protein turnover. 
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Association between lipodystrophy syndrome and antiretroviral therapy 
Studies have found NRTIs, PIs and NNRTIs all to be associated with increased risk of LS in 
adults223-227. In a cross-sectional study of HIV-infected adult women, fat alteration was 
associated with long-term antiretroviral use, with a significant correlation with use of lamivudine. 
Furthermore, PIs were associated with higher risk of developing fat alterations, although this 
was also seen in patients on non-PI regimens228.  
 
Investigation of body fat changes in a paediatric population can be blurred by the rapid growth 
and development that is characteristic of childhood and adolescence. This is further 
complicated by the fact that poor growth in HIV-infected children is well recognized200,229,230. 
Thus it may be difficult to separate these effects from the changes in body shape mediated by 
ART, especially as ART has been shown to improve growth231. The concurrent effects of natural 
growth, HIV-infection and ART may manifest in a dynamic of progression and regression of 
lipodystrophy which may not be seen in adults. 
 
Paediatric studies have reported significant increased risk of body fat alterations associated with 
both PI and NRTI use205,209. DEXA analysis of body fat tissue in children in Italy found a 
decreasing trend in the ratio of trunk fat to total fat, and an increasing trend in the ratio of limb 
fat to total fat, across HIV-infected children with LS, HIV-infected children without LS and HIV-
uninfected matched controls232, indicating similar patterns of fat alterations as seen in adults. 
Further analysis of 37 HIV-infected children (mean age, 12.2 years at baseline) from this study 
population indicated that both trunk lipohypertrophy and limb lipoatrophy are features of LS in 
children. Significant (p < 0.01) decreases in arm and limb fat over 12 months follow-up was 
reported. There were also significant (p < 0.05) associations of limb/lean muscle ratio with 
pubertal stage, sex, increasing body mass index (BMI) and duration of PI-based HAART 
therapy in multivariate models controlling for age and past and current immunosuppression. 
Pubertal stage and duration of PI-based HAART were found to be independent predictors of 
truncal adipose tissue, with a negative association seen in multivariable modelling233.  
 
The use and duration of use of indinavir were associated with the accumulation of intra-
abdominal fat in a US-based cross-sectional analysis of 30 HIV-infected adult males234. 
Progressive longitudinal monitoring of fat wasting in HIV patients on different drug regimens 
suggests that NRTIs are associated with lipoatrophy, with PIs having a synergistic effect235. In a 
prospective study (median follow-up time of 3.1 years) investigating the effect of different NRTIs 
in the presence of similar PI-based regimens, it was found that the different NRTI drugs were 
associated with varied fat disorder outcomes: stavudine and zidovudine were associated with 
decreases in subcutaneous fat in the mid-arm, mid-thigh and waist, while lamivudine was 
associated with increased subcutaneous adipose tissue in the same locations and waist non-
subcutaneous tissue236. Furthermore, an investigation into the effect of switching drug regimens 
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concluded that NRTIs, particularly thymidine analogues such as zidovudine and stavudine, are 
particularly associated with lipoatrophy in the extremities237. The role of thymidine analogues in 
lipoatrophy is documented by other studies238: however less toxicity is reported with newer 
drugs such as tenofovir and abacavir239 
 
Total cholesterol and LDL cholesterol was significantly higher in HIV-infected patients with LS (n 
= 10) compared to those without LS in a US-based cross-sectional study240. A US-based 
historic cohort which followed-up of 221 HIV-infected adults over 5 years reported that the 
cumulative incidence of hypercholesterolemia, hypertriglyceridemia and body fat alterations 
increased after the initiation of PI therapy, with increased triglyceride levels significantly 
associated with PI use, and increased cholesterol levels significantly associated with months of 
both PI use and NRTI use241. Furthermore switching from PI to nevirapine in treatment 
regiments resulted in significant reduced concentrations of cholesterol and triglyceride in 23 
treated HIV-infected adults242. Indeed, there were significant increases in median total 
cholesterol, LDL-cholesterol and HDL cholesterol in 48 HAART-naïve HIV-infected adults who 
commenced PI-based HAART in a US-based study243.  
 
Paediatric studies have also investigated metabolic abnormality in children on ART201,203,208.. In 
a UK-based cross-sectional study, using untreated controls, significantly increased total 
cholesterol levels were found in children on HAART with PIs (n = 24) and in those on non-PI 
HAART (n = 35) compared to untreated children (n=39). Furthermore, there were significant 
differences in several anthropometric measures between children on PI-containing HAART 
compared with untreated children, but such differences were not significant when comparing 
non-PI HAART-treated children and untreated children244. During 48-week follow-up of 50 
previously PI-naïve HIV-infected children in a Thai study, significant increases were seen in 
total cholesterol, LDL cholesterol, and triglyceride levels245. Furthermore, 48-week prospective 
follow-up of 28 HIV-infected children (aged 5-17.5 years) who were switched from PI to 
efavirenz (and from stavudine to tenofovir) resulted in significant decreases in levels of total 
cholesterol, LDL-cholesterol and triglyceride246. During 96-week prospective follow-up of 20 
HIV-infected children (median age 7.9 years) who had previously been on PI-containing 
regimens for >4 years, switching to a triple NRTI-based strategy resulted in significant 
decreases in levels of total cholesterol and triglyceride247. Indeed, several studies have reported 
hyperlipidemia to be associated with PI use in HIV-infected children248-250. In cross-sectional 
analysis of 386 HIV-infected children (7-24 years old), not only were significant predicted 
increases in mean total cholesterol, LDL-cholesterol, non-HDL cholesterol, and triglyceride seen 
to be associated with PI use (ritonavir and nelfinavir) 251, but the same study also reported 
opposite effects on HDL-cholesterol significantly associated with different NRTIs (decrease with 
zidovudine and increase with nevirapine)251. Furthermore, research in HIV-infected adults has 
suggested that NNRTI use may be associated with a significant and independent protective 
effect against low HDL-cholesterol252. 
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The role of ART as a key risk factor for LS in children is reinforced by results from studies that 
have investigated both body fat alterations and metabolic abnormality. The observational 
European Paediatric Lipodystrophy Group study of 477 HIV-infected children (median age 9.8 
years) found a prevalence of 26% for any fat alterations, with lipohypertrophy in the trunk and 
neck, and lipoatrophy in the face and limbs occurring more commonly than fat alterations in 
other locations. In adjusted analyses, increased risk of fat alterations was independently 
associated with ever use of PIs and ever use of stavudine. Prevalence of dyslipidemia in the 
study group was 38%, with significant 2-fold and 5-fold increased risk of hypercholesterolemia 
with gender and ever-use of PIs respectively (following adjustment for current ART use and 
lipohypertrophy). Ever-use of stavudine was associated with a significant 4-fold, and ever-use of 
ritonavir was associated with a significant 2-fold, increased risk of hypertriglyceridemia, after 
adjustment for lipoatrophy and CDC clinical status209. In a North American cross-sectional study 
of 386 HIV-infected children aged 7-24 years, mean total fat and limb adiposity were lower in 
HIV-infected subjects compared non-HIV infected controls, with trunk adiposity being lower in 
HIV-infected children on PI-therapy compared to those not on PI therapy (adiposity assessed 
using DEXA). Similarly, median triglyceride levels were highest in the HIV-infected group treated 
with PIs compared to the HIV-infected PI-naïve group and the uninfected controls251. In a 
Canadian study of 48 subjects, insulin sensitivity in PI-treated children was significantly lower 
than that seen in PI-naïve children, following adjustment for potential confounding variables, 
suggesting that LS-related insulin resistance also occurs in children. Central adipose tissue 
area, and the ratio of central to subcutaneous adipose tissue were non-significantly higher in PI-
treated children compared to PI-naïve children253.  
 
Postulated mechanisms for antiretroviral therapy-mediated lipodystrophy 
Several mechanisms of PI-mediated lipodystrophy have been proposed254. Elevated plasma 
glucose may be mediated by the effect of PIs on hepatic glucose production255,256 and also 
glucose disposal257. This may occur in several ways.  PIs258,259 including ritonavir 260 have been 
shown to reduced insulin-stimulated glucose uptake  by the Glucose Transporter Type 4 
(GLUT-4)   in rat adipocytes. Cytochrome P-450 enzymes, which are central to lipid 
metabolism261, are inhibited by PIs83. Animal, particularly murine, models have shown that 
ritonavir induces hyperlipidemia by  (a) reducing the activity of the enzyme hepatic lipase262 thus 
impeding hydrolysis of circulating triglycerides and the cellular uptake of lipoproteins and 
lipids263, and  (b) suppressing the down regulation of sterol regulatory protein (SREBP) an 
adipose-inducing lipid metabolism protein264.  
 
Direct effects on adipocyte differentiation and apoptosis (resulting in reductions in chylomicron 
uptake, triglyceride clearance and adiponectin release) may be associated with several PI-
induced pathways; increased release of inflammatory cytokine levels (TNF-α, IL-6, IL-1β); 
inhibited cytoplasmic retinoic acid binding protein 1 (CRABP-1); and inhibited lipoprotein 
receptor related protein (LRP) 221,255,265-267.  Increased rates of triglyceride lipolysis are then 
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responsible for elevated plasma free fatty acids, including LDL cholesterol and very low density 
lipoprotein (VLDL) cholesterol268-271. This metabolic abnormality may therefore lead to changes 
in insulin sensitivity, and ultimately to a state of insulin resistance, particularly in the muscle and 
liver 272. 
 
The mitochondrial toxicity of NRTIs has been widely investigated273. Indeed, the effect of NRTI-
containing ART regimen on mitochondria in infants and children has been noted274,275.  The 
lipodystrophy-promoting effects of these drugs may be linked to this toxicity276, with several 
features of NRTI mitochondrial toxicity, e.g. polyneuropathy, hepatic stenosis and 
hyperlactatemia occurring in HAART-associated LS277 (although these may in fact be occurring 
concurrently with LS). Mitochondrial dysfunction may result in lipohypertrophy through a 
reduction of the mitochondrial enzyme cytochrome oxidase, and impaired beta-oxidation of fatty 
acids resulting in accumulation of fat droplets within cells278.  
 
Mitochondrial toxicity is also implicated in lipoatrophy because of the observation of abdominal 
distension and lactic acidosis in lipoatrophic patients. The mechanisms postulated have 
included mutations in mitochondrial DNA polymerase (as seen in similar syndromes such as 
Multiple Symmetric Lipomatosis), or impairment of hepatic glycogen and fat oxidation resulting 
in increased oxidation of peripheral energy stores inducing lipoatrophy277. Levels of 
mitochondrial DNA (mtDNA) have been found to be lower in subcutaneous tissue in patients on 
NRTI compared to patients on either other regimes or who were ART naïve279,280. Depletion of 
mtDNA leads to disturbances in the balance of oxidative phosphorylation and can result in lactic 
acidaemia/acidosis281. It has also been suggested that the NRTI-mediated inhibition of mtDNA 
polymerase results in depletion of mtDNA in adipose tissue to below the threshold at which it 
can meet its energy requirements, resulting in decreased adipocyte size, increased adipocyte 
death and thus development of lipoatrophy. However, there are limitations to this theory, as 
both in vitro and in vivo experiments show that mitochondrial dysfunction can occur irrespective 
of mtDNA levels282. In addition, NRTIs have been shown to  be associated with reductions in 
both mRNA expression of adiponectin, and expression of SREBP which have been more 
commonly associated with PI use283. 
 
Insulin resistance has been associated with NRTIs, which may have a role in  lipoatrophy; 
NRTI-treated PI-naïve HIV-infected males with lipoatrophy have markedly reduced levels of 
adiponectin (levels of which are found to be lower in obesity, and is believed to lower insulin 
resistance284) mRNA and protein secretion285.  
 
Some of the potential pathways of pathogenesis between use of PIs and NRTIs and LS 
symptoms are summarized in Figure 1 9 (adapted from Carr (2003)286). The role that other 
classes of ART (fusion inhibitors and chemokine co-receptors antagonists), if any, play in LS in 
not known, reflecting their more recent introduction to clinical practice. Furthermore, any 
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associations with newer drugs may be complicated by their use in patients who are already 
highly ART experienced. Moreover, patients with LS may be switched to newer drugs which are 
designed to be less conducive to LS leading to confounding by indication287-289 where erroneous 
associations between newer drugs and current LS may be made, rather than true associations 
between past drugs and current LS.  
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Figure 1-9: proposed pathways of protease inhibitor and nucleoside reverse 
transcriptase inhibitor mediated lipodystrophy syndrome  
 
adapted from Carr 2003286 
On the basis of extensive documentation of stavudine-associated toxicities, in 2006 the WHO 
highlighted the need to reduce stavudine use and to monitor associated toxicities in areas 
where this drug is the first option for beginning ART290-296. Analysis of 2190 HIV-infected adults 
living in Rwanda revealed significant 2-3 fold increased risk of lipoatrophy and early (<6 months) 
neuropathy associated with stavudine use297. Indeed, the most common reason for switching 
ART regimen was stavudine-associated toxicity in a cohort of 559 women followed up for a 
median of 33 months in Uganda298, echoing a previous South African study where over one in 
five of ART substitutions occurred due to stavudine-associated symptomatic hyperlactataemia, 
lipodystrophy or peripheral neuropathy299.  
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1.5 Potential sequelae of lipodystrophy syndrome 
 
1.5.1 Cardiovascular disease 
Because of increases in life expectancy due to HAART72, there is on-going surveillance of CVD 
in HIV-infected individuals as they survive to ages where rates of CVD have been shown to 
increase in HIV-uninfected subjects300-303. In a retrospective analysis of a North American cohort 
of over 30,000 individuals, the age and gender-stratified relative risk of CVD was significantly 
higher in HIV-infected compared with HIV-uninfected individuals. Moreover, following 
adjustment for known CVD risk factors, there was a significant two-fold increased risk of CVD in 
patients receiving ART compared with those ART-naïve. Taken together, these findings suggest 
both HIV-dependant and ART-dependant pathways may have a role in the development of 
CVD304.  
 
An Italian cross-sectional study investigated differences between HIV-patients on ART and an 
ART-naïve group. The patients on ART had a significantly higher incidence of dyslipidemia, and 
a non-significant increased carotid intima media thickness (CIMT) which is correlated to extent 
of coronary atherosclerosis305. Furthermore, within the ART group the presence of LS was 
associated with increased CVD risk and subclinical carotid atherosclerosis306. In a US-based 
study of 253 adults, CIMT was significantly thicker in HIV-infected subjects compared to 
uninfected controls307. In a study in HIV-infected women, CIMT was significantly higher in PI-
treated individuals compared to both non-PI-treated individuals and HIV-uninfected controls, 
indicating that the effect of PIs may be via direct endothelial damage, or indirect via other known 
cardiovascular risk factors308. 
 
In the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study involving 33,347 HIV-
infected individuals across three continents, the incidence of myocardial infarction (MI) 
increased with longer exposure to HAART, with an adjusted relative rate per year of exposure of 
1.26 (95% confidence interval, 95% CI: 1.12, 1.41)309. Analysis of the same study population 
found that the NRTIs abacavir and didanosine were associated with an increased risk of MI, 
even after adjusting for established CVD risk factors. Furthermore, risk of MI was reduced after 
cessation of treatment with these drugs310.  
 
Significant positive associations between metabolic abnormalities and both progressive 
atherosclerosis and CVD have been reported311, with evidence of advancing development of 
atherosclerotic plaques during adolescence312.  Examination of autopsies of 204 subjects aged 
2-39 years who had died from all-causes (mainly trauma) suggests that not only do young 
people develop the atherosclerotic plaques characteristic of CVD, but the severity of 
asymptomatic coronary and aortic atherosclerosis increases as the number of cardiovascular 
risk factors (e.g. serum triglyceride, total cholesterol, LDL-cholesterol, HDL-cholesterol etc.) 
increases313. Given that atherosclerotic plaques develop in HIV-uninfected adolescents and that 
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ART is associated with metabolic alterations, ART may both induce metabolic abnormality in 
HIV-infected children and potentially accelerate development of atherosclerosis. ART is also 
increasing survival in HIV-infected patients, so that many are surviving to middle-age and 
beyond where CVD tends to manifest clinically. With improved survival of HAART-treated HIV-
infected children117, it is conceivable that many may survive past early adulthood. Increased 
survival may in itself increase the risk of CVD as age is an important risk factor for CVD314. 
Moreover, the increasing survival may mean that survivors are living with an abnormal 
metabolic profile for longer. The risk of developing CVD may therefore be affected by both 
increasing age and hyperlipidemia.   
 
Children and adolescents with high cholesterol levels are more likely to have high levels in 
adulthood315, and this may also apply in the context of LS. Furthermore, cholesterol levels in 
HIV-infected children treated with PIs have been shown to be similar to those observed in 
children who are heterozygous for familial hypercholesterolemia (who usually develop CVD in 
middle age).316 In a comparison of HIV-infected children with matched uninfected controls 
(median age 9 years), the HIV-infected group had higher levels of triglyceride and significant 
increased CMIT. Regression analysis showed that duration of ART predicted CMIT while 
traditional atherosclerosis risk factors, HIV disease factors and duration of PI use did not317. It is 
therefore possible that LS in adolescence may lead to CVD occurring at younger ages 
compared to the non-HIV infected population due to the cumulative lifetime effects of 
hyperlipidemia and insulin resistance. 
 
The metabolic syndrome, which includes many of the characteristics of LS, describes a number 
of metabolic abnormalities that are related to increased risk of not only CVD, but also  of obesity 
and of diabetes mellitus318. It is commonly defined as ≥1 of: impaired glucose tolerance, 
impaired fasting glycaemia, diabetes or insulin resistance, with ≥2 of: obesity, dyslipidemia, 
hypertension, microalbuminuria or hyperglycaemia (Figure 1-10). Although it is difficult to 
separate the independent effects of HIV, there is evidence that prevalence of diabetes is similar 
between HIV-infected ART-naïve individuals and those who are both uninfected and ART-naïve: 
prevalence is greater in HIV-infected ART-treated subjects in comparison to both the former 
groups319,320. Furthermore, specific ART drugs have been shown to have different effects on the 
extent to which insulin resistance may occur321. 
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Figure 1-10: Components of metabolic syndrome 
 
Metabolic syndrome is commonly defined as 1 of the conditions detailed in red with at least 2 of the conditions 
detailed in purple (see Eckel et al 2005, for details of different definitions and thresholds318) 
 
Thus the metabolic changes seen in LS, summarized in Table 1-4 (reproduced from Grunfeld et 
al 322) are important in the development of CVD and diabetes323. For example, the changing 
ratio of increased low density lipoprotein (LDL) cholesterol to decreased high density lipoprotein 
(HDL) cholesterol, and increased levels of mediators of inflammation such as TNF are 
conducive to atherosclerotic plaque genesis324.  
\ Impaired glucose tolerance 
Impaired fasting glycaemia 
Diabetes 
Insulin resistance 
Obesity/Central obesity Dyslipidemia 
Hypertriglyceridemia 
Reduced HDL-
cholesterol 
Hypertension 
Microalbuminuria 
Hyperglycaemia 
HIV and lipodystrophy          Chapter 1 
    
 
55 
 
 
 
Table 1-4: Summary of metabolic changes and body fat abnormalities seen in lipodystrophy syndrome (LS) and their relationship with HIV 
infection, and viral suppression. Reproduced from Grunfeld et al 2008322  
 
 Effect of untreated or 
ineffectively treated HIV 
Changes associated with 
viral suppression 
Changes with specific 
antiretroviral therapy 
Role of body shape 
changes 
Lipid metabolism High density lipoprotein 
(HDL) cholesterol 
Decreases early in infection Increases modestly but not to 
pre-morbid levels 
Greater increases seen with 
NNRTI and possibly 
atazanavir than other PI 
Increased visceral adipose 
tissue and upper trunk fat 
associated with low HDL 
Low density lipoprotein 
(LDL) cholesterol 
Decreases later in infection Increases modestly - - 
Triglycerides  Increases in late infection Decreased in early study of 
zidovudine mono-therapy 
No decrease or even further 
increase with HAART 
regimens containing some PIs 
Increases may also may be 
seen with stavudine and 
efavirenz 
Increased visceral adipose 
tissues and upper trunk fat 
Lower leg fat associated with 
increased triglyceride levels 
Glucose metabolism Insulin sensitivity Conflicting evidence of 
increase or decrease 
Decreases insulin sensitivity 
independent of regimen; 
some insulin resistance 
represents restoration to 
health 
Some PIs decrease 
NRTIs (particularly stavudine) 
may also contribute to 
decreases 
Increased visceral adipose 
tissue and upper trunk fat and 
lower limb fat associated with 
insulin resistance 
Insulin secretion No evidence of an effect No evidence of an effect Some PIs may decrease 
insulin secretion 
- 
Fasting glucose No evidence of an effect - Some PIs increase 
endogenous glucose 
production 
- 
Glucose tolerance No evidence of an effect - Higher rates  - 
Diabetes  No evidence of an effect Possible higher prevalence of 
diabetes 
Higher prevalence and 
incidence of type 2 diabetes 
Associated with PI (especially 
indinavir and ritonavir) 
Associated with NRTI 
especially stavudine 
- 
Body composition Lean body mass Decreases disproportionately 
with severe wasting 
Increases modestly with 
initiation of effective HAART 
No consistent evidence of 
direct drug effects 
- 
Peripheral fat Decreases proportionally with 
wasting 
Initially increases with 
initiation of effective HAART 
Subsequent preferential 
depletion of subcutaneous fat 
in arms, arms, legs, and 
buttocks more than upper 
trunk 
- 
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 Effect of untreated or 
ineffectively treated HIV 
Changes associated with 
viral suppression 
Changes with specific 
antiretroviral therapy 
Role of body shape 
changes 
Associated with some NRTIs 
(especially thymidine 
analogues) 
Role of different PIs and 
NNRTIs unclear 
Visceral fat Decreased but relatively 
preserved 
Weight cycling during 
episodic weight loss and 
regain 
Increases with initiation with 
effective HAART 
Preserved or increased 
visceral fat in some patients 
on HAART 
Association with specific 
drugs unclear 
- 
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It is possible that HIV may serve as a marker to identify a subgroup in the general population 
with an increased prevalence of traditional CVD risk factors such as sedentary lifestyle, smoking 
hypertension etc. Alternatively the HIV infection may have an independent pathogenic role, 
stimulating CVD through inflammation. ART may affect the risk of developing traditional CVD 
risk factors or have an independent pathogenic role. However it may be that all these processes 
work together325. Figure 1-11 (adapted from Grunfeld et al 322) highlights the possible interplay 
between the postulated pathways. 
 
While there is accumulating evidence that long term ART use may lead to a metabolic profile 
conducive to CVD in a subset of patients, the ART-associated risk of MI in HIV-infected adults is 
offset by the benefits of maintaining health and prolonging life326. There has been an upward 
trend in the prevalence of being overweighte in children resident in the developed world in 
recent years327, and thus it may be difficult to tease out the effects of ART-associated body fat 
disorder where HIV-infected children are being raised in an obesogenic environment328. 
Furthermore, the difficulty of assessing adiposity against the backdrop of changes in body 
habitus during adolescence and puberty329 complicates the situation further. Although there is 
abundant evidence to support the role of obesity in the pathogenesis of CVD330,331, there is 
conflicting evidence regarding the role of childhood obesity as an independent risk factor332.  
                                                 
e
 Methods used to assess obesity in children include weight-for-height z-scores (with WHO and US NHANES I reference 
populations), >120% ideal weight for height, 85th and 95th BMI percentiles, adult BMI thresholds of BMI≥25.  
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Figure 1-11: postulated interplay between traditional, inflammatory and lipodystrophy-mediated 
pathways in the pathogenesis of cardiovascular disease (adapted from Grunfeld et al  2008322) 
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Nevertheless, inflammation seen in obesity not only has been associated with CVD, but also 
other comorbidities such as diabetes (Figure 1-12).  The direct effects of HIV on the 
inflammatory response include increases in levels of specific cytokines such as IL-6 and TNF 
leading to impaired cell immunity333. It may be possible that the risk of CVD may be influenced 
by inflammation induced by both HIV infection and obesity. Indeed there has been recent  
interest in the emergence of obesity in HIV-infected populations334,335. 
 
Figure 1-12: Interrelationship between metabolic abnormality and clinical outcomes (from 
Rana et al336) 
 
 
Double arrows represent disorders that can perpetuate and affect each other. CRP: C-reactive protein.  
 
It has been argued that inflammation mediates insulin resistance (which itself is associated with 
obesity and diabetes), hypertension, prothrombosis and hyperlipidemia: inflammation and 
insulin have adverse effects on cardiac muscle, and the metabolic abnormalities collectively 
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cause cardiovascular complications336. A systematic inflammatory responsef to obesity has 
been reported in children337, and while obesity and LS are separate conditions, it is possible that 
LS will also illicit a similar inflammatory response. Furthermore, the inflammatory response to 
obesity/LS may be complicated by the inflammatory response to HIV. Obesity in infants has 
been shown to be associated with later obesity338, and it may be that the metabolic effects and 
accompanying inflammatory response associated with LS in childhood may be associated with 
LS and the postulated inflammatory response to LS/obesity later in life.  
 
The characteristics of a paediatric inflammatory response to LS remain unknown, as there are 
no cohorts of sufficient age to investigate the incidence of CVD.  For example, it is unknown 
whether the effect of childhood LS on the inflammatory system is relatively transient, or 
consistent throughout adolescence in children with LS. Moreover, the independent effect of HIV 
on inflammation is difficult to separate, as is the effect on normal growth and development. 
Furthermore, as HIV-infected children may be switched to less toxic drugs, it is unknown 
whether the consequences of previous inflammatory damage will continue to contribute to 
increased risk of CVD or not, given the influence of HIV, adolescence, diet and behaviour. 
 
1.5.2 Psychological effects 
High occurrence of poor psychological profile, including mental illness, depression, feelings of 
alienation, and stress, has been widely reported in HIV-infected individuals339,340, with negative 
implications for quality of  life, markers of HIV disease and adherence to ART341. However, there 
is evidence that HAART has led to stabilization of quality of life measures over time, irrespective 
of slight changes in HIV-related symptoms342. In a cross-sectional analysis of 13,601 
adolescents aged 16-18 years living in the US, self-perception of being underweight or 
overweight were both significantly associated with an increased risk of self-reported symptoms 
of depression343. There is a lack of research investigating the association between self-
perceived body image and depression in adults who do not have underlying medical conditions. 
However, a meta-analysis of longitudinal studies investigating obesity (defined as BMI ≥ 30) and 
depression in adults reported a pooled estimate of 55% increased risk of developing depression 
in obese individuals over time344.   
 
A Brazilian cross-sectional study of HIV-infected and ART-treated adults with clinically 
confirmed body fat alterations (median age 42 years) indicated a range of psychological 
consequences of LS: of 25 patients with facial lipoatrophy, all those reporting a change in self-
image lost the desire to look at themselves in the mirror, and 10 (40%) reported social 
disruption and isolation; furthermore, 4 (16%) reported that they would not have started ART 
had they known of the risk of lipoatrophy345. In a Canadian cross-sectional study of 77 HIV-
                                                 
f
 as defined by changes in circulating acute-phase reactants and cytokines including TNF, interleukin 1 (IL-1), IL-6, 
interleukin-10 (IL-10), adipnectin, leptin and resistin, being correlated to comorbid conditions (insulin resistance, 
dyslipidemia, non-alcoholic fatty liver disease, atherosclerosis and hypercoagulation)  
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infected adults (median age 44 years) on HAART with body fat changes, standard quality-of-life 
tools were used to assess the psychological effects of lipoatrophy and lipohypertrophy. Over 
70% of individuals displayed minimal depression, 23% had mild or worse depression, and 8% 
had moderate or severe depression, with significant association with patient lipodystrophy 
profile (defined as degree of self-reported fat alterations at specific body locations)346.  
 
Although there is increasing literature on children and adolescent pre-occupation with body 
image, and the relationship between negative self-image and low self-esteem347, this is an 
overlooked area of research in relation to LS-associated body changes. However, it is likely that 
HIV-infected children will have similar anxieties about body image as other children and 
adolescents. This is of concern since HIV-infected children have been shown to be shorter and 
lighter than uninfected children of the same age348. The psychological impact of poor body 
image in HIV-infected children may be similar to that seen in other chronically ill children where 
either illness or treatment has affected body shape. A systematic review of body image amongst 
children and adolescents with cancer found that there was an association between 
compromised body image and levels of anxiety, depression and behavioural problems349. 
Furthermore, survivors of adolescent cancer have reported negative self-assessments of their 
body image compared to independent assessments, suggesting that the psychological effects 
of treatment or disease-related body changes persist long after treatment cessation or recovery 
350
.  
 
 
Psychological state and adherence  
Associations between low self-esteem and also feelings of shame with body changes in ART-
treated HIV-infected adults have been reported351.  This may have implications for ART 
adherence. In an American investigation into self-reported adherence to HAART in 1671 
women, participants reported that they were more likely to stop taking HAART with self-
perceived fat gain in the abdomen, arms and legs, or fat loss in the chest or arms and legs352. 
Follow up of 277 HIV-infected adults who were initially adherent to HAART found one third to be 
non-adherent at 20 months: the number of self-reported lipodystrophy-related symptoms was 
significantly associated with failure to maintain adherence after adjusting for confounding 
variables353. Many factors influence the psychological state of mind of an HIV-infected child and 
teenager,  including the effects of living with a chronic illness, fear of stigmatization, cognitive 
development problems etc., adding to the complexity of pressures of adolescence. Fat 
alterations may also contribute additional stress. Children and particularly teenagers may 
associate their ART simply with the body dysmorphic adverse effects rather than the long-term 
health-promoting properties, leading to low adherence, viral rebound and the potential for the 
emergence of resistance. LS, together with other adverse effects of medication, and the fear of 
stigmatization and alienation have been identified as reasons for non-adherence133,354. Thus it is 
feasible that in a population where adherence may be problematic in some subjects, the 
HIV and lipodystrophy  Chapter 1
  
  
 
62
presence (or fear of) changes in body shape may cause a proportion of individuals to move 
from being adherent to non-adherent. 
 
1.5.3 Life-long use of antiretroviral therapy in children  
It is possible that the global incidence of paediatric LS may increase as more children have 
access to ART. However, the long-term survival in HIV-infected children in terms of co-
morbidities is yet to be investigated fully since there are few longitudinal studies in children 
which have accumulated sufficient follow-up time and data. Investigations in adults regarding 
emergence of factors such as CVD, and diabetes in ART-treated HIV-infected adults cannot 
necessarily to be extrapolated to similar populations of children because of concurrent 
adolescent physiological development, the different pharmokinetic properties of ART drugs in 
children compared to adults, and furthermore, different dosing in adults and children. The  roles 
of early life growth, nutrition and events355,356 in otherwise healthy children have been 
associated with later cardiovascular risk, and guidelines aimed at promoting health in children in 
relation to heart disease are being produced357. This may indicate the need to investigate the 
possible concurrent effects of HIV infection and ART357 . Moreover, knowledge of LS in children, 
and its applicability to wider populations of HIV-infected children and adolescents, is limited by 
previous research having been restricted to cross-sectional design, small size, single-centre 
construction, and highly specific outcomes (Table 1-5).  However, as survival rates in ART-
treated HIV-infected children are increasing, and with the availability of data from aging 
paediatric cohorts, research in this area is now feasible.  Thus it has become possible to 
investigate the implications of longer-term use of ART, including at times of adolescent 
development, on LS. Furthermore, the trends in ART use in HIV-infected children can be 
explored, i.e. cumulative exposure, switching between regimens, and adverse effects in addition 
to LS. Moreover, the emergence of CVD risk factors in ART treated children, or in adults who 
were treated with ART when children, can be examined.    
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Table 1-5: Summary of published studies looking at lipodystrophy in children and adolescents 
Study Design Location Number of 
participants 
Age range 
(years) 
Main outcomes 
Metabolic Fat alterations 
Amaya et al 
(2002)195 
Cross-sectional USA 
(single-centre) 
40 2-16 Hyperlipidemia Lipoatrophy and/or 
lipohypertrophy 
Arpadi et al 
(2001)200 
Prospective 52-
week follow-up 
USA 
(single-centre) 
28 4-12 - Lipoatrophy and/or 
lipohypertrophy 
Aurpubil et al 
(2007)201 
Prospective 144-
week follow-up 
Thailand 
(single-centre) 
90 7±2.9* Hypertriglyceridemia, 
hypercholesterolemia 
Lipoatrophy and/or 
lipohypertrophy 
Beregszaaszi et 
al (2005)211 
Prospective 104-
week follow-up 
France 
(multicentre)  
130 10.0 (9.4, 10.7)** Hypertriglyceridemia, 
hypercholesterolemia, 
hyperinsulinaemia# 
Central/peripheral 
skinfold thickness† 
Bitnun et al 
(2003)212 
Cross-sectional Canada 
(single-centre) 
50 3-18 Serum cholesterol, 
serum triglyceride, 
serum insulin 
Visceral to 
subcutaneous adipose 
tissue ratio 
Bockhorst et al 
(2003)202 
Cross-sectional USA 
(single-centre) 
26 4-15 Serum cholesterol, 
Serum triglyceride, 
Serum insulin 
Lipoatrophy and/or 
lipohypertrophy 
Carter et al 
(2006)203 
Retrospective 7-
year follow-up 
USA 
(multicentre) 
178 0-15  Hypercholesterolemia, 
hypertriglyceridemia 
Lipoatrophy and/or 
lipohypertrophy 
Cheseaux et al 
(2002)316 
Cross-sectional Switzerland 
(multicentre) 
66 <17*** Plasma cholesterol, 
plasma triglyceride 
- 
Desai et al 
(2008)204 
Prospective 72-
week follow-up 
USA 
(single-centre) 
48 6-15  Hyperlipidemia Lipoatrophy and/or 
lipohypertrophy 
Dos Reis et al 
(2011)358 
Cross-sectional Brazil 
(single-centre) 
119 6-19 Serum cholesterol, 
Serum triglyceride 
- 
Ene et al 
(2007)205 
Cross-sectional Belgium 
(single-centre) 
88 3-19 Hyperlipidemia## Lipoatrophy and/or 
lipohypertrophy 
European Cross-sectional Europe 477 3-18 Serum cholesterol, Lipoatrophy, 
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Paediatric 
Lipodystrophy 
Group (2004)209 
(multicentre) serum triglyceride lipohypertrophy 
Farley et al 
(2005)196 
Cross-sectional USA 
(multicentre) 
1812 4-19 Hypercholesterolemia  - 
Jaquet et al 
(2000)194 
Cross-sectional France 
(single-centre) 
39 9.1±4.0* Serum cholesterol, 
serum triglyceride, 
serum insulin 
Lipoatrophy, 
lipohypertrophy 
Kim et al 
(2009)359 
Retrospective 10-
year follow-up 
USA 
(single-centre) 
178 - Hypercholesterolemia  - 
Lainka et al 
(2002)360 
Cross-sectional Germany 
(single-centre) 
37 1-17 Serum cholesterol, 
serum triglyceride, 
serum insulin 
- 
Melvin et al 
(2000)213 
Cross-sectional USA 
(single-centre) 
23 4-18 Serum cholesterol, 
serum triglyceride, 
serum insulin 
Percentage body fat by 
location 
Parakh et al 
(2009)206 
Cross-sectional India 
(single-centre) 
52 2-12 Hypercholesterolemia, 
hypertriglyceridemia 
Lipoatrophy and/or 
lipohypertrophy 
Resino et al 
(2010)210 
Retrospective 
192-week follow-
up 
Spain 
(single-centre) 
27 4-13 - Lipoatrophy, 
lipohypertrophy 
Rhoads et al 
(2011)361 
Prospective 
cohort 
United Kingdom 
(single-centre) 
449 6.6 (3.3, 9.9)** Hypercholesterolemia  
Sanchez Torres 
et al (2005)207 
Cross-sectional Spain 
(single-centre††) 
56 1-18 Hypercholesterolemia, 
hypertriglyceridemia 
Lipoatrophy and/or 
lipohypertrophy 
Solorzano Santos 
et al (2006)208 
Prospective 24-
week follow-up 
Mexico 
(single-centre) 
24 0-15 Hypercholesterolemia, 
hypertriglyceridemia 
Lipoatrophy and/or 
lipohypertrophy 
Tassiopoulos et 
al (2008)197 
Prospective 200-
week follow-up 
USA 
(multicentre) 
2122 0-22 Hypercholesterolemia - 
*mean ± standard error, **median (interquartile range), ***range not given, #age and gender define thresholds to define cases, ## >95th centile of age and gender defined thresholds, 
†case defined as >3 standard deviations away from the mean. ††not explicitly state
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1.6 Key points  
 
• While the global incidence of new HIV infections among children has stabilized over the 
last decade, the prevalence of children living with the infection has increased to an 
estimated 2 million in 2007. 
 
• The increased number of children living with HIV is attributable to improved access to 
ART with global coverage of 28% in 2009. As global efforts move towards universal 
access, more children are likely to receive treatment.  
 
• LS is defined by alterations in body fat, with lipohypertrophy and/or lipoatrophy in 
specific locations, with/without distinctive metabolic abnormality (at least one of: 
hypercholesterolemia, fasting hypertriglyceridemia, and glucose intolerance).  Thus LS 
can manifest as a heterogeneous phenotype. 
 
• PIs, NRTIs and NNRTIs have been associated with increased risk of LS in a large 
number of adult and paediatric studies. Although a number of pathological mechanisms 
have been hypothesized, the relationship between metabolic abnormality and body fat 
alterations is still uncertain.  
 
• There is evidence to suggest that lipodystrophy may be conducive to the development 
of CVD: HIV-infected individuals are both surviving beyond middle age when clinical 
outcomes associated with CVD traditionally occur, and also have a metabolic profile 
consistent with early development of CVD. 
 
• Changes in body shape due to lipoatrophy and lipohypertrophy may lead to a negative 
self-image and may have implications for adherence to ART.  
 
• Because treatment is life-long, HIV-infected children are likely to accumulate long 
durations of ART and exposures to multiple regimens: the impact of this on the 
development of LS is unknown.   
 
• LS in children and adolescents is an increasingly important issue due to the possible 
effects on cardiovascular and psychological health.  
 
• While there have been a number of paediatric studies investigating lipodystrophy, many 
of their results have been limited by being cross-sectional in nature, or of small size and 
limited number of sites. 
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2. Rationale, objectives and data 
 
 
2.1 Rationale for this research  
 
While there has been a wealth of research into LS in HIV-infected adults in the past decade 
(Appendix H: Table H-1), there have been fewer paediatric studies (Table 1-5), despite LS 
being a key area of concern for HIV care in children. Studies to date have indicated that up to 
one-third of HIV-positive children receiving treatment have LS194,195,209, highlighting its 
importance as an area of study. Furthermore, the scale-up of ART in resource-limited settings 
will result in increasing numbers of children with HIV using treatment, which should be life-long 
once started. LS not only has the potential to decrease quality of life and treatment adherence 
among HIV-infected children and adolescents, but may also negatively impact on their future 
cardiovascular health.  
Most paediatric studies to date have been restricted by their cross-sectional nature, single-
centre design, and small number of study participants (Table 1-5). Although there is evidence 
that LS manifestation and risk factors are similar in children and adults, specific paediatric 
research is required, as results from adult studies cannot be generalised to children. Moreover, 
previous studies in children have tended to investigate either body fat alterations or metabolic 
abnormality in isolation, with few examining both. There have been few prospective paediatric 
studies196,202,203,208, and thus relatively little is known about the emergence of LS in the context 
of pubertal changes and childhood growth. Prospective data are urgently needed to better 
understand factors associated with the emergence, persistence and progression/regression of 
body fat changes and metabolic abnormalities, and to develop effective strategies to reduce or 
prevent, and to manage, lipodystrophy.  
This thesis uses data from an on-going large prospective multicentre study of children and 
adolescents living with HIV where specific information on both body fat alterations and 
metabolic abnormality has been collected longitudinally. The large study sample provided power 
to perform statistical modelling to identify postulated risk factors, while prospective follow-up of 
children with and without LS allowed estimation of incidence of LS, investigation of the 
progression or regression of LS symptoms over time, and examination of the temporal 
relationship between changes in body fat habitus and metabolic measures. Assessment of 
current management strategies will be important to inform future policy and guidelines for 
clinical management. 
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2.2 PhD aim and objectives 
 
This thesis aims to investigate paediatric lipodystrophy syndrome through active 
prospective surveillance of a cohort of HIV infected children and adolescents living in 
Europe: it will describe symptoms, identify risk factors, examine the emergence of the 
syndrome, and explore the relationship between the body fat alterations and metabolic 
abnormality. 
 
(1) To estimate the point prevalence and incidence of LS in a population of HIV-infected 
children and adolescents living in Europe and to describe the phenotypes of LS in HIV-
infected children and adolescents. 
 
(2) To evaluate risk factors for the emergence of body fat alterations and metabolic 
abnormalities presenting in these children and adolescents. 
 
(3) To assess prospectively the progression/regression of body fat alteration symptoms in 
lipodystrophy cases and associated risk factors, and to further define the relationship 
between body fat alterations and metabolic abnormality.  
  
(4) To model longitudinal changes on markers of lipid and carbohydrate metabolism to 
clarify the cumulative effect of HAART exposure over time on dyslipidemia 
 
(5) To report the clinical management of HIV-infected children and adolescents with LS 
with respect to interventions aimed at improving lipodystrophy symptoms.  
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2.3 Outline of thesis 
 
Chapter 2 describes the structure of the cohort with respect to data sources, methodology of 
data collection, and description of variables, key outcomes, and statistical methodology. In 
Chapter 3, the subjects are described based on characteristics at the time of recruitment; this 
includes background information such as ethnicity and age, but also characteristics related to 
HIV, i.e. mode of acquisition, clinical status, degree of immunosuppression etc. Chapter 3 also 
details estimates of prevalence of LS. Several estimates of prevalence are made, reflecting the 
different metabolic abnormality and body fat alteration symptoms reported in the published 
literature. Furthermore, differences in the concentration of metabolites, and anthropometric 
measures between subjects with LS and those without are explored in this chapter.  
Risk factors for LS, including fat alteration and metabolic abnormality, in cross-sectional 
analyses at recruitment are reported in chapters 4 and 5. These analyses will allow 
ascertainment as to whether risk factors are different for body fat alterations and metabolic 
abnormality. The role of ART as a possible risk factor is examined by investigating individual 
drugs, categories of ART, and specific regimens.  
The focus of chapter 6 is the emergence of LS, with estimates of incidence presented and 
associated risk factors identified: this allows determination as to whether risk factors at 
recruitment are similar to those associated with emergence. In addition, a comparison between 
subjects with regression of LS symptoms, and those with progression is conducted.  
 
The relationship between fat alteration and metabolic abnormality is investigated in Chapter 7: 
including analyses investigating temporal relationships between body fat alterations and 
metabolic abnormality. Multi-level modelling is used to examine the relationship between LS 
and concentrations of cholesterol and fasting triglyceride. In this chapter the management of LS 
within the cohort is also described. Chapter 8 includes a full discussion of the results, with 
implications for future work, and strengths and weakness of the study. 
Rationale, objectives and data  Chapter 2 
 
69
2.4 Key outcomes 
 
The definition of LS used in this study was the occurrence of any body fat alterations and/or any 
metabolic abnormality, regardless of severity. Box 2-1 and Box 2-2 give the definitions of body 
fat alterations and metabolic abnormality respectively.  
 
Box 2-1: Definition of fat alterations 
One or more of the following: 
• Facial lipoatrophy: sunken cheeks, sunken eyes, or prominent zygomatic arch 
• Arm lipoatrophy: skinny arms, prominent veins, prominent muscularity, or prominent 
bones 
• Leg lipoatrophy: skinny arms, prominent veins, prominent muscularity, or prominent 
bones 
• Abdominal lipohypertrophy: increased abdominal girth 
• Dorso-cervical lipohypertrophy: fat accumulation in the neck/back (“buffalo hump”) 
• Breast lipohypertrophy: breast enlargement 
 
Specific manifestations of body fat alterations were considered as outcomes for different 
analyses throughout this study: 
- Any body fat alterations 
- Lipoatrophy only (no lipohypertrophy) 
- Lipohypertrophy only (no lipoatrophy) 
- Combined lipoatrophy and lipohypertrophy occurring together 
 
Both hypercholesterolemia and hypertriglyceridemia were diagnosed according to gender and 
age-defined thresholds (Appendix B: Table B-1 and Table B-2).  
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Box 2-2: Definition of metabolic abnormality 
One or more of the following: 
• Hypercholesterolemia (assessed according to age and gender thresholds) 
• Fasting hypertriglyceridemia (assessed according to age and gender thresholds) 
• Impaired glucose tolerance 
 
 
Specific manifestations of metabolic abnormality were considered as outcome variables for 
various statistical models throughout this investigation: 
- Any metabolic abnormality 
- Hypercholesterolemia only (no fasting hypertriglyceridemia) 
- Fasting hypertriglyceridemia only (no hypercholesterolemia) 
- Concurrent hypercholesterolemia and fasting hypertriglyceridemia  
Outcomes including impaired glucose tolerance were not included in analyses because of small 
numbers of study subjects who had this condition.  
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2.5 Data source 
 
In 2004 the European Paediatric Lipodystrophy Group investigated body fat alterations and 
metabolic abnormality in a cross-sectional analysis of nearly 500 children recruited from 
paediatric HIV centres participating in the ECS and the Italian Register of HIV Infection in 
Children209. This study formed the basis for a larger investigation designed to examine body fat 
abnormalities and metabolic abnormality using active surveillance through the establishment of 
the European Paediatric Lipodystrophy Cohort.  
 
2.5.1 The European Paediatric HIV and Lipodystrophy Cohort 
Recruitment of subjects into the cohort occurred between 2007 and 2009. Participants were 
enrolled from a selection of participating paediatric HIV centres within the ECS in HIV-infected 
Pregnant Women and their Children, and the Italian Register of HIV Infection in Children. The 
ECS is a multi-centre, multi-country cohort comprising of HIV infected pregnant women and 
their children which was first set up in 1986168. The Italian Register for HIV infection in children 
was established in 1985 to establish the extent of paediatric HIV infection in children and 
explore its epidemiology across the country362.  
 
To be eligible for recruitment in this study, patients must have been HIV-infected and aged less 
than 18 years.  Subjects were excluded from recruitment if they were aged less than 2 years old 
or had been treated with anabolizing steroids in the previous six months. Recruitment took 
place in three European countries: Belgium, Italy and Poland. Within each country, subjects 
were recruited from University teaching hospitals with specialist paediatric HIV services. The 
participating paediatric centres are presented in Box 2-3 and Figure 2-1, Figure 2-2 and Figure 
2-3  
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Box 2-3: Paediatric HIV centres participating in the European Paediatric Lipodystrophy 
Cohort.  
Belgium 
Hospital Universitaire St. Pierre, Brussels* 
Hospital Universitaire St. Luc, Brussels* 
Centre Hospitalier Regional La Citadelle, Liege* 
Italy 
Pediatrics Clinic, Brescia University, Brescia† 
Departments of Pediatrics, University of Florence, Florence† 
San Martino Hospital/University of Genoa, Genoa*† 
San Paolo Hospital, Milan† 
Luigi Sacco Hospital/University of Milan, Milan*† 
University Federico II, Naples† 
Padua University, Padua*† 
Bambino Gesù Hospital, Rome† 
University of Turin, Turin† 
Poland 
Medical University of Warsaw/Regional Hospital of Infectious Disease, Warsaw * 
* Member of the European Collaborative Study on HIV-infected Women and their Children 
†
 Member of the Italian Register for HIV Infection in Children 
 
 
Children and adolescents receiving treatment from these centres were invited to participate in 
the study between January 2007 and December 2008. The clinician responsible for the long-
term treatment of the child would approach the child and family and introduce them to the study 
aims and protocol. Patients and their families were free to refuse to participate. Parents and 
guardians were involved in the enrolment process. Informed consent was sought from each 
participant according to the research ethics approval procedures at each site.  
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Figure 2-1: Clinical sites located in Belgium 
 
Hospitals: Hospital Universitaire St Pierre, Brussels; Hospital Universitaire St Luc, Brussels; Centre Hospitalier 
Regional La Citadelle, Liege 
 
Figure 2-2: Clinical sites located in Italy 
 
Hospitals: Brescia University, Brescia; University of Florence, Florence; San Martino Hospital, Genoa; San 
Paolo Hospital, Milan; Luigi Sacco Hospital, Milan; University Frederico II, Naples; Padua University, Padua. 
Bambino Gesu Hospital, Rome; University of Turin, Turin 
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Figure 2-3: Clinical site located in Poland 
 
Hospital: Medical University of Warsaw, Warsaw 
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2.6 Data collection  
 
The study is a prospective observational cohort monitoring L  by active surveillance. Figure 2-4 
illustrates the study design.  
 
Data were collected on study-specific paper data forms: all forms were in English language, and 
all data were collected in English. At enrolment, clinicians completed a recruitment 
questionnaire (Form A) for each subject. At this point complete information on socio-
demographic factors and ART history was collected, as well as metabolic and fat disorder data 
to categorize cases (of LS) or non-cases. At subsequent follow-up stages, Form B and Form C 
were completed on behalf of subjects: both forms were designed to collect data updating 
information on socio-demographic and ART regimen. Form B was devised to specifically collect 
information updating LS-related symptoms, whilst Form C was constructed to capture new 
incident cases.  
 
Data collection forms A, B and C are reproduced in Appendix B. 
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Figure 2-4: Flow chart summarizing data collection in the prospective cohort 
 
  
Form B 
Progression/regression of LS 
Management of LS 
Form C 
Update on background data 
Identification of new incident cases 
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Identification of lipodystrophy cases 
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Cases 
Non-
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Non-
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Form B 
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2.6.1 Specific data items collected and key variables created 
Data collection forms were completed, and relevant clinical assessments conducted by the 
child’s long-term physician at scheduled visits to the paediatric HIV clinic. Although these visits 
were part of the subject’s on-going care, a visit where a data collection form was completed is 
referred to as a “study visit” in this thesis.  
 
Data collected in Form A 
Form A (completed at recruitment) consisted of sections on socio-demographics (including date 
of birth, ethnicity),  birth details (including birth weight and gestational age), HIV-related 
variables (including mode of HIV acquisition, current and maximum CDC clinical status363, 
current and nadir CD4 count, current CD4%, HIV RNA viral load), ART (complete history and 
current use), HCV co-infection, pubertal stage, anthropometry, clinically-assessed body fat 
alterations and laboratory tests (Appendix B) . 
Box 2-4 summarizes CDC-defined clinical status of HIV used in this study:  specific definition of 
these CDC-categories is provided in Appendix B.  
 
Box 2-4: Definition of CDC-defined HIV clinical status 
N: No symptoms 
A: Mild symptoms 
B: Moderate symptoms 
C: Severe symptoms 
For specific details of symptoms see Section A2.1 in Appendix 2 
CD4 count variables were classified as degree of immunosuppression with reference to 
published age-based thresholds from the CDC (Appendix B: Table B-3) 34,35: Box 2-5  
 
Box 2-5: Definition of CDC-defined immunosuppression 
Stage 1: No immunosuppression 
Stage 2: Moderate immunosuppression 
Stage 3: Severe immunosuppression 
For specific details of symptoms see Table B-3 in Appendix B 
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Viral load measurements were used to create a detectable viral load variable, with undetectable 
viral load defined as <50 copies/ml.  
Complete ART history was collected, with drug names, dates of start and stop (if applicable), 
together with current use. For each drug entered on form A, two dichotomous variables were 
created: ever-use and current use of the drug. A variable was created for the use of HAART at 
recruitment: a conservative definition was used: use of ≥1 NRTI concurrently with either  ≥1 
NNRTI or ≥1 PI. Triple class therapy was defined as ≥1 NRTI with ≥1 NNRTI and ≥1 PI. NRTI 
mono-therapy was defined as use of NRTI drugs, but no NNRTI nor PI. Total duration of ART 
use was estimated using the interval between first exposure to ART and date of recruitment (or 
date of complete cessation of ART use, if this had occurred). 
Specific anthropometric measures recorded at recruitment were weight (kg), height (cm), waist 
circumference (cm), and hip circumference (cm).  A variable for body mass index (BMI) was 
created as follows: 
 = ℎ
		 (ℎℎ
		)  
A variable for waist/hip ratio (both in cm) was also created. Consistency checks were also 
performed on these two new variables. 
Tanner score for puberty364 was recorded as a categorical variable (I – V). Collected Tanner 
score was validated against age. A new categorical variable for puberty was created with the 
following levels: (i) Tanner I (pre-pubescent children), (ii) Tanner II-IV (children and adolescents 
who were undergoing puberty), and (iii) Tanner V (adolescents who had completed puberty). 
Body fat alterations 
Body fat alteration was collected in an ordinal variable with four levels: no alterations, mild 
symptoms, moderate symptoms and severe symptoms. Mild symptoms were defined as those 
only noticeable when specifically inspected, moderate symptoms as readily obvious to the child 
or carer, and severe symptoms as those obvious to the casual observer. The paediatrician 
completing the form was asked to record such assessments regarding fat loss in the face, arms, 
legs and buttocks, and fat accumulation in the trunk, neck, and breast, according to the criteria 
outlined in Box 1-1. 
Assessments of body fat alterations were made according to guidance included in the study 
protocol and by a clinician familiar with the patient through their duration of providing care. 
Details of fat alterations at each of the body locations illustrated in Box 1-1 were collected.  
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Metabolic Profile 
Test results for the following were recorded: total cholesterol (mg/dL), HDL-cholesterol (mg/dL), 
LDL-cholesterol (mg/dL), triglycerides (mg/dL), glucose (mg/dL), and insulin (mcU/ml), together 
with the sample date and whether sampling occurred in the fasting or non-fasting state. A 
variable for non-HDL cholesterol was created as the difference between total cholesterol and 
HDL-cholesterol.  
Dyslipidemia and glucose disorder 
Two tables were included in Form A, for use by the clinician in determining whether the child 
had hypercholesterolemia and/or hypertriglyceridemia based on most recent measurements. 
These thresholds were defined according to gender and age (Appendix B: Table B-1 and Table 
B-2). Impaired glucose tolerance was defined as either impaired fasting glucose 110-125mg/dL 
or impaired glucose tolerance (fasting glucose < 126mg/dL and glucose value 2 hours post oral 
glucose tolerance test of 140-199mg/dL).  
Management of lipodystrophy syndrome 
For children with LS, the data collections forms contained a section on the management of LS, 
including the use of medications (e.g. growth hormone, lipid lowering agents, steroids, or 
insulin-sensitizing agents), specific dietary interventions, increased physical activity, and 
surgery.  
 
Data collection form B  
Data Form B (Appendix B) was designed to collect information on subjects who had been 
categorized as having LS (by the treating paediatrician) at the previous data collection round. 
Variables that were collected and updated as detailed for Form A included: 
- Current CDC-defined  clinical condition 
- CD4 count and percentage 
- HIV-RNA  viral load 
- Anthropometric measurements and pubertal stage 
- Clinical assessment of body fat alterations by body location  
- Metabolic profile 
- ART:  change in treatment, with reasons for stopping previous regimen (classified as 
treatment failure, body fat alterations, dyslipidemia, some combination of the three, 
other)  
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Data collection Form C 
Data collection Form C (reproduced in Appendix B) was designed to collect follow-up data in 
subjects who had not previously been categorized as having LS.  
Variables that were collected and updated as detailed for Forms A and B included: 
- Current CDC-defined  clinical condition 
- CD4 count and percentage 
- HIV-RNA viral load 
- Anthropometric measurements and pubertal stage 
- Clinical assessment of body fat alterations by body location  
- Metabolic profile 
- Changes in ART as in Form B 
- Management of LS as in Forms A and B, if applicable 
 
Revision of data collection forms B and C 
During the follow-up period, forms B and C were modified in order to collect additional data. The 
new data items included:  
- Date of HIV diagnosis 
- Age at first menarche in female subjects 
Revised versions of data collection forms B and C are included in Appendix B. 
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2.7 Data management 
 
The databases were centrally managed at the UCL Institute of Child Health (ICH). At each 
round of data collection, the Belgian and Polish paper forms were entered into a Microsoft 
Access (version 2010) database centrally, whereas Italian forms were entered into a database 
locally which was then returned to ICH. At this point the datasets were imported into STATA 
(version 11): all data pre-processing and analysis was conducted in STATA unless otherwise 
stated. The Belgian/Polish and Italian datasets were then merged. Variables such as clinical 
site, date of birth, country of birth, and ART start and stop dates were used to identify duplicate 
cases which were then excluded. At recruitment, each participant was assigned a unique 
identifier.  
 
This process was conducted at recruitment, and for <3 follow-up datasets. Each cross-sectional 
dataset was then linked to the others by the unique identifier. Time-updated variables were 
created (see Section 2.8.8). Additional longitudinal variables including those detailing the 
regression and progression of symptoms of LS, and incidence or complete reversal of LS were 
created. A dataset suitable for fitting Cox proportional hazard and multilevel models was then 
created.  
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2.8 Overview of statistical methods 
 
The statistical significance in all analyses, except where explicitly stated, was p < 0.05. The 
Wilcoxon-Mann-Whitney and the Kruskal-Wallis tests were used to assess the equality of two or 
more means or medians from independent samples respectively. Equality of proportions was 
tested using the chi- squared (χ2) test. The Signed-rank test was used to investigate the equality 
of medians in paired samples365. 
 
2.8.1 Locally-weighted smoothing 
Locally weighted smoothing and fractional polynomial modelling was conducted to explore the 
relationship between age at recruitment and serum lipid concentrations. 
 Locally-weighted scatterplot smoothing creates smooth values for a continuous outcome 
variable (e.g. total cholesterol) obtained by performing a non-parametric local regression with 
moving-width windows at the explanatory variable (e.g. age at recruitment). The regression is 
then weighted using a kernel approach so that the central observation in the moving window is 
weighted highest. The regression function is then used to predict the smoothed values for the 
outcome variable. The number of regressions depends on the windows’ size: larger windows 
generate smoother (possibly biased) scatterplots; smaller windows yield rougher (though more 
faithful to the data) estimates with larger scatterplot variance.  There are many ways to reach a 
compromise in this bias/variance trade off; in the analyses included in this thesis, the local 
neighbourhood was defined as 80% for each smoothed curve. Smoothed values for the 
outcome variable are thus calculated for each observed values of the variable. The standard 
deviation of the smoothed predictions are then calculated by taking the square root of the 
residual difference between the smoothed values and the observed values of the outcome 
variables366,367.  
Because the smoothed curve is based on a number of local regressions, the curve can be 
influenced to deviate several times due to the local distribution of the data, rather than being 
changed overall by extreme values.  No assumptions are made about the functional form of the 
expected values of the outcome variable given the explanatory variable, and thus the model is 
completely data-driven. 
 
2.8.2 Fractional polynomial modelling 
These models differ from other polynomial models in that the explanatory variable can be raised 
to non-integer values368 in an attempt to transform the outcome variable to linearity as well as 
stabilising variance and achieving residuals’ normality. These models can represent a large 
variety of shapes using fewer terms than traditional polynomial regression models 369,370. 
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For each pair of variables (explanatory and outcome variable) several fractional polynomial 
models were constructed. Within each model, the regression was weighted using the 
Epanechnikov kernel function to estimate the conditional expectation of the outcome. 
Furthermore, models of order 1, 2, and 3 were constructed for each outcome i.e. models to the 
order of 1, 2 and 3 of the Box-Tidwell transformations370 constructing the fractional polynomial.  
The selection of the final fractional polynomial model was then conducted by examination of 
gain in deviance and visual examination of the selected curves for the three orders: the model 
was selected on the basis of having the lowest deviance and/or the fit to data points and size of 
the 95% confidence intervals. Within this investigation all final models were of order two, i.e. 
with two components defined by the Box-Tidwell transformation (Chapter 3).  
 
2.8.3 Logistic regression modelling  
Logistic regression models365,371 were fitted to determine the relationship between explanatory 
variables (e.g. age, use of PI etc.), and a dichotomous outcome variable (e.g. LS, 
hypercholesterolemia etc.). Explanatory variables used in analyses investigating risk factors for 
LS are summarized in Table 2-1, while key outcome variables are detailed in the specific 
methods sections in Chapters 4 and 5.  
 
ART was examined as both individual drug and classes of ART, assessed as binary variables: 
current-use vs. non-current use, and ever-use vs. never-use. Subjects who were ART-naïve 
were categorized as non-current or never-use.  
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Table 2-1: Explanatory variables used to investigate lipodystrophy syndrome 
 Variable Coding 
Demographic factors Age at recruitment  Continuous: per year 
 Sex Binary: male/female 
 Ethnicity Categorical: white/black/other 
Infection factors CDC immune stage at 
recruitment 
Categorical: no 
immunosuppression/moderate 
immunosuppression/severe 
immunosuppression  
 Nadir CDC immune stage Categorical: no 
immunosuppression/moderate 
immunosuppression/severe 
immunosuppression 
 CDC clinical stage at recruitment Categorical: no symptoms/ 
moderate symptoms/severe 
symptoms 
 Maximum CDC clinical stage Categorical: no symptoms/ 
moderate symptoms/severe 
symptoms 
 Detectable viral load (HIV-
RNA>50) 
Binary: HIV-RNA≤50 copies ml-1/ 
HIV-RNA>50 copies ml-1 
 Mode of acquisition Categorical: Blood 
products/vertical transmission/ 
other 
 Duration of antiretroviral therapy 
use at recruitment 
Continuous: per year 
Other factors Hepatitis C co-infection Binary: not co-infected/ co-
infected 
 Puberty (by Tanner score) Categorical: Pre-pubertal (I)/ 
undergoing puberty (II-IV)/ post 
puberty (V) 
 Body mass index Continuous: per kg/m2 
Categories of antiretroviral 
therapy 
Nucleoside reverse transcriptase 
inhibitors 
Binary: no use/use 
 Non-nucleoside reverse 
transcriptase inhibitors 
Binary: no use/use 
 Protease inhibitors Binary: no use/use 
Specific antiretroviral drugs Abacavir Binary: no use/use 
 Didanosine Binary: no use/use 
 Emtricitabine Binary: no use/use 
 Kivexa Binary: no use/use 
 Lamivudine Binary: no use/use 
 Stavudine Binary: no use/use 
 Tenofovir Binary: no use/use 
 Trizivir Binary: no use/use 
 Zalcitabine Binary: no use/use 
 Zidovudine Binary: no use/use 
 Atazanavir Binary: no use/use 
 Fosamprenavir Binary: no use/use 
 Indinavir Binary: no use/use 
 Nelfinavir Binary: no use/use 
 Ritonavir booster Binary: no use/use 
 Saquinavir Binary: no use/use 
 Tipranavir Binary: no use/use 
 Efavirenz Binary: no use/use 
 Nevirapine Binary: no use/use 
Type of antiretroviral therapy 
 Categorical: NRTI-mono-
therapy/PI-based 
HAART/NNRTI-based 
HAART/triple class therapy 
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Since univariable models can only investigate single risk factors in isolation, without taking into 
account the risk that may be due to other co-occurring factors, both univariable and 
multivariable models were constructed during this investigation. Multivariable models were 
either intuitively adjusted for specific variables, or were adjusted by variables selected by 
stepwise selection (the final multivariable model being selected using a backward stepwise 
approach). All multivariable models retained both age and duration of ART use at recruitment, 
as potential confounders a priori234. Furthermore, all multivariable models’ intercepts contained 
a random effect for clinical site in order to address systematic, unobserved differences in 
population and treatment at each hospital. The normality assumption of the random effect in 
each model was checked by examination of their histograms.  
 
Variables were systematically removed from the model containing all explanatory variables 
considered, until those remaining were statistically significant at the 5% level. Discarded 
variables were then methodically reintroduced to investigate any influence on effect size and 
significance. All possible variable combinations were investigated in nested models: 
reintroduced variables were retained and the process was repeated if the reintroduction resulted 
in a change in effect size >10% in other variables, led to other variables becoming statistically 
significant, or itself became significant. Thus although the criteria for retaining variables included 
significance at the 5% level, a variable may be included in the final model even if it was itself 
statistically non-significant. To prevent over-adjustment for puberty, Tanner score364 was not 
included in the models. However, in sensitivity analyses models were refit containing either 
Tanner score for puberty as a covariate, or an interaction between age and sex in order to 
investigate puberty at recruitment. Models were investigated to ensure that missing data had no 
substantial impact. 
 
2.8.4 Kaplan-Meir estimates 
Kaplan-Meir estimates372 were used to calculate the probability of emergence of a specific 
outcome (e.g. body fat alterations, metabolic abnormality etc.) over follow-up time, by subject 
characteristic (Table 2-1). Log-rank tests were used to formally test for differences in survival 
probabilities between groups.  
Both maximum HIV-related clinical status, and nadir level of immunosuppression were updated, 
if necessary, to reflect any changes that occurred during follow-up. Additional variables were 
constructed to investigate time-updated potential risk factors. Detectable viral load during follow-
up was defined as the occurrence of viral load >50copies/ml at any study visit at or following 
recruitment. Similarly CDC-defined HIV symptoms during follow-up was defined as the 
diagnosis of class B or C (Section B.2 in Appendix B) at recruitment or any subsequent study 
visit, and CDC-defined immunosuppression during follow-up was defined as evidence of 
immunosuppression at recruitment (by age thresholds: Section B.3 in Appendix B) or any 
subsequent study visit.  
Rationale, objectives and data  Chapter 2 
 
86
Hazard plots were used to ascertain each factor’s suitability to be included in Cox proportional 
hazard survival models.  
2.8.5 Cox proportional hazard survival models 
Cox proportional hazard models373 were used to investigate the factors associated with the 
incidence of LS during the follow-up period. Both univariable and multivariable models were 
investigated. As with multivariable logistic models, multivariable Cox models were either 
intuitively adjusted, or fitted including variables that were selected by stepwise selection (using 
the same method as outlined above in Section 2.8.3). Furthermore, all multivariable Cox models 
were adjusted for age and duration of ART use at recruitment, and included a random effect 
(frailty term) in the intercept to account for unobserved variables in different clinical sites.  
 
Models were refit containing either Tanner score for puberty as a covariate, or an interaction 
between age and sex in order to investigate puberty at recruitment: none of these terms 
reached statistical significance in any model, and thus these models were discarded.  
The proportional hazards assumption for the Cox regression models was investigated by 
examining Schoenfeld residuals for each variable included in the model against follow-up time, 
and also performing the Therneau-Grambsch global test of non-proportionality374  
 
2.8.6 Multilevel modelling 
 
Repeated measures of serum concentration of lipids for each individual, collected over follow-
up, were analysed by multilevel modelling375,376. These models investigate the relationship 
between explanatory variable(s) and the outcome by allowing for the correlation within clusters 
(i.e. repeated measures within the same subject) by modelling the variance and covariance 
between these measures.  Residuals are split into two components; (i) specific to each subject 
which is constant over each measure, and (ii) specific to each subject at each measure. This 
can be summarized in Equation 1, 
 = 	 +	 +	 , 
Equation 1 
where yij is the outcome on the j-th measure of the i-th subject, β are the coefficient(s) of the 
matrix Xi  of subject-specific explanatory variables in the regression model: βXi is known as the 
linear predictor. Furthermore,   are the residuals specific to subject i over each measure 
(known as the random intercept of each subject), and  are the residuals at measure j of 
subject i (the within-subject residual).  Both  and  are assumed to be normally distributed 
with mean = 0 and variances ψ and θ, respectively. Commonly, βXi is known as the fixed 
effects, whereas  is known as the random effects part. Since the objective of multilevel 
models in this investigation is to examine the effects of LS on metabolic outcomes, a mixed 
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effects approach has been adopted: the correlation within clusters is modelled such that we can 
treat individuals and measures as sampled from respective populations, and thus inferences 
regarding β can be made to this wider population.  
The model in Equation 1 is an example of a 2-level model. However, within this study repeated 
measures i.e. study visits (level 1) are obtained for each subject (level 2) and each subject is 
clustered within a number of clinical site (level 3). Thus outcomes were modelled using a 3-level 
model (Figure 2-5) as shown in Equation 2, 
 =	 +	() +	() +	, 
Equation 2 
where () is the random intercept for subject  j at clinical site k, and () is the random intercept 
for clinical site k. The random effect for subject is nested within clinical site: it does not take the 
same value for an individual across a given clinical sites, but takes on a different value for each 
combination of subject and clinical site. The term  represents the random effect at the 
repeat-measure level within an individual: a departure from the individual effect within a clinical 
site.  As subjects were recruited independently and there’s no reason to expect any association 
between clinical sites, we assumed that the corresponding covariances determining the random 
effects were 0. As above, β represents the fixed effects parameters. 
Multilevel modelling was used to investigate the relationship between LS and lipid outcomes 
(serum concentrations of total cholesterol, LDL-cholesterol, non-HDL cholesterol, HDL-
cholesterol, and fasting triglyceride). All models had 3 levels, with subject clustered in clinical 
site included in the random intercept. Maximum likelihood estimation procedures were used. 
Univariable models investigating all explanatory variables summarized in Table 2-1 were 
constructed: both recruitment variables and time-updated variables were investigated as 
appropriate. The covariates retained in the fixed effects for all multivariable models were age at 
recruitment, sex, and duration of ART use at recruitment, as possible confounding factors. 
Multivariable models were constructed by either including covariates by stepwise variable 
selection, or by intuitive selection, e.g. cholesterol and fasting triglyceride levels are known to be 
associated with sex and age, with further covariates chosen from results of previous regression 
models (Chapters 4- 6) also retained in all models (see Chapter 7 for details). As above the 
threshold to retain covariates in the stepwise selection procedure was 5%, However,  a non-
significant covariate could be retained if its inclusion caused a second covariate to become 
statistically significant or increased its effect size by >10%. 
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Figure 2-5: Multilevel structure of collected longitudinal data 
 
 
Log ratio tests were conducted to examine the effect of inclusion of the 2nd level and 3rd level. 
For each model two tests were conducted; (i) comparing the final 3-level model with the null 
model with no random effects, and (ii) comparing the 3-level model with the 2-level model with 
intercept random effects for individual. Twice the difference in log likelihoods of the two models 
was compared to the appropriate value of the χ2 distribution (against 2 degrees of freedom for 
comparisons with the null model, and 1 degree of freedom for comparison with the 2-level 
model). A 5% significance threshold was set to determine whether inclusion of the random 
effect terms improved the fit of the model to the data. 
The normal assumption in both the level 2 and level 3 residuals in the final 3-level models was 
checked by assessing linearity in quantile-quantile (QQ) plots of the inverse normal distribution 
against standardised residuals. The normal assumption of the random effects was assessed in 
the same way. 
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2.9 Role of the researcher 
The European Paediatric HIV and Lipodystrophy Study was set up based on a research 
concept formulated by Claire Thorne, Alessandra Vigano and Tessa Goetghebuer. All three 
designed the data collection tools.  Alessandra Vigano, Tessa Goetghebuer, and Magdalena 
Marczynska oversaw recruitment and data collection across sites in Italy, Belgium and Poland 
respectively. Recruitment into the study occurred during 2007 and 2008. I joined the study team 
in January 2009, having secured a Medical Research Council PhD studentship to investigate LS 
in HIV-infected children and adolescents.  
I was responsible for the coordinating the data entry in London of the paper questionnaires from 
sites in Belgium and Poland, entering some of these forms myself and overseeing data entry by 
an administrator for the remaining patients. I co-ordinated the data flow from sites in Belgium 
and Poland, and the electronic transfer of the Italian datasets to London. I carried out data 
cleaning, liaised with local clinicians with respect to data queries (i.e. where data were missing, 
ambiguous, or conflicting) and was responsible for overall data management for the study.   
I performed consistency and other validity checks on the data to identify data items that were 
not feasible. I also managed the final dataset before conducting all the analyses presented in 
this thesis, with statistical advice provided by Mario Cortina Borja.  
 
2.9.1 Dissemination of analyses from this thesis 
I am the first author of one original paper, reporting findings from this thesis, published in a peer 
reviewed journal. I have also had three conference abstracts published. A second original paper 
has been prepared: I am first author and this paper will be submitted for consideration for 
publication in a peer reviewed journal in autumn 2012. Documents are included in the Appendix 
A.  
 
Peer reviewed journal article 
• Alam N, Cortina-Borja M, Goetghebuer T, Marczynska M, Vigano A & Thorne C. Body 
fat abnormality in HIV-infected children and adolescents living in Europe: Prevalence 
and risk factors. JAIDS 2012; 59(3): 314-324 
 
Oral presentations  
• 18th International AIDS Conference 
o Risk factors for metabolic abnormality in a European cohort of HIV-infected 
children and adolescents 
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o Presented in Vienna, Austria in July 2010 
• 2nd International Workshop on HIV Pediatrics 
o Risk factors for metabolic abnormality in a European cohort of HIV-infected 
children and adolescents 
o Presented in Vienna, Austria in July 2010 
 
Poster presentations  
 
• 54th Society of Social Medicine Scientific Conference 
o Patterns of antiretroviral therapy in a European study of HIV-infected children 
and adolescents 
o Presented in Belfast, United Kingdom in September 2010 
• 11th International Workshop on Adverse Drug Reactions & Co-morbidities 
o Risk factors for body fat redistribution in a European cohort of HIV infected 
children and adolescents 
o Presented in Philadelphia, USA in November 2009 
• 16th Conference on Retroviruses and Opportunistic Infections (CROI): (Non-lead 
author) 
o Active surveillance of body fat changes and metabolic abnormalities in HIV-
infected children and adolescents in Europe: first round results 
o Presented in Montreal, Canada in February 2009 
  
Cohort characteristics at recruitment   Chapter 3 
 
91
3. Prevalence of lipodystrophy at recruitment: 
characterization of body fat alterations and metabolic 
abnormalities  
 
 
3.1 Objectives 
The main objective of this chapter is to describe the characteristics of subject participants at 
recruitment, and explore the manifestation of LS. Specific objectives include; 
 
• Description of missing data in both explanatory and outcome variables 
 
• To describe the socio-demographic and physiological characteristics of study 
participants at recruitment. 
 
• Outline the ART profile of subjects and examine the characteristics of those who are 
ART naïve. 
 
• Estimate the prevalence of LS at recruitment, investigating the proportions defined by 
body fat alterations (specifically lipoatrophy or lipohypertrophy) and metabolic 
abnormality (specifically hypercholesterolemia, fasting hypertriglyceridemia, and 
glucose intolerance). 
 
• Explore the manifestation of fat redistribution with reference to lipoatrophy and 
lipohypertrophy at specific body locations, and accompanying severity. 
 
• Investigate the distributions of covariates (body mass index: BMI, waist/hip ratio, total 
cholesterol, LDL-cholesterol, non-HDL-cholesterol, HDL-cholesterol, fasting triglyceride, 
fasting insulin and fasting glucose) across sexes and age bands, and body fat 
alterations and metabolic abnormality outcomes.  
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3.2 Methods 
Analyses presented in this chapter are based on enrolment data, i.e. collected in form A 
(Section B.4 in Appendix B) collected at the time of recruitment. Missing data were excluded 
from both the numerator and denominator of estimates of prevalence.   
3.2.1 Definitions 
When investigating gestational characteristics of subjects, full term gestational age was defined 
as 37 completed weeks, and low birth weight as less than 2500g. The CDC defines being risk of 
becoming overweight as having sex- and age-specific BMI of between the 85th and 95th 
percentile, being overweight a BMI ≥ 95th percentile, and being underweight as a BMI ≤ 5th 
percentile377,378:  These percentiles were conceived with reference to data collected in a 
representative sample of the US population in the National Health and Nutrition Examination 
Survey (NHANTES). The CDC percentiles were used to estimate prevalences of being at risk of 
being underweight or being overweight among subjects with lipoatrophy and those with 
lipohypertrophy.   
3.2.2 Comparison of medians and proportions 
Medians were compared with the Wilcoxon-Mann-Whitney and Kruskall-Wallis tests, while 
comparisons of proportions were conducted using χ2 tests: the level of significance was set at 
5%.  
3.2.3 Investigation of antiretroviral naïve subjects 
In order to investigate the participants who were ART-naïve at recruitment, subset analyses 
restricted to these subjects was conducted. To identify both the direction and magnitude of 
factors associated with ART-naivety, logistic regression models were constructed with a binary 
outcome (ART-naïve/not ART-naïve), and postulated risk factors as explanatory variables.    
3.2.4 Exploration of changes in anthropometric measures and serum 
lipids 
Serum cholesterol, triglyceride and fasting insulin vary with increasing age and between 
sexes379-382. The same is true of BMI: both the CDC and WHO providing age and sex dependent 
z-scores383,384. The CDC also provide z-scores for weight-by-height383. Thus, age and sex 
standardized (within the population) measures of these variables (Box 3-1) were calculated for 
males and females i.e. the individual values of the variable were standardized against the mean 
value of the value within each age and gender group, and errors calculated. Differences in 
medians of each variable in 2-year age groups were investigated in order to investigate whether 
differences occurred during puberty. Analysis with a single statistical model incorporating age 
and gender would result in the estimation of effect of age across the whole of adolescence: thus 
this approach was not used in these descriptive analyses. To explore patterns of joint variation 
in continuous variables in the study population at recruitment: the method of locally weighted 
scatterplot smoothing was used, as described by Cleveland in 1979366. 
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Box 3-1: Outcome measures investigated at recruitment 
Anthropometric measures 
Body mass index (BMI) 
Waist/hip ratio 
 
Metabolic measures 
Cholesterol 
Fasting triglyceride 
Fasting insulin 
Fasting glucose 
 
Locally weighted smoothing 
Since the size of this study population is less than 500 subjects, the approach of locally 
weighted nonparametric smoothing is convenient for examining the change in each of the 
variables listed up with increasing age for males, and for females385.  
Fractional polynomial modelling  
To further explore the relationship between age at recruitment and each outcome measure 
stratified by sex, as illustrated in Box 3-1, fractional polynomial models were fitted. Since the 
data are cross-sectional, the object is not to determine a causal or longitudinal relationship, i.e. 
these models are not looking at how an individual’s measures of a given characteristic change 
with increasing age. The smooth curves produced by these models allow inferences to be made 
regarding changes in these characteristics conditional on age. 
Since fractional polynomials define regression models usually based on small range of 
transformations for the explanatory variables, there may be qualitative differences in the smooth 
curves corresponding to, for example individuals with lipodystrophy and those without for a 
given covariate. However, this is only indicative of a possible effect of LS: such conclusions 
cannot be made from cross sectional data. Nevertheless structural differences in fractional 
polynomial models may be informative in this descriptive analysis investigating possible 
alterations with regard to specific continuous characteristics is subjects with and without LS. 
However differences between groups may still be attributable to chance. Conclusions regarding 
the role of lipodystrophy, if any, in the relationship between age at recruitment and participant 
characteristics can be insightful but should be treated with caution.  
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Mean order-two models were then constructed for each measure stratifying by sex either with or 
without LS, i.e. 4 models for each measure. Reasons for using mean order two models are 
discussed in Chapter 2.  
Anthropometric measures then had further models constructed for subjects with/without fat 
abnormality, and metabolic measures had further models constructed for subjects with/without 
metabolic abnormality. 
Comparisons using median and standardized measures 
Both crude and standardized measures of metabolic and anthropometric measures (Box 3-1) 
were plotted across age groups: 2-3, 4-5, 6-7, 8-9, 10-11, 12-13, 14-15, and 16-18 years. These 
age categories were used to examine age-related differences in LS outcomes with specific 
emphasis on differences that may occur during puberty. Both hypercholesterolemia and fasting 
hypertriglyceridemia were defined according to 1-year age bands in males above the age of 11 
years, and females aged above the age of 9 years (Appendix B, Section B.2). However, two-
year age bands were used in the comparisons presented in this chapter in order to circumvent 
the occurrence of categories with small numbers of subjects: for example, there were 5 females 
aged 2 years old, and 13 males aged 4 years. 
Age and gender standardized estimates of BMI and waist/hip ratio were compared using 
Wilcoxon-Mann-Whitney and Kruskall-Wallis tests between subjects (a) with and without LS, (b) 
with and without body fat disorder, and (c) with and without  metabolic abnormality.  
Median total cholesterol, LDL-cholesterol, non-HDL cholesterol, HDL-cholesterol, fasting 
triglyceride, fasting insulin, and fasting glucose were compared across age groups between 
subjects according to a) b) and c) as in the previous paragraph. However, each of these 
outcomes, with the exceptions of fasting insulin and fasting glucose are direct components in 
the definitions of metabolic abnormality and lipodystrophy syndrome. The objective of these 
comparisons was to look at the relationship between body fat alterations and metabolic 
outcomes, and to determine whether there were specific ages where the metabolic abnormality 
presented. Thus although the interpretation of differences seen with metabolic abnormality and 
lipodystrophy syndrome are confounded, an implication of the role of age may be postulated.  
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3.3 Missing data  
3.3.1 Lipodystrophy outcomes 
Data on LS outcomes was missing for 10 subjects: 7 subjects were missing data on metabolic 
abnormality but not body fat alterations, 1 subject was missing data on body fat alterations but 
not metabolic abnormality, and 2 subjects were missing data on both fat disorder and metabolic 
abnormality (Figure 3-1).  Of these 10 subjects, 7 were attending 5 hospitals in Italy. Half of the 
subjects with missing LS outcome data were male, and 6 were aged ≥15 years (all but one of 
these being female). With regard to ART use at recruitment, 3 were currently not on ART and 1 
was also missing this information.  
 
Figure 3-1: Missing data with regard to lipodystrophy outcomes  
 
3.3.2 Metabolic and physiological variables 
Table 3-1 shows the missing data related to each outcome: 1.5% of BMI, 25% of waist hip ratio, 
1.0% total cholesterol, 17%% LDL cholesterol, 15% non-HDL cholesterol, 15% HDL cholesterol, 
1.7% fasting insulin, and 1% fasting glucose were missing across each of the lipodystrophy 
outcomes. In contrast, no subjects with data on fasting triglyceride, had missing data for any of 
these variables.   
 
The proportions of missing values of HDL-cholesterol and LDL-cholesterol measures may lead 
to misestimating differences in levels of these measures between subjects with a given outcome 
and those without. However, there were no significant associations between neither metabolic 
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abnormality nor fasting hypertriglyceridemia with missing data for any of the following measures: 
total cholesterol, LDL-cholesterol, HDL-cholesterol, non-HDL-cholesterol, fasting triglyceride, 
fasting insulin, or fasting glucose. A significant association was found between 
hypercholesterolemia and missing insulin values. Despite this, it is unlikely that a diagnosis of 
some form of metabolic abnormality led to a greater likelihood of more metabolic tests in 
children with metabolic abnormality compared to those conducted in those children without.  
 
The only body fat alterations outcome which was significantly associated with missing data (in 
metabolic measures) was lipoatrophy, which was associated with missing values of HDL-
cholesterol, LDL-cholesterol, non-HDL-cholesterol and insulin (p < 0.05 for all tests)g. Neither 
missing data in waist/hip ratio nor BMI was significantly associated with any body fat alterations 
outcome. Missing values for waist/hip ratio also showed a significant association with ethnicity. 
This was driven by country differences in ethnicity: all subjects in Poland were of white ethnicity, 
and no subjects in Belgium were missing waist/hip ratio (Appendix C, Table C-1).  
 
Missing data in HDL-cholesterol, LDL-cholesterol and non-HDL-cholesterol were associated 
with country of residence. This may have been driven by a number of Italian hospitals which did 
not have missing data for any of these variables (Como, Genova and S. Paolo). Furthermore, 
missing data in BMI and waist/hip ratio were also significantly associated with country of 
residence, due to the one Polish hospital participating in the study not collecting this data. 
Indeed, the high levels of missing data for cholesterol (in comparison to missing data in other 
variables), may have led to no significant differences being seen in median levels between 
subjects with and those without body fat alterations.  
 
3.3.3 Explanatory variable data 
Data collection forms were designed so clinicians would enter patient past and current ART 
therapy as free text. Thus, as no direct questions were asked regarding specific ART, 
evaluation of missing data pertaining to HIV treatment was not possible. However, direct 
dichotomous or categorical questions were asked about other explanatory variables (Table 3.2). 
Only a small proportion of data was missing, and most explanatory variables were >94% 
complete. However recruitment and maximum CDC-defined clinical status had up to 16% and 
8% missing.  Furthermore, Tanner score for puberty had >16% missing data for each LS 
outcomes. However, Tanner score was not used in any of the main analyses presented in this 
thesis (only being used in sensitivity analyses.   
                                                 
g
 No analyses presented in this thesis focused on the relationship between lipoatrophy and 
these specific lipid subgroups. It is possible that analyses investigating body fat alterations and 
these cholesterols may be affected by this missing data. As only 34.7% of subjects with body fat 
alterations were characterized by lipoatrophy-alone, the effect of this potential bias is difficult to 
gauge. 
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Table 3-1: Missing physical and metabolic data by lipodystrophy outcome   
 
Total 
missing 
Lipodystrophy Fat alterations Lipohypertrophy Lipoatrophy Metabolic 
abnormality 
Hyper-
cholesterolemia 
Fasting hyper-
triglyceridemia 
Glucose 
intolerance 
 n % n/N % n/N % n/N % n/N % n/N % n/N % n/N % n/N 
BMI 8 1.4 6/416 1.4 6/422 1.4 6/421 1.4 6/420 1.4 6/415 1.4 6/423 1.4 6/418 1.4 6/417 
Waist/hip 
ratio 
109 25.0 104/416 24.9 105/422 24.9 105/421 24.5 103/420 25.3 105/415 25.1 106/423 24.9 104/418 25.4 106/417 
Total 
cholesterol 
7 0.5 2/416 1.0 4/422 1.0 4/421 1.0 4/420 0.2 1/415 1.0 4/423 0.0 0/418 1.0 4/417 
LDL 
cholesterol 
77 16.6 69/416 17.5 74/422 17.3 73/421 17.6 74/420 16.4 68/415 17.5 74/423 16.5 69/418 17.0 71/417 
Non-HDL 
cholesterol 
66 14.2 59/416 14.9 63/422 15.0 63/421 15.0 63/420 14.0 58/415 15.0 63/423 14.1 59/418 14.4 60/417 
HDL 
cholesterol 
66 14.2 59/416 14.9 63/422 15.0 63/421 15.0 63/420 14.0 58/415 14.9 63/423 14.1 59/418 14.4 60/417 
Fasting 
triglyceride 
8 0.0 0/416 0.0 0/422 0.0 0/421 0.0 0/421 0.0 0/423 0.0 0/423 0.0 0/418 0.0 0/417 
Fasting 
insulin 
182 1.7 7/416 1.7 7/422 1.4 6/421 1.7 7/420 1.7 7/415 1.7 7/423 1.7 7/418 1.7 7/417 
Fasting 
glucose 
16 0.05 2/416 0.05 2/422 0.10 4/421 0.05 2/420 0.05 2/415 0.05 2/423 0.05 2/418 0.05 2/417 
Missing data for outcomes: Lipodystrophy syndrome 2.3% (10/426), fat alterations 1.0 (4/426), lipohypertrophy 1.1% (5/426), lipoatrophy 1.4% (6/426), metabolic abnormality 2.6% 
(11/426), hypercholesterolemia 1.0% (3/426), fasting hypertriglyceridemia 0.0% (0/426), and glucose intolerance 2.1% (9/426) 
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Table 3-2: Missing explanatory variable data by lipodystrophy outcome   
  
Total 
missing 
Lipodystrophy Fat redistribution Lipohypertrophy Lipoatrophy Metabolic 
abnormality 
Hyper-
cholesterolemia 
Fasting hyper-
triglyceridemia 
  
n % n/N % n/N % n/N % n/N % n/N % n/N % n/N 
Demographic factors                
Gender 11 2.98 7/235 3.41 6/176 2.61 3/115 4.35 5/115 4.63 5/108 7.14* 4/56 0.00 0/71 
Ethnicity 17 4.68 11/235 5.68 10/176 2.61 3/115 5.88*** 10/170 3.70 4/108 7.14 4/56 1.41 1/71 
Country of residence 0 0.00 0/235 0.00 0/176 0.00 0/115 0.00 0/117 0.00 0/108 0.00 0/56 0.00 0/71 
HIV Clinical factors                
CDC immune stage at recruitment 0 0.00 0/235 0.00 0/176 0.00 0/115 0.00 0/117 0.00 0/108 0.00 0/56 0.00 0/71 
Nadir CDC immune stage at 
recruitment 
0 0.00 0/235 0.00 0/176 0.00 0/115 0.00 0/117 0.00 0/108 0.00 0/56 0.00 0/71 
CDC clinical stage at recruitment 48 13.2 31/235 13.07 23/176 13.04 15/115 14.53 17/117 12.96 14/108 16.07 9/56 11.27 8/71 
Maximum CDC clinical stage 24 5.11 12/235 4.55 8/176 1.74* 2/115 6.84 8/117 5.56 6/108 7.14 4/56 4.24 3/71 
HIV-RNA concentration at 
recruitment 
2 0.42 1/235 0.57 1/176 0.87 1/115 0.00 0/117 0.93 1/108 0.00 0/56 1.41 1/71 
Mode of HIV acquisition 17 3.83 9/235 4.55 8/176 3.48 4/115 4.27 5/117 4.63 5/108 5.36 3/56 0.00 0/71 
Other factors                
Hepatis C co-infection 10 1.70 4/235 1.70 3/176 0.87 1/115 1.71 2/117 0.92 1/108 1.79 1/56 1.41 1/71 
Tanner score for puberty 52 12.34 29/235 14.20 25/176 13.04 15/115 13.68 16/117 9.26 10/108 5.34 3/56 11.27 8/71 
BMI at recruitment 8 1.28 3/235 1.70 3/176 2.61 3/115 1.71 2/117 0.00 0/108 0.00 0/56 0.00 0/71 
χ
2
 test for difference in proportion of missing data with/without outcome * 0.01 ≤  p < 0.05, **0.001 ≤ p < 0.01, and *** p ≤ 0.001 
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Statistically significant associations between missing data and LS outcomes were seen only in 
three situations: (i) maximum CDC-defined clinical status with lipohypertrophy; p = 0.039, (ii) 
ethnicity with lipoatrophy; p = 0.004 and (iii) gender with hypercholesterolemia; p = 0.022. In the 
case of Maximum clinical status, missing data was seen more commonly in subjects without 
lipohypertrophy (Table 3.3), which may lead to overestimation of an effect size on body fat gain 
associated with this variable. However, in the case of ethnicity with lipoatrophy and sex with 
hypercholesterolemia, missing data was more common in subjects with the respective outcome: 
this may lead to bias in estimation of any associated effect size. 
 
Table 3-1: Comparison of missing data in explanatory variables where there was a 
significant difference in proportions with/without specific outcomes  
Explanatory variable Outcome Without outcome With Outcome p- value 
    % n % n 
  
Maximum clinical status Lipohypertrophy 6.86 21 1.74 2 0.039 
Ethnicity Lipoatrophy 2.31 7 8.55 10 0.004 
Sex Hypercholesterolemia 1.91 7 7.14 4 0.022 
Statistical test χ2 test 
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3.4 Socio-demographic and gestational variables 
Analysis was conducted on 426 subjects who were aged between 2 and 18 years at the time of 
recruitment. Table 3-4 illustrates the socio-demographic and HIV-related characteristics of 
participants at recruitment. Median age was 12.2 years (interquartile range, IQR: 9.0, 15.0). The 
largest ethnic group was of White ethnicity (n=285, 69.7%), with 26.2% of Black ethnicity 
(n=107). The majority of participants were patients from Italy (n=276, 69.7%): there was a 
significant association between ethnicity and country of residence (χ2 test: p<0.001) with 82.7% 
of Belgian patients of Black ethnicity compared to 14.7% among Italian and no Polish 
participants.  
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Table 3-2: Distribution of baseline socio-demographic and HIV-related characteristics (n=426) 
  2-6 years 7-11 years 12-18 years Whole cohort 
    n=43 n=117 n=266 n=426 
Demographic factors          
Gender Male 21 (50.0) 50 (43.9) 130 (50.2) 201 (48.4) 
Female 21 (50.0) 64 (56.1) 129 (49.8) 214 (51.6) 
Ethnicity Black 10 (24.4) 30 (27.3) 67 (26.0) 107 (26.2) 
White 29 (70.7) 73 (66.3) 183 (70.9) 285 (69.7) 
Other 2 (4.9) 7 (6.4) 8 (3.1) 17 (4.2) 
Country of residence 
  
Belgium 2 (4.7) 20 (17.1) 62 (23.3) 84 (19.7) 
Italy 26 (60.5) 76 (65.0) 174 (65.4) 276 (64.8) 
Poland 15 (34.9) 21 (17.9) 30 (11.3) 66 (15.5) 
HIV clinical factors          
CDC immune stage at recruitment Stage 1 27 (62.8) 101 (86.3) 196 (73.7) 324 (76.1) 
Stage 2 14 (32.6) 14 (12.0) 56 (21.1) 84 (19.7) 
Stage 3 2 (4.7) 2 (1.7) 14 (5.3) 18 (4.2) 
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  2-6 years 7-11 years 12-18 years Whole cohort 
    n=43 n=117 n=266 n=426 
Nadir CDC immune stage Stage 1 14 (32.6) 65 (55.7) 81 (30.5) 160 (37.6) 
Stage 2 22 (51.2) 40 (34.2) 117 (44.0) 179 (42.0) 
Stage 3 7 (16.3) 12 (10.3) 68 (25.6) 87 (20.4) 
CDC clinical stage at recruitment N+A 32 (89.0) 94 (93.1) 220 (91.3) 346 (91.5) 
B 2 (5.6) 6 (5.9) 13 (5.4) 21 (5.6) 
C 2 (5.6) 1 (1.0) 8 (3.3) 11 (2.9) 
Maximum CDC clinical stage N+A 18 (43.9) 59 (53.2) 93 (37.2) 170 (42.3) 
B 14 (34.2) 31 (27.9) 98 (39.2) 143 (35.6) 
C 9 (22.0) 21 (18.9) 59 (23.6) 89 (22.1) 
HIV-RNA at recruitment ≤50 copies/ml 29 (67.4) 78 (66.7) 139 (52.7) 246 (58.0) 
>50 copies/ml 14 (32.6) 39 (33.3) 125 (47.4) 178 (42.0) 
Mode of HIV acquisition 
  
Blood products 0 (0) 2 (1.8) 5 (2.0) 7 (1.7) 
Vertical transmission 43 (100) 111 (98.2) 246 (97.2) 400 (97.8) 
Other 0 (0) 0 (0) 2 (0.8) 2 (0.5) 
Other factors          
Hepatitis C co-infection No co-infection 39 (95.1) 111 (96.5) 241 (93.0) 391 (94.0) 
Co-infection 2 (5.0) 4 (3.5) 19 (7.3) 25 (6.0) 
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  2-6 years 7-11 years 12-18 years Whole cohort 
    n=43 n=117 n=266 n=426 
Tanner score for puberty I  37 (97.4) 87 (80.6) 11 (4.8) 135 (36.1) 
II-IV 1 (2.6) 21 (19.4) 123 (53.9) 145 (38.8) 
V  0 (0) 0 (0) 94 (41.2) 94 (25.1) 
BMI (kg/m2) 
  
16.01  
(14.38, 17.09) 
16.49  
(15.07, 18.94) 
19.73  
(17.69, 22.57) 
 
CDC-defined immune status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms.
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Data on gestational age at birth was missing for 164 subjects; of the remaining 264 subjects, 43 
(16.3%) were born preterm. Over two-thirds of the study population (n = 286) had data on birth 
weight. The prevalence of low birth weight was 22.0% (63/286). The relationship between 
gestational age at birth and birth weight is illustrated in Figure 3-2, with similar patterns seen in 
males and females.  
 
 
Figure 3-2: Relationship between gestational age and birth weight in males (n = 116) and 
females (n =121) 
 
 
Vertical line indicates gestation of 37 weeks; horizontal line indicates birth weight of 2500g 
 
 
The distribution of birth length and birth weight between subjects with/without body fat 
alterations at enrolment was similar (among subjects who had reached full gestational age of 37 
weeks) is shown in Figure 3-3. The distribution among children with body fat alterations appears 
to be wider, with a lesser weight for a given length compared to subjects without fat disorder at 
recruitment. However, regression of body length on body weight in these two groups resulted in 
similar estimates for the intercept and slope, but the sum of mean squares of the variance was 
a third greater in body fat alteration group compared to the no fat alteration group (Appendix C, 
Table C-2). 
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Figure 3-3: Relationship between birth weight and birth length in subjects who were born 
at gestational age ≥37 weeks: between subjects without body fat alterations (n = 59) and 
those with body fat alterations (n = 53) at recruitment. 
 
Only subjects who had been born at a gestational age ≥37 weeks shown. Median follow-up time: 11.8 years 
(IQR: 8.5, 14.3)) Horizontal line denotes birth weight of 2500g  
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3.5 Viral and clinical variables 
Only 9 subjects (2.2%) did not acquire HIV through vertical transmission. Of the 7 participants 
who acquired HIV through blood products, five were born in Romania, all aged between 16 and 
18 years. The remaining two subjects were born in the Ukraine and Poland, and both were 8 
years old.  
At recruitment, most participants showed no evidence of immunosuppression, with 76.1% (n = 
324) at CDC stage 1 (Table 3-4). However almost two thirds (n = 266, 62.4%) of the cohort had 
experienced some form of immunosuppression. One fifth (n = 89, 20.9%) of the study 
population had experienced the most advanced CDC-defined clinical stage at some point up to 
enrolment, although 80% (n = 346, 80.1%) were asymptomatic at this time. Indeed, at 
recruitment, most participants were either asymptomatic or had only mild symptoms, showed no 
immunosuppression and had undetectable viral load (>58% across all age groups).  
Of note, 25.6% (68/266) of adolescents (aged ≥12 years) had previously experienced severe 
immune-suppression, with 26.3% (59/250) having experienced severe clinical symptoms: 32 
subjects aged ≥12 years had experienced both severe clinical symptoms and severe 
immunosuppression. Of the 364 subjects on ART at recruitment, over one-third (n = 131, 
36.0%) had detectable viral load (1 subject was missing data on viral load): 44 of these subjects 
had either CDC-defined symptoms or evidence of immunosuppression.  
 
3.6 History of antiretroviral therapy 
The majority of participants (n = 364, 85.4%) were currently being treated with ART at 
recruitment: 29 subjects were ART naïve with no current or previous use. A further 33 subjects 
had ART history missing and so were excluded from calculation of prevalence of treatment. 
There were no subjects who had previously been on ART, but had discontinued ART use 
completely by the time of recruitment. The median age at initiation of ART was 5.2 years (Table 
3-5). There was a significant difference in median age at first ART with increasing age category 
(Mann-Whitney-Wilcoxon test: p < 0.001) with older children starting ART at older ages. The 
median duration of ART at recruitment was 5.8 years (IQR: 2.6, 9.9). 
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Table 3-3: Median age (interquartile range) at initiation of ART and median ART duration at recruitment  
 Age group Whole cohort 
 2-6 year olds 7-11 year olds 12-18 year olds   
 Median (IQR) N Median (IQR) n Median (IQR) n Median (IQR) n 
Age at first 
ART (years) 
2.78  
(0.84, 4.21) 
30 4.24  
(1.99, 7.39) 
90 6.21  
(2.52, 9.77) 
210 5.20  
(2.20, 8.80) 
330 
Duration of 
ART (years) 
1.48  
(0.69, 3.13) 
30 3.98  
(1.41, 6.77) 
92 7.54  
(4.28, 11.49) 
211 5.80  
(2.60, 9.90) 
333 
Kruskall-Wallis test for equality of medians: age at first ART (p <0.001): duration of ART (p < 0.001) 
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Figure 3-4 illustrates the pattern of common ART regimens used at the time of recruitment: the 
most popular form of cART at the time of recruitment was PI-based HAART, followed by NNRTI-
based HAART,   while 14 subjects (4%) were treated with triple class therapy (i.e. at least one 
each of PI, NRTI and NNRTI). Of note, a small proportion (8%) of the study population was 
treated with NRTI mono-therapy. 
 
Figure 3-4: Distribution of common combinations of antiretroviral therapies and NRTI-
based mono-therapy at the time of recruitment (n = 364). 
 
Table 3-6 shows the distribution of class of ART by both ever-use and use at the time of 
recruitment (current-use). All but two of the 364 subjects on ART (n = 362/393: 92% of all 
subjects whose ART status was known) at recruitment were being treated with NRTIs. The 
remaining two subjects were aged 15.4 years and 16.6 years, and on a NRTI-sparing regimen 
consisting of NNRTI and PI at recruitment (specifically efavirenz with fosamprenavir and 
lopinavir/ritonavir, and nevirapine with lopinavir/ritonavir respectively), and had both been 
treated by NRTI in the past. The second most popular class was PI in all age groups except the 
7-11 year olds. Over half of participants (55.5%, n = 218 were currently on PIs, while one third 
(33.8%, n = 133) were on NNRTI. Only three participants (0.7%) had a history of FI use, falling 
to one participant (0.3%) by the time of recruitment.  
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Table 3-4: Distribution of past and current class of ART use stratified by age in the cohort 
at recruitment (n = 393) 
  
Age group Whole cohort 
  
2-6 years 7-11 years 12-18 years 
  Ever Current Ever Current Ever Current Ever Current 
NRTI Yes 39 
(90.7) 
34 
(89.5) 
106 
(90.6) 
100 
(90.1) 
251  
(94.7) 
228 
(93.4) 
396 
(93.2) 
362 
(92.1) 
 No 4  
(9.3) 
4  
(10.5) 
11  
(9.4) 
11  
(9.9) 
14  
(5.3) 
16  
(6.6) 
29 
(6.8) 
31  
(7.9) 
 Missing 0 5 0 6 1 22 1 33 
NNRTI Yes 13 
(30.2) 
7 
(18.4) 
65 
(55.6) 
46 
(41.4) 
167 
(63.0) 
80 
(32.8) 
245 
(57.6) 
133 
(33.8) 
 No 30 
(69.8) 
31 
(81.6) 
52 
(44.4) 
65 
(58.6) 
98 
(37.0) 
164 
(67.2) 
180 
(42.4) 
260 
(66.2) 
 Missing 0 5 0 6 1 22 1 33 
PI Yes 34 
(79.1) 
24 
(63.2) 
84 
(71.8) 
47 
(42.3) 
210 
(79.2) 
147 
(60.2) 
328 
(77.2) 
218 
(55.5) 
 No 9 
(20.9) 
14 
(36.8) 
33 
(28.2) 
64 
(57.7) 
55 
(20.8) 
97 
(39.8) 
97 
(22.8) 
175 
(44.5) 
 Missing 0 5 0 6 1 22 1 33 
FI Yes 0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
3 
(1.1) 
1 
(0.4) 
3 
(0.7) 
1 
(0.3) 
 No 43 
(100.0) 
38 
(100.0) 
117 
(100.0) 
111 
(100.0) 
262  
(98.9)  
243 
(99.6) 
422 
(99.3) 
392 
(99.8) 
 Missing 0 5 0 6 1 22 1 33 
Subjects on/not on a specific class of ART are given as percentage of number of subjects within that age 
group/whole cohort, i.e. column percentages for each class.  Subjects where the ART history was unknown (n = 
33) are excluded. NRTI: nucleoside reverse transcriptase inhibitor, NNRTI: non-nucleoside reverse 
transcriptase inhibitor, PI: protease inhibitor, and FI: fusion inhibitors.  
 
Figure 3-5 and Figure 3-6 illustrate the distribution of ever-use and current use of specific ART 
drugs (Appendix C, Table C-3). The most commonly used NRTI, and the most commonly used 
drug overall, both historically and at recruitment was lamivudine. The second most common 
ever-used NRTI was zidovudine (n = 308, 72.5%), and the second most common NRTI in 
current use was abacavir (n= 118, 30.0%). While just over half of subjects had been exposed to 
stavudine at some point (n = 218, 51.3%), at recruitment only one in nine (n = 44, 11.2%) were 
using this drug. Lopinavir/ritonavir was the most common PI in both ever (n = 257, 60.47%) and 
current use (n = 197, 50.13%). Despite almost half (n = 204) of the study population having 
been exposed to nelfinavir, only one subject (0.25%) was currently on nelfinavir at the time of 
recruitment. 
Only two NNRTIs were used by participants, with efavirenz used by almost one quarter (n=94) 
at recruitment, and nevirapine used by almost 10% (n=39). The sole FI in use in the cohort was 
enfuvirtide, with three participants (0.7%) with a history of its use, and one participant (0.3%) 
currently on enfuvirtide therapy at recruitment.   
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Figure 3-5: Distribution of ever-use of specific antiretroviral drugs 
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Figure 3-6: Distribution of current use of specific antiretroviral drugs 
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3.7 Antiretroviral naïve participants 
Twenty-nine participants were ART-naïve; Table 3-7 illustrates their characteristics. Their 
median age was 10.48 years (IQR; 7.77, 15.26), which was lower than the median age in ART-
treated subjects, although this difference was not significant (p = 0.465). Two-thirds of ART-
naïve subjects were female, and the majority   (n = 19) were from Italy.  
Over 60% (n = 18) of these subjects showed either evidence of immune-suppression (n = 15) or 
HIV-related clinical symptoms (n = 3) at recruitment, and all but 4 had detectable viral load. At 
recruitment, 1 subject had serious clinical symptoms, and a further 3 subjects had severe 
immunosuppression. Furthermore, over three-quarters of ART-naïve subjects (n = 22) had a 
history of symptomatic disease and/or immunosuppression. Indeed being ART-naïve at 
recruitment was significantly associated with increased risk of current immuno-suppression in 
univariable analysis (Table 3-5). Furthermore, it was associated with a non-significant reduced 
risk of past clinical disease (p > 0.05). Multivariable models investigating factors associated with 
ART-naivety did not converge.  
Of interest, 4 subjects who were ART-naïve had undetectable viral load at recruitment. Of 
these, 1 subject had history of moderate immunosuppression, 1 had history of severe 
immunosuppression, and 1 had history of severe CDC-defined clinical symptoms. Thus 1 ART-
naïve subject had controlled viral suppression at recruitment, with no history of clinical 
symptoms and immunosuppression, i.e. was a long-term non-progressor.  
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Table 3-5: Characteristics of antiretroviral therapy naïve participants (n = 29) 
   
Prevalence Univariable analyses 
   n % n OR 95% CI p-value 
Demographic factors        
Age(years)†  29 10.48* (7.77, 
15.26)** 
393 0.95 (0.86, 1.04) 0.291 
Gender Male 9 (33.3) 187 1   
 Female 18 (66.7) 197 1.99 (0.87, 4.55) 0.103 
Ethnicity Black 8 (29.6) 95 1   
 White 19 (70.4) 269 0.83 (0.35, 1.96) 0.665 
 Other 0 (0.0) - - - - 
Country of residence Italy 19 (65.5) 264 1   
 Belgium 4 (13.8) 69 0.79 (0.26, 2.41) 0.684 
 Poland 6 (20.7) 60 1.43 (0.55, 3.76) 0.465 
HIV clinical factors        
CDC immune stage at 
recruitment 
Stage 1 14 (48.3) 304 1   
Stage 2 12 (41.4) 72 4.14 (1.83, 9.40) 0.001 
Stage 3 3 (10.3) 17 4.44 (1.14, 17.25) 0.031 
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Prevalence Univariable analyses 
   n % n OR 95% CI p-value 
Nadir CDC immune stage Stage 1 10 (34.5) 142 1   
Stage 2 17 (58.6) 166 1.51 (0.67, 3.40) 0.325 
Stage 3 2 (6.9) 85 0.32 (0.07, 1.49) 0.146 
CDC clinical stage at 
recruitment 
N/A 22 (88.0) 325 1   
B 2 (8.0) 20 1.53 (0.33, 7.02) 0.584 
C 1 (4.0) 11 1.38 (0.17, 11.25) 0.765 
Maximum CDC clinical stage N/A 17 (65.4) 155 1   
B 6 (23.1) 132 0.39 (0.15, 1.01) 0.053 
C 3 (11.5) 86 0.29 (0.08, 1.03) 0.056 
HIV-RNA at recruitment ≤50 copies/ml 4 (13.8) 236 1   
 >50 copies/ml 25 (86.2) 156 11.07 (3.77, 32.50) <0.001 
Mode of HIV acquisition Blood 
products 
1 (4.0) 7 1   
 Vertical 
transmission 
24 (96.0) 368 0.42 (0.05, 3.62) 0.429 
 Other 0 (0.0) - - - - 
 
 
 
      
Cohort characteristics at recruitment         Chapter3 
115 
 
 
   
Prevalence Univariable analyses 
   n % n OR 95% CI p-value 
Other factors        
Hepatitis C co-infection None 7 (96.4) 361 1   
 Co-infection 1 (3.6) 24 0.54 (0.07, 4.14) 0.551 
Tanner score for puberty I 11 (42.3) 123 1   
 II-IV 7 (26.9) 136 0.55 (0.21, 1.47) 0.236 
 V 8 (30.8) 86 1.04 (0.40, 2.72) 0.929 
BMI (kg/m2)††  27 17.7* (15.9, 
22.3)** 
388 1.03 (0.92, 1.14) 0.652 
CDC-defined immune status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. *median, **inter quartile range, †Odds ratio associated with age is risk associated per year of age, ††Odds ratio 
associated with BMI is risk associated per kg/m2 
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3.8 Prevalence of lipodystrophy syndrome at recruitment 
The study population size for the investigation of LS was 416: 7 subjects had missing data on 
metabolic abnormality, 1 had missing data on fat disorder, and 2 subjects had missing data on 
both. A total of 235 subjects had LS at recruitment, giving a prevalence of 56.5% (95% CI: 51.7, 
61.3, n/N = 235/416) (Figure 3-7).  
 
Figure 3-7: Prevalence of lipodystrophy syndrome at recruitment: metabolic abnormality 
and body fat alterations (n = 416) 
 
 
 
 
 
 
 
 
 
 
 
One quarter (n/N = 59/235) of LS cases were defined on the basis of metabolic abnormality 
alone, half (54.0%, n/N = 127/235) on the basis of body fat alterations alone, and the remainder 
(n = 49) were cases where metabolic abnormality and fat alterations occurred together. Thus, 
the prevalence of metabolic abnormality at recruitment was 26.0% (n = 108), and the 
prevalence of fat alterations was 41.7% (n = 176).  
  
Metabolic abnormality 
Body fat alterations 
No lipodystrophy 
syndrome 
59 
(14.2%) 
49 
(11.8%) 
127 
(  
181 
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3.9 Body fat alterations at recruitment 
3.9.1 Prevalence of body fat alterations 
Overall, 176 subjects had body fat alterations; while a further 4 subjects had data on fat 
alteration missing. Thus the prevalence of body fat alterations at recruitment was 41.7% (n/N = 
176/422). Figure 3-8 illustrates the distribution of types of body fat alterations at recruitment. 
Figure 3-8:  Prevalence of body fat alterations outcomes at recruitment (n=422).  
 
 
 
 
 
 
 
 
 
*Includes 2 subjects known to have lipohypertrophy but lipoatrophy status was unknown. **Includes 1 subject 
known to have lipoatrophy but lipohypertrophy status was unknown.  
 
The prevalence of lipohypertrophy at recruitment was 27.3% (n/N = 115/422). The prevalence of 
lipoatrophy was 27.7% (n/N = 117/422). Within the 176 subjects with fat alteration, one-third (n 
= 59) had lipohypertrophy alone, one third (n = 61) had lipoatrophy alone, and one third (n = 56) 
had both lipohypertrophy and lipoatrophy. Fat alterations was classed as being moderate or 
severe in 82 subjects, and severe in 28 subjects, i.e. in 46.6% and 15.9% of those 176 subjects 
with fat alterations respectively.  
Amongst the 422 subjects with data on body fat alterations, lipoatrophy was most commonly 
seen in the face with a prevalence of 22.0% (n = 93) (Figure 3.9). The prevalence of lipoatrophy 
in the legs was 21.1% (n = 89), in the arms was 20.6% (n = 87), and in the buttocks was 16.1% 
(n = 68). Lipohypertrophy was most frequently seen in the trunk, with a prevalence of 24.6% (n 
= 104). The prevalence of lipohypertrophy in the neck was 8.8% (n = 37). Lipohypertrophy of 
the breast was seen 10.1% (20/199) of males and 13.7% of females (29/211): these differences 
were not statistically significant (χ2 test: p = 0.249).  
Lipoatrophy 
59* (14%) 56 (13%) 61** (14%) 
Lipohypertrophy 
No fat alterations 
246 (58%) 
STUDY POPULATION 
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Figure 3-9: Distribution of body fat alterations by body site among the 176 subjects with alterations  
 
Percentages are given as a proportion of the number of subjects with body fat alterations at each location: missing data: arms; 1, leg; 1, buttocks; 5, neck; 1, breasts; 1 
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Over half of the subjects (n = 95) with fat redistribution (n = 176) were affected in ≥3 locations 
(Table 3-6).  
Table 3-6: Distribution of number of locations of body fat alterations at recruitment, by 
type of disorder (n = 176)  
 Body fat alterations Lipohypertrophy Lipoatrophy 
 n (%) n (%) n (%) 
0 N/A 60(34.5) 57 (33.7) 
1 52 (29.5) 61 (35.0) 25 (14.8) 
2 29 (16.5) 29 (16.7) 12 (7.1) 
3 26 (14.7) 24 (13.8) 22 (13.0) 
4 32 (18.2) 0 53 (31.4) 
5 13 (7.4) 0 0 
6 12 (6.8) 0 0 
7 12 (6.8) 0 0 
TOTAL 
 176(100) 174(100) 169(100) 
Missing data: lipohypertrophy; 2, and lipoatrophy; 7 
 
Over three-quarters (n = 87) of the 112 subjects with lipoatrophy, and 46.5% (n = 53) of 114 
subjects with lipohypertrophy were affected in ≥2 locations. The majority (62%) of subjects with 
one sign of fat alteration had mild (n = 25) or moderate (n = 6) trunk lipohypertrophy, while 22% 
(n = 11) had mild facial lipoatrophy. This may be indicative of a conservative approach to 
diagnosing body fat alterations in this cohort, since most cases were identified with one location 
of fat alterations and it could be argued that alteration is more apparent in the trunk and face.  
Associations between the occurrence of fat alterations in one body location with the occurrence 
in another specific location was tested using χ2 tests significant associations (p < 0.001) were 
found between fat alterations at all pairs of locations for both lipoatrophy and lipohypertrophy.   
Proportions of subjects with lipoatrophy at a given body location were consistently higher in 
males compared to females, but these differences were not significant (Table 3-8). Similarly the 
proportion with lipohypertrophy at specific body locations was higher in females compared to 
males: these differences were significant in the trunk and in the neck (p < 0.05) only.  
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Table 3-7:  Presence of fat alteration at specific body locations, stratified by sex  
 
MALE FEMALE p-value 
n/N % n/N % 
LIPOATROPHY Face 47/199 24 43/212 20 0.414 
Arms 46/198 23 39/212 18 0.227 
Legs  45/198 23 41/212 19 0.400 
Buttocks 33/196 17 31/210 15 0.566 
LIPO-
HYPERTROPHY 
Trunk 38/199 19 63/212 30 0.012 
Neck 11/198 6 24/212 11 0.037 
Breasts 20/199 10 29/211 14 0.249 
Proportions of male and female subjects with fat redistribution at specific sites compared with χ2 test for 
association 
 
Table 3-10 illustrates the age and gender stratified prevalence of fat alterations at specific body 
sites. There was greater prevalence of lipoatrophy in the arms, legs and buttocks in the 12-18 
and 7-11 year age groups compared with the 2-6 year old age group in both males and females. 
However, significant differences in facial lipoatrophy by age were only seen in males. 
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Table 3-8: Associations between body site of fat alterations and age, stratified by sex  
 
MALE FEMALE 
2-6 years 7-11 years 12-18 years p-
value 
2-6 years 7-11 years 12-18 years p-
value 
n/N % n/N % n/N % n/N % n/N % n/N % 
LIPOATROPHY Face 1/21 4.8 9/49 18.4 37/129 28.7 0.035 2/21 9.5 12/94 12.8 29/127 22.8 0.349 
Arms 0/21 0 11/49 22.4 35/128 27.3 0.023 1/21 4.8 8/64 12.5 30/127 23.6 0.041 
Legs 0/21 0 10/49 20.4 35/128 27.3 0.019 1/21 4.8 8/64 12.5 32/127 25.2 0.023 
LIPO-
HYPERTROPHY 
Buttocks 0/21 0 6/47 12.8 27/128 21.1 0.039 0/21 0 5/62 8.1 26/127 20.5 0.010 
Trunk 2/21 9.5 7/49 14.3 29/129 22.5 0.230 3/21 14.3 19/64 29.7 41/127 32.3 0.247 
Neck  0/21 0 2/49 4.1 9/128 7.0 0.374 1/21 4.8 7/64 10.9 16/127 12.6 0.572 
Breast 0/21 0 3/49 6.1 17/129 13.2 0.101 0/21 0 7/64 10.9 22/126 17.5 0.073 
Proportions with presence of body fat alterations by age compared using χ2test for association in male and in female subjects 
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3.9.2 Body mass index   
Figure 3-10 illustrates median BMI and standardized BMI across age groups in both males and 
females. Data were available to calculate BMI for 98% (n = 418) of the study population, and 
standardized BMI for 96% (n = 408), i.e. data were missing for 8 (BMI) and 18 (BMI and/or 
gender) subjects respectively.  
 
Figure 3-10: BMI across age groups: (a) median BMI and (b) median standardized BMI 
 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. n = 418 for BMI, and n = 408 for standardized BMI. Comparison of 
median standardized body mass index between males and females: p > 0.05 for all groups.  
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Median BMI increased with age, as would be expected. Moreover a slower increase in BMI was 
seen in younger age groups compared to older age groups. This reflect so-called adiposity 
rebound where BMI increases in the first year of life but then subsequently decreases before 
increasing again from the age of 5 years386, although increased BMI was seen in this population 
at aged 8 years onwards. Using the CDC sex-specific BMI-for-age definitions, 36 subjects were 
overweight, 43 were at risk of being overweight and 18 subjects were underweight. Of the 
overweight, 63.9% (n/N = 23/36) had body fat alterations: this percentage was 55.8% (n/N = 
24/43) for those at risk of being overweight and 38.9% (n/N = 7/18) amongst those who were 
underweight. Figure 3-11 illustrates the specific fat disorder in these 54 subjects who were in 
the CDC-defined unhealthy BMI categories and had diagnosis of specific body fat alteration: 
more than half had lipohypertrophy alone, while a quarter had both lipohypertrophy and 
lipoatrophy.  
 
Figure 3-11: Body fat characteristics of subjects with body fat alterations and who were 
CDC-defined underweight, potentially overweight or overweight (n = 54)  
 
 
Two subjects had a BMI greater than 30, the definition of obesity in adults 387. Both of these 
subjects were females aged over 14 years and both had body fat abnormality: the first with 
moderate symptoms of combined lipoatrophy and lipohypertrophy, while the second had 
lipohypertrophy in 3 locations including severe symptoms in the trunk.  
The fractional polynomial model for BMI with recruitment age as an explanatory variable in 
subjects with LS was different to the model in subjects without LS (Figure 3-12); this was true 
Lipoatrophy 
Lipohypertrophy 
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for models for males and those for females, i.e. while the order of the Box-Tidwell 
transformations in both models was 2, age was raised to different powers within each model, 
and estimates of accompanying coefficients also being different. This may be indicative of 
differences in the relationship between age at recruitment and BMI which may be associated 
with LS, with further differences due to sex. Smooth curves generated from the fractional 
polynomial models also indicated that subjects who were older at recruitment had higher BMI 
compared to younger subjects. For both sexes, examination of scatterplots suggested a greater 
heterogeneity in the individual age and BMI values in subjects with LS compared to those 
without (Figure C-2 in Appendix C). Furthermore, the smooth curve for males with LS suggests 
that adipose rebound may occur later in these subjects: however, estimates of parameter only 
reached statistical significance in females (Appendix C, Table C-5). For both sexes estimates of 
BMI at given age tended to be slightly higher in subjects with LS.  
Further visual inspection of curves to subjects without LS did not indicate that the relationship 
between BMI and age was different during puberty (i.e. between the ages of 9 and 15 years in 
females, and between 11 and 16 years in males), compared to either before or following 
puberty. However, there was evidence that the relationship between BMI and age did change 
during puberty in subjects with LS, as seen by the fluctuations in these curves.  
 
Similarly, the fractional polynomial models were different between subjects with fat disorder 
compared to those without in both males and females (Appendix C: Figure C-2 and Table C-6): 
in these models parameters reached significance in both male and female models. However, 
there was no significant difference in median values for standardized BMI between subjects 
with/without lipodystrophy syndrome, body fat abnormality, or metabolic abnormality (Figure 3-
12) amongst either males or females. Furthermore, there was no difference in median values 
between males and females, nor any median difference between subjects with each outcome, 
compared to subjects without the outcome.  The aim of the fractional polynomial models is to 
indirectly compare those with/without LS by assessing the differences in structure of the models 
thus characterizing the changes in BMI with age. However, the median comparisons investigate 
difference in overall BMI. This explains why the fractional polynomial models were seen to be 
different between groups, while the tests for differences in medians were statistically non-
significant.  
Thus while there is evidence that the relationship between age at recruitment and BMI varies in 
subjects with LS, there is no significant difference in median standardized values of BMI when 
comparing those with LS to those without.   
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Figure 3-12: Comparison of median standardized BMI, stratified by sex, between subjects 
with/without (a) lipodystrophy syndrome, (b) fat alterations, and (c) metabolic 
abnormality 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme values within 1.5 
interquartile range of the nearest quartile) of the distribution within each age band. Values outside adjacent values excluded for 
clarity. Comparison of median standardized BMI between subjects with outcome and without outcome: p ≥ 0.190. 
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3.9.3 Waist/hip ratio 
Waist/hip ratio was available for over almost three-quarters of the population (n = 317), while 
standardized estimates were available for over 70% (n = 310). Male median waist/hip ratio was 
greater than female at a given age, but these differences were not statistically significant (Figure 
3-13). Furthermore, a non-significant decrease in median waist/hip ratio was seen with 
increasing age.  
Figure 3-13: Waist/hip ratio across age groups: (a) median waist/hip ratio, and (b) median 
standardized waist/hip ratio 
 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. n = 317 for waist/hip ratio, and n = 310 for standardized waist/hip 
ratio.  Comparison of median standardized waist/hip ratio between males and females: p > 0.05 for all groups. 
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In males, the fractional polynomial model for waist/hip ratio by age at recruitment had a similar 
structure in both the model estimated for subjects with lipodystrophy and the model estimated 
for subjects without, i.e. within both models age was raised to the same powers although 
coefficients did not have the same value (Figure 3-15). However, the fractional polynomial 
model for females with LS differed in structure compared to the model for females without LS. 
Male and female models were also different.  Thus, the relationship between age at recruitment 
and waist/hip ratio between males and females may be different, and furthermore the 
relationship may be different in females with LS compared to females without LS. Moreover, LS 
did not seem to affect the pattern of age at recruitment and waist/hip ratio in males. However, 
coefficients of age were not statistically significant in any model (Appendix C: Table C-7). 
As illustrated in (Figure 3-14), standardized waist/hip ratio was comparable between subjects 
with LS compared to those without, those with fat disorder compared to those without, and 
those with metabolic abnormality compared to those without. Furthermore there were no 
differences seen between sexes for any outcome. 
Thus, while fractional polynomial modelling suggests that LS affects the relationship between 
age at recruitment and waist/hip ratio in girls, no significant difference was seen in standardized 
waist/hip ratio between subjects with/without LS outcomes in either males or females.  
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Figure 3-14: Comparison of median standardized waist/hip ratio, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat alterations, and (c) 
metabolic abnormality 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized waist/hip ratio between 
subjects with outcome and without outcome: p ≥ 0.157. 
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3.10 Metabolic abnormality at recruitment 
3.10.1 Prevalence of metabolic abnormality 
The prevalence of metabolic abnormality at recruitment was 26.0% (n = 108) (Figure 3-7. 
Prevalence of fasting hypertriglyceridemia was 17.0% (n = 71), of hypercholesterolemia was 
13.4% (n = 56), and of glucose intolerance was 1.6% (n = 7). 
Figure 3-15: Frequencies of metabolic abnormality outcomes of hypercholesterolemia, 
fasting hypertriglyceridemia and glucose intolerance (n = 419): 
 
 
 
 
 
 
 
 
 
 
 
 
*Includes 1 case where hypercholesterolemia and fasting hypertriglyceridemia status was known, but glucose 
tolerance was not known, and 1 case where hypercholesterolemia and glucose intolerance was not known 
while fasting hypertriglyceridemia status was not known. 
 
Less than half (43.5%, n = 47) of the 108 subjects with metabolic abnormality were defined by 
fasting hypertriglyceridemia alone, while 29.6% (n = 32) were defined by hypercholesterolemia 
alone, and 3.7% (n = 4) by glucose intolerance alone (Figure 3-13). The remaining 29 subjects 
with metabolic abnormality had mixed phenotype: 20.4% (n/N = 22/108) had both 
hypercholesterolemia and fasting hypertriglyceridemia, 1 had combined glucose intolerance and 
fasting hypertriglyceridemia, 1 had both glucose intolerance and hypertriglyceridemia, and, 1 
had glucose intolerance, hypercholesterolemia and fasting hypertriglyceridemia.  
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3.10.2 Cholesterol  
Overall prevalence of hypercholesterolemia was 13.4% (n/N = 56/423), with proportions of 
subjects with hypercholesterolemia higher in younger age groups compared with older age 
groups (Figure 3-16). There was a significant association between increasing age and 
decreasing cholesterol concentration (p < 0.001). In three subjects, data necessary to 
categorize the subject as a hypercholesterolemia case were missing. 
Figure 3-16: Distribution of hypercholesterolemia by age and gender (n = 412) 
 
2-3 years: male n=8, female n =16, 4-5 years: males n=13, females n=16, 6-7 years: males n=14, females n=16, 8-
9 years: males n=25, females n=31, 10-11 years: males n=29, females n=36, 12-13 years: males n=37, females 
n=36, 14-15 years: males n=39, females n=39, and 16-18: males n=34, females n=34.  
   
Measures of cholesterol were missing for 7 subjects and data required for calculation of age 
and gender standardized cholesterol was missing for a further 11 subjects: thus population-
standardized cholesterol could be estimated for 95.8% (n/N = 408/426) of subjects. Median 
cholesterol levels were non-significantly higher in males compared to females in the 2-3, 4-5, 6-
7 and 8-9 age groups, with a decrease in levels in these groups with ascending age (Figure 3-
17). However, median standardized cholesterol had no discernible patterns by gender or age 
group. 
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Figure 3-17: Total cholesterol across age groups: (a) median total cholesterol, and (b) 
median standardized total cholesterol 
 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. n = 419 for cholesterol, and n = 408 for standardized cholesterol 
Comparison of median standardized total-cholesterol between males and females: p > 0.05 for all groups. 
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Examination of scatterplots of age at recruitment with total serum cholesterol, suggests 
heterogeneity which may be more apparent in subjects with LS (Figure 3-18). However, plots 
using fractional polynomial modelling suggest that total serum cholesterol may vary little across 
subjects of increasing age at recruitment. Indeed the fractional polynomial models for males 
with LS, males without LS and females with LS all had a similar structure with age raised to the 
same powers in these three models (Appendix C: Table C-9). However, the fractional 
polynomial model for females without LS was of a different form. Statistical significance varied 
for coefficients across models.  
 
These models may suggest that LS does not influence the association between age at 
recruitment and serum cholesterol in males.  The models in males had the same structure but 
the estimated coefficients were of different value. Thus, although the slope between models is 
not different, the intercept is different: for a given age, total cholesterol in males with LS is 
higher than in males without LS. Since the regression function is different for lipodystrophy 
females compared to those without lipodystrophy, LS may be an influential factor on total serum 
cholesterol concentration in females.  
 
Regarding subjects with/without metabolic abnormality, all models had different structures 
(Appendix C: Table C-10), which suggests that metabolic abnormality has an effect on the 
relationship between age and total cholesterol in both males and females  
 
As would be expected, given hypercholesterolemia is a component of the definitions of 
metabolic abnormality and LS, total cholesterol levels were seen to be increased in subjects 
with LS compared to those without, and in subjects with metabolic abnormality compared to 
those without (Figure 3-21). Furthermore, standardized total cholesterol was similar in males 
and females across outcomes. Although subjects with fat disorder had increased standardized 
total cholesterol compared to subjects without fat disorder, but this difference was only 
significant in females (p = 0.008).  
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Figure 3-18: Comparison of median standardized total cholesterol, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat alterations, and (c) 
metabolic abnormality 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized total cholesterol ratio 
between subjects with outcome and without outcome: *p < 0.01, **p < 0.01, ***p < 0.001.  
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Low density lipoprotein (LDL) cholesterol 
LDL-cholesterol data was available for 81.9% (349/426) of subjects (77 missing). Age- and 
gender- standardized estimates for LDL cholesterol could be calculated for 80.0% (341/426). 
Male subjects had median LDL-cholesterol levels similar or greater than median levels seen in 
females (Appendix C: Figure C-6).  
As with total cholesterol, there was great heterogeneity between measures of age at recruitment 
and serum levels of LDL cholesterol (Appendix C: Figure C-8). However, differences in degree 
of heterogeneity between subjects with LS and those without were not as obvious. The structure 
of the fractional polynomial models investigating the cross sectional relationship between age 
and LDL-cholesterol in males with/without LS both had age raised to the same powers: this may 
imply that LS does not affect the relationship between age and LDL cholesterol (Appendix C: 
Table C-11). However, the models in subjects with/without LS did not have the same structure 
in females, indicating that LS may have an impact on this relationship: this is not surprising 
given that LS was seen to be influential on total cholesterol levels in females in the previous 
section.  While estimates of the intercepts in all four models were statistically significant, 
estimates of all coefficients were not. The regression models suggest that females with LS had 
higher values of LDL cholesterol at a given age at recruitment compared to females without LS. 
Males with LS had similar values of LDL-cholesterol at a given age as males without LS.  
Subjects with LS had significantly higher levels of standardized LDL-cholesterol compared to 
subjects without LS (Appendix C:  Figure C-9). While subjects with fat disorder had higher LDL-
cholesterol compared to subjects without fat disorder, these differences were not statistically 
significant.  
Thus, while there was evidence that LS had an effect on the relationship between age at 
recruitment and LDL-cholesterol, these results suggest that these differences may only be 
apparent in females.  
 
Non-high density lipoprotein (non-HDL) cholesterol 
Data on non-HDL cholesterol was estimated in 84.5% (360/426) of the study population, and 
standardized non-HDL cholesterol was calculated for 82.4% (351/426). Median non-HDL 
cholesterol in males was higher in males than in females in all age groups except the 10-11 
year olds (Appendix C: Table C-11).   
 
Fractional polynomial models in males showed that levels of non-HDL-cholesterol oscillated 
with increasing age of recruitment: this was especially true of males without LS (Appendix C: 
Figure C-14 and Table C-13). There were also lower levels in older children compared to 
younger children in subjects with LS. In contrast, the fractional polynomial models for females 
with/without LS were relatively flat, with older children having similar levels of non-HDL-
cholesterol as younger children at recruitment. This is reflected in the fact that all models 
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differed in structure. While the regression functions suggested that males with LS had higher 
values of non-HDL-cholesterol at a given age compared to males without LS, this difference 
was more visibly apparent for females. Indeed the structure of the fractional polynomial models 
was the same between males with/without LS, but differed between females with LS and those 
without, although the majority of coefficients were statistically non-significant. As with total and 
LDL cholesterol, this suggests that LS has an influence on serum concentrations of non-HDL 
cholesterol in females but not in males. 
Standardized measures of non-HDL cholesterol were significantly higher in subjects with LS 
compared to subjects without, and in subjects with metabolic abnormality compared to those 
without, in both males and females (Appendix C: Figure C-15). Despite this being expected (as 
hypercholesterolemia is part of the definition of both LS and metabolic abnormality used in this 
study), the differences were of a greater magnitude than seen for standardized measures of 
LDL-cholesterol (also part of the definition of LS) between subjects with/without outcome. While 
median standardized non-HDL-cholesterol was higher in subjects with fat disorder compared to 
those without, this was only significant in females. 
 
High density lipoprotein (HDL) cholesterol 
HDL-cholesterol was missing in 66 subjects, and thus was available for 84.5% of subjects. 
Sufficient data were available to estimate gender- and age- standardized values for 82% 
(351/426) of the study population. HDL-cholesterol was only higher in females compared with 
males in the 10-11 year olds: in all other age groups, female levels were lower than those in 
males (Appendix C: Figure C-16). The only significant sex difference in age and gender 
standardized HDL-cholesterol was seen among 6-7 year olds (p = 0.019).  
Figure C-18 in Appendix C illustrates scatter plots with estimated fractional polynomial curves 
using age at recruitment as the explanatory factory and serum HDL-cholesterol as the response 
variable: plots are shown for males with/without LS, and females with/without LS. All plots 
showed heterogeneity in the observed values of age and HDL-cholesterol: there was no 
evidence of differences in the degree of heterogeneity between subjects with/without LS The 
regression functions for males were similar to those for females (Appendix C: Table C-15): in 
the former peaks occurred at about 7 years and 12 years, while in the latter a peak occurred 
before 10 years (although the timing and gradient associated with this peak was different 
between subjects with/without LS). Furthermore, subjects with/without LS in both sexes had 
similar values for HDL-cholesterol at any given age. The structure of the fractional polynomial 
models for males were the same (although values of coefficients were different), indicating that 
LS may not influence the relationship between age and HDL cholesterol. In contrast, the model 
for females without LS had a different structure to the model for females without LS, indicating 
LS may influence the relationship. No coefficients were statistically significant in any model. 
Thus fractional polynomial models have consistently suggested that LS may influence serum 
concentrations of specific cholesterols in females, but not in males. 
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Standardized HDL was comparable between subjects with/without LS, with/without metabolic 
abnormality, and with/without fat disorder in females (Appendix C: Figure C-20). In contrast, 
male subjects without LS, metabolic abnormality or fat disorder had higher levels of HDL-
cholesterol compared to male subjects without these disorders: this difference was only 
significant between subjects with/without metabolic abnormality.  
 
3.10.3 Fasting triglyceride  
Data on fasting hypertriglyceridemia were available for all but 8 subjects. Almost one in five 
subjects had age and gender-defined fasting hypertriglyceridemia (71/418). Increasing age was 
significantly associated with decreases in fasting hypertriglyceridemia (p = 0.003), as illustrated 
in Figure 3-19). However, while this relationship remained significant when the population was 
restricted to females (p = 0.008) it was non-significant in males (p = 0.087).  
 
Figure 3-19: Percentage distribution of fasting hypertriglyceridemia by age and gender (n 
= 305)
 
2-3 years: male n=4, female n =5, 4-5 years: males n =8, females n =11, 6-7 years: males n =9, females n =12, 8-9 
years: males n =17, females n =23, 10-11 years: males n =24, females n =30, 12-13 years: males n =25, females n 
=26, 14-15 years: males n =30, females n =33, and 16-18: males n =22, females n =26. 
 
In addition to the 8 subjects with missing data on fasting hypertriglyceridemia status, there were 
107 subjects reported as not having fasting hypertriglyceridemia. i.e.  missing specific data on 
whether available triglyceride data had been collected as fasting or non-fasting. Thus, almost 
three quarters (311/426) of the study population had complete data on fasting triglyceride 
measures, and age and gender standardized estimates were calculated for 73% (309/426). 
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Males had higher fasting triglyceride levels in all age groups except 12-13 year olds (Figure 3-
20). However, there was no significant difference in standardized fasting triglyceride between 
males and females in any age group (p > 0.05).  
Greater heterogeneity in the observed values of fasting triglyceride (with increasing age at 
recruitment) was seen amongst subjects with LS compared to those without (Figure 3-24). 
Fractional polynomial models demonstrate a distinct pattern in males and in females. In males, 
subjects who are older at the time of recruitment had higher levels of fasting triglyceride than 
younger subjects. Furthermore, levels increase till age 12-13 years where levels briefly plateau 
before increasing again from age 15 years. However, in females, levels remain constant across 
ages with a brief increase and subsequent fall in subjects aged approximately 4 years. Across 
sexes, subjects with LS show exaggerated versions of these patterns compared to subjects 
without LS, and furthermore, levels of fasting triglyceride tend to be higher for any given age of 
recruitment. 
In contrast to the fractional polynomial models for cholesterol, the structure of the models for 
subjects with LS and those without were similar for females, i.e. the explanatory variable of age 
at recruitment was raised to the same powers in the two models (Appendix 3: Table C-17). 
However, although all coefficients were statistically significant in the model of subjects without 
LS, no coefficients were significant in the model for subjects with LS. The structure of the model 
for males with LS was different to that for males without LS. This may indicate LS influencing 
the relationship between age at recruitment and fasting triglyceride in males.  
Subjects with LS and those with metabolic abnormality had significantly higher median 
standardized fasting triglyceride than those without (Figure 3-21), as expected since 
hypertriglyceridemia is a constituent part of these definitions.  Although subjects with body fat 
disorder had increased median standardized fasting triglyceride compared to those with no fat 
disorder, these differences were not statistically significant. 
Thus it appears that older children may have increased levels of fasting triglyceride compared to 
younger children, with LS possibly having a greater effect on this relationship in males. 
However, while subjects with lipodystrophy had increased levels of fasting triglyceride 
compared to subjects without, differences in serum concentrations of fasting triglyceride were 
not significantly difference in subjects with body fat alterations compared to those without.   
 
 
  
Cohort characteristics at recruitment  Chapter 3 
138 
 
 
Figure 3-20: Total fasting triglyceride across age groups: (a) median fasting triglyceride, 
and (b) median standardized fasting triglyceride  
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Fasting triglyceride: n =311, and standardized fasting triglyceride:  
n = 309. No significant difference in standardized fasting triglyceride was seen between males and females in 2-
3, 4-5, 6-7, 8-9, 10-11, and 12-13, year olds( p > 0.05): significant difference seen in 14-15 and 16-18 year olds (p 
< 0.05). 
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Figure 3-21: Comparison of median standardized fasting triglyceride, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat alteration, and (c) 
metabolic abnormality  
 
Boxes demark 25th and 75th percentiles (1st and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized fasting triglyceride ratio 
between subjects with outcome and without outcome: *p < 0.01, **p < 0.01, ***p < 0.001  
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3.10.4 Fasting insulin  
Fasting insulin was available for almost half of the study population (199/426). Furthermore, 
additional subjects had missing data required for calculation of age and gender standardized 
fasting insulin: thus this was estimated in 46.0% of the population. Median fasting insulin levels 
were higher in males compared to females aged less than 7 years, with the converse being true 
for older subjects (Appendix C: Figure C-24). Furthermore, median levels increased with age.  
Greater heterogeneity was seen in subjects with LS compared to those without (Appendix C: 
Figure C-26): however, this inference is clouded by the fact that fewer observations were 
available. Fractional polynomial modelling suggests that subjects who were older at recruitment 
tended to have higher levels of fasting insulin than subjects who were younger. Furthermore, 
these curves suggested that this increase was more pronounced in subjects with LS compared 
to those who did not. A jump in fasting insulin was seen at specific ages (subjects >10 years in 
females, and subjects>12 years in males), indicating that puberty may be an important time, in 
terms of serum insulin levels, in children with LS. 
The fractional polynomial models for males and females raised age to different powers: all 
coefficients were significant in each the model for females, while all but one coefficient was 
significant in the model for males (Appendix C: Table C-19). This indicates that both sex and LS 
influence the relationship between age at recruitment and fasting insulin. 
No significant differences were seen in standardized insulin measures between subjects 
with/without LS, metabolic abnormality, or body fat disorder (Appendix  C: Figure C-27): in the 
majority of cases, subjects with an LS outcome had increased median values of standardized 
insulin compared to subjects without the outcome.  
 
3.10.5 Fasting glucose  
Data on fasting glucose was missing for 121 subjects, and a further 6 subjects were missing sex 
information. Thus fasting glucose was available for 71.6% of the study population while age and 
gender standardized fasting glucose could be calculated for 70.2%. Boxplots of both actual and 
standardized fasting glucose showed no significant differences by either age or gender 
(Appendix C: Figure C-29). 
 
Heterogeneity between observations of age at recruitment and fasting glucose were similar 
amongst subjects with LS and without LS (Appendix C Figure C-31). Fractional polynomial 
models were similar in males and females without LS (Appendix C: Table C-21): regression 
functions oscillated with three peaks occurring over the age bracket, occurring slightly earlier in 
females compared to males. However, regression functions for subjects with LS oscillated less, 
with values of 75-80mg/dL of glucose seen across all age groups.  
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The structure of the fractional polynomial models was different between genders and also with 
LS status, with all coefficients being statistically significant except for those in the model for 
females with LS. This may be indicative of both sex and lipodystrophy having an influence on 
age at recruitment and levels of fasting glucose.   
 
There were no significant differences in median standardized fasting glucose between subjects 
with LS compared to those without, in subjects with fat disorder compared to those without, and 
in those with metabolic abnormality compared to those without (Appendix C: Figure C-32).  
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3.11 Key points 
 
• 426 children and adolescents (70% white ethnicity) were recruited into the cohort, with 
median age 12.2 years (IQR: 9.0, 15.0)  
 
• 76% of participants showed no evidence of immunosuppression and 90% had no 
symptomatic disease at recruitment, while 32% had experienced either severe 
immunosuppression or clinical disease during their lifetime.  
 
• Over half (56%) of subjects on ART at recruitment were being treated with PI-based 
HAART, and a third were being treated with NNRTI-based HAART.  
 
• 29 subjects were ART-naïve (median age: 10.48 years, IQR: 7.77, 15.26) 
 
• Prevalence of lipodystrophy syndrome at recruitment was 56.5% (95% CI: 51.7, 61.3), with 
half of cases defined by body fat alterations alone, a quarter by metabolic abnormality 
alone, and a quarter defined by both.  
 
• Prevalence of body fat alterations at recruitment was 43.3% (95% CI: 37.0, 46.4): one third 
defined by lipohypertrophy alone, one third with lipoatrophy, and one third defined by both. 
Lipoatrophy occurred most commonly in the face and lipohypertrophy occurred most 
frequently in the trunk.  
 
• Half (51%) of the 176 subjects with body fat alterations were affected in three or more 
locations. 
 
• Trunk and neck lipohypertrophy occurred significantly more often in females compared with 
males, while age-specific differences in arm, leg and buttock lipoatrophy was seen in both 
males and females. 
 
• Prevalence of metabolic abnormality at recruitment was 26.0% (95% CI: 21.8, 30.3): 44% 
of cases defined by fasting hypertriglyceridemia alone, 30% by hypercholesterolemia, 4% 
by glucose non-tolerance alone, and 23% by some combination of the three. 
 
• There was evidence to suggest LS is more influential in serum concentrations of 
cholesterol in females but not males, whereas fasting triglyceride may be more effected by 
LS in males.   
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4. Fat alterations at recruitment 
 
4.1 Objectives 
The main objective of this chapter was to identify risk factors associated with prevalent body fat 
alterations at recruitment. Specific objectives were to:  
• Estimate prevalence of (i) any fat alterations, (ii) lipohypertrophy, (iii) lipoatrophy, and 
(iv) both lipohypertrophy and lipoatrophy occurring together across socio-demographic, 
clinical and treatment groups 
 
• Identify risk factors for each outcome fitting univariable logistic regression models 
 
• Determine multivariable models of factors associated with each fat alterations outcome, 
including use of individual antiretroviral drugs, and to refit this in order to explore the 
effects of inclusion of ART class exposure, or of ART regimen (e.g. PI-based HAART, 
triple class) in place of individual drug exposure  
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4.2 Specific methods 
Logistic regression modelling was used to identify potential risk factors for body fat alterations 
outcomes. The binary outcome measures are presented in Box 4-1. This was a cross-sectional 
analysis using data collected at recruitment (n = 428).  
 
Box 4-1: Outcomes investigated in this chapter 
Fat alterations outcomes 
Any fat alterations 
Any lipohypertrophy 
Any lipoatrophy 
Concurrent lipoatrophy and lipohypertrophy  
Definitions of outcomes are given in Box 2-1in Chapter 2 
 
 
4.2.1 Estimation of prevalence 
Prevalences of each outcome by potential risk factors (e.g. ethnicity, specific ART drug, etc.) 
were estimated with respect to the numbers of subjects with complete data for that factor from 
the total study population. Associations between prevalence of outcomes and demographic and 
clinical characteristics were investigated using χ2 tests. 
 
4.2.2 Univariable regression modelling 
The associations of potential risk factors and each outcome (Box 4-1) were investigated by 
fitting logistic regression models. The odds ratio (OR) measuring the association between each 
explanatory variable (Table 2-1 in Chapter 2) and outcome was estimated using univariable 
models.  
 
4.2.3 Multivariable regression modelling 
Three categories of multivariable models for each outcome were fitted yielding adjusted odds 
ratios (AOR): (i)   models for the outcomes using ART classes as explanatory variables together 
with non-treatment related variables, (ii) as (i) but using specific ART drugs instead of class, and 
(iii) models using type of ART (specific cART and mono-therapy) as an explanatory variable. 
The first two sets of models were fitted using a backward stepwise approach (Section 2.8.6 in 
Chapter 2), while the last was intuitively adjusted for potential confounders. Table 2-1 in 
Chapter 2 illustrates the explanatory variables investigated in the stepwise process. 
 
Multivariable models examining the role of type of cART (i.e. NRTI mono-therapy, PI-based 
HAART, NNRTI-based HAART, and triple class therapy) on fat alterations outcomes were not 
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determined using stepwise variable selection, but only included factors chosen a priori. These 
factors were age, total duration of ART, ethnicity and maximum CDC-clinical status, and the 
random effect for clinical site. The latter two variables were included in the models as they were 
statistically significant in univariable analysis and multivariable models (i.e. ethnicity was 
significant in multivariable models for all fat alterations outcomes except lipohypertrophy, and 
maximum CDC-defined clinical condition was significant in models for any body fat alterations 
and lipohypertrophy). 
Three sets of sensitivity analyses were conducted. In the first, the final multivariable models 
were refitted but using moderate/severe outcomes (as opposed to the presence of the 
outcomes summarized in Box 4-1). In the second, the backward stepwise covariate selection 
was conducted but using ever-use of specific ART drugs as explanatory variables (as opposed 
to current-use at recruitment): these models used presence of the outcomes summarized in Box 
4-1. The third set of sensitivity analyses repeated the backward stepwise selection process, but 
the threshold for statistical significance was set at 10%. Sensitivity analyses are included in 
Appendix D. 
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4.3 Results  
4.3.1 Prevalence of body fat alterations outcomes by subject 
characteristics 
There were significant differences in prevalence of body fat alterations outcomes by sex, age 
group, ethnicity, CDC-defined immune stage at recruitment, maximum CDC clinical stage, 
hepatitis-C co-infection, Tanner score for puberty, and with the specific ART drugs lamivudine, 
tenofovir, stavudine, zidovudine and efavirenz (Table 4-1). 
Prevalence of lipohypertrophy was significantly higher among females (33%, n = 69) compared 
to males (22%, n = 43), but significant sex differences were not seen for other body fat 
alterations outcomes (Table 4-1).  There was a significant (p < 0.001) association between 
increasing age and greater prevalence of fat alterations. Subjects of White ethnicity had the 
highest prevalence of all outcomes compared with other ethnic groups, with almost half of White 
children having body fat alterations (49%, n = 137): differences in prevalence between ethnic 
groups were significant for all outcomes (p ≤ 0.01). While prevalence of body alterations was 
higher in subjects co-infected with hepatitis-C compared with uninfected subjects, this was only 
significant (p ≤ 0.012) for any body fat alterations, and lipohypertrophy.  
There were significant differences in the prevalence of any body fat alterations (p < 0.001), 
lipohypertrophy (p = 0.010), and lipoatrophy (p = 0.004) between subjects with differing Tanner 
score (Table 4-1): there was a clear trend of increased prevalence in subjects who had 
completed puberty compared to those undergoing puberty, and increased prevalence in those 
undergoing puberty compared to pre-pubescent subjects, with regard to both body fat 
alterations and lipohypertrophy. Indeed prevalence of any fat alterations was over 40% in 
subjects undergoing or having completed puberty.  
There were significant differences in the prevalence of any body fat alterations (p = 0.033) and 
of lipohypertrophy (p = 0.030) with current immune status: prevalence was highest among 
subjects who showed no evidence of immunosuppression and lowest in those with moderate 
immunosuppression (Table 4-1). When considering nadir immune stage for both these 
outcomes, highest prevalence was seen in subjects with a history of severe 
immunosuppression, but this was not statistically significant (p ≥ 0.066). Significant (p ≤ 0.007) 
differences were seen in prevalence of any body fat alterations, lipohypertrophy, and 
lipoatrophy with maximum CDC clinical stage: prevalence in subjects who had been 
symptomatic at some point during their lifetime was at least 35%, and prevalence in subjects 
who had always been asymptomatic was at most 30% for each of these outcomes. No 
significant association was seen between current clinical condition and any body fat alteration 
outcome. Subjects with undetectable levels had a higher prevalence than those with detectable 
viral load though this difference did not reach statistical significance (p ≥ 0.341).  
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Table 4-1: Prevalence of fat alterations at recruitment by participant characteristic 
  
Body fat alterations Lipohypertrophy Lipoatrophy Combined lipohypertrophy 
and lipoatrophy 
  % n/N % n/N % n/N % n/N 
Demographic 
factors 
  
   
    
Sex Male 39 77/199 22* 43/199 29 57/198 12 23/199 
 Female 44 93/212 33* 69/211 26 55/211 15 31/212 
Age (years) 2-6 16*** 7/43 12* 5/43 7** 3/43 2* 1/43 
 7-11 37*** 37/100 26* 26/100 21*** 21/98 10* 10/100 
 12-18 50*** 111/223 32* 70/222 35** 78/223 17* 37/223 
Ethnicity Black 22*** 24/107 17* 18/107 9*** 10/106 4*** 4/107 
 White 49*** 137/281 32* 90/280 34*** 95/280 17*** 48/281 
 Other 29*** 5/17 24* 4/17 12*** 2/17 6*** 1/17 
Country of 
residence 
Italy 43*** 118/272 28 75/271 26*** 71/270 6*** 5/84 
Belgium 26*** 22/84 19 16/84 13*** 11/84 10*** 28/272 
Poland 55*** 36/66 36 24/66 53*** 35/66 35*** 23/66 
Infection 
factors 
  
 
      
CDC immune 
stage at 
recruitment 
Stage 1 45* 145/321 29 94/320 31* 99/319 15 48/321 
Stage 2 30* 25/84 21 18/84 17* 14/84 8 7/84 
Stage 3 35* 6/17 18 3/17 24* 4/17 6 1/17 
Nadir CDC 
immune 
stage 
Stage 1 43 68/158 25 39/157 31 49/158 13 20/158 
Stage 2 38 67/178 30 53/178 22 39/177 14 25/178 
Stage 3 48 41/86 27 23/86 34 29/85 13 11/86 
CDC clinical 
stage at 
recruitment 
N+A 41 140/344 27 91/343 26 90/343 12 41/344 
B 48 10/21 29 6/21 38 8/21 19 4/21 
C 27 3/11 27 3/11 18 2/11 18 2/11 
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Body fat alterations Lipohypertrophy Lipoatrophy Combined lipohypertrophy 
and lipoatrophy 
  % n/N % n/N % n/N % n/N 
Maximum 
CDC clinical 
stage  
N+A 30*** 51/169 20** 34/169 19** 32/168 9 15/169 
B 50*** 72/143 35** 49/142 34** 48/143 17 5/143 
C 52*** 45/*87 34** 30/87 34** 29/86 16 14/87 
Viral load 
(copies/ml) 
≤50 52 45/87 29 70/57 29 69/241 14 23/177 
>50 39 69/177 25 44/176 27 48/177 13 23/177 
Other factors          
Hepatitis C 
co-infection 
Uninfected 40* 157/389 26* 102/388 27 106/387 13 51/389 
Infected 67* 16/24 50* 12/24 38 9/24 21 5/24 
Tanner score 
for puberty 
I 27*** 36/135 19* 25/135 17** 23/134 9 121/135 
II-IV 47*** 68/145 28* 41144 34** 50/145 16 23/145 
V 50*** 47/94 36* 34/94 30** 28/94 16 15/94 
Antiretroviral therapy         
ART naive No 43* 170/394 28 110/393 29* 115/392 14 55/394 
 Yes 21* 6/28 18 5/28 7* 2/28 4 1/28 
NRTI          
Any NRTI Not current 23* 7/30 20 6/30 10* 3/30 7 2/30 
 Current 44* 159/360 28 100/359 30* 109/358 14 50/360 
Didanosine Not current 43 146/343 27 93/343 29 98/341 13 45/343 
 Current 43 20/47 13 13/46 30 14/47 15 7/47 
Lamivudine Not current 45 65/144 31 45/144 33 47/144 19* 27/144 
 Current 41 101/246 25 61/245 27 65/244 10* 25/246 
Tenofovir Not current 40 114/287 25 71/286 26 75/285 11* 32/287 
 Current 50 52/103 34 35/103 36 37/103 19* 20/103 
Stavudine Not current 39*** 136/364 26 89/345 26** 91/345 13 44/346 
 Current 68*** 30/44 39 17/44 49** 21/43 18 8/44 
Zidovudine Not current 46* 132289 30 86/288 32* 92/288 16* 46/289 
 Current 34* 34/101 20 20/101 20 20/100 6* 6/101 
NNRTI          
Any NNRTI Not current 42 96/231 26 59/230 28 64/257 12 27/231 
 Current 49 96/231 32 42/131 35 46/131 18 24/231 
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Body fat alterations Lipohypertrophy Lipoatrophy Combined lipohypertrophy 
and lipoatrophy 
  % n/N % n/N % n/N % n/N 
Efavirenz Not current 39* 117/297 25* 73/296 26* 76/295 11** 32/297 
 Current 53* 49/93 35* 33/93 39* 36/93 22** 20/93 
PI          
Any PI Not current 41 71/173 25 44/173 27 46/173 11 19/173 
 
Current 44 95/217 29 62/216 31 66/215 15 33/217 
Type of drug 
therapy at 
recruitment 
  
 
      
PI-based 
HAART 
42 86/204 27 55/203 29 58/202 13** 27/204 
NRTI mono-
therapy 
38 11/29 17 5/29 24 7/29 3** 1/29 
NNRTI-based 
HAART 
47 54/116 29 34/116 32 37/116 15** 17/116 
 Triple class 69 9/13 54 7/13 62 8/13 46** 6/13 
Association between participant characteristic and fat alterations (prevalence) investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. CDC-defined immune status - stage 1: 
no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate 
symptoms, C: severe  
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In all classes of ART, the prevalence of fat alterations was greater among subjects currently on 
the class at recruitment, compared to subjects not on the class (Table 4-1) Almost half of 
subjects currently on NRTIs had body fat alterations compared to almost one quarter of subjects 
not on these drugs (p = 0.027). Similarly, 30% of subjects on NRTI had lipoatrophy, in contrast 
to 10% of subjects not on these drugs (p = 0.018). While the size in the difference in prevalence 
was not as great, subjects who had ever been on NRTI had significantly higher prevalence of 
both any fat alterations, and lipoatrophy, compared to subjects who had never been on NRTI 
(Table 4-2).  However current use of any ART was highly correlated with current use of NRTI: 
only two subjects who were on ART at recruitment were not on NRTI. Investigating association 
between NRTI and body fat alteration outcomes excluding ART naïve subjects showed no 
significant association (Table D-1in Appendix D). 
Almost one in five of subjects on NNRTI at recruitment had combined lipoatrophy and 
lipohypertrophy compared to 12% not on this class (p = 0.039). However, none of the 
differences in fat alteration prevalence observed with recruitment PI use were statistically 
significant. Nevertheless, subjects who were on either NNRTI or PI at recruitment had higher 
prevalence of all fat alterations outcomes compared to subjects who had never been on these 
drugs (Figure 4-1). Furthermore, subjects who had ever been on NNRTI or PI had significantly 
increased prevalence of all body fat abnormality outcomes compared to subjects who had never 
been on these antiretroviral classes (Table 4-2). 
Significant differences were seen in the prevalence of any body fat alterations, and lipoatrophy 
between subjects who were ART-naïve and those who had been treated (Table 4-2):  this 
suggests that the significance differences seen in prevalence between these outcomes by each 
category of ART may be driven by the numbers of subjects who were treatment naïve. Indeed, 
exclusion of ART naïve subjects from these analyses resulted in non-significant associations 
between all classes of ART used at recruitment and body fat alteration outcomes (Table D-1 in 
Appendix D).  
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Table 4-2: Prevalence of fat alterations at recruitment by ever use of categories of 
antiretroviral therapy 
  
Body fat 
alterations 
Lipohypertrophy Lipoatrophy Combined 
lipohypertrophy 
and lipoatrophy 
  % n/N % n/N % n/N % n/N 
NRTI Never 
use 
21* 6/28 18 5/28 7* 2/28 4 1/28 
 Ever 
use 
43* 170/394 28 110/393 29* 115/392 14 55/394 
NNRTI Never 
use 
34** 60/179 22* 40/179 30** 36/177 9* 16/179 
 Ever 
use 
48** 116/243 31* 75/242 33** 81/243 16* 40/243 
PI Never 
use 
27** 27/95 17** 16/95 17** 16/95 5** 5/95 
 Ever 
use 
46** 149/327 30** 99/326 31** 101/325 16** 51/327 
ART 
naïve  
Treated 42 170/394 28 110/393 29* 115/392 14 55/394 
Naïve  21* 6/28 18 5/28 7* 2/28 4 1/28 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
Significant differences in prevalence of body fat alterations between subjects on a specific ART 
drug and those not on that drug were only seen for five drugs: lamivudine (concurrent 
lipoatrophy and lipohypertrophy: p = 0.016), stavudine, (body fat alterations, lipoatrophy: p ≤ 
0.002) zidovudine (body fat alterations, lipohypertrophy, concurrent lipoatrophy and 
lipohypertrophy: p ≤ 0.051), tenofovir, (concurrent lipoatrophy and lipohypertrophy: p = 0.034) 
and efavirenz (all outcomes: p ≤ 0.041), as illustrated in  Figure 4-2a, Figure 4-2b, and Figure 4-
3b. No other significant associations were found. 
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Figure 4-1: Association between class of antiretroviral therapy and body fat alterations 
outcomes 
 
Association between body fat alterations and (a) nucleotide reverse transcriptase inhibitors, (b) non-
nucleotide reverse transcriptase inhibitors, and (c) protease inhibitors. Not current includes ART-naïve 
subjects. Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001.  
  
(a) 
(b) 
(c) 
Nucleoside reverse transcriptase inhibitors 
Non-nucleoside reverse transcriptase inhibitors 
Protease inhibitors 
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Figure 4-2: Prevalence if fat alterations by current use of (a) lamivudine, and (b) stavudine 
 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
  
Lamivudine Stavudine (a) (b) 
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Figure 4-3: Prevalence of fat alterations by current use of (a) tenofovir, and (b) zidovudine 
 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
  
(a) (b) Tenofovir Zidovudine 
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Figure 4-4: Prevalence of fat alterations by current use of efavirenz 
 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
When considering type of ART regimen, across all fat alteration outcomes the highest 
prevalence was seen in subjects on triple class therapy at recruitment (n = 14), with 
prevalences being similar in subjects on PI-based HAART (n = 204) and NNRTI-based HAART 
(n = 117), as illustrated in Figure 4-5. Subjects on NRTI mono-therapy (n =29) had the lowest 
prevalence of fat alterations.  However, only the association between recruitment ART regimen 
and concurrent lipoatrophy and lipohypertrophy was statistically significant (p = 0.003). 
 
  
Efavirenz 
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Figure 4-5 : Prevalence of fat alterations outcomes at recruitment by antiretroviral 
therapy regimen 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
4.3.2 Univariable analyses of factors associated with body fat alterations 
A significant increased risk of any body fat alterations was seen with increasing age: compared 
to 2-6 year olds, 7-11 year olds had an almost 3-fold increase in risk, and 12-18 year olds had 
an almost 5-fold increase in risk (Table D-2 in Appendix D). However, the risks associated with 
undergoing puberty (OR: 2.43, 95% CI: 1.47, 4.01), and completed puberty (OR: 2.75, 95% CI: 
1.58, 4.79), compared to pre-pubescence, were equivalent with each other. White ethnicity was 
associated with a 3-4 fold increased risk compared to Black ethnicity (p < 0.001), while a history 
of CDC-defined clinical disease was associated with a 2-3 fold increased risk (p ≤ 0.001), and 
co-infection with hepatitis-C was associated with a 2-3 fold increased risk (p = 0.015). Use of 
any NRTI at recruitment (OR: 2.60, 95% CI: 1.09, 6.21), and specifically stavudine (OR: 3.31, 
95% CI: 1.69, 6.47) were significant risk factors for body fat alterations. Both NRTI and 
stavudine were significant risk factors for body fat alterations in univariable analysis despite only 
30% (n/N = 30/159) of the total number of subjects currently on NRTIs being on stavudine. 
Additionally, current efavirenz was associated with a 70% increase in risk of any body fat 
alterations (p = 0.024).  
Factors associated with a significant decrease in risk of body fat alterations included moderate 
immunosuppression at recruitment, (OR: 0.51, 95% CI: 0.31, 0.86), and current zidovudine at 
recruitment (OR: 0.60, 95% CI: 0.38, 0.97). There was no statistically significant association 
found between fat alterations and sex, nadir CDC-defined immune stage, recruitment CDC 
clinical stage, detectable viral load or current PI use.  
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With respect to lipohypertrophy, females had a significant 76% increased risk compared with 
males (Table D-2 in Appendix D). Furthermore, the 12-18 year old group had an increased risk 
that was over 3-times that for 2-6 year old group, and White ethnicity was associated with a 2-
fold increased risk compared to Black ethnicity (p < 0.05). Undergoing puberty (Tanner II-IV) 
and completion of puberty (Tanner V) were associated with an increased risk of lipohypertrophy, 
compared to a pre-pubescent state (Tanner I): OR: 1.75, 95% CI: 1.00, 3.08, and OR: 2.49, 
95% CI: 1.36, 4.56 respectively.  Symptomatic maximum clinical stage was associated with a 
significant 2-fold increase in risk, while hepatitis C co-infection was associated with a 3-fold 
increase in risk (p ≤ 0.015): the size of these associations was similar to those seen with any fat 
alterations. The only specific ART drug to be significantly associated with lipohypertrophy was 
efavirenz, which was associated with a 68% increase in risk. In comparison to PI-based 
HAART, triple class therapy was associated with a significant increased risk of lipohypertrophy 
(OR: 3.14, 95% CI: 1.01, 9.75). Immune stage, clinical stage at recruitment, detectable viral 
load, and current use of NRTI or PI did not show a statistically significant association with 
lipohypertrophy.   
In common with any fat alterations and lipohypertrophy, increasing age group was associated 
with an increase in risk of lipoatrophy: in comparison to the 2-6 year old group, the 7-11 year old 
group had a 3-4 fold risk, and the 12-18 year old group had a 6-7 fold  risk (p ≤ 0.039), as 
illustrated in Table 4-3. Similarly, black ethnicity (OR: 4.93, 95% CI: 2.46, 9.89), and both 
undergoing (OR: 2.54, 95% CI: 1.44, 4.47) or completion (OR: 2.05, 95% CI: 1.09, 3.84) of 
puberty were also significant risk factors for lipoatrophy (as with other fat alterations outcomes).  
HIV-related factors associated with a significant risk of lipoatrophy were immune stage at 
recruitment and maximum clinical stage: symptomatic maximum clinical status was associated 
with a 2-3 fold increased risk; while moderate immunosuppression at recruitment was 
associated with a 56% reduced risk. Indeed, moderate immunosuppression was associated with 
a decrease in risk of all body fat alterations outcomes, but was only statistically significant with 
respect to lipoatrophy.  
Use of any NRTI at recruitment was associated at a significant increased risk of lipoatrophy 
(OR: 3.94, 95% CI: 1.17, 13.26), as was stavudine (OR: 2.66, 95% CI: 1.40, 5.07). However 
zidovudine was associated with a 47% decreased risk of lipoatrophy (p = 0.025).  While current 
NNRTI was associated with a non-significant increase in risk, current efavirenz was associated 
with an 82% increased risk (p = 0.017). Moreover, triple class therapy at recruitment was 
associated with a significant, almost 4-fold increased risk of lipoatrophy compared to PI-based 
HAART.  
As with other fat alterations outcomes, increasing age and ethnicity were associated with a 
significant increased risk of the combined lipohypertrophy and lipoatrophy occurring together. 
However, the size of the increased risk was greater than with other outcomes: 12-18 years of 
age was associated with an 8-9 fold risk compared to 2-6 years, and Black ethnicity was 
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associated with a 5-6 fold risk compared to white ethnicity (Table D-2 in Appendix D). Children 
who had ever experienced CDC stage B (moderate) symptoms had a two-fold increased risk of 
the combined sub-type (p = 0.026). While current NRTI use was associated with a non-
significant increased risk of concurrent lipoatrophy and lipohypertrophy, current tenofovir was 
statistically significant (OR: 1.92, 95% CI: 1.04, 3.54). However, a significant reduced risk was 
associated with both current lamivudine (51%) and current zidovudine (33%) use. Use of any 
NNRTI, or efavirenz, at recruitment were both associated with a 2-fold increased risk of he 
combined phenotype (p ≤ 0.041). However, the association seen with any NNRTI may be driven 
by efavirenz since 70.7% (n/N = 94/133) of the subjects on NNRTI’s at recruitment were on this 
specific drug. The small number of children receiving triple class therapy had a more than 5-fold 
statistically significant increased risk compared with those on PI-based HAART.  
Viral load, and both CDC-defined immune and clinical status at recruitment, showed consistent 
associations across body fat alterations outcomes: both immunosuppression and detectable 
viral load were associated with a decrease in risk, and moderate clinical symptoms were 
associated with an increase in risk. Interestingly, despite all three covariates being (direct and 
indirect) markers of HIV infection, where one covariate was statistically significant with respect 
to an outcome, the remaining two were non-significant. Both detectable viral load and 
immunosuppression can occur as a result of treatment failure or the absence of treatment, and 
thus the protective effect against fat alterations seen in univariable analyses may be 
confounded by the increased risk associated with ART.  
Ever use of any ART was a significant risk factor for any body fat alterations (OR: 2.78, 95% CI: 
1.10, 7.01) and lipoatrophy (OR: 4.38, 95% CI: 1.26, 23.11), as illustrated in Table D-3 in 
Appendix D. Ever use of didanosine, stavudine, efavirenz, ritonavir booster, and indinavir were 
all associated with a significant increased risk of all fat alterations outcomes. Ever use of 
tenofovir was associated with a significant (p < 0.05) increased risk of all outcomes except 
lipohypertrophy. While nelfinavir was associated with a significant increased risk of any body fat 
alterations, and saquinavir was associated with a significant increased risk of lipohypertrophy. 
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4.3.3 Multivariable models including antiretroviral therapy class  
Use of NNRTI at recruitment was a positive risk factor in final multivariable models using 
classes of ART as explanatory variables (Figure 4-6 and Figure 4-7): this was consistent with 
univariable analyses where efavirenz was associated with increased risk of all outcomes (Table 
D-3 in Appendix D). An independent increased risk was seen for any fat alterations (AOR: 1.97, 
95% CI: 1.11, 3.50, p = 0.021), lipohypertrophy (AOR: 1.83, 95% CI: 1.03, 3.26, p = 0.039) and 
lipoatrophy (AOR: 1.85, 95% CI: 1.01, 3.42, p = 0.048), while a 7-8 fold risk was seen for 
combined lipohypertrophy and lipoatrophy (AOR: 7.82, 95% CI: 1.97, 31.04, p = 0.003): these 
associations were all of greater magnitude than the ORs seen with efavirenz. Maximum CDC 
clinical stage was associated with increased risk in all models, but was only significant in the 
models for any fat alterations where stage B was associated with 2 fold risk (AOR: 1.94, 95% 
CI: 1.05, 3.56, p = 0.034), and for lipohypertrophy where stage C was associated with a 2-3 fold 
risk (AOR: 2.40, 95% CI: 1.17, 4.91, p = 0.016), versus an asymptomatic CDC stage: both 
increases in magnitude compared to the univariable analyses. 
White ethnicity was also a consistent risk factor: this was significant for any body fat alterations 
(AOR: 3.48, 95% CI: 1.59, 7.62, p = 0.002), lipoatrophy (AOR: 5.08, 95% CI: 1.95, 13.27, p = 
0.001) and combined lipohypertrophy and lipoatrophy (AOR: 4.28, 95% CI: 1.09, 16.79, p = 
0.037), but non-significant for lipohypertrophy (AOR: 1.93, 95% CI: 0.94, 3.97, p = 0.074). As 
seen with efavirenz and NNRTI in univariable and multivariable analyses, the adjusted risk 
associated with White ethnicity was of greater magnitude compared to the unadjusted risk.   
Females were at increased risk of lipohypertrophy (AOR: 1.87, 95% CI: 1.08, 3.22, p = 0.025, p) 
compared to males. A 2-fold increased risk of the combined phenotype was also associated 
with female sex, but this was non-significant. BMI was only a significant risk factor for any fat 
alterations, with a 17% increased risk for each m/kg2 (AOR: 1.17, 95% CI: 1.07, 1.29, p = 
0.001). Current PI was associated with the combined lipoatrophy and lipohypertrophy (AOR: 
5.81, 95% CI: 1.46, 23.20 p = 0.013) despite not being significant in univariable analyses. 
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Figure 4-6: Final multivariable models for (a) any body fat alterations, and (b) lipohypertrophy using classes of antiretroviral therapy as 
explanatory variables 
 
All models adjusted for age and maximum duration of ART use. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms 
(a) (b) 
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Figure 4-7: Final multivariable models for (a) lipoatrophy, and (b) combined lipohypertrophy and lipoatrophy, using classes of antiretroviral therapy 
as explanatory variables 
 
All models adjusted for age and maximum duration of ART use. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms 
(a) (b) 
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4.3.4 Multivariable models including specific antiretroviral drugs 
Body fat alterations 
In the final multivariable model for any fat alterations (Table 4-3), stavudine at recruitment was 
associated with a significant 5-fold increased risk, and efavirenz was associated with a 
significant 2-fold increased risk. However, didanosine was associated with a non-significant 
reduction in risk (AOR: 0.42, 95% CI: 0.17, 1.01). Other factors associated with a significant risk 
were White ethnicity compared to Black ethnicity (AOR: 3.32, 95% CI: 1.49, 7.41), maximum 
CDC-clinical stage C compared to stage N/A (AOR: 2.34, 95% CI: 1.18, 4.65), and BMI (AOR: 
1.17, 95% CI: 1.06, 1.28). 
Similar significant associations were found between ethnicity, maximum CDC clinical status, 
BMI, and efavirenz (NNRTI) as in the ART class model for body fat alterations. Additional 
associations were made with stavudine (positive) and didanosine (negative) in the individual-
drug multivariable model.  
Didanosine did not show a significant association with any body fat alterations in either 
univariable or multivariable modelling. However, didanosine was retained in the final 
multivariable model because of its effect on the statistical significance of stavudine. Despite the 
reported toxicity of this ART combination296,388, toxicities have been shown to be relatively rare 
in children389.  Missing data for both didanosine and stavudine, and also interactions with other 
variables was investigated in the multivariable models: none of these factors were found to be 
statistically significant.    
In sensitivity analysis, rerunning the final model with moderate/severe fat alterations as the 
outcome, only White ethnicity (AOR: 3.17, 95% CI: 1.09, 9.28) and BMI (AOR: 1.21, 95% CI: 
1.09, 1.35) remained statistically significant as illustrated in the Table D-5 in Appendix D: no 
drug had a significant association to moderate/severe body fat alterations.   
The final multivariable model incorporating ever-use of specific ART drugs (Table D-4 in 
Appendix D) contained White ethnicity (AOR: 2.56, 95% CI: 1.25, 5.23), BMI (AOR: 1.2, 95% CI: 
1.09, 1.31), stavudine (AOR: 3.56, 95% CI: 2.08, 6.09), and efavirenz (AOR: 1.86, 95% CI: 
1.10, 3.16), No factor was associated with a significant decrease in risk of body fat alterations 
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Table 4-3: Final multivariable model for fat alterations using specific antiretroviral drugs 
  n AOR 95% CI p-value 
Age Per year 302 1.08 (0.99, 1.18) 0.102 
Maximum 
duration of 
ART 
Per year 302 1.03 (0.96, 1.12) 0.389 
Ethnicity Black 73 1   
White 215 3.32 (1.49, 7.41) 0.003 
Other 14 1.95 (0.46, 8.27) 0.364 
Maximum 
CDC clinical 
stage 
N/A 121 1   
B 110 1.87 (0.99, 3.52) 0.052 
C 71 2.34 (1.18, 4.65) 0.015 
BMI Per kg/m2 302 1.17 (1.06, 1.28) 0.002 
Stavudine Not current 266 1   
Current 36 5.40 (2.15, 13.56) <0.001 
Didanosine Not current 261 1   
Current 41 0.42 (0.17, 1.01) 0.052 
Efavirenz Not current 226 1   
Current 76 1.93 (1.03, 3.62) 0.042 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratios (AOR) and 95% 
confidence interval for fat redistribution by participant characteristic. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms 
 
 
Lipohypertrophy  
No specific ART drug remained statistically significant in the multivariable model for 
lipohypertrophy. In the adjusted model excluding any specific drug, both maximum CDC-defined 
clinical condition and BMI were associated with significantly increased risk (Table 4-4).   
Furthermore, in contrast to the multivariable models using class of ART, ethnicity was not 
statistically significant (and so not included in the model), while BMI at recruitment was 
significant. (AOR: 1.46, 95% CI: 1.30, 1.63) Risk associated with maximum clinical symptoms 
was similar to that seen in univariable analysis.  
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Table 4-4: Final multivariable model for lipohypertrophy using specific antiretroviral 
drugs 
  N AOR 95% CI p-value 
Age Per year 337 0.93 (0.85, 1.02) 0.127 
Maximum 
duration of 
ART 
Per year 337 0.99 (0.91, 1.07) 0.744 
Maximum 
CDC clinical 
condition 
N/A 139 1   
B 121 2.08 (1.07, 4.05) 0.031 
C 77 2.24 (1.07, 4.69) 0.040 
BMI Kg/m2 337 1.46 (1.30, 1.63) <0.001 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval for lipohypertrophy by participant characteristic. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms 
 
Only BMI (AOR: 1.51, 95% CI: 1.21, 1.75) remained statistically significant in the sensitivity 
analysis rerunning the final model with moderate/severe lipohypertrophy (Table D-5 in Appendix 
D). While history of severe clinical disease was associated with a 22% increase in risk, this was 
non-significant (p = 0.707). In contrast to the final model using current drugs at recruitment, a 
single specific ART drug was significant in the final model for lipohypertrophy using ever drug 
use: stavudine was associated with a 2-3 fold increase in risk (AOR: 2.53, 95% CI: 1.38, 4.63). 
The only other factor that was significant in this model was BMI (AOR: 1.46, 95% CI: 1.30, 1.64) 
as illustrated in the Table D-4 in Appendix D.  
 
Lipoatrophy 
Use of stavudine at recruitment was associated with an independent and significant 2-3 fold 
increase in risk of lipoatrophy in the final multivariable model (Table 4-5). Consistent with the 
previous models for any fat alterations and those using class of ART as explanatory variables, 
White ethnicity was associated with a significantly increased risk of lipoatrophy compared to 
Black ethnicity. (AOR: 4.01, 95% CI: 1.55, 10.38).  
While children who had ever had moderate symptoms of HIV disease had a nearly 2-fold 
increased risk (p = 0.053), having a history of moderate immunosuppression was associated 
with a significant 58% reduction in risk of lipoatrophy. However, in previous univariable analysis, 
maximum clinical stage had been associated with a significant two-fold increased risk, while the 
risk associated with nadir CDC-define immune stage was non-significant. Nadir clinical condition 
appeared to be confounded by both age and maximum clinical condition acting in the opposite 
direction (negative confounding) in univariable analysis. In contrast to previous multivariable 
models using class of ART, age was a significant risk factor, with a 20% increase in risk of 
lipoatrophy for every year of age.  
Body fat alterations at recruitment  Chapter 4 
165 
 
 
Table 4-5: Final multivariable model for lipoatrophy using specific antiretroviral therapy 
drugs 
  n AOR 95% CI p-value 
Age Per year 303 1.20 (1.09, 1.32) <0.001 
Maximum 
duration of 
ART 
Per year 303 1.03 (0.95, 1.11) 0.502 
Ethnicity Black 72 1   
White 217 4.01 (1.55, 10.38) 0.004 
Other 14 1.35 (0.22, 8.34) 0.746 
Maximum 
CDC clinical 
condition 
N/A 120 1   
B 111 1.95 (0.99, 3.85) 0.053 
C 72 1.58 (0.73, 3.45) 0.248 
Nadir CDC 
immune-
suppression 
Stage 1 111 1   
Stage 2 122 0.42 (0.21, 0.83) 0.012 
Stage 3 70 0.72 (0.33, 1.58) 0.410 
Stavudine Not current 268 1   
Current 35 2.69 (1.12, 6.47) 0.027 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval for lipoatrophy by participant characteristic. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. CDC-defined immune status - stage 1: 
no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. 
 
The independent significant negative association with nadir immune status may occur as a 
result of confounding by association. Previous poor viral control may result in 
immunosuppression which may lead to ART treatment: in such a situation both poor nadir 
immune status and current ART is associated with lipoatrophy. Since there is no measure of 
viral load at the nadir clinical status, this confounding is difficult to investigate. 
In sensitivity analysis modelling moderate/severe lipoatrophy, stavudine was associated with a 
non-significant increase in risk (AOR: 2.18, 95% CI: 0.77, 6.15), as illustrated in Table D-5 in 
Appendix D. However, both a history of moderate immunosuppression and age were significant 
risk factors, the former being associated with a reduced risk (AOR: 0.32, 95% CI: 0.14, 0.76), 
and the latter with an increased risk (AOR: 1.24, 95% CI: 1.09, 1.42), reinforcing the results 
summarized in Table 4-5. 
The final multivariable model incorporating ever-use of ART contained both stavudine (AOR: 
4.98, 95% CI: 2.58, 9.61), and efavirenz (AOR: 1.87, 95% CI: 1.05, 3.35). Furthermore, the 
association with White ethnicity in the ever-ART model was similar to that seen in the current-
ART model, i.e. AOR: 3.87, 95% CI: 1.50, 10.01). Age was also associated with a significant 
increase in risk (AOR: 1.17, 95% CI: 1.06, 1.28). No other factor was statistically significant in 
the final model (Table D-4 in Appendix D).  
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Lipohypertrophy and lipoatrophy occurring together 
Two drugs were significantly associated with a reduced risk of this concurrent lipoatrophy and 
lipohypertrophy: zidovudine and lamivudine, with 67% and 54% reductions in risk respectively. 
Both White ethnicity (4.15, 95% CI: 0.99, 17.45) and BMI (AOR: 1.20, 95% CI: 0.07, 11.70) 
were associated with an increase in risk, but this was only statistically significant in the latter 
(Table 4-6). All factors, with the exception of BMI, had a magnitude and direction similar to 
those seen in unadjusted analysis (Table D-3 in Appendix D). 
Table 4-6: Final multivariable model for both lipohypertrophy and lipoatrophy occurring 
together, using specific antiretroviral therapy drugs 
  n AOR 95% CI p-value 
Age Per year 317 1.04 (0.91, 1.19) 0.544 
Maximum 
duration of 
ART  
Per year 317 1.20 (1.06, 1.36) 0.003 
Ethnicity Black 82 1   
White 220 4.15 (0.99, 17.45) 0.052 
Other 15 0.90 (0.07, 11.70) 0.939 
BMI Per kg/m2 317 1.20 (1.06, 1.36) 0.003 
Zidovudine Not current 222 1   
Current use 95 0.33 (0.12, 0.91) 0.032 
Lamivudine Not current 98 1   
Current use 219 0.46 (0.21, 0.99) 0.047 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval (95% CI) for lipohypertrophy and lipoatrophy occurring together by participant 
characteristic. 
 
White ethnicity remained a significant factor associated with an increased risk of 
moderate/severe combined lipohypertrophy and lipoatrophy in sensitivity analysis (AOR: 20.19, 
95% CI: 1.40, 291.36). Furthermore, lamivudine was associated with a significant 94% 
reduction in risk (AOR: 0.06, 95% CI: 0.01, 0.58), as illustrated in (Table D-5 in Appendix D). 
Further sensitivity analyses where the threshold to include covariates was increased to 10%. 
Categories of ART thus significantly associated with body fat alteration outcomes were similar to 
those seen in the models where inclusion significance was set at 5% (Appendix D: Table D-8). 
However, in the models investigating specific drugs: the models for any body alterations and 
lipoatrophy resulting from using 5% and 10% thresholds differed: at the 10% level, zidovudine 
was significantly associated with increased risk of body fat alterations, while efavirenz was 
significantly associated with increased risk of lipoatrophy (Appendix D: Table D-8). 
In contrast to the model using current-ART, no factor in the final multivariable model for the 
combined phenotype using ever-ART was associated with a decrease in risk: age (AOR: 1.13, 
95% CI: 1.00, 1.27), efavirenz (AOR: 2.38, 95% CI: 1.11, 5.12), didanosine (AOR: 3.44, 95% CI: 
1.47, 8.07), ritonavir booster (AOR: 2.92, 95% CI: 1.16, 7.33), and indinavir (AOR: 4.00, 95% 
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CI: 1.04, 15.41) were all significant factors in the final model, as illustrated in Table D-4 in 
Appendix D. 
The stepwise multivariable modelling investigating current ART at recruitment indicates that 
while NNRTIs were consistently associated with all body fat alteration outcomes, only one 
specific drug, efavirenz was significant for a specific outcome (any body fat alterations). Use of 
any PI was associated with increased risk of concurrent lipoatrophy and lipohypertrophy at 
recruitment, but no specific PI was associated with any outcome. While NRTI’s as a whole were 
not associated with any outcome at recruitment, stavudine was associated with increased risk of 
any fat alterations, and lipoatrophy, didanosine with reduced risk of any alterations, and both 
zidovudine and lamivudine with reduced risk of the concurrent manifestation in multivariable 
models.  
White ethnicity was a consistent independent risk factor for all body fat alteration outcomes 
excluding lipohypertrophy, and a history of clinical disease was associated with increased risk of 
both any fat alterations, and lipohypertrophy. In contrast to the models using current-ART at 
recruitment as explanatory variables, all statistically significant drugs in the ever-ART 
multivariable models were associated with an increased risk: ever-stavudine was associated 
with a 2-5 fold increased risk of any fat alterations, lipohypertrophy, and lipoatrophy, ever-
efavirenz was associated with a <3-fold increased risk of any fat alterations, lipoatrophy, and the 
combined manifestation, while didanosine, ritonavir booster and indinavir were associated with 
an increased risk of the combined manifestation. Furthermore age was significantly associated 
with an increased risk of both lipoatrophy and lipohypertrophy in the ever-ART multivariable 
models. 
 
4.3.5 Multivariable models including type of ART regimen 
In these models in which type of ART regimen (e.g. PI-based HAART, NNRTI-based HAART, 
triple therapy, mono-therapy) was included, there was adjustment for age, duration of ART, 
ethnicity and maximum CDC clinical stage. Triple class therapy was the only type of regimen 
associated with body fat alterations outcomes, with a significant increased risk of any fat 
alterations (AOR: 5.41, 95% CI: 1.21, 24.13, p = 0.027) lipohypertrophy (AOR: 4.06, 95% CI: 
1.12, 14.75, p = 0.033), lipoatrophy (AOR: 8.32, 95% CI: 1.73, 40.07, p = 0.008), and combined 
lipohypertrophy and lipoatrophy (AOR: 6.30, 95% CI: 1.36, 29.11, p = 0.018): log adjusted AOR 
are illustrated in Figure 4-8. Adjusted odds ratios for triple class therapy were larger than the 
corresponding unadjusted odds ratios (Table D-3 in Appendix D).  
Age was associated with a significant 8-16% increased risk of each outcome per year (p ≤ 
0.044), while White ethnicity was significantly associated with an increased risk of body fat 
alterations (AOR: 3.09, 95% CI: 1.47, 6.48, p = 0.003), and lipoatrophy (AOR: 4.80, 95% CI: 
1.84, 12.54, p = 0.001). This was in contrast to the previous multivariable models where age 
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was not a significant risk factor, and White ethnicity was associated an increased risk of all 
outcomes except lipohypertrophy. As with the final stepwise multivariable models, maximum 
CDC-defined clinical state was a significant positive risk factor for both any fat alterations, and 
lipohypertrophy. 
4.3.6 Investigation of puberty as a risk factor 
As discussed in Section 4.1, Tanner score was not included in the backward stepwise logistic 
modelling to avoid over-controlling for puberty, given that age was included in all models, and 
sex was included in the stepwise process. However, sex was not significant in any of the final 
multivariable models. In order to investigate the role of puberty further, Tanner score was 
included in the previously constructed final models modelling specific ART drugs at recruitment. 
Further models were then fitted including an interaction term between sex and age, again using 
the previously fitted multivariable drugs for current ART. In all these models, the additional 
terms were not statistically significant (Table D-6 and Table D-7 in Appendix D).  
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Figure 4-8 Multivariable models for fat alterations outcomes using type of antiretroviral therapy as an explanatory variable 
 
Log adjusted odds ratio displayed for clarity. All models adjusted for age and maximum duration of ART use at recruitment, ethnicity and maximum CDC-defined clinical stage. Fat 
redistribution: n = 329, lipoatrophy n = 327, lipohypertrophy: n = 328, and combined lipoatrophy and lipohypertrophy: n = 329 
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4.4 Key points 
 
• Prevalence of body fat alteration outcomes were significantly higher in older 
adolescents compared to younger children, and in White subjects compared to Black 
subjects. Prevalence was also higher in subjects who were undergoing or had 
completed puberty, had experienced symptomatic HIV disease, and among hepatitis-C 
co-infected individuals: these were not statistically significant for all outcomes. 
 
• Current use of NNRTI was associated with an independent significant increased risk of 
all fat alterations outcomes: the size of this effect was similar for all outcomes (2-fold), 
but increased to 8-fold risk for the combined phenotype (Table 4-7).  
 
Table 4-7: Summary of risk factors for fat alterations outcomes across all multivariable 
models. 
 Fat alterations Lipohypertrophy Lipoatrophy Combined 
lipohypertrophy 
and lipoatrophy 
Age 
↑ ↑ ↑ ↑ 
Maximum 
duration of 
ART 
   ↑ 
Gender 
 ↑   
White ethnicity 
↑  ↑ ↑ 
Maximum CDC 
clinical 
condition 
↑ ↑   
Nadir CDC 
immune-
suppression 
  ↓  
BMI 
↑ ↑  ↑ 
NNRTI* 
↑ ↑ ↑ ↑ 
PI* 
   ↑ 
Stavudine* 
↑  ↑  
Zidovudine* 
   ↓ 
Lamivudine* 
   ↓ 
Didanosine* 
↓    
Efavirenz* 
↑    
Triple class 
therapy* ↑ ↑ ↑ ↑ 
Only factors that were statistically significant in at least one individual model are shown. Arrows indicate 
direction of association. *Current-use at the time of recruitment 
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• Although current PI use was a significant and independent risk factor for increased 
concurrent lipoatrophy and lipohypertrophy, individual PI drugs were not significant in 
any model. 
 
• Recruitment stavudine and efavirenz were associated with an independent significant 2-
5 fold increased risk of all body fat alterations outcomes 
 
• Zidovudine and lamivudine use at recruitment were associated with a 54-67% 
decreased risk of concurrent lipohypertrophy and lipoatrophy. 
 
• Current use of any specific ART drug was not significantly associated with 
lipohypertrophy, but ever use of stavudine and efavirenz were significant risk factors in 
multivariable models.  
 
• Ever use of stavudine, efavirenz, didanosine, ritonavir booster and indinavir were 
independent significant risk factors for specific body fat alterations: no ever-use of ART 
was associated with a significant decreased risk of body fat alterations. 
 
• Triple class therapy was associated with a 4-8 fold increased risk of all outcomes 
compared to PI-based HAART in multivariable analyses.  
 
• White ethnicity and maximum clinical status were consistently associated with a 
significant and independent increased risk of all types of body fat abnormality 
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5. Metabolic abnormality and lipodystrophy syndrome at 
recruitment 
 
5.1 Objectives 
The main objectives of this chapter were to identify risk factors associated with prevalent 
metabolic abnormality and lipodystrophy syndrome at recruitment. Specific objectives were to: 
• Investigate specific metabolic abnormality outcomes: (i) any metabolic abnormality, (ii) 
fasting hypertriglyceridemia, (iii) hypercholesterolemia, and (iv) both 
hypercholesterolemia and fasting hypertriglyceridemia occurring together, by estimating 
their prevalence  
 
• Identify risk factors for each outcome by fitting univariable regression models. 
 
• Determine the final multivariable model for each outcome using categories of 
antiretroviral therapy at recruitment as explanatory variables and to refit this in order to 
explore the effects of inclusion of specific drug exposure, or of ART regimen type (e.g. 
PI-based HAART, triple class) in place of ART class. 
 
• Estimate the prevalence of lipodystrophy syndrome (encompassing both/either body fat 
alterations and metabolic abnormality), and identify risk factors in the form of individual 
ART drugs, classes of ART, and ART regimen, as above.  
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5.2 Specific methods  
Methods are as described in the previous chapter (Chapter 4): this was a cross-sectional 
analysis using data collected at recruitment (n = 428). However, the outcome measures 
investigated here are: any metabolic abnormality, fasting hypertriglyceridemia, 
hypercholesterolemia, both hypercholesterolemia and fasting hypertriglyceridemia occurring 
together, and LS, as summarized in Box 5-1.   
Box 5-1: Core outcomes investigated in this chapter 
Any metabolic abnormality 
Any fasting hypertriglyceridemia 
Any hypercholesterolemia 
Both hypercholesterolemia and fasting hypertriglyceridemia occurring together 
Any lipodystrophy syndrome 
Definitions of metabolic abnormality, according to serum thresholds by gender and age are provided in Table 
B.1 and Table B.2 in Appendix B. Lipodystrophy syndrome is defined by the occurrence of at least one the 
symptoms presented in Box 2 1 and Box 2 2 in Chapter 2.  
ART explanatory variables are outlined in Table 2-1 in Section 2.8.6 in Chapter 2.  
 
5.2.1 Estimation of prevalence 
Prevalences of each outcome by potential risk factors (e.g. ethnicity, specific ART drug, etc.) 
were estimated with respect to the numbers of subjects with complete data for that factor from 
the total study population. 
 
5.2.2 Univariable and multivariable regression modelling 
Risk factors were identified by fitting univariable and multivariable logistic regression models 
using the methods described in Section 2.8.6. As previously, three groups of multivariable 
models were fitted: (i) models for the outcomes listed in Box 5-1 using classes of ART drugs as 
covariates, together with non-treatment related factors, (ii) models fitted using specific ART 
drugs and non-treatment related factors as explanatory variables, and (iii) models using type of 
ART regimen as an explanatory variable. Classes of ART and specific ART models were fitted 
using backward stepwise covariate selection, while ART regimen models were intuitively 
adjusted for other covariate.  
Sensitivity analyses were conducted by re-fitting the final models including specific ART drugs 
as explanatory variables using moderate/severe metabolic abnormality, fasting 
hypertriglyceridemia, and hypercholesterolemia as outcome measures. The threshold for 
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moderate/severe metabolic abnormalities was designated as 20% above the original age- and 
gender-defined limits (outlined in Table B-1 and Table B-2 in Appendix B).  Results are shown 
in Table E-5 in Appendix E.  
Further sensitivity analyses were conducted by repeating the stepwise covariate selection but 
using ever-use of specific ART drugs (in place of current-use at the time of recruitment). Results 
of sensitivity analyses of multivariable models, and models using ever-use of ART as 
explanatory variables are included in Table E-4 in Appendix E.  
A final set of sensitivity analyses were conducted by repeating the covariate selection procedure 
using a threshold of 10% statistical significance: these are illustrated in Appendix E. 
Multivariable logistic regression models examining the role of ART regimen (i.e. PI-based 
HAART, NNRTI-based HAART, NRTI-monotherapy, and triple class therapy) on metabolic 
outcomes were not determined using stepwise variable selection, but only included   covariates 
chosen a priori. These were age, maximum duration of ART and also detectable viral load at 
recruitment. Detectable viral load was included in these models as it was frequently statistically 
significant in the fitted univariable and multivariable models for metabolic abnormality, and 
furthermore reflect drug adherence. 
 
5.2.3 Metabolic abnormality outcomes and glucose intolerance  
Although glucose intolerance was included in the definition of metabolic abnormality (Box 2-2 in 
Chapter 2), only 7 subjects presented with this condition at recruitment: thus additional analyses 
investigating associations with participants’ characteristics, and risk factors could not be 
conducted for glucose intolerance.    
 
5.2.4 Investigation of lipodystrophy syndrome and antiretroviral regimen 
Multivariable logistic regression models using type of ART regimen as an explanatory variable 
and LS as the response variable also included age and maximum duration of ART at 
recruitment, ethnicity and maximum CDC-defined clinical status. These covariates were chosen 
as they were identified as being statistically significant risk factors in several of the 
specific/categorical ART models.  
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5.3 Results 
5.3.1 Prevalence of metabolic abnormality outcomes by subject 
characteristics 
Table 5-1 summarizes the distribution of metabolic abnormality at recruitment by subject 
characteristic. No statistically significant differences were seen for any metabolic abnormality 
outcomes by sex. However, significant (p < 0.05) differences in metabolic abnormality 
prevalence were seen between age groups, with a greater proportion of 2-6 year olds having an 
abnormality compared to 7-11 year olds, and a greater proportion of 7-11 year olds having 
abnormal results compared to 12-18 years, for most outcomes. Across all outcomes, subjects of 
White ethnicity had the highest prevalence of abnormality, but there were significant differences 
in prevalence for only two outcomes:  any metabolic abnormality (30% versus 18% for White 
versus Black subjects) and fasting hypertriglyceridemia (21% versus 10%). Regarding puberty, 
the highest prevalence of metabolic abnormality outcomes was seen in subjects at Tanner 
stage I. This was followed by stage V then stages II-IV in the case of any metabolic abnormality, 
with the converse being seen in fasting hypertriglyceridemia and combined hyperlipidemia (p < 
0.01 for both outcomes). While a greater percentage of subjects who were not co-infected with 
hepatitis-C had metabolic abnormality compared to co-infected subjects, these differences were 
not significant.   
There were no significant differences in prevalence of metabolic abnormality across maximum 
or recruitment CDC clinical status, or nadir or recruitment immune status. However, for most 
outcomes, subjects with current/previous immunosuppression or clinical symptoms had lower 
prevalence compared to subjects with no evidence of immunosuppression or clinical symptoms. 
Prevalence of all outcomes was higher in subjects with undetectable viral load: these 
differences were significant for any metabolic abnormality (30% vs. 20%: p = 0.016), 
hypercholesterolemia (19% vs. 6%: p < 0.001), or combined hypercholesterolemia and fasting 
hypertriglyceridemia (7% vs. 2%, p = 0.020). 
Prevalence of any metabolic abnormality, fasting hypertriglyceridemia and the combination of 
hypercholesterolemia and fasting hypertriglyceridemia occurring together was greater among 
subjects on NRTI compared to those not on this class of ART (Table 5-1), but these differences 
were non-significant. However, since all but 2 subjects on ART at recruitment were on NRTI 
(n/N = 362/364), these non-significant associations are analogous to the association between 
these outcomes and any current ART use. Indeed, following exclusion of subjects who were 
ART naïve at recruitment, of the 2 subjects on NRTI at recruitment only 1 had metabolic 
abnormality: the differences in prevalence were significant (p ≤ 0.032) for hypercholesterolemia, 
and for combined hypercholesterolemia with fasting hypertriglyceridemia (Table E-1 in Appendix 
E). Prevalence of all outcomes was non-significantly higher in subjects on NNRTI compared to 
those non on NNRTI: this is contrast to body fat alterations where prevalence was higher in 
subjects not currently on NNRTI.  
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Table 5-1: Prevalences of metabolic abnormality at recruitment (N = 428) 
 
 
Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Combined fasting 
hypertriglyceridemia, and 
hypercholesterolemia 
 
 
% n/N % n/N % n/N % n/N 
Demographic factors 
        
Sex Male 28 54/195 20 40/196 13 26/199 7 13/198 
 Female 24 50/209 15 31/211 12 26/213 4 9/210 
Age (years) 2-6 37*** 43 26* 11/43 26*** 11/43 14*** 6/43 
 7-11 37*** 42/115 23* 26/115 24*** 28/116 10*** 12/116 
 12-18 19*** 50/257 13* 34/260 6*** 17/264 2*** 4/260 
Ethnicity Black 18* 18/102 10* 10/105 9 10/107 3 3/103 
 White 30* 83/279 21* 58/279 15 14/282 6 18/282 
 Other 18* 3/17 12* 2/17 0 0/17 0 0/17 
Country of 
residence 
Italy 26 70/270 20 269 10*** 27/273 4* 11/273 
Belgium 20 16/80 10 83 11*** 9/84 4* 3/80 
Poland 
 
34 22/65 15 66 30*** 20/66 12* 8/66 
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Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Combined fasting 
hypertriglyceridemia, and 
hypercholesterolemia 
 
 
% n/N % n/N % n/N % n/N 
Infection factors 
        
CDC immune 
stage at 
recruitment 
Stage 1 28 90/316 18 56/318 15 48/322 5 17/320 
Stage 2 19 16/83 17 14/83 8 7/84 6 5/83 
Stage 3 13 2/16 6 1/17 6 1/17 0 0/16 
Nadir CDC 
immune 
stage 
Stage 1 30 48/158 18 29/158 18 28/159 7 11/158 
Stage 2 23 40/174 17 30/175 10 17/178 4 7/177 
Stage 3 24 20/83 14 12/85 13 11/86 5 4/84 
CDC clinical 
stage at 
recruitment 
N+A 26 88/340 17 59/342 13 44/344 5 18/342 
B 20 4/20 15 3/20 5 1/21 0 0/21 
C 22 2/9 11 1/9 18 2/11 9 1/11 
Maximum 
CDC clinical 
stage  
N+A 26 43/168 18 30/169 14 23/170 6 11/170 
B 28 39/140 17 24/141 12 17/143 3 4/140 
C 24 20/84 16 14/85 14 12/87 7 6/86 
Viral load 
(copies/ml) 
≤50 30* 73/241 23 13/57 19*** 46/244 7* 4/175 
>50 
 
20* 34/172 16 57/359 6*** 10/177 2* 4/175 
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Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Combined fasting 
hypertriglyceridemia, and 
hypercholesterolemia 
 
 
% n/N % n/N % n/N % n/N 
Other factors 
         
Hepatitis C 
co-infection 
Uninfected 27 104/381 18 68/384 14 54/389 5 21/385 
Infected 12 3/25 8 2/25 4 1/25 0 0/25 
Tanner score 
for puberty 
I 40*** 53/134 26** 35/134 26*** 35/135 13*** 17/135 
II-IV 19*** 142 13** 19/141 7*** 101/145 2*** 3/144 
V 20*** 18/91 10** 9/94 9*** 8/94 1*** 1/92 
ART naïve  Not naïve  26 102/389 17 67/391 13 52/395 14 55/394 
Naïve  23 6/26 15 4/27 14 4/28 4 1/28 
NRTI 
         
Any NRTI Not current 26 7/27 18 5/28 17 5/30 10 3/30 
 Current 27 96/356 18 63/358 13 48/361 5 18/358 
NNRTI 
         
Any NNRTI Not current 29 73/254 20 51/256 15 38/259 7 17/257 
 Current 
 
23 30/129 13 17/130 11 15/132 3 4/131 
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Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Combined fasting 
hypertriglyceridemia, and 
hypercholesterolemia 
 
 
% n/N % n/N % n/N % n/N 
PI 
         
Any PI Not current 19 32/170 10*** 18/172 10* 17/174 2* 4/173 
 
Current 33 71213 23*** 50/214 1/7* 36/217 8* 17/215 
Atazanavir Not current 28** 103/366 18 68/369 14 53/374 6 21/371 
 Current 0* 0/17 0 0/17 0 0/17 0 0/17 
Ritonavir 
booster 
Not current 17*** 33/189 10*** 19/192 9** 17/195 2** 17/193 
Current 36*** 70/194 26*** 49/194 18** 36/196 9** 17/195 
Type of drug 
regimen at 
recruitment 
         
PI-based 
HAART 
33** 65/200 23** 46/201 17 34/204 8 16/202 
NRTI 
immunotherapy 
10** 3/29 6** 2/29 3 1/29 0 0/29 
NNRTI-based 
HAART 
20** 23/115 10** 12/116 10 12/117 2 2/116 
 Triple class 46** 6/13 31 4/13 15 2/13 8 1/13 
Association between participant characteristic and metabolic abnormality  (prevalence) investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. CDC-defined immune status - 
stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: 
moderate symptoms, C: severe symptoms. 
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As with body fat alterations outcomes, prevalence of each outcome was greater in subjects on 
PI at recruitment compared to those not, with prevalence of any metabolic activity reaching 30% 
(Table 5-1). However, in contrast to current use of PIs, there was no significant difference in any 
metabolic abnormality outcome between subjects who had ever used these drugs compared to 
those who had never used PIs (Table 5-2). Indeed, only ever-use of NNRTI had a significant 
association with metabolic outcomes: prevalence of both any metabolic abnormality and 
combined hypercholesterolemia with fasting hypertriglyceridemia were higher in subjects who 
had never been on NNRTI compared to those who had ever used NNRTI (p < 0.05). 
Interestingly, prevalence of all body fat alterations outcomes was significantly higher in subjects 
who had ever been on NNRTI compared to those who had never been on this class of ART.  
 
Table 5-2: Prevalence of metabolic abnormality  at recruitment by ever use of categories 
of antiretroviral therapy 
  
Metabolic 
abnormality 
Fasting hyper-
triglyceridemia 
Hyper-
cholesterolemia 
Combined fasting 
hypertriglyceridemia, 
and hyper-
cholesterolemia 
  % n/N % n/N % n/N % n/N 
NRTI Never 
use 
23.1 6/26 14.8 4/27 14.3 4/28 7.1 2/28 
 Ever 
use 
26.2 102/389 17.1 67/391 13.2 52/395 5.1 20/391 
NNRTI Never 
use 
27.3* 48/176 18.5 33/178 16.8 30/179 8.5* 15/177 
 Ever 
use 
25.1* 60/239 15.8 38/240 10.7 26/244 2.9* 7/242 
PI Never 
use 
17.2  16/93 12.6 12/95 7.3 7/96 3.2 3/95 
 Ever 
use 
28.6 92/322 18.3 59/323 15.0 49/327 5.9 19/324 
ART 
naïve  
Treated 27.2 97/357 17.8 64/359 13.5 49/363 5.3 19/360 
Naïve  23.1 6/26 14.8 4/27 14.3 4/28 7.1 2/28 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
The only specific NRTI to show a significant association with metabolic outcomes was 
stavudine, with 9% of subjects on this drug having combined hypercholesterolemia with 
hypertriglyceridemia compared to 5% not on the drug (p = 0.025) as illustrated in Figure 5-1a. 
Indeed, subjects who were currently on stavudine also had a significantly higher prevalence of 
any body fat alterations and lipoatrophy (Chapter 4).  
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Five PI drugs showed a significant association with prevalence of metabolic abnormality. None 
of the 17 subjects on atazanavir at recruitment had fasting hypertriglyceridemia (Table 5-1), 
while the prevalence was 18% in subjects who were not on the drug (p = 0.011) as illustrated in 
Figure 5-1b. Similarly, the prevalence of fasting hypertriglyceridemia among subjects currently 
on tipranavir was higher (33%) compared to those not on the drug (17%) as illustrated in Figure 
5-2b, with this difference reaching statistical significance (p = 0.047). Subjects who were 
currently on ritonavir booster at recruitment had a higher prevalence of each outcome (p < 0.01) 
as illustrated Figure 5-3. Unlike body fat alterations outcomes there were no significant 
differences in metabolic abnormality outcomes with current/not current use of either categorical, 
or specific, NNRTI (Table 5-1) .  
A similar relationship between types of ART across each outcome was seen: the highest 
prevalence was seen in subjects on triple class therapy, followed by PI-based HAART, NNRTI-
based HAART and finally NRTI mono-therapy (Figure 5-4): this pattern was seen with body fat 
alteration outcomes (Chapter 4). These differences were significant (p < 0.01) for any metabolic 
abnormality and fasting hypertriglyceridemia; for both outcomes, the prevalence exceeded 30% 
in subjects on triple class therapy at recruitment.  
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Figure 5-1: Prevalence of metabolic abnormality outcomes by (a) stavudine, and (b) atazanavir 
 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
  
(a) (b) Stavudine Atazanavir 
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Figure 5-2: Prevalence of metabolic abnormality by (a) nelfinavir, and (b) tipranavir  
 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
(a) (b) Nelfinavir Tipranavir 
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Figure 5-3: Prevalence of metabolic abnormality by ritonavir booster 
 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
Figure 5-4: Prevalence of metabolic abnormality outcomes at recruitment by 
antiretroviral therapy regimen 
 
Association investigated using χ2 test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
Ritonavir booster 
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5.3.2 Univariable analyses of factors associated with metabolic 
abnormality 
In univariable analysis, White ethnicity was seen to be significantly (p = 0.019) associated with a 
2-fold increased risk of any metabolic abnormality compared to Black ethnicity (Table E-2 in 
Appendix E). While female sex was associated with a decreased risk of all outcomes, this was 
not statistically significant. A significant reduced risk of all outcomes was seen in subjects aged 
12-18 years compared to subjects aged 2-6 years old: the reduction in risk ranged from 56% for 
fasting hypertriglyceridemia, to 90% for the combined phenotype. Furthermore, subjects who 
were undergoing puberty (Tanner II-IV) had a significant (p < 0.01) 56-85% reduced risk of all 
metabolic outcomes compared to pre-pubescent subjects (Tanner I), and subjects who had 
completed puberty (Tanner V) had a significant (p < 0.05) 62-92% reduced risk compared to 
pre-pubescent subjects. This is in direct contrast to body fat alterations outcomes where 
increasing age, and both undergoing and completion of puberty were associated with significant 
increased risk.  
A history of moderate immunosuppression was associated with a 51% reduced risk (p = 0.032) 
of hypercholesterolemia, but no other immunosuppression or clinical disease covariate was 
significantly associated with metabolic abnormality. However, detectable viral load, was 
associated with a reduced risk of any metabolic abnormality of over 60% (p = 0.001). 
While both recruitment NNRTIs and NRTIs had been shown to be significantly associated with 
body fat alterations, no statistically significant associations between these drugs and metabolic 
abnormality was seen in univariable models. Use of any PI at recruitment was associated with 
increased risk of any metabolic abnormality (OR: 2.16, 95% CI 1.34, 3.48), fasting 
hypertriglyceridemia (OR: 2.61, 95% CI: 1.46, 4.67), hypercholesterolemia (OR: 1.84, 95% CI: 
0.99, 3.40), and the combined phenotype (OR: 3.63, 95% CI: 1.20, 10.99). Furthermore, 
ritonavir booster was a risk factor for all metabolic outcomes, associated with a 2-5 fold 
significant increased risk (p < 0.01). Neither current use of PI, nor current use of any specific PI 
drug was a significant risk factor for any body fat alterations outcome (Chapter 4). NRTI-
monotherapy was associated with a 76% reduced risk (p = 0.023), and NNRTI-based HAART a 
48% reduced risk (p = 0.018) of any metabolic abnormality (compared to PI-based HAART). 
Similarly, triple class therapy was associated with a significant 80% reduced risk of concurrent 
hypercholesterolemia and fasting hypertriglyceridemia. 
In univariable analyses with ever-use of either categorical or specific ART as explanatory 
variables, only use of any PI and of ritonavir booster were significant risk factors: both were 
associated with increased risk of metabolic abnormality outcomes (p < 0.05), as summarized in 
Table E-3 in Appendix E.  
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5.3.3 Multivariable models for metabolic abnormality outcomes including 
antiretroviral therapy class 
In constructing the final multivariable models for class of ART, the models included age and 
maximum duration of ART at recruitment. The models are summarized in Figure 5-5 and Figure 
5-6.  
Current use of PI at recruitment was a significant risk factor for all outcomes: over 2-fold for any 
metabolic abnormality (AOR: 2.26, 95% CI: 1.25, 4.06), 2.5 fold for fasting hypertriglyceridemia 
(AOR: 2.57, 95% CI: 1.22, 5.40), 2-fold for hypercholesterolemia (AOR: 2.21, 95% CI: 1.07, 
4.56), and over 6-fold for concurrent hypercholesterolemia and fasting hypertriglyceridemia 
(AOR: 6.18, 95% CI: 1.37, 37.85).  
The only other significant risk factor for metabolic abnormality outcomes was detectable viral 
load. This was associated with a reduced risk of hypercholesterolemia (AOR: 0.40, 95% CI; 
0.18, 0.89). 
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Figure 5-5: Final multivariable model for (a) any metabolic abnormality (n = 317), and (b) fasting hypertriglyceridemia (n = 309) using classes of 
antiretroviral therapy as explanatory variables 
 
All models adjusted for age and maximum duration of ART 
(a) (b) 
Metabolic abnormality at recruitment          Chapter 5 
188 
 
 
Figure 5-6: Final multivariable model for (a) hypercholesterolemia (n = 331), and (b) hypercholesterolemia and fasting hypertriglyceridemia (n = 
329) using classes of antiretroviral therapy as explanatory variables 
 
All models adjusted for age and maximum duration of ART 
(a) (b) 
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5.3.4 Multivariable models for metabolic abnormality outcomes including 
specific antiretroviral drugs  
Metabolic abnormality 
The final model for any metabolic abnormality included covariates for age and duration of ART 
at recruitment, and ethnicity (Table 5-3). Only one drug remained significant in the final model: 
use of ritonavir booster was associated with an independent almost 3-fold increased risk of 
metabolic abnormality (reinforcing results from the multivariable model using class of ART). At 
the same time, age was significantly (p < 0.001) associated with a 13% decrease in risk per 
year.  
 
Table 5-3: Final multivariable model for metabolic abnormality using specific 
antiretroviral therapy drugs (n = 315) 
  n AOR 95% CI p-value 
Age Per year 315 0.87 (0.81, 0.94) <0.001 
Maximum 
duration of 
ART 
Per year 315 0.97 (0.90, 1.05) 0.483 
Ethnicity Black 77 1   
White 223 1.64 (0.77, 3.49) 0.201 
Other 15 0.75 (0.17,3.25) 0.699 
Ritonavir 
booster 
Not current 144 1   
Current 171 2.79 (1.56, 4.99) 0.001 
 Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval (95% CI) for metabolic abnormality by participant characteristic.  
 
Fasting hypertriglyceridemia 
The final multivariable model for fasting hypertriglyceridemia risk factors included covariates for 
age, viral load, duration of ART, sex, and ethnicity. Ritonavir booster was associated with a 
significantly increased risk (AOR = 3.35), while a yearly increment of age significantly (p = 
0.004) reduced risk by 12% (Table 5-4).  
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Table 5-4: Final multivariable model for fasting hypertriglyceridemia using specific 
antiretroviral drugs (n = 309)  
  n AOR 95% CI p-value 
Age Per year 309 0.88 (0.80, 0.96) 0.004 
Maximum 
duration of 
ART 
Per year 309 0.99 (0.90, 1.09) 0.830 
Sex Male 161 1   
 Female 148 0.69 (0.36, 1.32) 0.263 
Ethnicity Black 79 1   
White 215 2.20 (0.85, 6.22) 0.102 
Other 15 0.96 (0.16, 5.96) 0.969 
Viral load 
(copies/ml) 
<50 195 1   
>50 114 1.30 (0.64, 2.66) 0.471 
Ritonavir 
booster 
Not current 141 1   
Current 168 3.35 (1.60, 7.04) 0.001 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval (95% CI) for fasting hypertriglyceridemia by participant characteristic  
 
Hypercholesterolemia  
Age was associated with an 18% reduced risk per year, and detectable viral load 61% reduced 
risk of hypercholesterolemia (p ≤ 0.02), as illustrated in Table 5-5. Ritonavir booster use at 
recruitment was associated with an almost 3-fold significant increased risk of 
hypercholesterolemia (AOR: 2.82, 95% CI: 1.36, 5.83).  
 
Table 5-5: Final multivariable model for hypercholesterolemia using specific antiretroviral 
therapy drugs (n = 331) 
  n AOR 95% CI p-value 
Age Per year 331 0.82 (0.75, 0.90) <0.001 
Maximum 
duration of 
ART 
Per year 331 1.01 (0.91, 1.12) 0.887 
Viral load 
(copies/ml) 
≤50 208 1   
>50 123 0.39 (0.17, 0.86) 0.020 
Ritonavir 
booster 
Not current 152 1   
Current 179 2.82 (1.36, 5.83) 0.005 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval (95% CI) for hypercholesterolemia by participant characteristic. 
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Concurrent hypercholesterolemia and fasting hypertriglyceridemia  
As with other metabolic outcome multivariable models, both age and use of ritonavir at 
recruitment were significant risk factors for the combined phenotype of both 
hypercholesterolemia and fasting hypertriglyceridemia occurring together. Current use of 
ritonavir was associated with a significant (p = 0.009) 7.5-fold increased risk, but this was 
accompanied by a very wide 95% confidence interval (Table 5-6). Age was significantly 
associated (p < 0.001) with a 29% reduced risk per year in the final multivariable model 
adjusted for maximum duration of ART at recruitment. 
 
Table 5-6: Final multivariable model for concurrent fasting hypertriglyceridemia and 
hypercholesterolemia occurring together using specific antiretroviral drugs (n =329) 
  n AOR 95% CI p-value 
Age Per year 329 0.71 (0.59, 0.85) <0.001 
Maximum 
duration of 
ART 
Per year 329 1.22 (1.01, 1.48) 0.037 
Ritonavir 
booster 
Not current 151 1   
Current 178 7.46 (1.66, 33.57) 0.009 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval (95% CI) for hypercholesterolemia by participant characteristic. 
 
Sensitivity analyses, where the final models were refitted using moderate/severe outcomes, 
confirmed the results of the multivariable models: in each model current-use of ritonavir was 
associated with a significant and independent increase in risk. However, the magnitude of the 
estimated risk ranged between 4 to 5 fold (Table E-5 in Appendix E). In additional analysis 
where final models were ascertained using stepwise covariate selection using ever-use of 
specific ART as explanatory variables, ever use of ritonavir booster was the only significant ART 
risk factor. However, for each metabolic outcome, the significant risk associated with ever-use 
of ritonavir booster was lower than the risk seen for current-ritonavir booster use (Table E-4 in 
Appendix E). In sensitivity analyses where the threshold for inclusion of covariates in the 
multivariable models was raised to 10%, both PI and NNRTI use were associated with 
increased risk of any metabolic abnormity, while detectable viral load was significantly 
associated with decreased risk of hypercholesterolemia, and also of hypercholesterolemia with 
fasting hypertriglyceridemia occurring together (Appendix E: Table E-8). Neither NNRTI nor 
detectable viral load were statistically significant in the models resulting from a 5% significance 
threshold. With regard to models investigating specific ART drugs, efavirenz was seen to be 
associated with increased risk of fasting hypertriglyceridemia (in addition to ritonavir booster), as 
illustrated in Table E-9 in Appendix E. Other models with the 10% threshold were of similar 
structure to the models with the 5% threshold. 
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Across multivariable models for metabolic abnormality outcomes, use of PI, and specifically 
ritonavir booster, at recruitment was a positive independent risk factor. Similarly, age at 
recruitment was consistently a significant risk factor for a decrease in risk.  The largest effect 
sizes associated with either drug use or increasing age were seen in children and adolescents 
with both hypercholesterolemia and fasting hypertriglyceridemia occurring together. This is in 
contrast to body fat alterations models (Chapter 4) where neither age nor specific PI use was 
associated with outcomes, but categorical NNRTI and specific NNRTI and NRTI drugs were 
significant risk factors. Moreover, while HIV-related factors, such as degree of 
immunosuppression or clinical condition, were significant risk factors for body fat alterations, 
they were not significant factors for metabolic abnormality.  
5.3.5 Multivariable models for metabolic abnormality outcomes including 
type of antiretroviral therapy regimen 
In order to investigate the effects of type of ART regimen (i.e. PI-based HAART, NNRTI-based 
HAART, etc.), multivariable models adjusted for age, maximum duration of ART and viral load at 
recruitment were constructed. Children receiving NNRTI-based HAART at enrolment had a 
significant reduced risk of metabolic abnormality (AOR: 0.50, 95% CI: 0.28, 0.92), of fasting 
hypertriglyceridemia (AOR: 0.37, 95% CI: 0.17, 0.80), and of both hypercholesterolemia and 
fasting hypertriglyceridemia occurring together (AOR: 0.20, 95% CI: 0.04, 0.93), compared with 
those receiving PI-based HAART (Figure 5-7)  
While a 47% reduced risk of hypercholesterolemia was seen with NNRTI-based HAART, this 
was statistically not significant (p = 0.107). The small number of children receiving NRTI mono-
therapy had a significantly reduced risk of any metabolic abnormality (AOR: 0.23, 95% CI: 0.07, 
0.85, p = 0.027) and of fasting hypertriglyceridemia (AOR: 0.20, 95% CI: 0.04, 0.96, p = 0.044) 
compared with those on -PI-based HAART.   
In contrast to findings for body fat alterations where it was the only ART regimen which was 
statistically significant, triple class therapy was associated with a non-significant  increased risk 
of each metabolic outcome, the large confidence interval reflecting the fact that relatively few (n 
= 14) subjects were on triple class therapy at recruitment.    
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Figure 5-7: Multivariable models for metabolic abnormality outcomes using type of antiretroviral therapy as an explanatory variable 
 
Log adjusted odds ratio displayed for clarity. All models including terms for age, maximum duration of ART use and viral load. Metabolic abnormality: n = 325, fasting 
hypertriglyceridemia: n = 327, hypercholesterolemia: n = 331, and combined hypercholesterolemia and fasting hypertriglyceridemia: n = 328 
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5.3.6 Investigation of puberty as a risk factor for metabolic abnormality 
outcomes 
The final multivariable models using specific antiretroviral drugs as explanatory variables were 
refitted with the addition of Tanner score to explore the possible effects of puberty, beyond 
including age and sex in the model selection process. Tanner score was statistically non-
significant (p > 0.05) in the models for hypercholesterolemia, fasting hypertriglyceridemia, and 
concurrent hypercholesterolemia with fasting hypertriglyceridemia (Table E-6 in Appendix E).  
However, Tanner score was significant in the model for any metabolic abnormality with subjects 
who were undergoing puberty having a reduced risk compared with pre-pubescent subjects 
(AOR: 0.37, 95% CI: 0.15, 0.94, p = 0.036). Furthermore, although age was still associated with 
a reduced risk of metabolic abnormality in this model, it became non-significant. However, on 
the addition of an interaction term between age and sex to the original final models, no 
metabolic outcome model retained significant terms for either sex or the sex/age interaction 
(Table E-7 in Appendix E), while age remained significant only  in the model for metabolic 
abnormality (AOR: 0.91, 95% CI: 0.82, 1.00, p = 0.047). This suggests that while puberty may 
have an independent association with the risk of any metabolic abnormality, the independent 
negative effect of age, also seen across metabolic outcomes, may be an important risk factor.  
 
5.3.7 Prevalence of lipodystrophy syndrome by subject characteristics   
There were no significant differences in prevalence of LS between sexes, age groups, Tanner 
score groups and those with/without hepatitis C infection (Table 5-7). Despite significant 
differences in prevalence of both body fat alterations and of metabolic outcome across age 
group, no significant differences were seen with LS. Similarly, while significant differences by 
Tanner score across metabolic abnormality outcomes, and all but one (combined phenotype) of 
body fat alterations outcomes, no significant differences were seen with LS. 
However, as illustrated in Table 5-7, the prevalence of LS was significantly higher in subjects of 
White compared to Black and “Other” ethnicity. Among subjects with LS, over 80% (n = 183) 
were of White ethnicity, compared to 54.3% (n = 95) of subjects without LS (Figure 5-8).  
Indeed, prevalence of either body fat alterations or metabolic abnormalities had been seen to be 
significantly higher among subjects of White ethnicity compared to other subjects.  
No significant differences were seen in LS prevalence between nadir immune status groups 
(Table 5-7). However, in common with body fat alterations, there were significant differences (p 
= 0.005) in prevalence in recruitment immune status, with prevalence highest in subjects without 
immunosuppression. Indeed, among subjects with LS, over 80% (n = 193) has a history of no 
immunosuppression (Figure 5-8).    
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Table 5-7: Prevalences of lipodystrophy syndrome at recruitment 
  % n/N p-value 
Demographic factors    
Gender Male 55 108/196 0.639 
Female 57 120/209  
Age (years) 2-6 47 20/43 0.314 
7-11 60 69/115  
12-18 57 146/258  
Ethnicity Black 34 35/104 <0.001 
White 66 183/278  
Other 35 6/17  
Country of residence Italy 58 156/269 <0.001 
Belgium 38 31/82  
Poland 74 48/65  
Infection factors    
CDC immune stage at 
recruitment 
Stage 1 61 193/317 0.005 
Stage 2 42 35/83  
Stage 3 44 7/16  
Nadir CDC immune stage Stage 1 60 94/158 0.444 
Stage 2 53 94/174  
Stage 3 58 49/84  
CDC clinical stage at 
recruitment 
N+A 55 189/341 0.627 
B 55 11/20  
C 40 4/10  
Maximum CDC clinical 
stage  
N+B 46 78/168 <0.001 
B 66 93/141  
C 62 52/84  
Viral load (copies/ml) ≤50 62 149/242 0.014 
>50 49 85/172  
Other factors    
Hepatitis C co-infection Uninfected 56 215/383  
Infected 67 16/24 0.312 
Tanner score for puberty I 56 75/134  
II-IV 54 75/143  
V 58 53/91 0.786 
ART naive     
 
Not naive  58 226/390  
 
ART naïve  35 9/26 0.020 
NRTI    
Any NRTI Not current 39 11/28  
Current 60 212/356 0.036 
Stavudine Not current 57 161/282  
Current 61 66/102 0.016 
NNRTI    
Any NNRTI Not current 57 144/255  
Current 61 79/129 0.0371 
PI    
Any PI Not current 52 87/169  
Current 63 136/215 0.020 
Ritonavir booster Not current 50 94/188  
Current 66 129/196 0.002 
Type of drug therapy at recruitment    
 PI-based HAART 62 125/202 0.047 
NRTI mono-therapy 41 12/29  
NNRTI-based HAART 58 66/114  
Triple class 85 11/13  
Association between participant characteristic and lipodystrophy syndrome (prevalence) investigated using χ2 
test: CDC-defined immune status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, 
stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: 
moderate symptoms, C: severe symptoms. 
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No statistically significant (p = 0.627) differences were seen between LS and CDC clinical status 
at recruitment, but significant (p < 0.001) differences occurred between LS and maximum CDC 
clinical status: 46% were asymptomatic, 66% were at clinical stage B, and 62% were at clinical 
stage C (Table 5-7). Indeed, among subjects with LS, the greatest proportion of subjects had a 
history of moderate clinical symptoms (Figure 5-8) Significant differences with body fat 
alterations, but not metabolic abnormality, had previously been seen with maximum CDC 
clinical condition. While a similar pattern in prevalence was seen between immunosuppression 
groups at nadir and recruitment measurements, the pattern of LS prevalence with clinical 
symptoms was different between maximum and recruitment measurements.   
LS prevalence was significantly (p = 0.014) higher among subjects with undetectable viral load, 
compared to subjects with detectable viral load (Table 5-7).  While prevalence of both fat 
alterations outcomes and metabolic outcomes has been higher in subjects with undetectable 
viral load, these differences were only significant in the latter. 
As with any body fat alterations and lipoatrophy, there was a significant (p = 0.036) difference in 
the prevalence of LS between subjects on NRTI at the time of recruitment, compared to those 
not, as illustrated in Figure 5-9: over 95% of subjects with LS were on NRTI at recruitment. A 
significant (p = 0.020) difference was seen in LS prevalence with current PI use: prevalence 
was 63% in subjects currently on PI, compared to 52% in subjects not on these drugs. 
Significant differences in combined lipoatrophy and lipohypertrophy had previously been seen 
with current NNRTI use at recruitment.  Although the prevalence of LS was higher among 
subjects currently on NNRTI compared to those not on this class of drug (Table 5-7), this 
difference was not statistically significant with approximately two-thirds of both subjects with LS 
and those without LS currently on NNRTI on recruitment: thus only significant differences in 
prevalence of metabolic abnormality outcomes were seen with current PI use.  
Ever-use of all class of ART, except NNRTI, was associated with an increased prevalence of LS 
compared to never use, and this difference was statistically significant (Table 5-8). However, as 
discussed previously, ever-use of NRTI is correlated to ever-use of any ART, and thus the 
independent prevalence of LS with NRTI-use is difficult to estimate.  
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Figure 5-8: Distribution of subject characteristics by lipodystrophy syndrome status at 
recruitment 
 
 
     
  
  
  
Lipodystrophy syndrome n = 235, no lipodystrophy syndrome: n = 181 
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Table 5-8: Prevalence of lipodystrophy syndrome by ever-use of categories of 
antiretroviral therapy 
  
Percentage n/N 
NRTI Never use 34.6* 9/26 
Ever use 58.0* 226/390 
NNRTI Never use 51.4 91/177 
Ever use 60.3 144/239 
PI Never use 41.3*** 38/92 
Ever use 60.8*** 197/324 
ART naïve  Not naïve  59.8* 214/358 
Naive 34.6* 9/26 
Association between participant characteristic and lipodystrophy syndrome (prevalence) investigated using χ2 
test: *p < 0.05, **p < 0.01, and ***p < 0.001. 
 
There were significant differences (p = 0.002) in prevalence of LS between subjects who were 
currently on ritonavir booster (50%, n = 94) and those who were not (66%, n = 129): less than 
half of subjects with LS were on ritonavir booster at recruitment, whereas more than half of 
subjects without LS were on this specific ART (Figure 5-9). No significant differences were seen 
with other specific ART drugs.  
 
The highest prevalence of LS was seen in subjects currently on triple class therapy at the time 
of recruitment followed by PI-based HAART NNRTI-based HAART and finally NRTI mono-
therapy (Table 5-7). Differences in prevalence between different ART combination groups were 
statistically significant (p = 0.047). Indeed the proportion of subjects on either PI-based HAART 
or triple class therapy was greater among subjects with LS compared to subjects without LS 
(Figure 5-10). However, less than 10% of the whole study population (n = 43) were on either 
NRTI mono-therapy and triple class therapy at recruitment.  
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Figure 5-9: Distribution of antiretroviral therapy by lipodystrophy syndrome status at 
recruitment. 
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Figure 5-10: Distribution of antiretroviral therapy regimen by lipodystrophy syndrome 
status at recruitment. 
  
Lipodystrophy syndrome n = 235, no lipodystrophy syndrome: n = 181. Blue: PI-based HAART, red: NRTI-based 
mono-therapy, green: NNRTI-based HAART, yellow: triple class therapy 
 
5.3.8 Univariable analyses of factors associated with lipodystrophy 
syndrome  
There was a significant increased risk of LS associated with White compared to Black ethnicity 
(OR: 3.80, 95% CI: 2.36, 6.11) as illustrated in Table 5-9. Maximum CDC clinical stage was also 
associated with a significantly increased risk of LS compared to the asymptomatic stage: a 2-
fold risk was associated with both stage B and stage C.  
A significant 2-3 fold increased risk of LS was seen with current use of NRTI, and also with 
stavudine specifically: significant 2-4 fold increased risk of any body fat alterations or 
lipoatrophy had previously been seen in children on any NRTI or stavudine at recruitment. 
Similarly, a significant increased risk of LS was associated with use of any PI (OR: 1.62, 95% 
CI: 1.08, 2.44) and with ritonavir-booster (OR: 1.93, 95% CI: 1.28, 2.90) specifically at 
recruitment.  
Significant factors associated with a reduced risk of LS were moderate CDC immune stage at 
recruitment, detectable viral load, and NRTI mono-therapy: reductions in risk being 53%, 39% 
and 57% (compared to PI-based HAART) respectively. 
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Table 5-9: Univariable analyses for lipodystrophy syndrome 
  OR 95% CI p-value 
Demographic factors 
   
Gender Male 1   
Female 1.10 (0.74, 1.63) 0.639 
Age (years) 2-6 1   
7-11 1.72 (0.85, 3.49) 0.130 
12-18 1.50 (0.78, 2.87) 0.221 
Ethnicity Black 1   
White 3.80 (2.36, 6.11) <0.001 
Other 1.08 (0.37, 3.15) 0.895 
Country of residence Italy 1   
Belgium 0.44 (0.26, 0.73) 0.002 
Poland 2.05 (1.12, 3.74) 0.020 
Infection factors 
   
CDC immune stage at 
recruitment 
Stage 1 1   
Stage 2 0.47 (0.29, 0.77) 0.002 
Stage 3 0.50 (0.18, 1.38) 0.180 
Nadir CDC immune stage Stage 1 1   
Stage 2 0.76 (0.49, 1.18) 0.225 
Stage 3 0.95 (0.56, 1.63) 0.861 
CDC clinical stage at 
recruitment 
N+A 1   
B 0.98 (0.40, 2.43) 0.970 
C 0.54 (0.15, 1.93) 0.341 
Maximum CDC clinical 
stage  
N+B 1   
B 2.24 (1.41, 3.55) 0.001 
C 1.87 (1.10, 3.20) 0.021 
Viral load (copies/ml) ≤50 1   
>50 0.61 (0.41, 0.91) 0.014 
Other factors 
   
Hepatitis C co-infection Uninfected 1   
Infected 1.56 (0.65, 3.74) 0.316 
Tanner score for puberty I 1   
II-IV 0.89 (0.55, 1.43) 0.631 
V 1.06 (0.62, 1.82) 0.820 
NRTI 
   
Any NRTI Not current 1   
Current 2.28 (1.04, 5.00) 0.041 
Stavudine Not current 1   
Current 2.37 (1.16, 4.84) 0.018 
NNRTI 
   
Any NNRTI Not current 1   
Current 1.22 (0.79, 1.88) 0.371 
PI 
   
Any PI Not current 1   
Current 1.62 (1.08, 2.44) 0.021 
Ritonavir booster Not current 1   
Current 1.93 (1.28, 2.90) 0.002 
Type of drug therapy at recruitment 
   
 PI-based HAART 1   
NRTI mono-therapy 0.43 (0.20, 0.96) 0.039 
NNRTI-based 
HAART 
0.85 (0.53, 1.35) 0.457 
Triple class 3.39 (0.73, 15.70) 0.119 
OR: odds ratio and 95% CI: 95% confidence interval 
Metabolic abnormality at recruitment   Chapter 5 
202 
 
5.3.9 Multivariable models of factors associated with lipodystrophy 
syndrome 
Final model for class of antiretroviral therapy  
In the final multivariable model (adjusted for age and maximum duration of ART at recruitment) 
with class of ART as explanatory variables (Figure 5-11), several factors were associated with 
increased risk of LS: White compared to Black ethnicity (AOR: 3.65, 95% CI: 2.06, 4.46, p = 
0.001), current PI (AOR: 2.56, 95% CI: 1.20, 5.45, p = 0.015), current NNRTI (AOR: 2.78, 95% 
CI: 1.26, 6.11,  p= 0.011), and BMI per 1 unit kg/m2 (AOR: 1.09, 95% CI: 1.00, 1.19, p = 0.049).  
No factors were associated with a significant reduced risk, and neither the effects of neither age 
nor duration of ART were statistically significant (p > 0.167). 
 
Figure 5-11: Final multivariable model for lipodystrophy using classes of antiretroviral 
therapy as an explanatory variable (n = 313) 
 
Model includes age and maximum duration of ART use. 
In sensitivity analysis investigating class of ART as explanatory variables where the threshold 
for stepwise variable selection was raised to 10% significance, independent risk factors were 
similar. However, maximum clinical status was a significant risk factor for LS in the 10% model 
(it was not significant in the 5% model): illustrated in Table E-15 in Appendix E. 
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Comparison of final ART-class models for lipodystrophy syndrome, body 
fat alterations, and metabolic abnormality 
White ethnicity was associated with increased risk in several of the previous multivariable 
models investigating categories of ART: this risk was statistically significant for any body fat 
alterations, lipoatrophy, and combined lipoatrophy with lipohypertrophy. Similarly, children 
currently on any PI were at significantly higher risk of all metabolic abnormality outcomes, and 
also combined lipohypertrophy with lipoatrophy. While NNRTI use at recruitment was not a 
significant risk factor for metabolic abnormality outcomes, it was a significant risk factor for all 
body fat alterations outcomes. Furthermore, BMI was associated with a significant increased 
risk of any body fat alterations, but was not significantly associated with any other outcome. 
Figure 5-12 summarizes statistically significant and independent risk factors for lipodystrophy 
outcomes (metabolic abnormality, body fat alterations or LS), as identified by stepwise logistic 
regression modelling with classes of ART.  
 
While maximum clinical status was a consistent risk factor for body fat abnormality outcomes, it 
was not associated with LS in the final multivariable models. Other covariates which had been 
significant in multivariable models for either body fat alterations outcomes or metabolic 
abnormality, but not in the final model for LS, were sex (lipohypertrophy) and detectable viral 
load (hypercholesterolemia).  
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Figure 5-12: Schematic representation of statistically significant risk factors for lipodystrophy syndrome, body fat alterations, and metabolic 
abnormality identified by stepwise logistic modelling: models incorporating current ART use by class 
 
Lipodystrophy 
syndrome 
Metabolic abnormality 
Body fat alterations 
Detectable viral load* PI NNRTI 
BMI 
White ethnicity 
Maximum clinical status 
Sex 
Risk factors are significant at the 5% level. Risk factors are associated with increase in risk, except detectable 
viral load was associated with a decrease in risk . PI and NNRTI use at recruitment, * Associated with a decrease 
in risk 
Metabolic abnormality at recruitment   Chapter 5 
205 
 
Final model for specific antiretroviral drugs at recruitment 
Table 5-10 illustrates the final multivariable model for LS using specific antiretroviral drugs as 
explanatory variables. As in the multivariable model investigating class of ART, White ethnicity 
was associated with a 3-fold increased risk of LS compared to Black ethnicity. BMI was 
associated with a  significant 17% increased risk per 1 unit increase (kg/m2) while children with 
a history of symptomatic HIV disease had a significant 2-fold increased risk compared with 
those who had not experienced HIV symptoms. Use of specific ART drugs were significantly (p 
≤ 0.042) associated with risk of LS: stavudine and efavirenz were associated with a 5-fold and 
2-fold increments in risk respectively. However children receiving didanosine at enrolment had a 
decreased risk of LS which did not reach statistical significance (p = 0.052).  
 
Table 5-10: Final multivariable model for lipodystrophy syndrome using specific 
antiretroviral therapy drugs (n = 302) 
  n AOR 95% CI p-value 
Age Per year 302 1.08 (0.99, 1.18) 0.102 
Maximum 
duration of 
ART 
Per year 302 1.03 (0.96, 1.12) 0.389 
Ethnicity Black 73 1   
White 215 3.32 (1.49, 7.41) 0.003 
Other 14 1.95 (0.46, 8.27) 0.364 
Maximum 
CDC clinical 
stage 
N/A 121 1   
B 110 1.87 (0.99, 3.52) 0.052 
C 71 2.34 (1.18, 4.65) 0.015 
BMI Per kg/m2 302 1.17 (1.06, 1.28) 0.002 
Stavudine Not current 266 1   
Current 36 5.40 (2.15, 13.56) <0.001 
Didanosine Not current 261 1   
Current 41 0.42 (0.17, 1.01) 0.052 
Efavirenz Not current 226 1   
Current 76 1.93 (1.03, 3.62) 0.042 
Model intuitively adjusted for age and duration of ART at recruitment: Adjusted odds ratio (AOR) and 95% 
confidence interval (95% CI) for lipodystrophy syndrome by participant characteristic.  CDC-defined clinical 
status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
 
The final adjusted model, developed using stepwise selection of variables including ever-use of 
specific drugs, was similar to the final model investigating current-use of specific drugs as risk 
factors for LS (Appendix E: Table E-12). Factors associated with an increase in risk of LS 
included White ethnicity (AOR: 3.09, 95% CI: 1.77, 5.39), BMI (AOR: 1.11, 95% CI: 1.02, 1.21), 
and ever-use of stavudine (AOR: 2.24, 95% CI: 1.29, 3.88). However, in contrast to the model 
presented in Table 5-10, ever-use of didanosine was associated with a significant increased risk 
of LS (AOR: 1.95, 95% CI: 1.09, 3.49). In addition, ever-use of indinavir was a significant risk 
factor (AOR: 4.20, 95% CI: 1.08, 16.37), while ever-use of abacavir was associated with a 
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significant reduced risk (AOR: 0.57, 95% CI: 0.35, 0.93). This protective effect of abacavir may 
reflect previous regimen switching to this drug after reported reversibility of fat alterations 
symptoms238, i.e. confounding by indication. Finally, maximum clinical condition was no longer 
statistically significant.  Further sensitivity analyses were conducted investigating use of specific 
ART drugs as explanatory variables, but setting the threshold for statistical significance at 5%: 
in the 5% multivariable model both stavudine and efavirenz were significantly associated with 
increased risk of LS, while in the 10% model stavudine and ritonavir-booster were significantly 
associated with increased risk (Appendix E: Table E - 16). 
 
Investigation of puberty as a risk factor for lipodystrophy syndrome 
Neither Tanner score nor an interaction between age and sex were statistically significant (p ≥ 
0.521) on addition to the final model for LS using recruitment specific ART as explanatory 
variables (Table E-13 and Table E-14 in Appendix E).  
 
Comparison of final specific-ART models for lipodystrophy syndrome, 
body fat alterations, and metabolic abnormality 
In the final multivariable models risk factors associated with any fat alterations and lipoatrophy 
incorporating specific ART drugs, current stavudine was an independent and significant risk 
factor. Furthermore current efavirenz was a significant risk factor for LS. However stavudine 
was not a significant risk factor for any metabolic outcome (Figure 5-13). Use of efavirenz at 
recruitment was associated with a significant increased risk of any fat alterations, and use of 
didanosine was associated with a non-significant decrease in risk (Chapter 4): these same 
associations were seen with LS. Although use of ritonavir booster at recruitment was seen as a 
significant risk factor in multivariable models for all the individual metabolic abnormality 
outcomes, it was not a significant risk factor for LS or any fat alterations outcomes.  
Children and adolescents who had experienced maximum clinical status had increased risk of 
body fat alterations, lipohypertrophy, and LS in multivariable analysis using specific ART as 
explanatory variables (p < 0.05). However maximum clinical status was not a significant factor in 
any metabolic abnormality models. White ethnicity was a significant risk factor for any body fat 
alterations, lipoatrophy and LS in the multivariable models using specific ART drugs, while BMI 
was an independent risk factor significantly associated with increased risk of body fat 
alterations, lipohypertrophy, combined lipoatrophy with lipohypertrophy and LS.  
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Figure 5-13: Schematic representation of statistically significant risk factors for lipodystrophy outcomes, body fat alterations, and metabolic 
abnormality identified by stepwise logistic modelling: specific antiretroviral drugs as explanatory variables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lipodystrophy 
syndrome 
Metabolic abnormality 
Body fat alterations 
Ritonavir booster 
Detectable viral load* 
Stavudine 
Efavirenz 
BMI 
Maximum clinical 
status 
White ethnicity 
Nadir immune stage* 
Zidovudine* 
Lamivudine* 
Risk factors are significant at the 5% level. Risk factors are associated with increase in risk, *risk factors 
associated with a decrease in risk. Specific drugs refer to drug use at recruitment  
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Furthermore, while ritonavir booster and detectable viral load were associated with risk of 
metabolic abnormality outcomes, and nadir immune status, zidovudine, and lamivudine were 
associated with body fat alterations outcomes, none of these covariates were significantly 
associated with LS.  
 
Model for lipodystrophy syndrome including type of ART regimen and 
comparison with models for metabolic abnormality and for body fat 
alterations 
The multivariable model for LS investigating type of ART, adjusted for age, duration of ART at 
recruitment, maximum CDC clinical status and ethnicity, is summarized in Figure 5-14. Neither 
age nor duration of ART was statistically significant in the model (p ≥ 0.477). Children who had 
had moderate clinical symptoms at some point during their lifetime had an almost two-fold 
increased risk of LS (AOR: 1.86, 95% CI: 1.06, 3.28, p = 0.032). White ethnicity was associated 
with a three-fold increased risk of LS (AOR: 3.03, 95% CI: 1.69, 5.45, p < 0.001), compared to 
Black ethnicity.  
 
While NNRTI-based HAART and triple class therapy were associated with increased risk of LS, 
and NRTI mono-therapy was associated with a decreased risk compared to PI-based HAART, 
none of these associations reached statistical significance. This is in contrast to fat alterations 
outcomes where triple class therapy was associated with an independent and significant 
increased risk of all outcomes, (Chapter 4), and metabolic abnormality outcomes, where 
NNRTI-based HAART was associated with a reduced risk of all outcomes except 
hypercholesterolemia, and NRTI-based mono-therapy which was associated with a significant 
reduced risk of any metabolic abnormality, and fasting hypercholesterolemia.   
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 Figure 5-14: Multivariable model for lipodystrophy syndrome using type of antiretroviral therapy as an explanatory variable  
 
Log adjusted odds ratio displayed for clarity. Model adjusted for age and maximum duration of ART use (not shown), and ethnicity and maximum CDC-defined clinical status. CDC-
defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms 
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5.4 Key points 
 
• Prevalence of metabolic outcomes was higher in older subjects compared to younger 
subjects, and in pre-pubescent subjects compared to those undergoing or who had 
completed puberty: these differences were statistically significant  
 
• Undetectable viral load was associated with significantly increased prevalence of any 
metabolic abnormality, hypercholesterolemia, and both hypercholesterolemia and 
fasting hypertriglyceridemia occurring together (compared to detectable viral load).  
 
• Subjects on PIs at recruitment had a significantly higher prevalence of all metabolic 
outcomes compared to those not on these drugs: 90% of subjects on PIs were on 
boosted ritonavir which was itself associated with significant increased prevalence of all 
outcomes.  
 
• Prevalence of all metabolic outcomes was highest in subjects on triple class therapy, 
followed by PI-based HAART, then NNRTI-based HAART and finally NRTI mono-
therapy: this was statistically significant for any metabolic abnormality and fasting 
hypertriglyceridemia.  
 
• Current use of PI at recruitment was an independent, statistically significant risk factor 
associated with a 2-fold risk of metabolic outcomes, and a 6-fold increased risk of 
concurrent hypercholesterolemia and fasting hypertriglyceridemia: ritonavir booster was 
the only specific drug significantly associated with risk of each outcome (<8-fold 
increase).  
 
• Current NNRTI-based HAART was associated with a significant decreased risk of any 
metabolic abnormality, fasting hypertriglyceridemia, and concurrent 
hypercholesterolemia and fasting hypertriglyceridemia, compared to PI-based HAART. 
 
• A significant and independent 60% decreased risk of hypercholesterolemia was seen 
with detectable viral load. Age was associated with a reduction in risk of metabolic 
abnormality outcomes. Statistically significant risk factors for metabolic outcomes are 
summarized in Table 5-11. 
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Table 5-11: Summary of risk factors for metabolic outcomes across all final multivariable 
models 
 
Metabolic 
abnormality 
Fasting 
hypertriglyceridemia 
Hypercholesterolemia Both fasting 
hypertriglyceridemia 
and 
hypercholesterolemia 
Age* 
↓ ↓ ↓ ↓ 
Maximum 
duration of 
ART* 
   ↑ 
Detectable 
viral load   ↓  
PI 
↑ ↑ ↑ ↑ 
Ritonavir 
booster ↑ ↑ ↑ ↑ 
NRTI mono-
therapy** ↓ ↓   
NNRTI-based 
HAART** ↓ ↓  ↓ 
Only factors that were statistically significant in at least one individual model are shown. Arrows indicate 
direction of association. *Unit: ascending year, **comparison group: PI-based HAART. 
 
• The prevalence of LS was significantly higher in: subjects of White ethnicity compared 
to those of Black ethnicity; those who were immunosuppressed at recruitment 
compared to those who were not; subjects who had a history of CDC-defined 
symptomatic disease compared to subjects who did not; and subjects with non-
detectable viral load at recruitment compared to those who have detectable viral load.   
 
• Prevalence of LS was significantly higher in subject on PI, compared to those not on 
these drugs at recruitment. The percentage of the study population with LS was highest 
in subjects on triple class therapy followed by those on HAART, and lowest in subjects 
on NRTI mono-therapy. However, numbers of subjects on triple class therapy at 
recruitment was very small (n = 13)  
 
• In multivariable models, White ethnicity, BMI, and maximum CDC-defined clinical 
condition were associated with increased risk of LS (<4 fold, 10-17% per kg/m2, 2-fold 
respectively).  
 
• Both use of PI and NNRTI at recruitment were significantly associated with a 3-fold 
increased independent risk of LS, with stavudine associated with a 5-fold increased risk, 
and efavirenz associated with a 2-fold increased risk. However, current didanosine was 
associated with a statistically significant 58% decreased risk 
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6. Factors associated with the incidence of lipodystrophy 
syndrome 
 
6.1 Objectives 
This chapter describes the cohort at the end of the follow-up period, investigating the incidence 
of LS in subjects without symptoms at recruitment, and identifying factors associated with its 
emergence. 
Specific objectives include:- 
• Description of the longitudinal dataset including changing clinical and treatment 
characteristics. 
 
• Estimation of the prevalence of LS outcomes at the end of follow-up. 
 
• Estimation of incidence of fat alterations, metabolic abnormality, and LS over follow-up.  
 
• Investigation of recruitment factors and changing clinical factors over follow-up 
associated with the incidence of body fat alterations, metabolic abnormality, and LS. 
 
• Examination of regression or progression of symptoms of LS in subjects who had the 
syndrome at recruitment. 
  
Incidence over follow-up  Chapter 6 
213 
 
6.2 Specific methods 
6.2.1 Estimation of prevalence at the end of follow-up 
The prevalence of LS, and its component phenotypes (Table 6-1), at the end of the follow-up 
period was estimated using methods as described in previously. 
Table 6-1: Longitudinal analyses: outcome measures 
Measure Prevalence at 
end of follow-
up 
Incidence rate 
during follow-
up 
Risk factors 
Lipodystrophy syndrome  
Components of lipodystrophy syndrome 
   Any body fat alterations 
   Any lipoatrophy 
   Any lipohypertrophy 
   Any metabolic abnormality 
   Any hypercholesterolemia 
   Any fasting hypertriglyceridemia 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
X 
X 
X 
X 
X 
 
X 
 
 
X 
 
6.2.2 Definition of incident lipodystrophy syndrome 
The outcomes that were investigated for the incidence of LS symptoms are illustrated in Table 
6-1. Data collection occurred at up to four points. However, not all subjects had data collected at 
four time points, e.g. Individual C in Figure 6-1. Indeed, no subject who was resident in Italy had 
more than three data collection points.  
A subject was newly diagnosed with LS at a follow-up study visit where he/she was known not 
to have LS at the previous study visith. For example, as illustrated in Figure 6-1, subject A was 
assessed as not having LS symptoms at recruitment, and the second visit, but did have LS 
symptoms at third visit and the fourth visit: this subject was classed as having incident LS at the 
third visit.  Complete reversal of LS was defined as a subject going from a state of metabolic 
abnormality to acceptable cholesterol/fasting triglyceride/glucose tolerance and/or going from 
having body fat alterations to no alterations (e.g. Subject B in Figure 6-1 goes from having 
prevalent LS at recruitment to complete reversal at the second study visit). 
Assumptions were made about missing data at a study visit. Where LS data were missing at a 
follow-up visit, but were available from the previous study visit and at the subsequent follow-up, 
                                                 
h
 Since all time-to-event analyses aimed to investigate the emergence of LS symptoms: all subjects with prevalent 
symptoms were excluded and a structure of right censoring was assumed. Examination of when symptoms may have 
appeared in prevalent cases was not an objective of in this investigation, and was not required for modelling incidence 
in the susceptible population, Thus, interval censoring was not used to assume the point at which symptoms occurred 
between study visits.     
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the LS status of the subject was assumed to be the same as at the previous study visit (e.g. 
Subject E in Figure 6-1). For example, subject B in Figure 6-1, was assessed to have LS 
symptoms at recruitment, no symptoms at the second study visit, data was missing at the third 
visit, and no symptoms at the fourth visit: since the LS status was known at the second study 
visit and the fourth visit, subject B was assumed to have no LS symptoms between these visits. 
This assumption was only applicable to 5 subjects: 1 subject was assumed to have LS at a 
hospital visit where data was missing, and 4 were assumed to have no LS symptoms at hospital 
visits with missing data. Right censoring was used in the development of assumptions regarding 
LS status over follow-up: it was assumed that symptoms (or lack of symptoms) were consistent 
for an individual unless otherwise known. Thus for Subject C, (s)he was known not to have LS 
at his/her last study visit (visit 3), and it was therefore assumed that (s)he did not develop LS by 
the end of follow-up as no contradictory evidence had been collected.    Because of these 
assumptions, the size of the population at the end of follow-up can be comparable to the size at 
the beginning, regardless of the number of follow-up visits. Section 2 of Appendix F illustrates 
this approach further and includes sensitivity analyses conducted to investigate these 
assumptions.  
Date of onset of symptoms (incidence), and date of complete reversal of symptoms, was 
estimated as the date of completion of the data collection form which coincided with the study 
visit when the diagnosis was made. 
 
 6.2.3 Estimation of incidence 
Incidence was estimated from the study population who were free of any symptoms of LS 
outcomes at recruitment: subjects who had, or were assumed to have prevalent LS symptoms 
at recruitment were excluded from both estimation of incidence, and Cox regression models. 
For estimation of incidence of each LS outcome, the number of excluded subjects was as 
follows: body fat alterations; n = 172, lipohypertrophy; n = 122 = 114, lipoatrophy; n = 122 = 
113, metabolic abnormality; n =87, fasting hypertriglyceridemia; n = 122 = 38, 
hypercholesterolemia; n = 122 = 54, and LS; n = 228. Examples of prevalent cases include 
subjects B and E in Figure 6-1. This ensured that the denominator person-years in estimation of 
incidence was calculated correctly, and that the Cox models were comparing incident cases to 
non-cases as opposed to incident cases to a mixture of cases and non-cases.  
Subjects who had more than one change in LS status during follow-up (e.g. subject D in Figure 
6-1) were not included in the estimation of incidence. Such cases were also excluded from Cox 
regression modelling (body fat alterations; n = 19, metabolic abnormality; n = 20, and LS; n = 
17). Including cases with this added complexity would make inferences from the models more 
difficult.  
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However, it is important to note that incident cases of either body fat alterations or metabolic 
abnormality can occur in prevalent cases of LS. For example, a subject can have body fat 
alterations, but no metabolic abnormality at recruitment and thus be a prevalent case of LS, but 
would be considered “at-risk” for the emergence of metabolic abnormality. This same subject 
would contribute to the denominator for estimation of incidence of metabolic abnormality, but 
not to the denominator of estimation of body fat alterations incidence. If this same subject was 
to later develop fasting hypertriglyceridemia, s(he) would be an incident case of metabolic 
abnormality, i.e. also contribute to the numerator for incident metabolic abnormality. Similarly a 
subject with fasting hypertriglyceridemia and no body fat alterations at recruitment would be 
categorized as a prevalent case of LS (at recruitment) but susceptible for incident body fat 
alterations (during follow-up): if (s)he developed lipoatrophy over the follow-up period, the 
subject would be included in estimation of the rate of incidence of body fat alterations.  
Incidence of each component of LS (Table 6-1) was estimated as the number of subjects with 
incident symptoms per 100 years of follow-up time (person-time). Total person-time was 
estimated as the sum of the interval between date of recruitment and date of the last follow-up 
for each subject.  Person-time at risk for incidence of LS was calculated as the difference 
between the date of recruitment and the date diagnosis in incident cases. Thus the total person-
time at risk for incidence of LS was the sum of each individual person-time at risk. In the same 
way, total person-time at risk for reversal of LS symptoms was the sum of the individual 
differences between date of recruitment and date of report of complete reversal of symptoms (or 
the date of last follow-up if the patient did not experience full reversal of symptoms).  
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Figure 6-1: Follow-up of subjects with respect to lipodystrophy syndrome status 
 
Subject A is a case of incident lipodystrophy syndrome, subject B has complete reversal of lipodystrophy syndrome, subject D has both incident lipodystrophy syndrome and 
regression of symptoms to pre-LS state, and subject E has consistent symptoms. Assumptions are made about the symptoms of subjects B, C and E over the follow-up period. 
Subjects D and E are excluded from Cox regression models.  
Recruitment Second visit Third visit Fourth visit 
No symptoms No symptoms Symptoms Symptoms 
No symptoms No symptoms 
No symptoms 
No symptoms No symptoms 
Symptoms 
Symptoms Symptoms 
Symptoms Missing 
(assumed: symptoms) 
Symptoms Symptoms 
Missing 
(assumed: no symptoms) 
No symptoms Missing (assumed: no symptoms) 
 
 
A 
B 
C 
D 
E 
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6.2.4 Time to event (incident lipodystrophy syndrome) analysis 
Baseline factors that were significantly associated with risk of fat alterations, metabolic 
abnormality and LS in logistic regression models (Chapters 4 and 5) are summarized in Table 
6-2: two sets of multivariable analyses were conducted: (i) models investigating variables at 
recruitment, and (ii) models investigating time-updated variables. 
Table 6-2: Explanatory variables in Cox regression models 
Variable Models investigating factors at 
recruitment 
Models investigating time updated 
variables 
Gender X X 
Ethnicity X X 
Detectable viral load at recruitment X  
Maximum CDC-defined clinical status X  
Body mass index at recruitment X X 
Protease inhibitor use at recruitment X X 
Non-nucleotide reverse transcriptase 
inhibitors at recruitment  
X X 
Detectable viral load during follow-up  X 
CDC-defined HIV symptoms during 
follow-up 
 X 
CDC-defined HIV immunosuppression 
during follow-up 
 X 
 
The probability of incidence of LS symptoms during follow-up associated with each of the 
factors in Table 6-2 was investigated by using Kaplan-Meir survival estimates.   
The association between recruitment factors and incidence was assessed using Cox 
proportional hazard models. Both univariable and multivariable models were explored. Each 
multivariable model initially contained all factors included in Table 6-2, and were additionally 
adjusted for age and duration of ART use at recruitment. Thresholds used to define 
underweight, normal weight, and overweight and obesity were WHO BMI cut offs for adults390-392 
(Table 6-3). Each multivariable model contained a random effect for clinical site. A backwards 
covariate selection procedure was conducted to ascertain covariates in the final model as 
outlined in Chapter 2. All final models retained age, duration of ART use at recruitment and the 
random effect for clinical site regardless of their statistical significance in the model.  
Additional multivariable Cox regression models were fitted to investigate ART regimen 
(classified as PI-based HAART, NRTI mono-therapy, NNRTI-based HAART, and triple class 
therapy): these models were adjusted for both age and duration of ART use at recruitment, and 
also contained a random effect term for clinical site at recruitment.  
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Table 6-3: International classification of adult underweight, overweight and obesity 
according to body mass index 
 BMI range (kg/m2) 
Severely underweight <16.00 
Underweight 16.0 – 18.5 
Healthy weight 18.5 – 25.0 
Overweight 25.0 – 30.0 
Obese >30.0 
Thresholds for adults defined by the World Health Organization (WHO)390-392 
 
Further univariable and multivariable models were constructed to investigate the association 
with time-updated covariates over follow-up and the incidence of LS outcomes. Table 6-2 
illustrates the covariates examined in these models.  
Sensitivity analyses were conducted by repeating the stepwise covariate selection process but 
relaxing the criteria for inclusion of variables to 10% statistical significance. No difference was 
seen between the 5% and the 10% multivariable models.  
 
6.2.5 Exploration of progression or regression of lipodystrophy syndrome 
symptoms 
Subjects who were diagnosed as having LS at recruitment, but who had subsequently had a 
change in severity of symptoms over the follow-up period, were identified. Eight (8) specific 
outcomes, 4 related to body fat alterations, and 4 to metabolic abnormality were investigated  
Regression of body fat alterations was defined as a subjects having at least one of the 
following: 
- having been diagnosed as having severe fat alterations at a given study visit and then 
diagnosed as having moderate, mild or no symptoms at the subsequent visit; 
- having moderate fat alterations at a given study visit and then diagnosed as having mild 
or no symptoms at the subsequent hospital visit  
- having mild symptoms at a given study visit and subsequently having no symptoms.  
Similarly, progression of symptoms of body fat alterations was defined as at least one of:  
- no symptoms at a given study visit and mild/moderate/severe symptoms at the 
subsequent hospital visit; 
- mild symptoms at a given study visit followed by either moderate/severe symptoms at 
the subsequent study visit  
- moderate symptoms at a given study visit followed by severe fat alterations at the 
subsequent study.  
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Regression of metabolic abnormality was defined as the subject: 
- having been diagnosed as having LS at a given study visit, and then seeing  a  20% 
decrease in serum cholesterol and/or 20% decrease in serum fasting triglyceride at the 
subsequent study visit. 
Progression of metabolic abnormality was defined as the subject: 
- having been diagnosed as having LS at a given study visit, and then seeing a 20% 
increase in cholesterol and/or 20% increase in serum fasting triglyceride at the 
subsequent study visit.  
 
Thus, examination of progression/regression of LS symptoms was not only restricted to those 
subjects who had LS at recruitment, but could also include both examples where symptoms 
may have disappeared completely (in investigation of regression of symptoms) or examples of 
incident cases following previous complete reversal of symptoms (in investigation of both 
progression and regression of symptoms).  
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6.3 Results 
6.3.1 Follow-up of the cohort 
Of the 426 children and adolescents enrolled into the cohort, prospective data were collected up 
to close of follow-up (at the end of December 2011) from 388 (83.3%) subjects, i.e. 38 subjects 
(21 of whom had LS symptoms) attended only 1 study visit (Table 6-4). Over 3% of the cohort 
had data collected at two study visits, and over half (55.2%, n = 235) had attended three study 
visits. Furthermore, 88 subjects (20.1%) had attended 4 study visits (all were resident in 
Belgium and Poland); no Italian-resident subjects had >3 visits during follow-up. Median follow-
up for the cohort was 4.19 years (IQR: 3.00, 4.59), and was 3.25, 3.00 and 4.47 years (Table 6-
4) for Belgian-, Poland- and Italy-resident subjects respectively. The median time-lag between 
study visits for Poland/Belgian residents was between 0.50 and 0.65 years, while the median 
difference in Italian residents was over 1 year (Appendix F: Table F-3). Both the differences in 
total follow-up, and the differences in study visit intervals, were significant between countries (p 
< 0.001).  
 
Table 6-4:  Number of hospital visits by country of residence 
 
Total number of subjects 
at recruitment 
1 visit 2 visits 3 visits 4 visits Median total 
follow up* (IQR**) % n % n % n % n 
Belgium 84 1.19 1 3.57 3 21.43 18 73.81 62 3.25 (1.69, 3.81) 
Italy 275 22.54 33 2.91 8 74.55 28 0 0 4.47 (4.05, 4.75) 
Poland 67 11.94 4 2.99 2 17.91 12 67.16 45 3.00 (2.63, 3.07) 
TOTAL 426 16.67 38 3.05 13 55.16 268 25.12 107 4.19 (3.00, 4.59) 
* Median interval between first and last clinical visits in years. **Inter quartile range. Mann-Whitney-U test for 
medians between countries: p < 0.001 
 
Antiretroviral therapy use through follow-up 
Of the 29 subjects who were ART-naïve at recruitment (Chapter 3), all commenced ART at 
some point during follow-up, i.e. no subject was ART-naïve at the end of follow-up. Of these 
subjects, 1 commenced with NNRTI-based HAART, and 2 commenced on PI-based HAART. 
Interestingly, 26 commenced on NRTI mono-therapy (lamivudine): 10 subsequently started 
NNRTI-based HAART by the end of follow-up, while no subsequent data was available for the 
remaining 16 (all Italian-resident).  At the end of follow-up, 5 of the 29 subjects who were ART-
naïve at recruitment had symptomatic HIV disease, 22 had detectable viral load, but no subject 
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had immunosuppression. Furthermore, data on ART was collected during following up for all 33 
subjects whose ART status was unknown at recruitment (Appendix F: Figure F-5)i.  
Overall, 27.4% of subjects (n/N = 106/387) experienced at least one change in the type of ART 
regimen (i.e. change between PI/NNRTI-based HAART/triple class therapy/NRTI mono-
therapy), and all subjects who were being treated at recruitment were continuing with ART at 
the end of follow-up.  
 
Changing HIV-disease status during follow-up 
At the end of follow-up, the prevalence of detectable viral load was 53.1% (n/N = 221/416), of 
symptomatic HIV disease was 28.1% (n/N = 115/410) and of moderate or severe 
immunosuppression was 5.5% (n/N = 23/416), as illustrated in Figures F-2 to F-4 in Appendix F. 
Thus, while there were increases in prevalence of detectable viral load and clinical symptoms 
since recruitment, this was accompanied by a decrease in the prevalence of 
immunosuppression. At the end of follow-up, the prevalence of subjects with at least one of 
detectable viral load, symptomatic disease, or immunosuppression was 70.0% (n/N = 287/410), 
with the prevalence of subjects with either symptomatic disease or severe immunosuppression 
being 30.0% (n/N = 123/410). The prevalence of subjects with all three was 0.5% (n/N = 2/410).  
 
6.3.2 Prevalence of lipodystrophy syndrome at the end of follow-up 
At the end of the follow-up period, the prevalence of LS was 61.1% (95% CI: 56.4, 65.8, n/N = 
253/414), with the prevalence of fat alterations alone being 29.0% (95% CI: 24.6, 33.4, n/N = 
120/414), of metabolic abnormality alone being 17.3% (95% CI: 13.7, 21.0, n/N = 72/414), and 
of both body fat alterations and metabolic abnormality was 14.7% (95% CI: 11.3, 118.1, n/N 
=61/414) as illustrated in Figure 6-2.   
 
                                                 
i
 Data was only collected on change in ART use over follow-up: thus these 33 subjects were 
known to be on ART during follow-up, but no information on past ART use, if known, was 
collected. 
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Figure 6-2: Prevalence of lipodystrophy syndrome at the end of follow-up: metabolic 
abnormality and body fat alterations (n = 414) 
 
*Includes 18 subjects with body fat alterations at the end of follow-up, but whose metabolic abnormality status 
was unknown. **Includes 1 subject with metabolic abnormality at the end of follow-up, but whose body fat 
alteration status was unknown. 
 
There were increases in prevalence of LS, body fat alterations and metabolic abnormality 
between recruitment and the final follow-up, as illustrated in Table 6-5. However, as at 
recruitment, nearly half (47.4%) of final-round LS cases were defined by body fat abnormality 
alone, just over one-quarter (28.5%) by metabolic abnormality alone, and almost one-quarter 
(24.1%) by the combined metabolic abnormality and fat alterations occurring together. 
Of the 181 children and adolescents with fat alterations at the end of follow-up, 34.8% (n = 63) 
had lipoatrophy alone, 35.4% (n = 64) had lipohypertrophy alone and 29.8 (n = 54) had both 
(Figure 6-3): this distribution of body fat alteration symptoms was similar to that seen at 
recruitment.  
  
No lipodystrophy syndrome 
161 (38.9%) 
Body fat alterations 
Metabolic 
abnormality 
120* (29.0%) 
61 (14.7%) 
72** (17.4%) 
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Table 6-5: Comparison of prevalence of lipodystrophy syndrome outcomes at recruitment and at end of follow-up 
 Recruitment End of follow-up 
 n/N Prevalence (95% CI) n/N Prevalence (95% CI) 
Lipodystrophy syndrome 235/416 56.5 (51.7, 61.3) 253/414 61.1 (56.4, 5.8) 
Any fat alterations 176/422 41.7 (37.0,  46.4) 181/413 43.8 (39.0, 48.8) 
Any lipohypertrophy 115/422 27.3 (23.0, 31.5) 118/414 28.5 (24.2, 33.1) 
Any lipoatrophy 117/422 27.7 (23.5, 32.0) 117/413 28.3 (24.0, 32.9) 
Concurrent lipohypertrophy and lipoatrophy 56/422 13.3 (10.0, 16.5) 54/413 13.1 (10.0, 16.7) 
Any metabolic abnormality 108/416 26.0 (21.6, 30.0) 116/414 28.0 (23.8, 32.7) 
Any fasting hypertriglyceridemia 71/419 16.9 (13.4, 20.5) 55/414 13.3 (10.3, 17.0) 
Any hypercholesterolemia 56/419 13.4 (10.1, 16.6) 76/414 18.4 (14.8, 22.5) 
Concurrent hypercholesterolemia and fasting hypertriglyceridemia 23/419 5.5 (3.1, 7.4) 16/414 3.9 (2.3, 6.3) 
Glucose intolerance 7/419 1.7 (0.4, 3.0) 2/414 0.5 (0.0, 1.9) 
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Figure 6-3: Prevalence of body fat alterations outcomes at the end of follow-up: 
lipoatrophy and lipohypertrophy (n = 414) 
 
 
The proportions of subjects with each manifestation of metabolic abnormality varied between 
recruitment and the end of follow-up (Figure 6-4). While only 29.6% of subjects with metabolic 
abnormality had hypercholesterolemia alone at recruitment, this had increased to 51.7% at the 
end of follow-up. In contrast, the proportions of subjects with fasting hypertriglyceridemia alone, 
hypercholesterolemia with fasting hypertriglyceridemia, and glucose intolerance alone had 
decreased from 43.5% to 33.6% (n = 39), 20.4% to 12.9% (n = 15), and 3.7% to 1.0% (n = 1) 
respectively.  While there had been 3 cases of mixed phenotype including glucose intolerance 
at recruitment, by the end of follow-up mixed phenotype this was reduced to 1.  
  
Lipoatrophy Lipohypertrophy 
54 (13.0%) 
63 (15.20%) 64 (15.5%) 
No fat alterations 
233 (56.3%) 
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Figure 6-4: Prevalence of metabolic abnormality outcomes at the end of follow-up: 
hypercholesterolemia, fasting hypertriglyceridemia and glucose intolerance (n = 414)  
 
 
6.3.3 Incidence of lipodystrophy syndrome outcomes over follow-up 
Total person-years of follow-up was 1318.7, with almost 70% (923.0 person-years) contributed 
by the 276 Italian subjects and over 30% (395.7 person-years) contributed by 150 
Polish/Belgium subjects. 
Rates of incidence of new cases of body fat alterations are summarized in Table 6-6 and Figure 
6-5. The rate of incidence of new cases of LS (i.e. body fat alterations and/or metabolic 
abnormality) was 17.8 cases per 100 person years (95% CI: 14.1, 21.5), i.e. 74 subjects 
developed LS over 416.2 person-years at risk. New cases of body fat alterations occurred at a 
rate of 8.0 cases per 100 person years (95% CI: 6.0, 10.7), i.e. 45 cases over 561.7 person-
years at risk. Over the follow-up period, 29 new cases of metabolic abnormality occurred during 
712.9 person-years at risk: this was equivalent to a rate of 4.1 cases per 100 person-years 
(95% CI: 2.8, 5.9).  
Hypercholesterolemia 
Fasting 
hypertriglyceridemia 
Glucose intolerance 
No metabolic abnormality 
298 (72.0%)  
60 (14.5%)  
15 (3.6%)  
39 (9.4%)  
1  
 
1   
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The rate of incidence of new cases of lipoatrophy was 5.9 per 100 person-years (95% CI: 4.3, 
8.0), i.e. 42 cases over 710.8 person years at risk: lipoatrophy emerged most commonly in the 
buttocks with a rate of 5.3 cases per 100 person-years (95% CI: 3.9, 7.2: 43 cases over 806.5 
person-years at risk).  Rates of incidence of lipoatrophy and of lipohypertrophy were similar: the 
rate of lipohypertrophy was 5.2 cases per 100 person-years of follow-up (95% CI: 3.7, 7.2): 
equivalent to 36 new cases over 687.8 person-years at risk. Although rates of lipohypertrophy 
incidence in the breast and trunk were similar, the magnitude of the latter was slightly higher 
(3.9 per 100 person-years at risk, 95% CI: 2.7, 5.7: 28 cases with 714.0 person-years at risk.  
Over 830.7 person-years at risk, 16 subjects developed fasting hypertriglyceridemia, i.e. a rate 
of incidence of 1.9 cases per 100 person-years (95% CI: 1.2, 3.2), as illustrated in Figure 6-6. 
The number of incident new cases of hypercholesterolemia was 37: over 798.9 person-years of 
risk, this was equivalent to a rate of 4.6 per 100 person-years (95% CI: 3.3, 6.4). 
 
Table 6-6: Rates of (i) incidence of new cases lipodystrophy outcomes, and (ii) complete 
reversal of symptoms in prevalent cases 
 Rate of incidence of new cases Rate of reversal of prevalent cases 
Number of 
events 
Person 
years at 
risk 
Rate  
(95% CI) 
Number of 
events 
Person 
years at 
risk 
Rate  
(95% CI) 
Body fat alterations 45 561.72 8.01  
(5.96, 10.65) 
38 387.17 9.81  
(7.13, 13.34) 
Lipoatrophy 42 710.80 5.91  
(4.34, 7.97) 
37 315.12 11.74  
(8.51, 15.95) 
Lipohypertrophy 36 687.77 5.2 
(3.7, 7.2) 
34 257.53 13.2 
(9.4, 18.1) 
Metabolic abnormality 29 712.93 4.07  
(2.79, 5.86) 
42 488.98 8.59  
(6.33, 11.52) 
Fasting 
hypertriglyceridemia 
16 830.70 1.93  
(1.15, 3.18) 
29 459.93 6.31  
(4.33, 9.03) 
Hypercholesterolemia 37 798.94 4.63  
(3.32, 6.39) 
27 178.87 15.09  
(10.34, 21.36) 
Incidence per 100 years of person-time follow-up 
 
6.3.4 Complete reversal of lipodystrophy syndrome   
Among subjects with prevalent LS, 80 experienced complete reversal of symptoms equivalent 
to pre-LS levels: this corresponded with a rate of reversal of 12.7 per 100 person-years (95% 
10.2, 15.6: 629.7 person-years at risk). The rate of complete reversal of body fat alterations (9.8 
per 100 person-years, 95% CI: 7.1, 13.3; 38 cases over 387.2 person-years) was greater than 
the rate of reversal of metabolic abnormality (8.6 per 100 person-years, 95% CI: 6.3, 11.5; 42 
cases over 489.0 person-years at risk). Rates of complete reversal of LS symptoms in prevalent 
cases are summarized in Table 6-6, Figure 6-5 and Figure 6-6.  
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The rate of complete reversal of lipoatrophy was 11.7 cases per 100 person-years (95 % CI: 
8.5, 16.0; 37 cases over 315.1 person-years of risk), with the greatest rate seen in the arm (19.9 
cases per 100 person-years, 95% CI: 14.1, 27.2; 31 cases over 156.0 person-years at risk).  
However, the rate of complete reversal of lipohypertrophy was higher: 13.2 per 100 person-
years (95% CI: 9.4, 18.1; 34 cases over 257.5 person-years). The rate of complete reversal of 
fasting hypertriglyceridemia was 6.3 cases per 100 person-years (95% CI: 4.3, 9.0), i.e. 29 
cases over 459.9 person-years at risk. Of the prevalent cases of hypercholesterolemia, 27 
experienced normalization of cholesterol levels: the rate of complete reversal of symptoms was 
15.1 per 100 person-years (95% CI: 10.3, 21.4; 178.9 person-years at risk). 
 
6.3.5 Subjects with more than one change in lipodystrophy syndrome 
status over follow-up 
Less than one tenth of the cohort, (n = 44) had more than one change in their LS status over the 
follow-up period, (e.g. subject D in Figure 6-1). Of these 44 subjects, 19 (43.2%) were defined 
by having more than one change in fat alterations status over the follow-up period, while 45.5% 
(n = 20) were defined by having more than one change in metabolic abnormality status (Figure 
6-7). The remaining 11.4% (n = 5) had more than one change in both fat alterations and 
metabolic abnormality status.  
The median age at recruitment of these 44 subjects was 13.5 years (IQR: 11.1, 13.5), and 
duration of ART at recruitment was 4.9 years (IQR: 1.9, 4.9): there was no statistically 
significant difference in either recruitment age, nor recruitment duration of ART between this 
group and subjects who were consistently free of LS symptoms during follow-up. Similarly, no 
significant association (p > 0.05) was seen between subjects with >1 change in LS symptoms 
and those with no symptoms throughout follow-up with respect to maximum and recruitment 
CDC-defined clinical status, or recruitment degree of immunosuppression. However, a 
significant association was seen between nadir degree of immunosuppression and having >1 
change in LS status (p = 0.039). 
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Figure 6-5: Rates of incidence or complete reversal of specific body fat alterations 
  
Incident fat alterations – face: n = 27, arms: n = 31, legs: n = 33, buttocks: n =43, trunk: n = 28, neck: n = 22, and breast: n = 30. Reversed fat alterations - face: n = 29, arms: n = 31, legs: 
n = 30, buttocks: n = 26, trunk: n = 31, neck: n = 20, and breast: n = 25. See Appendix F: Table F-3  for details of specific person time at risk
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Figure 6-6: Rates of incidence or complete reversal of specific metabolic abnormality 
 
Incident metabolic abnormality – hypercholesterolemia: n = 27, fasting hypertriglyceridemia: n = 29. Reversed metabolic abnormality - hypercholesterolemia: n = 37, fasting 
hypertriglyceridemia: n = 16. Total follow-up: 1318.65 person-years. See Appendix F: Table F3 for details of specific person time at risk 
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Figure 6-7: Subjects at least one occurrence of lipodystrophy syndrome incidence and at 
least one occurrence of lipodystrophy syndrome symptoms complete reversal over 
follow-up 
 
6.3.6 Probability of incident lipodystrophy syndrome outcomes 
The probabilities of incident fat alterations, metabolic abnormality and LS among subjects 
without LS at recruitment were assessed by plotting Kaplan Meier plots: plots for LS, body fat 
alterations or metabolic abnormality are reproduced in the Section F.5 in Appendix F. Log-rank 
testing was used to explore differences in survival function between groups for each outcome: 
p–values are presented in Table 6-7.  
There was no consistent pattern in the incidence of LS symptoms by maximum clinical status: 
while the probability of incidence of fat alterations (Appendix F: Figure F-10a) was highest 
44 subjects
>1 change in LS status
19 subjects
>1 change in fat 
alterations only
16 subjects
2 changes
3 subjects
3 changes
20 subjects
>1 change in metabolic 
abnormality only
15 subjects
2 changes
5 subjects
3 changes
5 subjects
>1 change accross fat 
alterations and metabolic 
abnormality
4 subjects
1 change in fat alterations 
and 1 change in 
metabolic abnormality
1 subject
2 changes in fat 
alterations and 2 changes 
in metabolic abnormality
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amongst subjects without a history of symptomatic disease for much of the follow-up, this was 
less clear with respect to the incidence of metabolic abnormality (Appendix F: Figure F-10b) or 
LS (Appendix F: Figure F-9a). Indeed, significant differences were seen between subjects of 
differing maximum clinical status with respect to body fat alterations (p = 0.034): at 4 years 
follow-up, the probability for LS was approximately 25% in subjects with a history of moderate 
clinical symptoms while the estimated probability of LS in either subjects with no symptoms or 
severe symptoms was 60%. Differences in maximum clinical status were non-significant for both 
metabolic abnormality and LS. While the incidence of fat alterations or metabolic abnormality 
varied with history of immunosuppression, subjects with past nadir moderate 
immunosuppression had a higher probability of incident LS for the first 3 years of follow-up 
(Appendix F: Figure F-9b). However, there was no significant difference in the survival between 
subjects of differing immunosuppression for any outcome (p ≥ 0.183).  
The probability of incident metabolic abnormality or LS was higher in subjects who were 
symptomatic for HIV at recruitment (Appendix F: Figure F-13b and Figure F-11a respectively). 
The probability of incident body fat alterations was highest in subjects who were asymptomatic 
at recruitment (Appendix F: Figure F-13a). Indeed, significant differences in survival function 
between groups was seen only for body fat alterations (p = 0.002). In contrast, similar patterns 
in incidence of LS symptoms were seen across subjects with differing CDC-defined 
immunosuppression at recruitment. During early follow-up, subjects with the most severe 
immunosuppression at recruitment had the highest probability of LS (Appendix F: Figure F-11b): 
the probability of LS was 100% in subjects with severe immunosuppression at 2 years of follow-
up, compared with approximately 80% for subjects with either no or moderate 
immunosuppression. During later follow-up subjects with moderate immunosuppression or no 
immunosuppression had the highest probability, i.e. approximately 50% for no/moderate 
immunosuppression at 4 years of follow-up compared to 0% probability of LS with severe 
immunosuppression. There was no evidence of differences in survival function between groups 
of differing recruitment immunosuppression with any outcome (p ≥ 0.117). 
The probability of two LS outcomes (incident metabolic abnormality and incident LS) was 
highest in subjects who had yet to undergo puberty at recruitment, followed by those who had 
completed puberty (Appendix F: Figure F-16b and Figure F-15a in this chapter). However the 
opposite was seen with incident fat alterations: the highest probability was in subjects with who 
had completed puberty (approximately 70% compared to 60% in pre-pubescent children, and 
45% in post-pubertal adolescents: Appendix F Figure F-16a). While significant differences were 
seen in survival function between groups of different Tanner score by LS status (p = 0.011), 
differences were not statistically significant for body fat alterations (p = 0.974), and metabolic 
abnormality (p = 0.634). 
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Use of NNRTI at recruitment was associated with a greater probability of incident metabolic 
abnormality (Appendix F: Figure F-17b) and LS (Figure F-15b) during follow-up compared to no-
use at recruitment: these differences were only significant for body fat alterations (p = 0.012), 
where the probability at four years of follow-up amongst subjects on NNRTI at recruitment was 
almost 85%, but was approximately 60% in subjects not on this class of ART. The probabilities 
of incident body fat alterations and metabolic abnormality was lower amongst subjects using PI 
at recruitment, compared to subjects not using this class of ART (Appendix F: Figure F-19): 
while this pattern was also true for incident LS, it was not as obvious (Figure F-18).  Significant 
differences in survival function were not seen with recruitment PI use for any LS outcome (p ≥ 
0.732). 
A similar pattern of incidence of fat alterations, metabolic abnormality, or LS, was seen with use 
of HAART at recruitment (Appendix F: Figure F-20, and Figure 6-18b in this chapter): in early 
follow-up the probability was greater among subjects on HAART at recruitment, but after 
approximately 2 years of follow-up the converse was true with the probability being 
comparatively higher amongst subjects not on HAART at recruitment.  At 4-years of follow-up 
the probability of incident body fat alterations amongst subjects not on HAART was 
approximately 70% compared to 25% in those subjects on HAART at recruitment (Figure F-
20a): this difference was statistically significant (p = 0.003). However no significant difference 
were seen either incident metabolic abnormality (p = 0.054), nor incident LS (p = 0.621). 
When investigating specific ART regimen used at recruitment, no incident body fat alteration 
during follow-up were seen in subjects who were on triple class therapy at recruitment 
(Appendix F: Figure F-22a). The highest probability of incident body fat alterations was seen in 
subjects on NNRTI-based HAART at recruitment, followed by those on PI-based HAART, i.e. 
approximately 70% and 50% at 4 years follow-up. In contrast, for the majority of follow-up, the 
highest probability of incident metabolic abnormality was seen with NNRTI-based HAART, 
followed by NRTI-mono-therapy, PI-based HAART and triple class therapy (Figure F-22b). For 
much of the follow-up period, NNRTI-based HAART was associated with the greatest probability 
of incident LS, PI-based HAART and NRTI mono-therapy (Figure F-21a). However, at 3.5 years 
of follow-up, the probability of LS was highest amongst subjects on NRTI mono-therapy at 
recruitment. Significant differences in survival function were seen between subjects on different 
ART regimens at recruitment for body fat alterations (p = 0.003), but not for either metabolic 
abnormality or LS (p ≥ 0.118). 
Significant differences were seen in the survival function between subjects who were on 
zidovudine at recruitment and those not on this drug for body fat alterations (p = 0.009) and 
metabolic abnormality (p = 0.034), as illustrated in Table 6 7. Furthermore there were significant 
differences in the survival function for incident LS between subjects who had detectable viral 
load during follow-up compared to those who did not for both LS (p = 0.040, Figure F-24a), and 
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body fat alterations (p <0.001, Appendix F: Figure F-26a).  Significant differences were also 
seen in the survival function for body fat alterations (p < 0.001) and for metabolic abnormality (p 
= 0.040) between subjects who had experienced any CDC-defined clinical symptoms over 
follow-up (Appendix F: Figure F-27). Similarly, the survival functions for LS in subjects who had 
experienced CDC-defined immunosuppression over follow-up and those who had not were 
significantly different (p = 0.046) as illustrated in Figure F-25. 
Table 6-7: Log-rank tests comparing survival functions by lipodystrophy outcome 
 
p –value for log-rank test 
  
Lipodystrophy 
syndrome 
Body fat 
alterations 
Metabolic 
abnormality 
Recruitment age 0.036 0.069 0.581 
Gender 0.952 0.918 0.860 
Maximum CDC clinical stage 0.284 0.034 0.280 
Nadir CDC-defined immunosuppression 0.770 0.183 0.507 
Recruitment CDC-defined clinical status 0.365 0.002 0.085 
Recruitment immune status 0.620 0.117 0.297 
Recruitment Tanner score 0.011 0.974 0.634 
Recruitment lamivudine 0.292 0.244 0.254 
Recruitment stavudine 0.965 0.147 0.406 
Recruitment efavirenz 0.678 0.432 0.835 
Recruitment tenofovir 0.730 0.671 0.989 
Recruitment zidovudine 0.868 0.009 0.034 
Recruitment ritonavir booster 0.193 0.782 0.556 
Recruitment PI use 0.732 0.837 0.975 
Recruitment NRTI use 0.436 0.706 0.191 
Recruitment NNRTI use 0.974 0.012 0.155 
Recruitment HAART 0.621 0.003 0.054 
Recruitment ART regimen 0.821 0.003 0.118 
Recruitment duration of ART use 0.635 0.638 0.698 
Recruitment BMI 0.476 0.179 0.099 
Any detectable virus during follow-up 0.040 <0.001 0.143 
Any clinical symptoms during follow-up 0.597 <0.001 0.040 
Any severe (CDC class C) clinical symptom 
during follow-up 0.225 0.391 0.672 
Any immunosuppression during follow-up 0.046 0.964 0.939 
Any severe immunosuppression during follow-
up <0.001 0.009 0.284 
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6.3.7 Factors associated with the incidence of lipodystrophy syndrome 
outcomes 
Body fat alterations 
While there was no statistically significant association between recruitment factors and incident 
fat alterations in univariable Cox proportional hazard models, detectable viral load and use of PI 
were associated with a non-significant increased risk (Table 6-8). Any detectable viral load and 
any CDC-clinical symptoms during follow-up were both associated with a non-significant 
increased risk of incident body fat alterations. Any CDC-defined immunosuppression was 
associated with a non-significant decrease in risk. Furthermore, female sex and maximum 
clinical symptoms was associated with a non-significant increase in risk.  
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Table 6-8: Univariable Cox regression models for incidence of lipodystrophy syndrome outcomes  
  Body fat alterations Metabolic abnormality Lipodystrophy syndrome 
  Hazard 
ratio 
95% 
confidence 
interval 
p - value Hazard 
ratio 
95% 
confidence 
interval 
p - value Hazard 
ratio 
95% 
confidence 
interval 
p- value 
Age (years)* 2-11 1   1   1   
12-18 1.37 (0.76, 2.48) 0.300 1.30 (0.62, 2.76) 0.488 2.26 (1.14, 4.48) 0.019 
Duration of 
ART (years)* 
<2.5 1   1   1   
2.5-4.9 0.89 (0.34, 2.34) 0.818 0.57 (0.17, 1.91) 0.364 1.01 (0.37, 2.81) 0.978 
5.0-7.4 1.57 (0.55, 4.46) 0.397 0.57 (0.15, 2.17) 0.430 0.59 (0.17, 2.03) 0.405 
7.5-9.9 1.96 (0.82, 4.70) 0.132 0.65 (0.20, 2.17) 0.487 1.03 (0.37, 2.86) 0.953 
≥10.0 0.69 (0.19, 2.57) 0.582 0.96 (0.33, 2.78) 0.947 1.40 (0.51, 3.87) 0.517 
Sex Male 1   1   1   
 Female 1.58 (0.84, 2.95) 0.156 0.89 (0.43, 1.85) 0.757 1.11 (0.59, 2.10) 0.744 
Ethnicity Black 1   1   1   
 White 0.94 (0.48, 1.83) 0.858 0.38 (0.17, 0.88) 0.024 0.21 (0.10, 0.45) <0.001 
 Other 1.26 (0.28, 5.69) 0.762 0.53 (0.07, 4.17) 0.547 0.37 (0.05, 2.74) 0.328 
Tanner score 
for puberty 
I 1   1   1   
II-IV 1.31 (0.62, 2.77) 0.477 3.52 (1.17, 10.62) 0.026 5.25 (1.96, 14.01) 0.001 
V 0.98 (0.38, 2.55) 0.973 2.35 (0.69, 8.02) 0.174 3.74 (1.25, 11.21) 0.018 
Detectable 
viral load* 
<50 copies/ml 1   1   1   
≥50 copies/ml 1.59 (0.38, 6.76) 0.523 1.43 (0.34, 6.11) 0.626 4.25 (0.58, 31.15) 0.15 
Detectable 
viral load at 
any  time** 
No 1   1   -   
Yes 1.20 (0.28, 5.07) 0.809 2.43 (0.33, 18.04) 0.385 - - - 
CDC-defined 
clinical  
status * 
N/A 1   1   1   
B 0.82 (0.29, 2.36) 0.715 0.52 (0.07, 3.91) 0.529 0.57 (0.08, 4.21) 0.580 
C 2.53 (0.59, 10.80) 0.209 - - - - - - 
Maximum 
CDC-defined 
clinical status 
N/A 1   1   1   
B 1.93 (0.88, 4.22) 0.101 1.01 (0.41, 2.49) 0.978 1.28 (0.58, 2.84) 0.536 
C 1.85 (0.81, 4.22) 0.146 0.98 (0.37, 2.60) 0.970 0.89 (0.37, 2.15) 0.793 
Any CDC-
defined 
symptoms** 
No 1   1   1   
Yes 1.22 (0.65, 2.31) 0.535 0.60 (0.25, 1.46) 0.264 0.86 (0.42, 1.78) 0.694 
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  Body fat alterations Metabolic abnormality Lipodystrophy syndrome 
  Hazard 
ratio 
95% 
confidence 
interval 
p - value Hazard 
ratio 
95% 
confidence 
interval 
p - value Hazard 
ratio 
95% 
confidence 
interval 
p- value 
CDC-defined 
immuno-
suppression* 
1 1   1   1   
2 0.75 (0.37, 1.50) 0.418 1.10 (0.48, 2.50) 0.824 0.91 (0.43, 1.92) 0.807 
3 1.03 (0.14, 7.67) 0.974 1.53 (0.20, 11.40) 0.681 3.07 (0.92, 10.26) 0.068 
Nadir CDC-
defined 
immuno-
suppression 
1 1   1   1   
2 1.69 (0.82, 3.51) 0.155 1.56 (0.67, 3.64) 0.306 0.86 (0.40, 1.85) 0.703 
3 1.05 (0.48, 2.31) 0.901 0.75 (0.25, 2.29) 0.614 1.13 (0.50, 2.53) 0.773 
Any CDC-
defined 
immuno-
suppression** 
No 1   1   1   
Yes 0.61 (0.33, 1.14) 0.123 0.93 (0.45, 1.93) 0.842 1.17 (0.62, 2.21) 0.619 
Body Mass 
index* 
Healthy 
weight 
1   1   1   
Severely 
underweight 
0.59 (0.25, 1.36) 0.212 0.60 (0.17, 2.11) 0.430 0.42 (0.15, 1.27) 0.127 
Underweight 0.53 (0.24, 1.18) 0.123 0.56 (0.20, 1.57) 0.273 0.78 (0.37, 1.64) 0.514 
Overweight 0.66 (0.09, 4.93) 0.683 3.45 (1.32, 9.02) 0.012 2.68 (0.89, 8.04) 0.079 
PI* No use 1   1   1   
 Use 1.13 (0.61, 2.09) 0.693 2.72 (1.15, 6.44) 0.023 1.15 (0.58, 2.26) 0.690 
NNRTI* No  use 1   1   1   
 Use 1.02 (0.50, 2.07) 0.959 0.44 (0.16, 1.19) 0.108 0.84 (0.38, 1.84) 0.657 
CDC-defined immune status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. *Status at recruitment **Occurring over follow-up period.  
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None of the postulated risk factors (Table 6-2) were statistically significant in the multivariable 
model examining the association between recruitment factors and incident body fat alterations: 
consequently the final model only included age and BMI at recruitment, and the random effect 
of clinical site (Table 6-9). In the multivariable model including ART regimen at recruitment, 
NRTI use was associated with a non-significant decreased risk (Adjusted hazard ratio, AHR: 
0.40, 95% CI: 0.13, 1.24), and NNRTI-based HAART with a non-significant increased risk (AHR: 
1.13, 95% CI: 0.49, 2.61) compared to PI-based HAART (Appendix F: Table F-4).   
 
Table 6-9: Final multivariable Cox regression model for incident body fat alterations: 
covariates at recruitment (n = 194)   
  
Adjusted 
hazard ratio 
95% confidence 
interval 
p – value 
Age (years)* 2-11 1   
 12-18 1.35 (0.67, 2.74) 0.400 
Duration of 
ART (years)* 
<2.5 1   
2.5-4.9 0.95 (0.36, 2.51) 0.919 
5.0-7.4 1.62 (0.57, 4.61) 0.366 
7.5-9.9 1.71 (0.69. 4.21) 0.244 
≥10.0 0.60 (0.15, 2.31) 0.454 
Multivariable model contains a random effect for clinical site of treatment. *Status at recruitment. Therneau-
Grambsch global test for proportional hazards: p = 0.8841 
 
In contrast to the model including recruitment covariates, in the final multivariable model 
including time-updated covariates during follow-up, any immunosuppression during the follow-
up period was associated with a significant decrease in risk of incident body fat alterations 
(AHR: 0.41, 95% CI: 0.19, 0.91), as illustrated in Table 6-10: no other factor remained 
statistically significant in this model. 
 
Table 6-10: Final multivariable Cox regression models for incident body fat alterations: 
covariates during follow-up (n = 194)   
   
Adjusted 
hazard ratio 
95% 
confidence 
interval 
p – value 
Age (years)* 2-11 1   
 12-18 1.84 (0.86, 3.94) 0.116 
Duration of ART 
(years)* 
<2.5 1   
2.5-4.9 1.02 (0.38, 2.79) 0.960 
5.0-7.4 1.86 (0.63, 5.47) 0.261 
7.5-9.9 2.00 (0.81, 4.96) 0.135 
≥10.0 - - - 
Immuno-
suppression** 
No 
immunosuppression 
1   
Immunosuppression 0.41 (0.19, 0.91) 0.027 
Multivariable model contains a random effect for clinical site of treatment. *Status at recruitment. **Time 
updated covariate. Therneau-Grambsch global test for proportional hazards: p = 0.6726 
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Metabolic abnormality 
A significant reduced risk of incident metabolic abnormality was found to be associated with 
White ethnicity (HR: 0.38, 95% CI: 0.17, 0.88) in unadjusted Cox modelling (Table 6-9). A 
significantly increased risk seen in subjects who were undergoing puberty (HR: 3.52, 95% CI: 
1.17, 10.62), compared to those who were yet to begin puberty. Although an increased risk was 
also seen in subjects who had completed puberty, this was non-significant (p = 0.174). 
Furthermore an overweight BMI (25.0m/kg2 ≤ BMI < 30.025.0m/kg2) was also a significant risk 
factor for incident metabolic abnormality (HR: 3.45. 95% CI: 1.32, 9.02), compared to subjects 
who had a healthy BMI at recruitment (Table 6-8).  Use of PIs at recruitment was associated 
with a significant increased risk (HR: 2.72, 95% CI: 1.15, 6.44), while use of NNRTI was 
associated with a non-significant (p = 0.108) reduced risk (HR: 0.44, 95% CI: 0.16, 1.19).  
Both overweight BMI (AHR: 4.83, 95% CI: 1.38, 16.91), and recruitment use of PI (AHR: 3.56, 
95% CI: 1.18, 10.80) were significant and independent risk factors for incident metabolic 
abnormality in the final multivariable model including recruitment risk factors (Table 6-11). This 
is supported by the multivariable model including ART regimen at recruitment (Appendix F: 
Table F-4), where NNRTI-based HAART was associated with a reduced risk (AHR: 0.27, 95% 
CI: 0.08, 0.95), compared to PI-based HAART.  
 
Table 6-11: Final multivariable Cox regression models for incident metabolic alterations: 
covariates at recruitment (n = 401) 
  
Adjusted 
hazard ratio 
95% confidence 
interval 
p – value 
Age (years)* 2-11 1   
 12-18 0.97 (0.35, 2.71) 0.951 
Duration of 
ART (years)* 
<2.5 1   
2.5-4.9 0.50 (0.14, 1.81) 0.293 
5.0-7.4 0.48 (0.12, 1.90) 0.297 
7.5-9.9 0.58 (0.16, 2.09) 0.401 
≥10.0 0.47 (0.11, 2.00) 0.307 
Body Mass 
index* 
Healthy weight 1   
Severely 
underweight 
0.48 (0.09, 2.55) 0.390 
Underweight 0.92 (0.30, 2.81) 0.884 
Overweight 4.83 (1.38, 16.91) 0.014 
PI* No use 1   
 Use 3.56 (1.18, 10.80) 0.025 
Multivariable model contains a random effect for clinical site of treatment. *Status at recruitment. Therneau-
Grambsch global test for proportional hazards: p = 0.6684 
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Furthermore, recruitment PI remained statistically significant in the final multivariable model 
including risk factors during follow-up (Table 6-12) being associated with a 4-fold increase in 
risk (AHR: 4.44, 95% CI: 1.40, 14.12). Moreover, recruitment obese BMI remained a significant 
risk model in this model. However, any CDC-defined immunosuppression during the follow-up 
period was associated with a significant and independent decrease in risk of incident metabolic 
abnormality (AHR: 0.34, 95% CI: 0.12, 0.98).  
 
Table 6-12: Final multivariable Cox regression models for incident metabolic alterations: 
covariates during follow-up (n = 401) 
  
Adjusted 
hazard ratio 
95% 
confidence 
interval 
p – value 
Age (years)* 2-11 1   
 12-18 1.06 (0.38, 2.91) 0.915 
Duration of 
ART (years)* 
<2.5 1   
2.5-4.9 0.61 (0.17, 2.18) 0.450 
5.0-7.4 0.43 (0.11, 1.72) 0.232 
7.5-9.9 0.63 (0.17, 2.26) 0.476 
≥10.0 0.56 (0.13, 2.43) 0.443 
Body Mass 
index* 
Healthy weight 1   
Severely underweight 0.47 (0.09, 2.51) 0.381 
Underweight 0.91 (0.29, 2.79) 0.862 
Overweight 7.21 (1.91, 27.27) 0.004 
PI* No use 1   
 Use 4.44 (1.40, 14.12) 0.012 
Immuno-
suppression**  
No 
immunosuppression 
1   
Immunosuppression 0.34 (0.12, 0.98) 0.046 
*Status at recruitment. **Time updated covariate. Therneau-Grambsch global test for proportional hazards: p = 
0.8547 
 
Lipodystrophy syndrome 
In univariable analyses, subjects who were of White ethnicity had a statistically significant 
reduced risk of incident LS (HR: 0.21, 95% CI: 0.10, 0.45) (Table 6-8). Children and 
adolescents aged 12-18 years at recruitment had a significant increase in risk that was over 
two-fold that for 2-11 year olds (HR: 2.26, 95% CI: 1.14, 4.48). Indeed, subjects who were 
undergoing puberty (HR: 5.25, 95% CI: 1.96, 14.01), or had completed puberty (HR: 3.74, 95% 
CI: 1.25, 11.21), had a significantly increased risk compared to subjects who had yet to 
commence puberty.  
In adjusted analyses, both White ethnicity and maximum CDC-defined clinical condition were 
significant risk factors for incident LS (Table 6-13). However, while White ethnicity was 
associated with a decreased risk (AHR: 0.15, 95% CI: 0.05, 0.38), maximum clinical status B 
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was associated with increased risk (AHR: 2.56, 95% CI: 1.00, 6.54). Neither use of PIs nor 
NNRTIs at recruitment were significant risk factors for incident LS. Indeed, no ART regimen was 
significantly associated with incident LS in the multivariable Cox modelling (Appendix F: Table 
F-4). 
Table 6-13: Final multivariable Cox regression models for incident lipodystrophy 
syndrome: covariates during follow-up 
  
Adjusted 
hazard ratio 
95% confidence 
interval 
p – value 
Age( years)*  2-11 1   
 12-18 1.70 (0.68, 4.15) 0.243 
Duration of ART 
(years)* 
<2.5 1   
2.5-4.9 0.49 (0.16, 1.51) 0.218 
5.0-7.4 0.44 (0.11, 1.70) 0.234 
7.5-9.9 1.48 (0.49, 4.46) 0.489 
 ≥10.0 0.53 (0.15, 1.89) 0.331 
Ethnicity Black 1   
 White 0.15 (0.05, 0.38) <0.001 
 Other 0.69 (0.08, 5.54) 0.724 
Maximum CDC-
defined clinical status 
N/A 1   
B 2.56 (1.00, 6.54) 0.049 
C 0.83 (0.31, 2.26) 0.720 
CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
Multivariable model contains a random effect for clinical site of treatment. *Status at recruitment. Therneau-
Grambsch global test for proportional hazards: p = 0.8430 
 
Survival analysis of follow-up factors associated with incidence of LS did not result in a Cox 
model which converged.  
 
Proportional hazards assumption in Cox regression models 
Both examination of Schoenfeld residual plots with follow-up time, and performing GLOBAL 
significant tests of the multivariable models showed that the proportional hazards assumptions 
in explanatory variables had been met. Results from the GLOBAL tests are included in the 
Appendix F: Section F.7. 
  
6.3.8 Progression and/or regression of lipodystrophy syndrome 
symptoms 
At recruitment, 235 subjects had LS: of these subjects 221 had prospective data collected from 
which assessment regarding progression or regression of these symptoms could be made: data 
was available for 134 subjects who had body fat alterations alone, 49 subjects who had 
metabolic abnormality alone, and 38 subjects who had both (Table 6-14). In each of these 
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groups, change in severity of body fat alterations symptoms was similar: ~75% experienced 
regression alone, and ~25% experienced both progression and regression over follow-up. 
However, differences were seen in change in metabolic symptoms over time between the three 
groups. Children with initial body fat alterations only most frequently experienced progression 
alone (n = 49, 38.9%), those with metabolic abnormality only, or both at recruitment most 
frequently experienced regression alone (n = 15, 34.1% and n = 13, 35.1% respectively).  
All these 221 subjects experienced both progression and regression of symptoms during the 
follow up period. The most common manifestation was progression of metabolic abnormality 
symptoms with accompanying regression of body fat alteration symptoms (41.7%, n = 95), 
followed by regression of both fat alteration and metabolic abnormality symptoms (36.4%, n = 
83) as illustrated in Figure 6-8.  
 
Change in severity of body fat alteration symptoms 
Over 70% (n/N = 143/201) of subjects with recruitment LS experienced regression with no 
progression of body fat alterations, while 28.9% (n/N = 58/201) had both progression and 
regression (Figure 6-9). However 27 subjects were missing data on change in symptoms of 
body fat alterations. No significant difference was seen in either median age, or median duration 
of ART use between subjects with only regression of body fat alteration compared to those with 
both progression and regression (p ≥ 0.410).  
 
Change in severity of metabolic abnormality symptoms 
The proportion of subjects who had no change in the severity of metabolic abnormality, or who 
had experienced regression without progression over follow up was similar: 24.8% (n/N = 
53/214), and 24.3% (n/N = 52/214) respectively (Figure 6-9b). Almost 30% (n/N = 64/214) of 
subjects who had LS at recruitment had progression of metabolic abnormality during follow-up, 
while 21.0% (n/N = 45/214) experienced both progression and regression. The number of 
subjects who were missing data on change in metabolic symptoms over the follow-up period 
was 14. There was no significant difference in either age or duration of ART use at recruitment 
between subjects with differing metabolic abnormality symptom profiles over follow-up.
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Table 6-14: Specific changes in symptom severity over follow-up by initial lipodystrophy status (n = 221) 
    
 
    
 Metabolic abnormality  Body fat alterations 
Both 
progression 
and 
regression 
Progression 
only 
Regression 
only 
Neither 
progression 
nor 
regression 
INITIAL 
DIAGNOSES 
Neither 
progression 
nor 
regression 
Regression 
only 
Progression 
only 
Both 
progression 
and 
regression 
25 (19.8%) 49 (38.9%) 22 (17.5%) 30 (23.8%) Body fat 
alterations 
only 
(n = 134) 
0 79 (67.0%) 0 39 (33.1%) 
11 (25.0%) 9 (20.5%) 15 (34.1%) 9 (20.5%) Metabolic 
abnormality 
only  
(n = 49) 
0 31 (75.6%) 0 10 (24.4%) 
9 (24.3%) 6 (16.2%) 13 (35.1%) 9 (24.3%) Both body fat 
alterations 
and metabolic 
abnormality 
(n = 38) 
0 27 (75.0%) 0 9 (25.0%) 
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Figure 6-8: Manifestation of progression/regression of symptoms over follow-up in subjects with lipodystrophy syndrome at recruitment (n = 221*) 
 
*221 of the 235 subjects with LS at recruitment had data available on progression/regression of symptoms over follow-up
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Figure 6-9: Distribution of progression and regression of symptoms of lipodystrophy 
syndrome:  as (a) frequency distribution, and percentage distribution of (b) body fat 
alterations; n = 201, and (c) metabolic abnormality; n = 214 
 
 
Missing data: body fat alterations; 27, and metabolic abnormality; 14 
 
Associated factors 
Subject characteristics were examined in relation to 4 symptom-change outcomes with respect 
to body fat alterations and metabolic abnormality: no change, progression only, regression only, 
both progression and regression  
No significant associations were seen with any subject characteristic and changes in symptom 
severity of either body fat alterations (Table 6-15) or metabolic abnormality (Table 6-16). 
24.77%
29.91%
24.3%
21.03%
No progression/regression Progression only
Regression only Both progression/regression
71.14%
28.86%
Regression only Both progression/regression
(b) (c) 
(a) 
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Although the difference was statistically non-significant, 97% of subjects with regression of body 
fat alterations symptoms only had detectable viral load over follow-up, while this percentage 
was 91% in subjects with both progression and regression.   
Table 6-15: Characteristics of subjects with changes in severity of symptoms of body fat 
alterations during follow-up (n = 201) 
  
No 
progression/ 
regression 
Progression 
only 
Regression 
only 
Both 
progression 
and 
regression 
p-
value 
Recruitment 
clinical 
condition 
N/A 0 0 114 (90.48) 45 (93.75)  
B 0 0 10 (7.94) 2 (4.17)  
C 0 0 2 (1.59) 1 (2.08) 0.668 
Recruitment 
immuno-
suppression 
Stage 1 0 0 116 (81.12) 47 (81.03)  
Stage 2 0 0 22 (15.38) 10 (17.24)  
Stage 3 0 0 5(3.50) 1 (1.72) 0.770 
Maximum 
clinical 
condition 
N/A 0 0 37 (27.82) 13 (24.53)  
B 0 0 57 (42.86) 22 (41.51)  
C 0 0 39 (29.32) 18 (33.96) 0.805 
Nadir immune 
status 
Stage 1 0 0 36 (25.17) 14 (24.14)  
Stage 2 0 0 64(44.76) 26 (44.83)  
Stage 3 0 0 43 (30.07) 18 (31.03) 0.985 
Any clinical 
symptoms* 
No symptoms 0 0 3(3.03) 5 (9.26)  
Symptoms 0 0 96 (96.97) 49 (90.74) 0.098 
Any immuno-
suppression* 
None 0 0 99 (69.23) 44 (30.77)  
Immunosuppression 0 0 40 (68.97) 18 (31.03) 0.971 
Recruitment 
viral load 
Undetectable 0 0 21 (14.69) 9 (15.52)  
Detectable 0 0 122 (85.31) 49 (84.48) 0.881 
Any detectable 
viral load* 
No detection 0 0 4 (7.14) 5 (14.71)  
Detected 0 0 52 (92.86) 29 (85.29) 0.246 
Recruitment 
antiretroviral 
regiment 
NRTI mono-therapy 0 0 9 (6.98) 3 (5.77)  
PI-based HAART 0 0 75 (58.14) 31(59.62)  
NNRTI-based HAART 0 0 37 (28.68) 17 (32.69)  
Triple class therapy 0 0 8 (6.20) 1 (1.92) 0.646 
Any change in 
ART regimen* 
No change 0 0 108 (80.60) 41 (73.21)  
Change 0 0 26 (19.40) 15 (26.79) 0.259 
All subjects had lipodystrophy syndrome at recruitment. CDC-defined immune status - stage 1: no 
immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-
defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
Detectable viral load defined as >50 copies/mL. *Over follow-up 
 
Non-significant differences were also seen between some patient characteristics and changes 
in metabolic abnormality symptoms (Table 6-16). Approximately 86% of subjects either with (i) 
no changes in metabolic abnormality severity or (ii) regression of symptoms only had no 
immunosuppression at recruitment: this proportion was approximately 75% for subjects with 
either progression of symptoms only, or those with both progression and regression.  Almost 
one quarter of subjects who experienced both progression and regression of metabolic 
abnormality had undetectable viral load, with this proportion being less than 15% for other 
symptom-change outcomes. Over half of subjects with each symptom-change outcome were on 
PI-based HAART at recruitment: 55-57% of subjects with either progression only or regression 
only, 65% of subjects with no change in severity of metabolic abnormality, and 46% in subjects 
with both progression and regression of symptoms.  
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Table 6-16: Characteristics of subjects with changes on severity of symptoms of 
metabolic abnormality (n = 214) 
  
No 
progression/ 
regression 
Progression 
only 
Regression 
only 
Both 
progression 
and 
regression 
p-value 
Recruitment 
clinical 
condition 
N/A 40 (86.96) 53 (92.98) 39 (88.64) 37 (97.37)  
B 4 (8.70) 4 (7.02) 4 (9.09) 0  
C 2 (4.35) 0 1 (2.27) 1 (2.63) 0.436 
Recruitment 
immuno-
suppression 
Stage 1 46 (86.79) 48 (75.00) 45 (86.54) 35 (77.78)  
Stage 2 7 (13.21) 13 (20.31) 6 (11.54) 9 (20.00)  
Stage 3 0 3 (4.69) 1 (1.92) 1 (2.22) 0.471 
Maximum 
clinical 
condition 
N/A 13 (27.66) 18 (29.03) 15 (30.00) 12 (30.77)  
B 19 (40.43) 21 (33.87) 22 (44.00) 82 (41.41)  
C 15 (31.91) 23 (37.10) 13 (26.00) 58 (29.29) 0.513 
Nadir immune 
status 
Stage 1 15 (28.30) 17 (26.56) 13 (25.00) 11 (24.44)  
Stage 2 21 (39.62) 30 (46.88) 21 (40.38) 22 (48.89)  
Stage 3 17 (32.08) 17 (26.56) 18 (34.62) 12 (26.67) 0.938 
Any clinical 
symptoms* 
No symptoms 3 (10.34) 5 (8.62) 2 (4.76) 6 (15.38)  
Symptoms 26 (89.66) 53 (91.38) 40 (95.24) 33 (84.62) 0.434 
Any immuno-
suppression* 
None 39 (73.58) 42 (65.63) 35 (67.31) 29 (64.44)  
Immunosuppression 14 (26.42) 22 (34.38) 17 (32.69) 16 (35.56) 0.756 
Recruitment 
viral load 
Undetectable 7 (13.21) 9 (14.06) 6 (11.54) 11 (24.44)  
Detectable 46 (86.79) 55 (85.94) 46 (88.46) 34 (75.56) 0.296 
Any 
detectable 
viral load* 
No detection 4 (22.22) 5 (14.29) 3 (11.11) 7 (25.00)  
Detected 14 (77.78) 30 (85.71) 24 (88.89) 21 (75.00) 0.499 
Recruitment 
antiretroviral 
regiment 
NRTI mono-therapy 3 (6.52) 7 (11.67) 0 2 (4.88)  
PI-based HAART 30 (65.22) 33 (55.00) 27 (56.25) 19 (46.34)  
NNRTI-based HAART 12 (26.09) 19 (31.67) 17 (35.42) 16.(39.02)  
Triple class therapy 1 (2.17) 1 (1.67) 4 (8.33) 4 (9.76) 0.140 
Any change 
in ART 
regimen* 
No change 39 (76.47) 48 (77.42) 42 (85.71 30 (69.77)  
Change 12 (23.53) 14 (22.58) 7 (14.29) 13 (30.23) 0.333 
All subjects had lipodystrophy syndrome at recruitment. CDC-defined immune status - stage 1: no 
immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-
defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
Detectable viral load defined as >50 copies/mL. *Over follow-up 
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6.4 Key points 
 
• The median duration of follow-up of subjects was 4.19 years (IQR CI: 3.00, 3.97) (total 
person years = 1318.65 years) with up to 4 data collections points for each subject.  
  
• There were increases in the prevalence of detectable viral load and symptomatic clinical 
disease at the end of follow-up compared to recruitment, with the prevalence of subjects 
with at least one of detectable viral load, symptomatic disease, or immunosuppression 
being 70.00% (n = 287). 
 
• All subjects who were ART-naïve at recruitment commenced ART at some point during 
follow-up 
 
• The prevalence of LS increased over follow-up to 61.1% (n = 253): however, the 
proportions of subjects defined by body fat alterations alone, metabolic abnormality 
alone, and by both fat alterations and metabolic abnormality was consistent with those 
seen at recruitment.  
 
• While the percentage distributions of subjects with specific fat alterations were similar to 
those seen at recruitment, the percentage distributions of specific metabolic 
abnormalities were different: at both recruitment and the end of follow-up approximately 
one-third of subjects with metabolic abnormality were defined by fasting 
hypertriglyceridemia alone, while the percentage defined by hypercholesterolemia 
increased from 36.1% to 51.7%, and the percentage defined by mixed abnormality fell 
from 23.1% to 13.8%.   
 
• The incidence of new LS cases was estimated to be 17.8 per 100 years of person-time 
(95% CI: 14.1, 21.5), with a higher incidence of body fat alterations compared with 
metabolic abnormality: arm lipoatrophy, trunk lipohypertrophy, and 
hypercholesterolemia emergence were seen most frequently.  
 
• Use of PIs at recruitment was a significant and independent risk factor for incident 
metabolic abnormality, being associated with an approximate 4-fold increase in risk in 
multivariable models. In contrast, while moderate CDC-defined clinical status was 
associated with a 2-3 fold increase in risk for incident LS), White ethnicity was 
associated with an 85% decrease in risk in multivariable Cox models. 
Immunosuppression over the follow-up period was associated with a significant 60% 
reduced risk of incident body fat alterations in multivariable modelling. 
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• Over the follow-up period, 221 subjects had both regression and progression of LS 
symptoms, most commonly manifesting as progression of metabolic abnormality with 
accompanying regression of body fat alterations (n = 95).  
 
• There were no significant differences in any subject characteristic (including HIV-related 
factors and ART regimen) with change in symptom severity of either body fat alterations 
or metabolic abnormality. 
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7. Relationship between body fat alterations and metabolic 
abnormality 
 
7.1 Objectives 
This chapter investigates the temporal relationship between body fat alterations and metabolic 
abnormality, models the relationship between LS and serum concentrations of metabolites, and 
investigates strategies used in the management of LS symptoms in this cohort.  
Specific objectives include:- 
• Description of the metabolic profile in subjects with incident body fat alterations over 
follow-up and investigation as to whether recruitment metabolic abnormality is a risk 
factor for incident body fat alterations. 
 
• Description of body fat habitus in subjects with incident metabolic abnormality over 
follow-up and investigation as to whether recruitment body fat alteration is a risk factor 
for incident metabolic abnormality.  
 
• Modelling longitudinal changes in concentration of cholesterol and fasting triglyceride  
and their association with LS  
 
• Examination of management of LS with identification of possible indicators used for 
treatment. 
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7.2 Specific methods 
7.2.1 Description of metabolic profile in subjects with incident body fat 
alterations 
Subjects with incident body fat alterations over follow-up were identified as outlined in the 
previous chapter. Comparisons of median levels of metabolic outcomes at recruitment and at 
the end of follow-up in these subjects were made using the Signed-rank test for paired medians. 
The metabolic outcomes examined include median levels of: fasting triglyceride, total 
cholesterol, LDL-cholesterol, HDL-cholesterol and non-HDL cholesterol. 
 
7.2.2 Description of body fat alterations in subjects with incident 
metabolic abnormality 
The proportion of subjects with incident metabolic abnormality by (i) severity of lipohypertrophy 
symptoms, (ii) severity of lipoatrophy symptoms, and (iii) manifestation of body fat alterations, 
(i.e. lipohypertrophy, lipoatrophy or both) at both recruitment and end of follow-up were 
compared using Chi squared tests (Chapter 2: Section 2.8.3).  
 
7.2.3 Time-to-event analyses 
Time-to-event analyses were conducted to determine whether metabolic abnormality was a risk 
factor for incident body fat alterations, and vice versa. Two sets of time-to-event analyses, using 
Cox proportional hazards models, were conducted:- 
1. Models with incident body fat alterations as the outcome, and metabolic abnormality  
included in the explanatory variables 
2. Models with incident metabolic abnormality as the outcome, and body fat alterations 
included in the explanatory variables.  
For each set of analyses, several models were fitted: 
• Kaplan-Meier estimates investigating the probability of incidence in subjects between 
groups 
• A univariable model with the relevant recruitment LS explanatory variable 
• A multivariable model with covariates selected by backward covariate selection as 
outlined in Chapter 2 (explanatory variables summarized in Table 2-1). All final models 
retained the relevant recruitment LS explanatory variable, age, duration of ART use at 
recruitment and a random effect on the intercept for clinical site, regardless of their 
statistical significance in the model. 
• A second multivariable model with covariates selected by backward model selection 
retaining the relevant time-updated LS explanatory variable, age, duration of ART use 
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at recruitment and a random effect term on the intercept for clinical site, regardless of 
their statistical significance in the model 
• A multivariable model with the relevant recruitment LS explanatory variable, and ART 
regimen at recruitment:  intuitively adjusted for age and duration of ART at recruitment, 
and including a random effect on the intercept for clinical site. All models were intuitively 
adjusted by the same covariates to facilitate comparison between models. 
 
Sensitivity analyses could not be performed on these models because few cases of 
moderate/severe LS occurred: for example, only 7 cases of moderate/severe fat alterations 
(from a previous symptom-free state) occurred during follow-up. 
 
7.2.4 Longitudinal analyses 
The effect of LS on metabolic outcomes (Box 7-1) was investigated using multilevel modelling 
as described in Chapter 2. 
Box 7-1: Serum concentrations of metabolites (mg/dL) modelled by multilevel approach 
Total cholesterol 
Low density lipoprotein cholesterol 
Non-high density lipoprotein cholesterol 
High density lipoprotein cholesterol 
Fasting triglyceride 
 
All models were 3-level with subject clustered in clinical site in the random intercept. For each 
outcome, 4 separate multivariable models examining the influence of LS were investigated: 
1. Recruitment variables included in the final model chosen by stepwise covariate-
selection (including categories of ART used at recruitment) 
2. Time-updated variables included in the final model by stepwise model selection 
(including time-updated categories of ART use) 
3. Model investigating LS and ART regimen at recruitment intuitively adjusted by age at 
recruitment, sex, ethnicity, BMI at recruitment, maximum CDC-defined clinical status, 
degree of CDC-defined immunosuppression at recruitment, and detectable viral load at 
recruitment.  
4. Models investigating time-updated LS and ART regimen which was intuitively adjusted 
as for 3.  
The variables included in the fixed part of the final multivariable models are summarized Table 
7-1.  
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Table 7-1: Explanatory variables in multivariable models 
  Models investigating 
factors at recruitment 
Models investigating 
time updated 
variables 
Lipodystrophy syndrome At recruitment X  
Time-updated  X 
Ethnicity  X X 
Body mass index  At recruitment X X 
Detectable viral load At recruitment X  
Time-updated  X 
CDC-defined HIV symptoms  Time-updated  X 
Maximum CDC-defined HIV symptoms  X X 
CDC-defined HIV immunosuppression  Time-updated  X 
Protease inhibitor use At recruitment X  
Time-updated  X 
Non-nucleoside reverse transcriptase inhibitor 
use 
At recruitment X  
Time-updated  X 
Antiretroviral therapy use At recruitment X  
Time-updated  X 
All models include age at recruitment, duration of drug use at recruitment, and sex 
Confounding variables included in models 3 and 4 above were selected due to their statistical 
significance in univariable models and in multivariable models 1 and 2. However, it is important 
to note that the explanatory variable LS is related to the outcome variables of the models as the 
definition of LS may incorporate hypercholesterolemia, fasting hypertriglyceridemia, or both. 
The method of stepwise selection of variables was as described in Section 2.8 in Chapter 2. 
Log ratio tests were conducted to compare the fit of the 3-level model with either a 2-level 
(random intercept for subject only) or null model (no random intercept). The normality 
assumption for 2-level and 3-level residuals was investigated using quantile-quantile (QQ) plots.  
7.2.5 Strategies for management of lipodystrophy syndrome 
Among prevalent LS cases at recruitment, the proportion receiving pharmacological, dietary or 
physical intervention at any time during follow-up was calculated. To explore the most common 
management strategies, the distribution of combinations of these interventions among subjects 
with LS was estimated at both recruitment and the end of follow-up. Comparison of the 
proportion of subjects with each intervention and specific symptoms (LS, body fat alterations, or 
metabolic abnormality) at recruitment and then the end of follow-up was made using Chi- 
squared tests.  Specific pharmaceutical interventions are described in relation to initial and final 
symptoms of subjects.  
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7.3 Results 
7.3.1 Metabolic profile of subjects with incident body fat alterations 
Among subjects with incident body fat alterations, median total fasting triglyceride was non-
significantly (p = 0.666, n = 60) higher at the end of follow-up compared to recruitment (Figure 
7-1); although recruitment levels were significantly (p = 0.006) higher in male adolescents aged 
12-18 years (179.0mg/dL, IQR: 83.0, 253.0, n = 12) compared to the end of follow-up 
(107.0mg/dL, IQR: 58.0, 133.0, n = 16), significant differences were not seen for any other 
age/sex group (Appendix G: Table G-1). Total cholesterol (p = 0.609, n = 64), LDL-cholesterol 
(p = 0.229, n = 63: Figure 7-2), and non-HDL cholesterol (p = 0.999, n = 60, Figure 7-3b) were 
non-significantly higher at the end of follow-up compared to recruitment, whilst median HDL-
cholesterol was non-significantly lower (p = 0.435, n = 63, Figure 7-3a). 
 
Figure 7-1: Comparison of median levels of fasting triglyceride at recruitment and the 
end of follow-up in subjects with incident body fat alterations 
 
Median and IQR: recruitment fasting triglyceride; 84.0mg/dL (55.0, 147.9, n =50), follow-up fasting triglyceride; 
107mg/dL (56.3, 162.6, n = 60); signed-rank test for paired medians; p = 0.666   
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Figure 7-2: Comparison of median levels of (a) total cholesterol, and (b) LDL-cholesterol, 
at recruitment and at the end of follow-up in subjects with incident body fat alterations 
 
 
Median and IQR:  recruitment total cholesterol; 177.0 (153.3, 198.8, n =64), follow-up total cholesterol; 180mg/dL 
(147.3, 203.1, n =64); signed-rank test for paired medians; p = 0.609. Median and IQR: recruitment LDL-
cholesterol; 87.4 (76.8, 112.5, n =58), follow-up LDL-cholesterol; 96.0mg/dL (74.0, 124.0, n =63); signed-rank test 
for paired medians; p = 0.229. 
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Figure 7-3: Comparison of median levels of (a) HDL-cholesterol, and (b) non- HDL-
cholesterol, at recruitment and at the end of follow-up in subjects with incident body fat 
alterations 
 
 
Median and interquartile range  HDL-cholesterol; 53.2 (95% CI: 39.0, 66.8, n =60), follow-up HDL-cholesterol; 
52.0 (39.0, 65.3, n =63); signed-rank test for paired medians; p = 0.435. Median and IQR: recruitment non-HDL 
cholesterol; 117.0mg/dL (91.3, 142.3, n =60), non-HDL cholesterol; 126mg/dL (89.0, 150.0, n =63): signed-rank 
test for paired medians; p = 1.000 
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7.3.2 Body fat alterations in subjects with incident metabolic abnormality 
Among the 48 children and adolescents with incident metabolic abnormality, there were 
significant (p<0.001) increases in the proportion with any body fat alterations (Figure 7-4), 
lipohypertrophy (Figure 7-5) and lipoatrophy (Figure 7-6) between recruitment and the end of 
follow-up.  
Figure 7-4: Comparison of lipohypertrophy in subjects with incident metabolic 
abnormality (n = 48) at (a) recruitment, and (b) end of follow-up  
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Figure 7-5: Comparison of lipoatrophy in subjects with incident metabolic abnormality (n = 
48) at (a) recruitment, and (b) end of follow-up 
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Figure 7-6: Body fat alterations in subjects with incident metabolic abnormality (n = 48) at 
(a) recruitment, and (b) end of follow-up 
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7.3.3 Relationship between metabolic abnormality and body fat alterations 
During the first 2 years of follow-up, the probability of incident body fat alterations was greater 
amongst subjects with no metabolic abnormality at recruitment (Figure 7-7a). However, by the 
end of 4 years, the probability of developing new body fat alterations was approximately 60% 
among subjects with metabolic abnormality at recruitment compared to approximately 45% in 
subjects without.  The probability of incident body fat alterations among subjects with any 
metabolic abnormality over follow-up and among subjects without was similar over the whole 
study period: respective probabilities at 4 years were approximately 20% and 10% (Figure 7-
7b).  
In contrast, subjects with body fat alterations at recruitment had a greater probability of incident 
metabolic abnormality for most of the follow-up period: the estimated probability was 90% in 
subjects with recruitment body fat alterations compared to 80% in subjects without at 3 years of 
follow-up (Figure 7-8a). Similarly, the probability of incident metabolic abnormality was greater 
in subjects who had body fat alterations over the follow-up period compared to those who did 
not, for the majority of the follow-up period: percentages at 3 years were similar to those seen 
with recruitment body fat abnormality (Figure 7-8b). 
In all cases, there was no significant difference in probability function for incidence between 
groups (p ≥ 0.365)   
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Figure 7-7: Kaplan-Meier estimates for incident body fat alterations by (a) recruitment 
metabolic abnormality, and (b) time-updated metabolic abnormality 
 
Log rank test for equality of survival functions: (a) χ2 statistic = 0.82 p = 0.365 (b) χ2 statistic = 0.01 p = 0.919 
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Figure 7-8: Kaplan-Meier estimates for incident metabolic abnormality by (a) recruitment 
body fat alterations, and (b) time-updated body fat alterations 
 
Log rank test for equality of survival functions: (a) χ2 statistic = 0.42 p = 0.516 (b) χ2 statistic = 0.45 p = 0.500 
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In univariable Cox proportional hazards regression models, neither metabolic abnormality at 
recruitment nor metabolic abnormality occurring during follow-up was significantly associated 
with incident body fat alterations (Table 7-2).  
 
Table 7-2: Univariable models investigating metabolic abnormality as a risk factor for 
body fat alterations  
 n Hazard ratio 95% confidence 
interval 
p-value 
Recruitment metabolic 
abnormality 
200 0.88 (0.38, 2.02) 0.757 
Time-updated metabolic 
abnormality 
237 1.03 (0.58, 1.84) 0.919 
 
In comparison to the univariate analyses metabolic abnormality was a significant risk factor in 
multivariable models adjusted by age, duration of ART use clinical condition, 
immunosuppression and metabolic abnormality.  The presence of metabolic abnormality at 
recruitment was associated with a significant increased risk of incident body fat alterations 
(AHR: 5.37, 95% CI: 1.07, 26.90) in multivariable modelling with duration of ART of more than 
10 years the only other significant factor (Table 7-3). Despite this, in the final multivariable 
investigating body fat alterations with time-updated covariates, metabolic abnormality did not 
reach statistical significance (Table 7-3): the occurrence of metabolic abnormality during follow-
up was associated with a non-significant (p = 0.775) increase in risk.  
Further models investigating the association of metabolic abnormality and specific ART-regimen 
with incident body fat alterations were explored: both recruitment and time-updated metabolic 
abnormality was associated with a non-significant (p ≥ 0.204) increased risk of incident body fat 
alterations (Table 7-4). 
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Table 7-3: Multivariable model for risk of incident body fat alterations with recruitment/time-updated metabolic abnormality as an explanatory 
variable  
 
Model with recruitment metabolic abnormality* 
(n = 113) 
Model with time-updated metabolic abnormality** 
(n = 186) 
  
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Age at recruitment <12 years 1   1   
12-18 years 0.63 (0.16, 2.50) 0.511 1.00 (0.47, 2.15) 0.998 
Duration of ART use at 
recruitment 
<2.5 years 1   1   
2.5-4.9  years 1.57 (0.23, 10.55) 0.644 0.89 (0.27, 2.91) 0.848 
5-7.49 years 2.69 (0.19, 38.54) 0.465 1.42 (0.41, 4.93) 0.586 
7.5-9.99  years 2.58 (0.42, 15.68) 0.303 1.89 (0.72, 4.95) 0.195 
≥10  years 6.25 (1.12, 34.86) 0.037 1.42 (0.48, 4.26) 0.525 
CDC-defined clinical 
condition 
N/A 1      
B 0.12 (0.01, 1.55) 0.106    
C 0.41 (0.06, 2.74) 0.355    
CDC-defined 
immunosuppression 
None 1      
Moderate 0.25 (0.06, 1.03) 0.056    
Severe 1.26 (0.18, 8.70) 0.813    
Metabolic abnormality Absent 1   1   
Present 5.37 (1.07, 26.90) 0.041 1.12 (0.52, 2.40) 0.775 
Protease inhibitor No use 1      
Use 0.28*** (0.07, 1.19) 0.085    
* Therneau-Grambsch global test of non-proportionality: p = 0.181, ** Therneau-Grambsch global test of non-proportionality: p = 0.905 ***Use at recruitment 
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Table 7-4: Multivariable model for risk of incident body fat alterations with recruitment/time-updated metabolic abnormality and treatment regimen 
as explanatory variables 
 
Model with recruitment metabolic abnormality* 
(n = 187) 
Model with time-updated metabolic abnormality** 
(n = 159) 
  
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Age at recruitment <12 years 1   1   
12-18 years 2.56 (0.70, 9.31) 0.154 2.63 (1.06, 6.53) 0.037 
Duration of ART use at 
recruitment 
<2.5 years 1   1   
2.5-4.9  years 0.13 (0.01, 1.11) 0.062 0.61 (0.19, 1.95) 0.406 
5-7.49 years 0.81 (0.15, 4.42) 0.804 1.09 (0.31, 3.76) 0.894 
7.5-9.99  years 1.08 (0.32, 3.64) 0.900 1.32 (0.47, 3.68) 0.598 
≥10  years 0.22 (0.04, 1.28) 0.091 0.26 (0.05, 1.37) 0.112 
Metabolic abnormality Absent 1   1   
Present 1.78 (0.54, 5.87) 0.347 2.00 (0.83, 4.80) 0.120 
ART regimen at 
recruitment 
PI-based HAART 1   1   
NRTI mono-therapy 0.35 (0.07, 1.68) 0.189 0.48 (0.15, 1.51) 0.212 
NNRTI-based HAART 2.17 (0.66, 7.18) 0.204 1.02 (0.40, 2.62) 0.967 
Triple  class therapy - - - - - - 
* Therneau-Grambsch global test of non-proportionality: p < 0.001, ** Therneau-Grambsch global test of non-proportionality: p = 0.838 
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7.3.4 Body fat alterations as a risk factor for incident metabolic 
abnormality 
Children with recruitment body fat alterations and those with any body fat alterations occurring 
during follow-up had a non-significant reduced risk of incident metabolic abnormality (Table 7-
5).  
Table 7-5: Univariable models for incident metabolic abnormality using body fat 
alterations as the explanatory variable 
 n Hazard ratio 95% confidence 
interval 
p-value 
Recruitment body fat alterations 292 0.79 (0.40, 1.59) 0.516 
Time-updated body fat alterations 298 0.79 (0.39, 1.58) 0.501 
 
The association of body fat alterations with incident metabolic abnormality was further explored 
in multivariable models: neither body fat alterations at recruitment nor time-updated alterations 
were significant (p ≥ 0.351) risk factors in either of the final models (Table 7-6).  
Finally, models investigating the association between both body fat alterations and specific ART 
regimen with incident metabolic abnormality were investigated. Although body fat redistribution 
at recruitment and time-updated alterations were associated with reduced risk of incident body 
fat alterations in intuitively adjusted multivariable models including ART regimen at recruitment, 
these associations were also not statistically significant (Table 7-6).  
In common with models presented in Chapter 6, PI was associated with significant increased 
risk of incident metabolic abnormality: recruitment PI (AHR: 3.86, 95% CI: 1.29, 11.55), and 
time-updated PI (AHR: 4.22, 95% CI: 1.22, 14.59), as illustrated in Table 7-7 Furthermore, 
NNRTI-based HAART was associated with a significant decreased risk of incident metabolic 
abnormality compared to PI-based HAART (Table 7-7).   
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Table 7-6: Multivariable model for risk of incident metabolic abnormality with recruitment/time-updated body fat alterations as an explanatory 
variable 
 
Model with recruitment metabolic abnormality* 
(n = 187) 
Model with time-updated metabolic abnormality** 
(n = 178) 
  
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Age at recruitment <12 years 1   1   
12-18 years 1.40 (0.55, 3.57) 0.482 1.19 (0.44, 3.19) 0.730 
Duration of ART use at 
recruitment 
<2.5 years 1   11   
2.5-4.9  years 0.72 (0.21, 2.43) 0.592 0.47 (0.12, 1.83) 0.276 
5-7.49 years 0.52 (0.14, 1.99) 0.338 0.55 (0.15, 2.10) 0.385 
7.5-9.99  years 0.57 (0.17, 1.95) 0.370 0.75 (0.21, 2.62) 0.648 
≥10  years 0.73 (0.20, 2.69) 0.640 0.57 (0.14, 2.26) 0.420 
Ethnicity Black 
   1   
White 
   0.33 (0.11, 0.98) 0.046 
Other 
   0.56 (0.06, 4.95) 0.599 
Body fat alterations Absent 1   1   
Present 1.01 (0.42, 2.40) 0.986 4.22 (1.22, 14.59) 0.351 
Protease inhibitor Absent 1   1   
Present 3.86*** (1.29, 11.55) 0.016 4.22^ (1.22, 14.59) 0.023 
* Therneau-Grambsch global test of non-proportionality: p = 0.583, ** Therneau-Grambsch global test of non-proportionality: p = 0.727. ***Use at recruitment. ^Use during follow-up 
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Table 7-7: Multivariable model for risk of incident metabolic abnormality with recruitment/time-updated body fat alterations and treatment regimen 
as explanatory variables 
 
Model with recruitment body fat alterations* 
(n = 206) 
Model with time-updated body fat alterations** 
(n = 189) 
  
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Adjusted hazard 
ratio 
95% confidence 
interval 
p-
value 
Age at recruitment <12 years 1   1   
12-18 years 1.40 (0.55, 3.59) 0.483 1.35 (0.52, 3.48) 0.533 
Duration of ART use at 
recruitment 
<2.5 years 1   1   
2.5-4.9  years 0.70 (0.21, 2.40) 0.574 0.77 (0.22, 2.66) 0.680 
5-7.49 years 0.52 (0.14, 1.99) 0.341 0.57 (0.15, 2.18) 0.408 
7.5-9.99  years 0.54 (0.16, 1.87) 0.330 0.63 (0.18, 2.16) 0.465 
≥10  years 0.69 (0.18, 2.56) 0.574 0.84 (0.23, 3.07) 0.794 
Body fat alterations 
 
Absent 1   1   
Present 0.95 (0.39, 2.31) 0.913 0.90 (0.37, 2.22) 0.821 
ART regimen at 
recruitment 
PI-based HAART 1   1   
NRTI mono-therapy 0.25 (0.03, 2.03) 0.196 0.26 (0.03, 2.06) 0.201 
NNRTI-based HAART 0.28 (0.08, 0.99) 0.047 0.28 (0.08, 0.96) 0.043 
Triple  class therapy 1.99 (0.41, 9.56) 0.390 1.26 (0.26, 6.04) 0.770 
* Therneau-Grambsch global test of non-proportionality: p = 0.391, ** Therneau-Grambsch global test of non-proportionality: p = 0.200
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7.3.5 Longitudinal modelling of serum cholesterol and fasting triglyceride 
Serum levels of total cholesterol were more varied over follow-up among subjects with LS 
compared to those without, however individual measures appeared to be lower in this second 
group (Figure 7-9).  
Figure 7-9: Serum measures of total cholesterol over follow-up  
 
Total-cholesterol: number of observations = 537 and n = 302  
 
Serum concentrations of LDL-cholesterol and non-HDL cholesterol appeared to be higher in 
subjects with LS compared to concentrations in subjects without LS over the follow-up period 
(Figure 7-10). In contrast, similar levels of HDL-cholesterol were seen in subjects with LS 
compared to those without LS (Figure 7-11a). However, subjects with LS had higher serum 
concentrations of fasting triglyceride over follow-up compared to those without LS (Figure 7-
11b): the spread of values in subjects with LS was greater than the spread seen without LS. 
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Figure 7-10: Serum measures of (a) LDL-cholesterol and (b) non-HDL cholesterol over 
follow-up  
 
 
LDL-cholesterol: number of observations = 548 and n =294, and non-HDL cholesterol: number of observations 
= 546 and n = 292 
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Figure 7-11: Serum measures of (a) HDL-cholesterol and (b) fasting triglyceride over 
follow-up  
 
HDL-cholesterol: number of observations = 530 and n = 292, and fasting triglyceride: number of observations = 
537 and n = 297 
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Univariable models 
In univariable analyses, the presence of LS at recruitment was associated with significant (p < 
0.001) 18–42mg/dL increases in all outcomes except HDL-cholesterol as illustrated in 
(Appendix G: Table G-3). Significant increases of similar magnitude were seen with time-
updated LS. Non-significant decreases in HDL-cholesterol were seen with both recruitment and 
time-updated LS. 
Increased age (12-18 years compared to <12 years) was associated with significant reduced 
serum concentrations (5-18mg/dL) of total, LDL, and non-HDL cholesterol. While White ethnicity 
was associated (p ≤ 0.042) with increases in non-HDL-cholesterol and fasting triglyceride: it was 
also associated (p < 0.001) with decreased HDL-cholesterol. Female sex was significantly 
associated with increased in HDL-cholesterol and decreased fasting triglyceride.  
Both recruitment and time-updated detectable viral load was significantly associated with 
decreases in all metabolic outcomes except fasting triglyceride: with reference to time-updated 
viral load, significant decreases were seen in all outcomes except HDL-cholesterol.  Moderate 
immunosuppression at recruitment or any immunosuppression over follow-up was significantly 
associated with small (<20mg/dL) decreases in total, LDL, and HDL-cholesterol.   Maximum 
CDC-defined clinical status B was significantly associated with increased fasting triglyceride, 
while status C was associated with significant increased LDL-cholesterol, non-HDL cholesterol, 
and fasting triglyceride.  
Duration of ART use at recruitment was significantly associated with changes in all outcomes 
over follow-up. The greatest decreases were seen in total, LDL, and non-HDL-cholesterol with 
>10 years of use: however, decreases in fasting triglyceride of a similar magnitude were seen 
with 2.5-4.9 years of use. Between 2.5 and 7.5 years of ART use was associated with a 5-
7mg/dL increase in HDL-cholesterol (although this association was not significant for >10 years 
use). Both recruitment and time-updated PI use was significantly associated with all metabolic 
outcomes in univariable models: 12-24mg/dl increase with cholesterol outcomes (excluding 
HDL-cholesterol), and 49-52mg/dL with triglycerides. In contrast, both recruitment and time-
updated PI-use were significantly associated with significant 5-7mg/dL decreases in HDL-
cholesterol levels. NNRTI use at recruitment was associated (p ≤ 0.001) with decreases in non-
HDL cholesterol and fasting triglyceride, but increased HDL-cholesterol. Time-updated NNRTI 
was significantly associated with 11-22mg/dL increases in total, LDL, and non-HDL cholesterol: 
it was also associated with increased fasting triglyceride (30.8mg/dL, 95% CI: 9.8, 51.8). In 
comparison to PI-based HAART, NRTI mono-therapy or NNRTI-based HAART was significantly 
associated with 10-27mg/dL decrease in total, LDL, and non-HDL cholesterol: there was also a 
significant 49-52mg/dL increase with fasting triglyceride. Time updated NNRTI-based HAART 
was also significantly associated with an 8.1 mg/dL increase in HDL-cholesterol. 
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Multivariable multilevel modelling of total cholesterol 
Recruitment LS was associated with an independent and significant increase in total cholesterol 
(21.2mg/dL, 95% CI: 11.0, 31.5) in the final model including recruitment factors (Table 7-8). 
Other variables that remained statistically significant, and that were associated with increased 
total cholesterol were maximum clinical condition B (12.0mg/dL, 95% CI: 1.2, 22.6), and 
recruitment PI (10.0mg/dL, 95% CI: 0.5, 19.5). However, recruitment age of 12-18 years, White 
ethnicity, and detectable viral load at recruitment, were all significantly associated with 
decreases in total cholesterol. 
 
Table 7-8: Final multivariable multilevel model for total cholesterol: covariates at 
recruitment (n = 214) 
  Estimate 95% confidence interval p - value 
Age* <12 years Comparison   
12-18 years 
-17.21 (-26.74, -7.68) <0.001 
Sex Male Comparison   
Female 2.70 (-6.34, 11.75) 0.558 
Ethnicity Black Comparison   
White 
-14.92 (-26.71, -3.13) 0.013 
Other 
-19.02 (-42.24, 4.20) 0.108 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 21.23 (11.01, 31.45) <0.001 
Maximum 
clinical 
condition 
N/A Comparison   
B 11.95 (1.31, 22.60) 0.028 
C 6.70 (-5.43, 18.82) 0.279 
Detectable 
viral load* 
<50 copies/ml Comparison   
≥50 copies/ml 
-16.50 (-29.99, -3.01) 0.017 
Protease 
inhibitors* 
No use Comparison   
Use 10.01 (0.48, 19.54) 0.040 
Duration of 
ART use* 
<2.5 years Comparison   
2.5 - 4.9 years 
-2.88 (-16.10, 10.33) 0.669 
5.0 – 7.4 years 
-3.51 (-17.62, 10.60) 0.626 
7.5 – 9.9 years 
-5.36 (-18.55, 7.84) 0.426 
≥10 years 
-10.75 (-26.20, 4.71) 0.173 
Intercept  186.32 (165.19, 207.44) <0.001 
*Variables at recruitment. Random effects parameters (standard deviation): clinical site (4.35, 95% CI: 0.93, 
20.30), individual (28.84, 95% CI: 25.35, 32.58), with residual (23.3, 95% CI: 21.73, 24.98): 214 subjects clustered 
into 15 clinical sites with 607 observations. See section “Investigating the random intercept of constructed models” on 
p283 for rationale on use of 3-level multi-level models 
The increase in total cholesterol associated with time-updated LS (24.3mg/dL, 95% CI: 14.3, 
34.3) was comparable to that seen with recruitment LS (Table 7-9). However, unlike the final 
recruitment model, time-updated PI was no longer statistically significant. Time-updated NNRTI 
was associated with an independent and significant increase in total cholesterol (19.5mg/dL, 
95% CI: 5.4, 33.6). Both detectable viral load over follow-up, and recruitment age of 12-18 years 
were associated with decreases in total cholesterol.  
 
Relationship between components  Chapter 7 
273 
 
Table 7-9: Final multivariable multilevel model for total cholesterol: time-updated 
covariates (n = 277) 
  Estimate 95% confidence interval p - value 
Age at 
recruitment 
<12 years Comparison   
12-18 years 
-13.50 (-21.42, -5.58) 0.001 
Sex Male Comparison   
Female 1.68 (-5.79, 9.14) 0.660 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 24.30 (14.27, 34.33) <0.001 
Detectable 
viral load* 
<50 copies/ml Comparison   
≥50 copies/ml 
-18.27 (-29.42, -7.12) 0.012 
Non-
nucleoside 
reverse 
transcriptase* 
No use Comparison   
Use 19.47 (5.35, 33.59) 0.007 
Duration of 
ART use at 
recruitment 
<2.5 years Comparison   
2.5 - 4.9 years 
-5.00 (-16.14, 6.13) 0.379 
5.0 – 7.4 years 2.66 (-9.07, 14.40) 0.657 
7.5 – 9.9 years 
-8.52 (-19.47, 2.44) 0.127 
≥10 years 
-8.50 (-20.98, 3.97) 0.182 
Intercept  167.57 (145.68, 189.45) <0.001 
*Time-updated variable. Random effects parameters (standard deviation): clinical site (0.00, 95% CI: 0.00, 0.00), 
individual (27.93, 95% CI: 25.11, 31.07), with residual (23.41, 95% CI: 22.03, 24.88): 277 subjects clustered into 15 
clinical sites with 797 observations. See section “Investigating the random intercept of constructed models” on p283 for 
rationale on use of 3-level multi-level models 
 
Multivariable multilevel modelling of low density lipoprotein cholesterol 
Older age and 7.5-9.9 years of ART use at recruitment were both associated with decreases in 
LDL-cholesterol (Table 7-10). In contrast recruitment LS was associated with an increase in 
LDL cholesterol (11.5mg/dL, 95% CI: 3.9, 19.1) in the final model. Other factors associated with 
an increase in LDL-cholesterol were recruitment PI use (8.3mg/dL, 95% CI: 1.1, 15.6) and a 
history of moderate clinical symptoms (9.5mg/dL, 95% CI: 1.2, 17.8).  
Similar results were seen in the final model including time-updated covariates. The occurrence 
of LS over follow-up was associated with a significant increase in LDL cholesterol (14.5mg/dL, 
95% CI: 5.9, 23.0) as illustrated in Table 7-11. Furthermore, time-updated PI use was also 
associated with increased concentrations (10.0mg/dL, 95% CI: 3.5, 16.6). Significant variables 
associated with a reduction in LDL-cholesterol included time-updated detectable viral load, 
recruitment age of 12-18, and recruitment duration of ART ≥10 years.  
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Table 7-10: Final multivariable multilevel model for low density lipoprotein (LDL) 
cholesterol at recruitment (n = 218) 
  Estimate 95% confidence interval p - value 
Age* <12 years Comparison   
12-18 years 
-11.24 (-18.60, -3.87) 0.003 
Sex Male Comparison   
Female 3.84 (-3.17, 10.84) 0.283 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 11.49 (3.90, 19.09) 0.003 
Maximum 
clinical 
condition 
N/A Comparison   
B 9.51 (1.24, 17.78) 0.024 
C 7.24 (-2.08, 16.57) 0.128 
Protease 
inhibitors * 
No use Comparison   
Use 8.32 (1.09, 15.55) 0.024 
Duration of 
ART use* 
<2.5 years Comparison   
2.5 - 4.9 years 
-0.76 (-10.88, 9.35) 0.882 
5.0 – 7.4 years 3.84 (-6.92, 14.61) 0.484 
7.5 – 9.9 years 
-5.46 (-15.41, 4.50) 0.283 
≥10 years 
-14.39 (-26.24, -2.54) 0.017 
Intercept  89.64 (78.28, 100.99) <0.001 
*Variable at recruitment. Random effects parameters (standard deviation): clinical site (0, 95% CI: -), individual 
(22.6, 95% CI: 20.1, 25.5), with residual (18.3, 95% CI: 17.1, 19.7)): 218 subjects clustered into 15 clinical sites 
with 579 observations. See section “Investigating the random intercept of constructed models” on p283 for rationale on use 
of 3-level multi-level models  
 
Table 7-11: Final multivariable multilevel model for low density lipoprotein (LDL) 
cholesterol: time-updated covariates (n = 259) 
  Estimate 95% confidence interval p - value 
Age* <12 years Comparison   
12-18 years 
-8.26 (-14.77, -1.74) 0.013 
Sex Male Comparison   
Female 2.93 (-3.34, 9.20) 0.360 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 14.49 (5.93, 23.04) 0.001 
Detectable 
viral load* 
<50 copies/ml Comparison   
≥50 copies/ml 
-9.95 (-19.42, -0.47) 0.040 
Protease 
inhibitors* 
No use Comparison   
Use 10.03 (3.52, 16.55) 0.003 
Duration of 
ART* 
<2.5 years Comparison   
2.5 - 4.9 years 
-3.23 (-12.35, 5.88) 0.487 
5.0 – 7.4 years 1.76 (-7.86, 11.38) 0.719 
7.5 – 9.9 years 
-6.57 (-15.55, 2.41) 0.152 
≥10 years 
-12.58 (-23.48, -1.68) 0.024 
Intercept  97.36 (82.99, 111.74) <0.001 
*Time-updated variables. Random effects parameters (standard deviation): clinical site (1.89, 95% CI: 0.02, 
194.74), individual (22.29, 95% CI: 19.90, 24.96), with residual (18.26, 95% CI: 17.09, 19.50): 259 subjects 
clustered into 15 clinical sites with 694 observations. See section “Investigating the random intercept of constructed 
models” on p283 for rationale on use of 3-level multi-level models 
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Multivariable multilevel modelling of non-high density lipoprotein 
cholesterol  
Recruitment LS was significantly associated with an independent increase in non-HDL 
cholesterol (20.9mg/dL, 95% CI: 12.0, 30.0) in the final model including recruitment covariates 
(Table 7-12). Other significant covariates included age at recruitment and ≥10 years of ART use 
at recruitment, both associated with a decrease in non-HDL cholesterol. Use of PI at recruitment 
was associated (p < 0.01) with an independent increase in non-HDL cholesterol of 17.7mg/dL 
(95% CI: 9.2, 26.2). 
Variables included in the final model including time-updated variables differed from the model 
including recruitment covariates (Table 7-13). The increase in non-HDL cholesterol associated 
(p < 0.001) with LS occurring over follow-up was similar to that seen with recruitment LS being 
21.7mg/dL (95% CI: 11.7, 31.6). Use of PI over the follow-up period was also associated with a 
significant and independent increase: 20.0mg/dL (95% CI: 12.4, 27.5). Time-updated variables 
associated with statistically significant reductions in non-HDL cholesterol included 
immunosuppression and detectable viral load (Table 7-13). Use of ART for ≥10 years at 
recruitment was also associated with a significant and independent decrease.  
 
Table 7-12: Final multivariable multilevel model for non-high density lipoprotein (HDL) 
cholesterol at recruitment (n = 217) 
  Estimate 95% confidence interval p - value 
Age * <12 years Comparison   
12-18 years 
-10.71 (-19.35, -2.08) 0.015 
Sex Male Comparison   
Female 
-0.44 (-8.65, 7.78) 0.917 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 20.87 (11.95, 29.78) <0.001 
Maximum 
clinical 
condition 
N/A Comparison   
B 9.71 (-0.01, 19.43) 0.050 
C 4.52 (-6.39, 15.42) 0.417 
Protease 
inhibitors* 
No use Comparison   
Use 17.67 (9.18, 26.16) <0.001 
Duration of 
ART * 
<2.5 years Comparison   
2.5 - 4.9 years 
-7.97 (-19.84, 3.91) 0.189 
5.0 – 7.4 years 
-0.89 (-13.51, 11.73) 0.890 
7.5 – 9.9 years 
-7.80 (-19.47, 3.86) 0.190 
≥10 years 
-16.58 (-30.45, -2.72) 0.019 
Intercept  105.96 (92.64, 119.27) <0.001 
*Variable at recruitment.  Random effects parameters (standard deviation): clinical site (0.00, 95% CI: 0.00, 0.11), 
individual (27.0, 95% CI: 24.00, 30.44), with residual (19.81, 95% CI: 18.41, 21.33)): 217 subjects clustered into 15 
clinical sites with 580 observations. See section “Investigating the random intercept of constructed models” on p283 for 
rationale on use of 3-level multi-level models 
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Table 7-13: Final multivariable multilevel model for non-high density lipoprotein (HDL) 
cholesterol: time-updated covariates (n = 258)  
  Estimate 95% confidence interval p - value 
Age at 
recruitment 
<12 years Comparison   
12-18 years 
-6.69 (-14.21, 0.84) 0.082 
Sex Male Comparison   
Female 
-0.95 (-8.19, 6.29) 0.798 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 21.66 (11.74, 31.59) <0.001 
Any immuno-
suppression* 
None Comparison   
Any 
-9.28 (-16.84, -1.72) 0.016 
Detectable 
viral load*  
<50 copies/ml Comparison   
≥50 copies/ml 
-16.38 (-27.76, -5.00) 0.005 
Protease 
inhibitors* 
No use Comparison   
Use 19.96 (12.41, 27.50) <0.001 
Duration of 
ART use at 
recruitment 
<2.5 years Comparison   
2.5 - 4.9 years 
-10.58 (-21.15, 0.00) 0.050 
5.0 – 7.4 years 
-3.43 (-14.54, 7.78) 0.545 
7.5 – 9.9 years 
-9.81 (-20.22, 0.61) 0.065 
≥10 years 
-12.84 (-25.47, -0.21) 0.045 
Intercept  120.80 (103.39, 138.20) <0.001 
*Time-updated variable. Random effects parameters (standard deviation): clinical site (3.75, 95% CI: 0.82, 17.1), 
individual (25.90, 95% CI: 23.22, 28.89), with residual (19.90, 95% CI: 18.64, 21.25): 258 subjects clustered into 15 
clinical sites with 695 observations. See section “Investigating the random intercept of constructed models” on p283 for 
rationale on use of 3-level multi-level models 
 
Multivariable multilevel modelling of high density lipoprotein (HDL) 
cholesterol 
In contrast to previous models where LS at recruitment was significantly associated to total, LDL 
and non-HDL cholesterol, LS was non-significantly associated with increased HDL cholesterol 
(Table 7-14): 2.1mg/dL (95% CI: -2.0, 6.2, p = 0.320). Only two covariates were significantly 
associated with a decrease: -4.9mg/dL (95% CI: -8.7, -1.0) with age at recruitment of 12-18 
years, and -8.7mg/dL (95% CI: -13.4, -4.0) with White ethnicity (compared to Black ethnicity). 
Female sex was associated with a significant increase in HDL-cholesterol of 8.0mg/dL (95% CI: 
4.2, 11.9): this was the only outcome where female sex was associated with a significant and 
independent positive association.  Other significant variables in the final model were associated 
with increases included NNRTI use, and 2.5-4.9 years duration of ART.  
The occurrence of LS over follow-up was also non-significantly (p = 0.267) associated with an 
increase in HDL-cholesterol (2.7mg/dL, 95% CI: -2.0, 7.3) in the final model with time-updated 
covariates (Table 7-15). Female sex (4.9mg/dL, 95% CI: 1.6, 8.3), NNRTI-use over follow-up 
(7.7mg/dL, 95% CI: 1.3, 14.1), and increasing duration of ART use at recruitment (6.4mg/dL 
with ≥10 years, 95% CI: 0.5, 12.3), were all significantly associated with increased HDL-
cholesterol. Time-updated variables associated (p ≤ 0.017) with decreases in HDL-cholesterol 
included PI-use (-9.9mg/dL, 95% CI: -13.7, -6.1), and detectable viral load (-6.5mg/dL, 95% CI: 
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-11.8, -1.2). Other independent factors significantly associated with a decrease were age 12-18 
years at recruitment, and White ethnicity. 
Table 7-14: Final multivariable multilevel model for high density lipoprotein (HDL) 
cholesterol at recruitment (n =220) 
  Estimate 95% confidence interval p - value 
Age* <12 years Comparison   
12-18 years 
-4.87 (-8.70, -1.04) 0.013 
Sex Male Comparison   
Female 4.76 (1.07, 8.46) 0.011 
Ethnicity Black Comparison   
White 
-8.69 (-13.41, -3.97) <0.001 
Other 
-12.86 (-22.27, -3.44) 0.007 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 2.10 (-2.04, 6.24) 0.320 
Non-
nucleoside 
reverse 
transcriptase 
inhibitors* 
No use Comparison   
Use 8.04 (4.18, 11.91) <0.001 
Duration of 
ART * 
<2.5 years Comparison   
2.5 - 4.9 years 6.33 (0.92, 11.73) 0.022 
5.0 – 7.4 years 5.70 (-0.01, 11.41) 0.050 
7.5 – 9.9 years 1.95 (-3.43, 7.33) 0.478 
≥10 years 5.94 (-0.37, 12.15) 0.061 
Intercept  51.82 (45.74, 57.90) <0.001 
*Variable at recruitment.  Random effects parameters (standard deviation): clinical site (1.45, 95% CI: 0.08, 
27.78), individual (12.27, 95% CI: 10.91, 13.80), with residual (8.59, 95% CI: 7.99, 9.23): 220 subjects clustered 
into 15 clinical sites with 590 observations. See section “Investigating the random intercept of constructed models” on 
p283 for rationale on use of 3-level multi-level models 
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Table 7-15: Final multivariable multilevel model for high density lipoprotein (HDL) 
cholesterol: time-updated variables (n = 244) 
  Estimate 95% confidence interval p - value 
Age at 
recruitment 
<12 years Comparison   
12-18 years 
-4.53 (-8.06, -1.00) 0.012 
Sex Male Comparison   
Female 4.94 (1.56, 8.32) 0.004 
Ethnicity Black Comparison   
White 
-8.72 (-12.92, -4.52) <0.001 
Other 
-7.08 (-15.49, 1.33) 0.099 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 2.65 (-2.02, 7.32) 0.267 
Detectable 
viral load* 
<50 copies/ml Comparison   
≥50 copies/ml 
-6.46 (-11.75, -1.17) 0.017 
Protease 
inhibitors* 
No use Comparison   
Use 
-9.85 (-13.65, -6.06) <0.001 
Non-
nucleoside 
reverse 
transcriptase* 
No use Comparison   
Use 7.67 (1.26, 14.07) 0.019 
Duration of 
ART use at 
recruitment 
<2.5 years Comparison   
2.5 - 4.9 years 5.83 (0.88, 10.77) 0.021 
5.0 – 7.4 years 6.22 (0.92, 11.52) 0.021 
7.5 – 9.9 years 0.73 (-4.18, 5.64) 0.771 
≥10 years 6.41 (0.54, 12.29) 0.032 
Intercept  58.92 (48.85, 68.99) <0.001 
*Time-updated variable. Random effects parameters (standard deviation): clinical site (1.22, 95% CI: 0.05, 
30.49), individual (11.69, 95% CI: 10.41, 13.12), with residual (9.12, 95% CI: 8.52, 9.77): 244 subjects clustered 
into 15 clinical sites with 660 observations. See section “Investigating the random intercept of constructed models” on 
p283 for rationale on use of 3-level multi-level models 
 
Multivariable multilevel modelling of fasting triglyceride 
Recruitment LS and PI use were both significantly associated with increased serum 
concentrations of fasting triglyceride in the final model including recruitment factors (Table 7 
16). Significant and independent factors associated with a decrease in fasting triglyceride were 
female sex, and severely underweight BMI.    
However, in the model with time-updated variables (Table 7-17), not only were the occurrence 
of LS and PI-use during follow-up significantly associated with increased fasting triglyceride, but 
White ethnicity was also associated (p = 0.001) with an increase (31.8mg/dL, 95% CI: 13.9, 
49.8). Female sex was associated with an independent and significant decrease in fasting 
triglyceride.  
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Table 7-16: Final multivariable multilevel model for fasting triglyceride at recruitment (n = 
219) 
  Estimate 95% confidence interval p - value 
Age* <12 years Comparison   
12-18 years 
-0.27 (-18.13, 17.58) 0.976 
Sex Male Comparison   
Female 
-20.77 (-36.78, -4.77) 0.011 
Body mass 
index * 
Healthy weight Comparison   
Severely 
underweight 
-25.68 (-50.80, -0.55) 0.045 
Underweight 
-1.44 (-20.57, 17.69) 0.883 
Overweight 
-8.27 (-40.44, 23.90) 0.614 
Obese 
-89.62 (-199.59, 20.34) 0.110 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 38.61 (20.72, 56.51) <0.001 
Protease 
inhibitors* 
No use Comparison   
Use 43.64 (27.35, 59.93) <0.001 
Duration of 
ART* 
<2.5 years Comparison   
2.5 - 4.9 years 
-21.69 (-44.98, 1.62) 0.068 
5.0 – 7.4 years 
-16.68 (-41.32, 7.95) 0.184 
7.5 – 9.9 years 
-2.49 (-26.14, 21.16) 0.837 
≥10 years 
-7.53 (-34.03, 18.97) 0.578 
Intercept  70.24 (40.80, 99.69) <0.001 
*Recruitment variable. Random effects parameters (standard deviation): clinical site (0.00, 95% CI: 0.00, 0.17), 
individual (46.92, 95% CI: 40.35, 54.56), with residual (49.92, 95% CI: 46.18, 53.97): 219 subjects clustered into 15 
clinical sites with 546 observations. See section “Investigating the random intercept of constructed models” on p283 for 
rationale on use of 3-level multi-level models 
 
Table 7-17: Final multivariable multilevel model for fasting triglyceride: time-updated 
variables (n = 245) 
  Estimate 95% confidence interval p - value 
Age at 
recruitment 
<12 years Comparison   
12-18 years 2.16 (-12.56, 17.89) 0.787 
Sex Male Comparison   
Female 
-18.24 (-33.49, -2.99) 0.019 
Ethnicity Black Comparison   
White 31.84 (13.88, 49.79) 0.001 
Other 13.49 (-24.05, 51.03) 0.481 
Lipodystrophy 
syndrome* 
Absent Comparison   
Present 38.27 (17.60, 58.95) <0.001 
Protease 
inhibitors*  
No use Recruitment   
Use 45.74 (29.82, 61.67) <0.001 
Duration of 
ART use at 
recruitment 
<2.5 years Comparison   
2.5 - 4.9 years 
-18.85 (-41.24, 3.54) 0.099 
5.0 – 7.4 years 
-13.57 (-37.34, 10.21) 0.263 
7.5 – 9.9 years 3.75 (-18.43, 25.92) 0.741 
≥10 years 
-2.00 (-28.09, 24.09) 0.881 
Intercept  45.28 (17.12, 73.44) 0.002 
*Time-updated variables. Random effects parameters (standard deviation): clinical site (0.00, 95% CI: 0.00, 
0.00), individual (49.28, 95% CI: 42.91, 56.60), with residual (49.81, 95% CI: 46.23, 53.65): 245 subjects clustered 
into 15 clinical sites with 608 observations. See section “Investigating the random intercept of constructed models” on 
p283 for rationale on use of 3-level multi-level models 
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Examination of the effect of lipodystrophy syndrome and antiretroviral 
regimen 
Further models were constructed to explore the independent effects of LS and specific ART 
regimens on changes in cholesterol and fasting triglyceride levels over follow-up. In intuitively 
adjusted models including recruitment explanatory variables, LS was significantly associated (p 
≤ 0.008) with increases in total cholesterol, LDL-cholesterol, non-HDL cholesterol and fasting 
hypertriglyceridemia (Figure 7-12). The increase seen with total cholesterol was 20.5mg/dL 
(95% CI: 10.0, 31.0), with LDL-cholesterol was 11.1mg/dL (95% CI: 2.9, 19.2), with non-HDL 
cholesterol was 19.7mg/dL (95% CI: 10.3, 29.1), and with fasting triglyceride was 37.0mg/dL 
(95% CI: 18.5, 55.5). In comparison to PI-based HAART, NRTI mono-therapy (-17.6mg/dL, 95% 
CI: -32.4, -2.9), and NNRTI-based HAART (-16.2mg/dL, 95% CI: -25.7, -6.6) were associated 
with decreases in non-HDL cholesterol. Similarly, both NRTI mono-therapy (-37.4mg/dL, 95% 
CI: -67.1, -7.8) and NNRTI-based HAART (-45.4mg/dL, 95% CI: -64.0, -26.8) were significantly 
associated with reduced fasting triglyceride. Of note only 29 subjects (8% of the cohort) were 
being treated with NRTI non-therapy, reflecting that this is not a standard treatment strategy. In 
contrast, a 7.3mg/dL (95% CI: 3.1, 11.4) increase in HDL-cholesterol was seen with NNRTI-
based HAART (p = 0.001).  Full models are presented in Table G-3 in Appendix G 
Similar results were seen in the model including time-updated variables (Figure 7-13). Time-
updated LS was associated (p ≤ 0.005) with increases in total cholesterol (19.4mg/dL, 95% CI: 
8.2, 30.6), LDL-cholesterol (12.6, 95% CI: 3.8, 21.3), non-HDL cholesterol (19.3mg/dL, 95% CI: 
9.3, 29.4), and fasting triglyceride (37.3mg/dL, 95% CI: 16.3, 58.2). A non-significant (p = 0.824) 
increase in HDL-cholesterol was also seen (0.5mg/dL, 95% CI: -4.1, 5.1). Specific time-updated 
ART regimens remained significant (p ≤ 0.023) for all metabolic outcomes. Compared to PI-
based HAART, NRTI mono-therapy was associated with decreases in total cholesterol (-
13.4mg/dL, 95% CI: -24.4, -2.4), LDL-cholesterol (-12.5mg/dL, 95% CI: -21.0, -3.9), non-HDL 
cholesterol (-17.3mg/dL, 95% CI: -27.0, -7.7), and fasting triglyceride (-33.5mg/dL, 95% CI: -
55.5, -11.6). In addition, NNRTI-based HAART was associated (p < 0.001) with decreases in 
non-HDL cholesterol (-14.7mg/dL, 95% CI: -22.7, -6.6) and fasting triglyceride (-47.1mg/dL, 
95% CI: -64.4, -29.8). In contrast, significant increases in HDL cholesterol were seen with time-
updated NNRTI-based HAART (8.4mg/dL, 95% CI: 4.7, 12.1) and triple-class therapy 
(4.2mg/dL, 95% CI: 0.7, 7.7), in comparison to time-updated PI-based HAART. Full details of 
each model are presented in Table G-5 of Appendix G. 
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Figure 7-12: Estimated change in serum concentrations during follow-up by adjusted multivariate multilevel models including recruitment 
covariates 
 
Comparison group for ART regimen is PI-based HAART. Models are 3-level  containing random intercept with subjects clustered within clinical site. Fixed part of models adjusted for sex, ethnicity, maximum 
clinical status, and variables at recruitment: age, BMI,  immunosuppression, detectable viral load, and duration of ART use. See Table G-3 and Table G-4 in Appendix G for full models. See section “Investigating 
the random intercept of constructed models” on p283 for rationale on use of 3-level multi-level models 
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Figure 7-13: Estimated change in serum concentrations during follow-up by adjusted multivariable multilevel models including time-updated 
variables 
 
Comparison group for ART regimen is PI-based HAART. Models are 3-level  containing random intercept with subjects clustered within clinical site. Fixed part of models adjusted for sex, ethnicity, maximum 
clinical status, and time-updated variables: age, BMI,  immunosuppression, detectable viral load, and duration of ART use. See Table G-5 and Table G-6 in Appendix G for full models. See section “Investigating 
the random intercept of constructed models” on p283 for rationale on use of 3-level multi-level models.  
Relationship between components  Chapter 7 
283 
 
Investigating the random intercept of constructed models 
In order to validate the use of a 3-level multivariable model (repeated measures in individuals 
clustered in clinical sites) over a 2-level (repeated measures in individuals) or null (no random 
intercept, i.e. linear regression model), log likelihood tests were conducted.  
Tests were conducted to compare the 3-level models with 2-level models: all stepwise-devised 
models including recruitment covariates showed no significant differences between the 2 and 3-
level models (p ≥ 0.493), indicating that the addition of the extra parameter in the random 
intercept did not improve the model (Appendix G: Table G-7). This was also true of the 
intuitively adjusted multivariable model for non-HDL cholesterol including ART regimen at 
recruitment (p >0.999). All other models including recruitment explanatory variables showed a 
significant (p < 0.001) difference between 2-level and 3-level models, indicating inclusion of 
individuals clustered in the clinical site in the random intercept improved the fit of the model.  
In contrast, log ratio tests comparing 3-level models and null models (no random intercept) 
showed significant differences (p < 0.001) for all previously derived recruitment and time-
updated models (Appendix G: Table G-8): thus inclusion of the random intercept has improved 
all models. 
All multilevel models presented in this chapter are 3-level in order to show consistent and 
comparable models.  
QQ plots were constructed to examine the normal assumption in level-2 and level-3 residuals. 
All plots demonstrated that the normal assumption had not been violated.  
 
7.3.6 Management of lipodystrophy syndrome 
Data on management of LS was collected for 207 subjects in total, of whom 59% (n = 123) were 
receiving an intervention: 10.4% (n/N = 18/155) had pharmacological intervention (including use 
of omega 3 fatty acid, testosterone, other steroids, statins and growth hormones), 33.5% (n/N = 
91/181) had dietary intervention, and 26.5% (n/N = 72/200) had physical activity intervention. 
Table 7-18 summarizes the distribution of management interventions in relation to LS symptoms 
at the beginning and at the end of follow-up. There was no significant difference in the 
proportion of subjects managed by each management strategy (for LS, any body fat alterations 
or any metabolic abnormality) by country (p ≥ 0. 136) 
The most common management approach to LS at recruitment was dietary and physical 
activity, with one quarter (n = 41) of children being managed in this way. The second most 
common approach was dietary intervention only (19%, n = 30), followed by physical activity 
alone (8.9%, n= 14). This pattern was seen with both recruitment body fat alterations and 
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recruitment metabolic abnormality at recruitment (and also with all outcomes at the end of 
follow-up).  The proportion of subjects who had body fat alterations and were undergoing 
physical activity intervention alone increased (p = 0.009) between recruitment (9%, n = 11) and 
the end of follow-up (17%, n =19).  Although there were significant differences in the proportion 
of subjects with specific LS symptoms and undergoing particular interventions between 
recruitment and the end of follow-up (Table 7-18), numbers were small.  
 
Management strategy by lipodystrophy symptoms 
Among the 12 subjects with body fat alterations at recruitment and who had their LS managed 
by pharmacological intervention (Figure 7-14), treatment was most common in subjects with 
lipoatrophy alone or together with lipohypertrophy (n = 9). Of the 47 children and adolescents 
with fat alterations at recruitment who were managed with physical activity, most had both 
lipoatrophy and lipohypertrophy (38.3%, n =1 8) or lipohypertrophy alone (36.2%, n = 17).  Of 
63 children managed with dietary intervention for initial body fat alterations, 42.9% (n =2 7) had 
both lipoatrophy and lipohypertrophy, while 36.5% (n = 23) had lipohypertrophy (p = 0.020). No 
statistical association (p ≥ 0.05) was seen between severity of lipoatrophy or lipohypertrophy 
and management by diet, nor between severity of lipohypertrophy and management by physical 
activity. However, increasing severity of lipoatrophy was associated with use of physical activity 
as an intervention with such management in 19% (n/N = 9/47) of subjects with mild, 34% (n/N = 
10/29) with moderate, and 59% (n/N = 10/17) with severe symptoms (p = 0.009), 
Management with pharmacological, physical activity or dietary intervention (Figure 7-14) was 
more common among subjects with hypercholesterolemia as their only manifestation of 
dyslipidemia, at 80.0% (n=4), 46.2% (n=12), and 58.1% (n=18) respectively. The second most 
common manifestation was fasting hypertriglyceridemia alone, treated with pharmacology (20%, 
n=1), physical activity (30.8%, n=8), and dietary intervention (22.6%, n=7).  
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Table 7-18: Distribution of subjects with specific lipodystrophy symptoms being managed with particular interventions at recruitment and end of 
follow-up symptoms 
 
Body fat alterations Metabolic abnormality Lipodystrophy syndrome 
 Recruitment End of follow-up Recruitment End of follow-up Recruitment End of follow-up 
No intervention 40 (32.8) 29 (25.7) 25 (41.7) 35 (43.8) 58 (37.1) 56 (35.0) 
Pharmacological intervention only 6 (4.9) 5 (4.4) 2 (3.3)** 0** 6 (3.8) 5 (3.1) 
Dietary intervention only 25 (20.5) 24 (21.2) 10 (16.7) 13 (16.3) 30 (19.0) 33 (20.6) 
Physical activity only 11 (9.0)** 19 (16.8)** 3 (5.0) 10 (12.5) 14 (8.9) 20 (12.5) 
Pharmacological and dietary intervention 3 (2.5) 3 (2.7) 0 0 3 (1.9)* 4 (2.5) 
Pharmacological and physical activity intervention 1 (0.8) 1 (0.9) 1 (1.7)* 0* 2 (1.3) 1 (0.6) 
Dietary and physical activity intervention 33 (27.1) 29 (25.7) 17 (28.3) 18 (22.5) 41 (26.0) 37 (23.1) 
Pharmacological, dietary and physical activity intervention 2 (1.6) 3 (2.7) 2 (3.3) 4 (5.0) 3 (1.9) 4 (2.5) 
Percentages are given in brackets χ2 tests used to compare proportions of subjects with specific lipodystrophy syndromes and particular managements strategies at recruitment and 
the end of follow-up: * p < 0.05,** p < 0.01, *** p < 0.001 
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Figure 7-14: Initial symptoms of lipodystrophy syndrome by management intervention  
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Specific management by pharmaceutical strategies 
Specific drug interventions were known for 14 subjects (Table 7-19): 2 were treated with omega 
3 fatty acids, 2 with testosterone, 4 with steroids, 1 with statin, and 5 with growth hormone. 
Details on duration of treatment by LS management interventions were not collected.  
Table 7-19: Subjects with details on specific pharmaceutical management of 
lipodystrophy syndrome (n = 14) 
 Age * 
(years) 
Drug Lipodystrophy status 
Initial End of follow-up 
Patient 1 9.9 Omega 3 
fatty acid 
Metabolic abnormality 
alone 
No symptoms 
Patient 2 11.3 Both** Both 
Patient 3 16.6 Testosterone Body fat alterations only Body fat alterations only 
Patient 4 15.6 Both Body fat alterations only 
Patient 5 15.0 Steroid Body fat alterations only No symptoms 
Patient 6 15.9 Body fat alterations only Body fat alterations only 
Patient 7 16.1 Body fat alterations only Body fat alterations only 
Patient 8  4.9 Body fat alterations only** Body fat alterations only 
Patient 9 9.6 Statin Both Both 
Patient 10 14.4 Growth 
hormone 
Body fat alterations only Body fat alterations only 
Patient 11 13.3 Body fat alterations only Body fat alterations only 
Patient 12 12.1 Body fat alterations only Metabolic abnormality only 
Patient 13 9.8 Both No symptoms 
Patient 14 3.2 Body fat alterations only** Body fat alterations only 
Initial lipodystrophy status is status at recruitment unless otherwise stated. Both refers to symptoms of body 
fat alterations and metabolic abnormality occurring concurrently. *Age at recruitment. **Incident case at second 
study visit 
Among these 14 subjects, 5 experienced changes in LS symptoms over the follow-up period. 
Patient 1 no longer had any metabolic abnormality at the end of recruitment, and remained free 
of any body fat abnormalities. Patient 4, treated with testosterone, had both body fat alterations 
and metabolic abnormality at recruitment but only had body fat alterations at the end of follow-
up. Patient 5, treated with (unspecified) steroids, had body fat alterations at recruitment, but had 
no LS symptoms at the end of follow-up. Of the 5 subjects treated with growth hormone, 2 
experienced changes in LS symptoms over the follow-up period: Patient 13 had complete 
regression of LS, with neither body fat alterations nor metabolic abnormality at the end of follow-
up, while Patient 12 had body fat alterations at recruitment, but had developed metabolic 
abnormality (without body fat alterations) by the end of the study period.   
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7.4 Key points 
 
• Subjects with incident body fat alterations had non-significant increases in levels of 
fasting triglyceride, total cholesterol, LDL-cholesterol and non-HDL cholesterol, with 
non-significant decreases in HDL-cholesterol over the follow-up period. 
 
• Significant increases in the proportion of subjects with body fat alterations over follow-
up were seen in the children and adolescents who developed incident metabolic 
abnormality 
 
• Metabolic abnormality at recruitment was an independent risk factor for incident body 
fat alterations in Cox proportional hazards models, associated with a significant 
increased risk. No statistically significant association was seen between (either 
recruitment or time-updated) body fat alterations and incident metabolic abnormality.  
 
• Both recruitment and time-updated LS was significantly associated with increased total 
cholesterol, LDL-cholesterol, non-HDL cholesterol and fasting triglyceride levels in 
prospective multivariable multilevel analyses No significant association was found with 
HDL-cholesterol. 
 
• Both recruitment and time-updated PI use was independently associated with an 
increase in LDL-cholesterol, non-HDL cholesterol and fasting triglyceride (p < 0.05), 
after adjusting for LS. Furthermore, in comparison to PI-based HAART use at 
recruitment, both NRTI mono-therapy and NNRTI-based HAART were associated with 
independent and significant decreases in total cholesterol, LDL-cholesterol, non-HDL 
cholesterol, and fasting triglyceride: similar results were seen for non-HDL cholesterol 
and fasting triglyceride in analyses investigating time-updated ART regimens. 
 
• NNRTIs were significantly associated with increased HDL-cholesterol, following 
adjustment for LS: this was true of both NNRTI use at recruitment or at any time during 
follow-up. Moreover, significant increased HDL-cholesterol was associated with 
(recruitment and time-updated) NNRTI-based HAART (in comparison to PI-based 
HAART) in prospective multivariable modelling.  An independent and significant 
increase in HDL-cholesterol was also seen with triple-class therapy use during follow-
up.  
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• Older age was significantly associated with decreases in all cholesterol outcomes in 
prospective multivariable multilevel models, and maximum clinical status was 
associated with decreases in total, LDL and non-HDL cholesterol.  
 
• Statistically significant factors associated with HDL-cholesterol over follow-up were 
White compared to Black ethnicity (negative association) and female sex compared to 
male sex (positive association). 
 
• Almost 60% of the 207 subjects who had LS-management data available were being 
treated with a specific intervention. The most common strategy employed to manage 
symptoms of LS were lifestyle modification by physical activity or nutritional 
interventions.  
 
• Only 10% of subjects with LS (and who had management data available) were treated 
with pharmaceutical intervention: the most common approach was growth hormone 
use, followed by steroid use. Indicators for treatment by a specific strategy were 
unclear.  
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8. Discussion 
8.1 Introduction 
Cross sectional estimates of LS prevalence in HIV-infected adults as high as 83% have been 
estimated 226, with the association of LS with ART being well established in many adult 
studies199,215,235,393-398. Fewer studies have investigated the syndrome in children: generally 
these have been smaller and limited to a cross-sectional design. Nevertheless, study of 
paediatric LS is of increasing relevance as greater numbers of HIV-infected children gain 
access to ART60, and accumulate longer durations of exposure to these drugs.  
This is the largest, multicentre, prospective study designed specifically to investigate both body 
fat alterations and metabolic abnormality in children and adolescents. This thesis has explored 
the phenotype of LS in children, estimated both prevalence and incidence of multiple 
manifestations of LS, and used both cross sectional and prospective analyses to identify 
associated risk factors in subjects aged <18 years. Statistical models have been fitted to 
investigate how LS affects serum concentrations of cholesterol and triglyceride. Finally it 
describes strategies used by clinicians to manage LS symptoms in patients.   
The pathogenesis of LS and biological plausibility of HIV and ART as causal agents are 
discussed in Chapter 1: additional proposed biological mechanisms are introduced in this 
chapter. The effects of these causal agents on LS outcomes were investigated in cross-
sectional analyses in Chapters 4 and 5, and in longitudinal analyses in Chapters 6 and 7. The 
results and consequent inferences from this thesis are reviewed in the context of the published 
literature in Section 8.2, establishing consistency with other studies. Furthermore, this chapter 
discusses novel findings from this study in the context of the published literature. Strength of the 
association between risk factors and outcomes are discussed in Section 8.3 of this chapter. 
Possible confounding factors are discussed in Section 8.2 and the measures used to address 
them are explained in Section 8.3. The possible role of chance in the analyses is discussed in 
Section 8.3. The strength of the evidence of the research presented in this thesis is judged 
within this framework.  
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8.2 Main findings  
This is a prospective observational study that followed-up 426 HIV-infected children aged 2-18 
years for a median of 4.2 years. The prevalence of LS at recruitment was 56.5%, which 
increased to 61.6% at the end of follow-up. Incidence was 17.8 per 100 person-years. 
Significant risk factors for LS included White ethnicity, increasing BMI, PI-use and NNRTI-use 
(and specifically efavirenz), and stavudine-use (all associated with increased risk). Indeed, while 
LS, PI-use, maximum clinical status was significantly associated with increases in serum 
concentrations of >1 of LDL-cholesterol/non-HDL-cholesterol/LDL-cholesterol,/fasting 
triglyceride, older age was significantly associated with decreases. NNRTI-use and female sex 
was significantly associated with increased HDL-cholesterol concentrations; Black ethnicity was 
significantly associated with a decrease. The most frequent approach to managing symptoms of 
LS in this cohort was lifestyle modification by nutritional modification or recommendation of 
physical activity.  
Comparison of results with other LS-studies is problematic due to the diversity in study design 
and population, including differences in definitions and assessments of LS. Table H-1 in 
Appendix H summarizes the major adult studies cited in this thesis (excluding clinical trials). 
Notwithstanding overlapping study populations between investigations, the vast majority of 
previous adult studies have been conducted in the developed world, with only 3 conducted in 
Africa (2 in Rwanda193,399 and 1 in Benin400), and 2 in Asia (1 in Singapore401 and 1 in India227).   
Several studies were of prospective design ranging from 3-months402 to 101 weeks403, with one 
study utilizing 5 years of data in a historical cohort398: only 1 prospective study was conducted in 
the developing world400. However, the greatest heterogeneity between studies was seen in 
definitions of LS.  While the largest studies (n ≥ 925)215,394,404,405 have relied on clinician 
assessed lipoatrophy and lipohypertrophy, a 1-year prospective study of 745 Canadian resident 
patients relied on patient-assessed fat alterations406, and a cross-sectional US study of 416 
patients calculated indices of alterations from circumference (mid-arm, mid-thigh, and mid-
waist), with skinfold (subscapular, mid-thigh, triceps and abdomen skinfold) measures236. 
Similarly, thresholds in the definition of hyperlipidemia have varied between studies: 
hypercholesterolemia was defined as total cholesterol levels ≥193mg/dL225 to ≥250mg/dL407, 
while hypertriglyceridemia was defined as triglycerides ≥150mg/dL227,408 to ≥531mg/dL409. 
However, other studies used definition reliant on HDL-cholesterol, LDL-cholesterol and fasting 
triglyceride thresholds193,216,225,227,394,402,406,408,410-412, Similar heterogeneity is seen in 
investigations of LS in HIV-infected children: (Table 8-1 and Table 8-2). Within this study, body 
fat alterations were clearly defined by severity at specific locations, and metabolic abnormality 
according to age and sex-defined thresholds of cholesterol and fasting triglyceride. The 
approaches taken by other individual paediatric studies will be discussed in the context of their 
results.  
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8.2.1 Prevalence and incidence  
The estimates of prevalence of body fat alterations, both at recruitment and at the end of follow-
up, were substantially higher than the 18-33% reported by previous studies (Table 8-1). Of note, 
all but one study had less than 60 participants. Crucially, samples in previous paediatric studies 
were younger compared to this cohort (median age: 12.2 years). It has been argued that the 
development of LS is a graded and progressive process, while the natural development of 
adipose tissue in children may have a protective effect which wanes during and after puberty194. 
Moreover, given ART is life-long, older children are more likely to have longer durations of 
exposure to drugs, and furthermore, exposure to older toxic drugs commonly used before the 
introduction of newer, more benign formulations. Thus, the comparatively older ages of subjects 
in this cohort may help to explain the greater prevalence observed.     
While adult studies have not found the pattern in proportions of type of body fat alterations seen 
here (i.e. similar proportions of subjects with lipohypertrophy, lipoatrophy, and the combined 
phenotype), they have reported higher prevalences401,413. Similar to baseline prevalences seen 
in this cohort, prevalence of lipoatrophy-only was 15%, of lipohypertrophy-only was 12%, and of 
mixed lipoatrophy and lipohypertrophy was 10% in 581 HIV-infected adults enrolled in the multi-
centre French Aquitaine Cohort, with significant differences seen in the prevalence of 
lipoatrophy-only between the genders216.  Indeed, in the current study, significant differences 
were seen in the prevalence of lipohypertrophy in the trunk and the neck between sexes with 
higher proportions seen in males compared to females. However, analysis of 1348 adults 
attending 15 clinical centres in Australia resulted in estimated lipoatrophy-only prevalence of 
20%, lipohypertrophy-only of 6%, and combined lipoatrophy and lipohypertrophy of 27%405.  
Similarly, among 194 subjects with body fat alterations in a Rwanda/South Africa based study 
the proportion of subjects with concurrent lipohypertrophy and lipoatrophy was highest (three-
quarters), followed by lipohypertrophy alone (one in twenty), and then lipoatrophy alone (one in 
ten)193. Thus, while this study and previous paediatric investigations suggest the prevalence of 
body fat alterations does increase from adolescence into adulthood, there is conflicting 
evidence as to whether the manifestation of the concurrent lipoatrophy and lipohypertrophy 
phenotype also occurs more frequently.   
Among subjects with body fat alterations in this cohort, the most common location was the 
trunk, followed by the face, legs, arms and buttocks, with the least common locations being the 
neck and breast. This pattern is similar to that seen in studies investigating adult 
populations216,226, and identical to that seen in 124 children with body fat alterations in a 
previous European Cohort209. 
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Table 8-1: Estimated prevalence of body fat alterations in published paediatric studies 
Study Study type Location Number 
of 
subjects 
Age Assessment of 
body fat 
alterations 
Definition of body fat alteration Estimated 
prevalence 
Amaya et al, 
(2002)195 
Cross-sectional USA 40 9.1† Investigator Fat wasting in extremities, buttocks and 
face. 
Fat accumulation in the abdomen and 
dorsocervical spine 
18 
Arpadi et al, 
(2001)200 
Cross-sectional USA 28 4.3 – 12.2††† DEXA scan Both decrease in arm and leg fat and an 
increase in trunk fat, by repeated 
scanning 
29 
Bockhorst et al, 
(2003)202 
Prospective 6-
month follow-up 
USA 26  Not disclosed Fat wasting in the face, arms or legs 
and/or fat accumulation (central obesity 
or breast hypertrophy) 
23.1 
European 
Paediatric 
Lipodystrophy 
Cohort (2004)209 
Cross-sectional Multi-country 
Europe 
477 9.78†† Clinician Lipoatrophy: sunken cheeks/sunken 
eyes/ prominent zygomatic arch on face. 
Skinny/prominent veins/prominent 
muscularity or bones in limbs. Buttocks 
have loose skin folds, prominent 
muscles/loss of contouring/hallowing. 
Lipohypertrophy: increased abdominal 
girth/ buffalo hump/enlarged breast 
26.0  
(22.1, 30.2)** 
Jacquet et 
al.(2000)194 
Cross-Sectional France 39 9.1† Not disclosed Peripheral fat wasting: facial and/or 
buttock and/or limp atrophy with arm 
skinfold thickness <3rd percentile of the 
reference values for sex and age.* 
Truncal adiposity: breast enlargement 
and/or buffalo neck and/or relative 
abdominal obesity with trunk:arm skinfold 
ratio >2 standard deviations 
33.3 
Sanchez-Torres et 
al. (2005)207 
Cross-sectional Spain 57 9.5† Clinician Lipoatrophy: sunken cheeks and thin 
extremities with prominent veins 
with/without buttock atrophy 
Lipohypertrophy: increased abdominal 
girth and breast enlargement with/without 
buffalo hump and/or limpomas 
25.0  
(14.8, 34.6)** 
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In subgroup analyses of children and adolescents with body fat alterations in this study, 
subjects with concurrent lipoatrophy and lipodystrophy  had higher median fasting triglyceride 
than either those subjects with lipoatrophy-alone or with lipohypertrophy-alone. It has been 
suggested that the occurrence of concurrent lipoatrophy and lipohypertrophy occurs as the 
endpoint of systematic pathogenesis involving progressive metabolic changes and insulin 
resistance209,414. This theory is supported by significant trends in metabolic outcomes being 
seen with increasing severity of fat disturbance405, and both normal and pathological insulin 
sensitivity observed in HIV-infected patients with impaired glucose tolerance397. Results from 
this thesis endorse this hypothesis as subjects with both types of body fat alterations 
demonstrated metabolic changes characteristic of insulin resistance.  
Female subjects with body fat alterations had significantly increased standardized median total 
cholesterol, and standardized median (pro-atherosclerotic) non-HDL cholesterol, compared to 
female subjects without alterations. Male subjects without body fat alterations had significantly 
higher levels of (anti-atherosclerotic) HDL-cholesterol compared to males with body fat 
alterations. Several pro-atherosclerotic pathways stem from alterations in the ratio of HDL-
cholesterol to LDL-cholesterol415, which have implications in established inflammatory cascades 
implicated in CVD pathogenesis416. Thus children who were symptomatic with body fat 
alterations had also developed an unhealthy metabolic profile, regardless of whether they had 
manifest hyperlipidemia.  
Table 8-2 illustrates the prevalence of hypercholesterolemia, hypertriglyceridemia, and 
hyperlipidemia in previously published paediatric studies. Only two previous studies employed 
age and gender thresholds in their definitions of hyperlipidemia196,208, while the remainder use 
thresholds which were consistent between sexes and age groups. For example, prospective 
data from 2122 children and adolescents enrolled in the PACTG 219C reported a prevalence of 
hypercholesterolemia of 26% using a threshold of 220mg/dL197, while a much higher prevalence 
of 53.4% was reported in a USA-based retrospective cohort of 178 children using the lower 
threshold of 200mg/dL359. Nevertheless, the estimated prevalence of hypercholesterolemia at 
the end of follow-up in the current study (13.3%) is similar to the (age and gender defined) 
prevalence of hypercholesterolemia (13.0%) reported in an earlier analysis from the PACTG 
219C study196. Moreover, the finding that hypertriglyceridemia occurs more frequently than 
hypercholesterolemia here is consistent with previous studies201,203,206,208, although the converse 
has also been reported195. 
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Table 8-2: Estimated prevalence of metabolic abnormality in published paediatric studies 
Study Study type Location Number 
of 
subjects 
Age 
(years) 
Definition of metabolic abnormality Estimated 
prevalence 
Amaya et al, 
(2002)195 
Cross -sectional USA 40 9.1† HC: cholesterol > 170mg/dL 
HT: triglyceride >135mg/dL 
HC: 68 
HT: 28 
Aurpibul et al , 
(2007)201 
Prospective  144 
weeks follow-up 
Thailand 90 7.6† 
(at enrolment) 
HC: total cholesterol >200mg/dL and LDL cholesterol 
≥130mg/dL 
HT: triglyceride >200mg/dL 
HC: 11 
Fasting HT: 12 
Carter et al, 
(2006)203 
Prospective <7 years 
follow-up 
USA 
(multicentre) 
178 6.3†  
(at enrolment) 
HC: cholesterol ≥200mg/dL 
HT: triglyceride ≥ 150mg/dL 
HC: 47 
HT: 67 
Desai et al 
(2008)204 
Prospective 18 month 
follow-up 
USA 48 6-15††† HL: cholesterol ≥ 200mg/dL and/or triglycerides ≥ 150mg/dL HL: 58 
European 
Paediatric 
Lipodystrophy 
Cohort (2004)209 
Cross-sectional Multi-
country 
European 
477 9.78†† HC: cholesterol ≥ 200mg/dL 
HT: triglyceride ≥ 150mg/dL 
HC: 21  
HT: 27 
Farley et al 
(2005)196 
Prospective follow-up USA 1812 4-19††† HC: cholesterol >95th percentile from NHANES III standards 
(by age, race and gender) 
HC: 13.0 
Jaquet et al, 
(2000)194 
Cross-sectional France 29 9.1† HC: cholesterol > 95th percentile HC: 17.9 
Kim et al, (2009)359 Retrospective cohort 
10 year follow-up 
USA 178 2.74† 
(at presentation) 
HC: cholesterol > 200mg/dL HC: 53.4 
Parakh et al, 
(2009)206 
Cross-sectional India 52 6.0†† HC: cholesterol ≥ 200mg/dL 
HT: triglycerides ≥ 150mg/dL 
HC: 7.7 
HT:19.2  
Dos Reis et al 
(2011)358 
Cross-sectional Brazil 119 11.9† HC: cholesterol ≥ 150mg/dL 
HT: triglycerides ≥ 100mg/dL 
HC: 33.9 
HT: 35.6 
Solórzano Santos 
et al, (2006)208 
Prospective 27 month 
follow-up 
Mexico 24 <17 years††† HC: cholesterol > 200mg/dL 
HT: gender and age defined thresholds 
HC: 62.5 
HT: 79.2 
Tassiopoulos et al, 
(2008)197 
Prospective follow-up USA 2122 9.21† HC: cholesterol ≥ 220mg/dL HC: 26 
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Several studies in adults have reported higher prevalences of hyperlipidemia with prevalences 
of hypercholesterolemia of ≤57% and of (fasting and non-fasting) hypertriglyceridemia ≤52% in 
both developed and less-developed countries225,411 394. Thus it is likely that pathogenesis of 
metabolic abnormality may be on-going as duration of ART use, or HIV-infection, increases, 
concurrent with normal increases in plasma lipids that occur from childhood into adolescence 
and, from a post-pubertal trough into early adulthood (cholesterol), and from childhood to early 
adulthood (triglyceride)381,417-419.  
The incidence of body fat alterations was 8.01 per 100 person-years here, where follow-up 
averaged 4 years, which was similar to that reported in an Italian study in adults commencing 
PI-based HAART420  Indeed, estimates of specific body fat alterations were similar  to those 
reported in the  LipoICoNa study of 655 adults where incident lipohypertrophy was reported as 
5.5 per 100 person-years, lipoatrophy as 3.8 per 100 person-years, and the combined 
lipohypertrophy with lipoatrophy had an incidence of 2.6 per 100 person-years421. Only one 
previous study reported incidence of body fat alterations: in a cohort of 48 HIV-infected children 
(aged 6-15 years) living in the USA, the incidence was reported  as being 31% after follow-up of 
18 months204. However, estimates of incidence were lower in a African study of HIV-infected 
adults400. While the current study reported similar estimates for incidence of lipoatrophy and 
lipohypertrophy, two North American studies in HIV-infected adults have reported the incidence 
of lipohypertrophy being smaller than that of lipoatrophy406,422,423,   
Previous adult studies have reported the incidence of hypertriglyceridemia to be higher than the 
incidence of hypercholesterolemia in the same study population410. However, in common with 
the current study, the comparatively higher incidence of hypercholesterolemia in HIV-infected 
adults has also been reported241,406. The incidence of metabolic abnormality in this investigation 
was 4.8 per 100 person-years, while the incidence of hypercholesterolemia was 5.6 per 100 
person-years. This hypercholesterolemia incidence is higher than  that reported in  the PACTG 
219C study in HIV-infected children: 3.4 cases per 100 person-years (95% CI: 3.0, 3.9)197. This 
difference may be partly attributable to differences in diagnosis in hypercholesterolemia 
between the two studies, and a lower mean age (9.2 years) within PACTG. Furthermore, a 
greater proportion within PACTG was of non-White ethnicity (86% vs. 30.4% in the current 
study): HDL-cholesterol levels have been shown to be higher in children and adolescents of 
Black compared to White ethnicity424-426.  In comparison with adult studies, incidence of 
metabolic abnormality in this study was lower than the incidence to the Metabolic Syndrome 
(defined as ≥3 of hypertriglyceridemia, low HDL-cholesterol, hypertension, abdominal obesity 
and high serum glucose)  in a US HIV cohort408, but higher than the incidence of severe 
hypertriglyceridemia (serum triglyceride >531mg/dL) in a French cohort409.  
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8.2.2 Factors associated with lipodystrophy syndrome 
Protease inhibitors 
As discussed in Chapter 1, several mechanisms of PI-induced pathogenesis of LS have been 
proposed. These have included direct effects on glucose production 255,256, glucose disposal257, 
triglyceride metabolism263,427, and adipocyte differentiation and apoptosis221,255,265-267. At 
recruitment, 56% of subjects were being treated with PIs: use of PI at recruitment was 
significantly associated with increased risk of concurrent lipoatrophy and lipodystrophy (AOR: 
5.81) in cross-sectional analyses. However no individual PI (including ritonavir booster) 
remained significant in any multivariable model: this may be because there was insufficient 
statistical power to detect an association in the multivariable models as there was no significant 
difference (p ≥ 0.341) in the proportions of subjects with body fat alterations either on or not on 
PIs at recruitment. However, significant (p < 0.01) differences were seen between the 
proportions of subjects who had ever been on PIs with respect to all body fat alterations 
outcomes. This may indicate that body fat alterations had occurred in these subjects, and they 
had been switched to less toxic medication before enrolment making it more difficult to identify 
an association between current PI and body fat alteration at recruitment. The associations 
between PIs and LS are well recognised, with prescribing information for many PIs explicitly 
stating that adverse reactions for these drugs include LS. In adult studies PI use has been 
shown to be associated with lipohypertrophy, but inconsistently with lipoatrophy184,214,226 215.  
An increased risk of body fat alterations with PI-use (AOR: 7.79) was seen in 88 HIV-infected 
children (mean age: 11.1 years) living in Belgium in analysis adjusted for gender, age, CDC 
stage, CD4 counts and duration of treatment205. Furthermore, the European Paediatric 
Lipodystrophy Group reported a significant increased risk of any body fat alterations associated 
with ever use of PIs (AOR: 2.41, 95% CI: 1.18, 4.91), in multivariable models of 423 children 
aged >3 years adjusted for sex, age, CDC clinical class, and ever use of stavudine209: no 
significant association was seen with either central lipohypertrophy or peripheral lipoatrophy. 
However the evidence of an association has been weaker or absent in two US-based paediatric 
studies: PI treatment was associated with a significant increased risk of body fat alterations 
(OR: 7.0, 95% CI: 1.1, 45.2) in unadjusted analysis of pre-pubescent children (mean age: 7.5 
years) in the first200, and no significant association between duration of PI use in children and 
body fat alterations was seen in the second study195. However both these studies were small 
(40 and 28 subjects respectively) cross sectional studies.  
In this study, use of PI at recruitment was associated with a significant 2-7 fold increased risk of 
all metabolic abnormality outcomes in multivariable logistic regression models including class of 
ART, while recruitment ritonavir was associated with a significant 2-8 fold increased risk in 
additional models: in both sets of models the greatest magnitude of risk was seen for concurrent 
hypercholesterolemia and fasting hypertriglyceridemia.  Furthermore, use of PI was associated 
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with a 4-4.5 fold increased risk of incident metabolic abnormality (Chapter 6). Adult studies have 
shown elevated triglycerides and total cholesterol levels to be associated with any 
PI184,186,216,226,397,428, and with ritonavir in both HIV-infected262,396,402,429,430, and uninfected 
subjects431. Paediatric studies have also demonstrated PI use to be associated with 
hyperlipidemia213,360. In a Swiss study of 66 children aged <17 years, PI-use was significantly 
associated with increases in both total cholesterol and triglyceride levels in previously PI-naïve 
subjects, with the greater increases seen with ritonavir-treated compared with nelfinavir-treated 
children: ritonavir use was associated with a non-significant 70% increase in risk of 
hypercholesterolemia (defined as ≥90th percentile for age and sex) compared to nelfinavir use 
(AOR: 1.7, 95% CI: 0.4, 6.6)432. Two small prospective studies with subjects aged <18 years 
switched from PI-based cART to NRTI/NNRTI-based regimens reported decreases in serum 
levels of total cholesterol and triglyceride after 48 weeks of follow-up246,433.  Respective 
estimates for the independent risk associated with PIs for dyslipidemia, hypercholesterolemia 
and hypertriglyceridemia in children are 2-fold211 (multicentre French study of 130 subjects), 5-
14 fold196,197 (≤2122 subjects enrolled in the PACTG 219C), and 3-fold (178 subjects enrolled in 
the Perinatal AIDS Collaborative Transmission Study, PACTS, and 178 children enrolled in a 
single-centre US study)203,359.In addition to inherent differences in the study population and 
factors in the statistical modelling, the heterogeneity in the definitions of metabolic abnormalityj 
may have contributed to the range in estimates of the effect size.  However, the estimates from 
previous paediatric studies are in broad agreement to those calculated here: within the PACTS-
HOPE study, PI-inclusive regimens were independently and significantly associated with a 4-
fold increased risk of cholesterol ≥200mg/dL, and a 2-3 fold increased risk of 
hypertriglyceridemia. Furthermore, on restricting the study population to subjects who were PI-
treated in PACTS-HOPE, a 2-fold increased risk of hypertriglyceridemia was seen with ritonavir 
containing regimens (AOR: 2.1, 95% 1.2, 3.5)203. Comparison of the magnitude of the 
independent associations between paediatric and adult studies suggests that it is possible that 
children and adolescents are at greater risk of developing LS than adults. 
The association of PI use with a poor metabolic profile is underscored by the results from the 
multivariable multilevel model: recruitment PI use was associated with significant increases in 
total cholesterol, LDL-cholesterol, non-HDL cholesterol and fasting triglyceride, with time-
updated PI use associated with increases in both LDL-cholesterol and non-HDL cholesterol. 
Although evidence from the current study strongly suggests that PI use is a risk factor, there is a 
possibility of residual confounding and confounding by indication. Moreover, the follow-up time 
may be too limited to investigate the effects of these newer drugs.  
                                                 
j
 The French study defined elevated triglyceride and cholesterol as >+2 standard deviations in z-scores from 
age/gender/ethnicity defined reference distributions, the P219C study defined hypercholesterolemia as serum 
cholesterol ≥220 mg/dL, PACTS-HOPE defined hypertriglyceridemia as triglycerides ≥150mg/dL and 
hypercholesterolemia as cholesterol ≥200mg/dL, while the US study defined hypercholesterolemia as cholesterol 
≥200mg/dL. 
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Non-nucleoside reverse transcriptase inhibitors 
At recruitment one third of subjects were being treated with NNRTI. Use of NNRTI was a 
significant risk factor for any fat alterations, lipohypertrophy, lipoatrophy, and concurrent 
lipohypertrophy with lipoatrophy. In analyses incorporating specific drugs, efavirenz but not 
nevirapine was associated with a significant increased risk of any body fat alterations. Few 
paediatric studies have  found an association between use of NNRTI and body fat alterations: 
no significant association has been reported in a US-based investigation, but this study only 
included 7 subjects with body fat alterations195. However, several investigations in adult 
populations have reported a significant association. Analysis of 338 women enrolled in FRAM 
identified NNRTI to be a significant risk factor for lipoatrophy in the leg in adjusted analyses434, 
while multivariable analysis of 416 adults in an American cross-sectional study found efavirenz 
and nevirapine to be  significant risk factors for dorsal lipohypertrophy236. Furthermore, the DAD 
study showed that NNRTI-use was significantly associated with a 13-fold (AOR: 12.99, 95% CI: 
9.46, 17.8) increased risk of body fat alterations394. Although results from the current study are 
consistent with adult studies suggesting that NNRTI, and specifically efavirenz, is a risk factor 
for body alterations, there is an absence of (both paediatric and adult) studies which have 
investigated comparisons of risk for different fat alteration outcomes. Thus, the finding that the 
risk associated with concurrent lipoatrophy and lipohypertrophy was approximately 4 times that 
associated with other body fat outcomes may be novel. 
Within this study, time-updated NNRTI use was significantly associated with an increased total 
cholesterol concentration in multivariable multilevel models, most likely driven by significant 
increases in HDL-cholesterol, as NNRTI use was not significantly associated with changes in 
either LDL-cholesterol or non-HDL cholesterol. In a recently published prospective study of HIV-
infected children, Jacobson and colleagues, also used multivariable multilevel modelling to 
investigate cholesterol levels361: total cholesterol, LDL-cholesterol, non-HDL cholesterol and, 
interestingly, HDL-cholesterol levels all increased significantly with duration of use of nevirapine, 
efavirenz, nelfinavir, and lopinavir in 449 children followed for a median 4.5 years. These results 
support the findings here that both NNRTI and PI are significantly associated with increased 
total cholesterol, despite the age of participants being substantially lower (6.6 years at 
baseline).  
Results from the current study suggest that NNRTI use may be associated with an anti-
atherosclerotic cholesterol profile in children and adolescents, consistent with previous studies 
where NNRTI-based regimens were associated with increases in HDL-cholesterol and 
decreases in the total cholesterol to HDL-cholesterol ratio435-438. Moreover, in a randomised 
controlled trial of HIV-infected adults where PI in ART regimens were substituted, replacement 
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with NNRTI was associated with significant increased HDL-cholesterol and significant 
decreased non-HDL cholesterol439.   
In multivariable multilevel models here, NNRTI during follow-up was associated with increased 
fasting triglyceride. This may seem a puzzling result as several studies have demonstrated a 
more healthy metabolic profile associated with NNRTI-based ART in comparison to PI-based 
ART435,440-442. Jacobson and colleagues reported mixed results: 2-3 years of nevirapine use was 
associated with significant decreases in triglyceride levels, while <2 years and >3 years was 
non-significant,  and >2 years of efavirenz use was associated with significant increases361. 
Indeed previous studies in adults have reported a better triglyceride profile to be associated with 
nevirapine compared to efavirenz443-445.  However, it is possible that the result in the current 
investigation is an example of confounding by indication where children have developed a poor 
metabolic profile due to long-term exposure to PIs, and thus been switched to NNRTI as a 
management strategy of LS symptoms. This argument is strengthened by the fact that 
recruitment NNRTI did not remain significant in the final models for triglyceride levels. Taken 
together, results from this study suggest that NNRTIs are associated with body fat alterations, 
and also a healthier metabolic profile (through increased HDL-cholesterol). It is possible that 
these results may have been confounded by switching to NNRTI in order to either improve 
metabolic profile in children with LS, and thus an erroneous association with body fat alterations 
has been made. However, given that both improved metabolic profile and increased body fat 
alterations have been shown in other studies, the possibility of this confounding by indication 
recedes. The clinical importance of the simultaneous pro-body fat alterations and pro-HDL 
cholesterol of NNRTI is substantial. Patients on these drugs would require to be routinely, and 
possibly frequently, examined for both aspects of LS, especially in cases where a child with 
body fat alterations may switched to NNRTIs to improve metabolic profile.  
NNRTIs are mildly inhibitive of the protein SREBP446 (Chapter 1), which can lead to increases in 
triglyceride and cholesterol concentrations, and increased peripheral lipoatrophy, as seen in PIs 
(where the inhibition is stronger)286. This mechanism supports the postulated role of NNRTI in 
body fat alterations, and may partly explain a possible role in increasing HDL-cholesterol. The 
observation that NNRTI inhibition of SREBP is to a lesser extent than that seen with PI induced 
inhibition446 may support association of NNRTI with increased HDL-cholesterol, but not with 
non-HDL cholesterol seen in the current study.  
 
Nucleoside Reverse Transcriptase Inhibitors 
Several mechanisms of NRTI induced body fat alterations have been proposed, relating to the 
postulated mitochondrial toxicity of these drugs (Chapter 1)273,277,278,283: stavudine is well 
recognised for its association to LS in adults and children, particularly with lipoatrophy215,399,447. 
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The European Paediatric Lipodystrophy group reported increased risk of body fat alteration 
associated with stavudine – of around 3-fold for any alterations and for lipohypertrophy alone, 
and 4-fold for lipoatrophy209, while in an analysis of 88 children resident in Belgium, use of 
stavudine was associated with a significant and independent 14-15 fold increased risk of body 
fat alterations205,238. The finding here that stavudine use at recruitment was significantly 
associated with increased risk of any body fat alterations, and lipoatrophy was therefore 
expected. Given current guidelines recommending avoidance of this drug if possible, it was 
reassuring to see that only 11.2% of subjects were on stavudine at recruitment, with 51.3% 
having used the drug in the past.  
Several prospective studies in adult populations have identified either NRTI or specifically 
stavudine as risk factors for body fat alterations (including the specific phenotypes of 
lipoatrophy, lipohypertrophy and the concurrent phenotype)199,235 404,406,421.   In prospective trials 
involving HIV-infected adults with lipoatrophy, switching from NRTI-based therapy to abacavir or 
tenofovir was shown to be significantly associated with reversal of fat alteration symptoms237., 
Indeed, within this study, ever-use of stavudine was associated with significant and independent 
2-5 fold increased risk of all body fat alteration outcomes.   Longer duration of NRTI use was 
associated with significant increased risk of lipoatrophy in adjusted analyses from the Western 
Australian Study HIV Cohort 235. Furthermore, within the same study, the effect size was almost 
increased from 10% to approximately 200% in cART with PIs. The authors argue that PIs may 
be the predominant influence in lipoatrophy, and may act synergistically with NRTIs235.  
An unexpected finding in this study was the statistically significant decreased risk of concurrent 
lipoatrophy and lipohypertrophy associated with zidovudine, and lamivudine. Indeed, this 
combination of drugs has been associated with lipoatrophy448. It is unlikely that these 
associations are the result of confounding by indication. Neither lamivudine nor zidovudine has 
been associated with improved LS profile in other studies; furthermore, confounding by 
indication would give an erroneous positive association unlike the negative association 
observed. Median duration of ART use in subjects with concurrent lipoatrophy and 
lipohypertrophy and who were on either of these drugs here was 6.05 years (IQR: 1.25. 9.12), 
with median age of 13.15 years (IQR:10.30, 15.38): thus these subjects may be long-term non-
progressors who had not switched to newer ART. Subgroup analyses suggested that the 
negative association observed between lamivudine and zidovudine with the combined 
phenotype was driven by males and children/adolescents aged > 11 years. Studies in adult 
populations have shown a positive association between specific body fat alterations and older 
age434,447, or female gender199,412,413. However few studies have investigated the combined 
phenotype277,278,283.  
Within the current study, both PI and NRTI were significant risk factors for body fat alterations 
including lipoatrophy. It has been argued that because PI/NRTI-associated lipoatrophy occurs at 
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a faster rate to NRTI-associated lipoatrophy, then PI therapy has a strong independent effect on 
fat loss, and long-term NRTI therapy may lead to a predisposition to lipoatrophy235. In Cox 
adjusted analyses of 178 HIV-infected children followed up for ≥10 years, NRTI mono-therapy, 
NRTI/NNRTI dual therapy, and NRTI/PI dual therapy were all associated with increased risk of 
triglycerides >200mg/dL: this was statistically non-significant in the first group but significant in 
the latter two groups with the risk greater with NRTI/PI (AHR: 3.45, 95% CI: 2.65, 4.51) 
compared to NRTI/NNRTI (AHR: 1.86, 95% CI: 1.34, 2.19)359. Moreover, in subgroup analysis 
of 94 previously ART naïve adults in the Prometheus randomized clinical trial, patients on  
ritonavir/saquinavir/stavudine had an independent and significant 7-fold increased risk of body 
fat alterations compared to patients on ritonavir/saquinavir: this association was also significant 
in patients regardless of previous ART status449. Furthermore, adults who developed lipoatrophy 
in a prospective French cohort were shown to have accumulated longer durations of NRTI 
treatment before they commenced HAART compared to those not developing lipoatrophy450. 
Thus it is possible that the children in this cohort may not have accumulated durations of NRTI 
therapy associated with the increased risk seen in adult studies. Further analysis in deciphering 
the ART history of subjects in this study, e.g. the time on NRTI and PI therapies and the time on 
combined NRTI and PI therapy, may help to ascertain whether a similar synergistic effect of 
these drugs occurs in children with shorter durations of treatment in comparison to adults 
.Simplification of treatment with PI-based mono-therapy has been associated with lower viral 
suppression and increased risk of virological failure in adults451. An on-going observational 
study of 5 children switched to PI-based mono-therapy reported controlled viral load, increased 
CD4 count, no side-effects, and improved or maintained serum lipid concentration (at 20 
months of follow-up): such results need to be validated in large paediatric clinical trials before 
their routine use as maintenance therapy can be ascertained452. 
 
HIV-associated clinical disease and immunosuppression 
The possible role of HIV, as indicated by viral load, immuno-suppression and clinical disease in 
LS pathogenesis is complex. During HIV-infection, the differential pathways of immune system 
activation are mediated by inflammatory cytokines (the HIV-specific response) and homeostatic 
cytokines (the homeostatic response to lymphocyte depletion)453-455. Both increased cytokine 
secretion from adipose tissue and increased systemic pro-inflammatory cytokine activity have 
been speculated to have a significant role in the pathogenesis of LS221,222,456-458. It is possible 
that the HIV-induced cytokine pathways may also have a role in body fat alterations and 
metabolic abnormality: common cytokine pathways may be multifaceted and thus difficult to 
elucidate.  
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Over 57% of subjects enrolled in the cohort had a history of symptomatic HIV disease, including 
22% with AIDS, while over 62% had moderate or severe immunosuppression at some point 
during their lifetime. Experience of symptomatic HIV disease was an independent risk factor in 
multivariable models for any body fat alterations, and lipohypertrophy: a history of AIDS was 
associated with 2-fold increased risk of any body fat disorder, while CDC clinical stages B and C 
were each associated with a 2-fold increased risk of lipohypertrophy.  The effect size is 
comparable to those reported in the European Paediatric Lipodystrophy Group Study209. 
However, this previous study also reported a significant two-fold increased risk of lipoatrophy209 
which was not seen here. The role of HIV-associated disease as a risk factor was supported by 
the finding that incident LS was significantly associated with a history of moderate CDC-defined 
clinical.  
The Italian Coordinators for the Study of Allergies and HIV Infection (CISAI) cohort of adults 
reported a 30% increased risk of lipoatrophy with an AIDS-defined clinical status404, supporting 
the finding in cross-sectional analysis here of a 2-3 fold increased risk of body fat alterations, 
lipohypertrophy and LS with symptomatic clinical status. It is possible that past disease may 
predispose children to LS, and specifically lipoatrophy. Indeed, growth retardation in HIV-
infected children compared to uninfected children is well established230,459, indicating the direct 
impact on body habitus of untreated HIV.  
In the longitudinal analyses of lipids here, maximum CDC-defined clinical status B was 
associated with increases in total cholesterol, which was driven by significant increases in LDL-
cholesterol. Although no association was found with triglyceride levels, AIDS-defining illness 
has been associated with a significant and independent increase in triglyceride levels in HIV-
infected men460, with cytokine pathways proposed to be a potential mechanism461. It can also be 
speculated that subjects with a history of severe disease may have accumulated more complex 
treatment history than subjects who had been healthy. Although duration of ART included in all 
analyses would control for some of the confounding due to previous treatment history, further 
analyses of the cohort investigating specific treatment history will help to address this theory.   
In cross-sectional analysis, recruitment immunosuppression was not a significant risk factor for 
any fat alteration outcome in the current study (106 subjects in total had moderate or severe 
immunosuppression at recruitment). However a reduced risk of incident body fat alterations was 
significantly associated with the occurrence of any immunosuppression during follow-up (AHR: 
0.41, 95% CI: 0.19, 0.91). An association between immunosuppression and body fat alterations 
has been reported in adult studies: significant reduced risk of lipoatrophy associated with 
increasing current CD4 cell count (AOR: 0.58 per 100 cell increase, 95% CI: 0.36, 0.93), was 
found in the NOVAVIR trial462, and an even greater reduced risk of incident cases was seen in 
an Italian study407.  
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Observational studies in  adults have also demonstrated that increased of risk body fat 
alterations and/or metabolic abnormality are significantly associated with reductions in both 
current215 and nadir cell count463,464. However, in the current study, the occurrence of 
immunosuppression at any time during follow-up was associated with a significantly reduced 
risk in the incidence of metabolic abnormality (AHR: 0.34, 95% CI: 0.12, 0.98). Indeed, in 
multivariable multilevel models the occurrence of immunosuppression over follow-up was 
associated with a significant decrease in non-HDL cholesterol. This is in agreement with results 
from the PACTS-HOPE paediatric cohort, which demonstrated that severe immunosuppression 
(AOR: 0.4, 95% CI: 0.2, 0.95) and undetectable viral load (AOR: 2.5, 95% CI: 1.5, 4.1) were 
significant risk factors203. Indeed, detectable viral load was also independently and significantly 
associated with significant decreases in all cholesterol outcomes (7-19mg/dL) in the current 
study. This negative association may be representative of reduced adherence to drugs and thus 
a reduction in the pro-LS effects of ART. 
Within the current investigation, detectable viral load was not a significant risk factor for incident 
metabolic abnormality, but immunosuppression during follow-up was associated with reduced 
incidence and PI use at recruitment with increased risk. No interaction between these latter 
factors was found. However, within the PACTS-HOPE study, severe immunosuppression 
remained a statistically significant risk factor for hypercholesterolemia, even after exclusion of 
subjects not on PI-based regimens203. Thus it is possible that reduced CD4 counts have an 
independent protective effect against metabolic abnormality.  
This study has shown that time-updated markers of HIV during follow up were associated with 
reduced risk of LS outcomes in prospective analyses, whereas markers of maximum and 
recruitment HIV were associated with increased risk in cross-sectional analyses. This may be 
indicative of the pathogenesis of LS being associated with past symptomatic disease and/or 
complex treatment history, with reduced occurrence with incomplete adherence to ART. 
Furthermore, the concurrent findings in longitudinal models that detectable viral load was 
associated with reduced total cholesterol, and clinical symptoms with increased LDL-
cholesterol, may suggest that there may be an independent protective effect with markers of 
HIV.  
 
Age and Puberty 
At recruitment, 10.0% of the study population were aged 2-6 years, 27.5% were 7-11 years, and 
62.4% were 12-18 years.  Increasing age was a risk factor for all body fat alteration outcomes in 
various multivariable models, with the greatest magnitude of risk seen for lipoatrophy (5-fold in 
models including specific ART regimen as an explanatory variable). Although significant 
associations between age and body fat alterations have been reported in adult studies, the 
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magnitude of the effect size was smaller447. However it is difficult to be certain to what extent 
observed body fat alterations in this study are the result of “normal” age-associated fat gain 
unrelated to HIV in adults465-467. Indeed, the natural development of adipose tissue in childhood 
may have a protective effect against LS, which wanes during and after puberty194. 
Puberty (as measured by Tanner score) was not included in the stepwise variable selection in 
multivariable modelling in the current study: this was to prevent over-adjustment as all models 
included age, and sex was included in the covariate selection process. However, puberty was 
then included in the final multivariable models in additional analyses in order to investigate 
whether there was an independent effect. Tanner score was statistically significant in 
univariable models for decreased risk of metabolic abnormality, with subjects who were 
undergoing puberty or who had completed puberty being at reduced risk of all outcomes, but did 
not remain significant in any multivariable model. However, independent significant 10-29% 
reduction in risk per year in age of all metabolic outcomes was seen. Other paediatric studies 
investigating hypercholesterolemia have also reported reduced risk in older children and 
adolescents compared to younger children.  Within the PACTS-HOPE study, children aged 11-
15 years (AOR: 0.4, 0.98, p = 0.045) was associated with increased risk of metabolic 
abnormality (cholesterol ≥200 mg/dL and triglyceride ≥150 mg/dL), compared to being aged ≤ 5 
years in multivariable models203. In the PACTG 219C study, in comparison to adolescents aged 
12-19 years, younger children had a significantly increased risk of hypercholesterolemia: 3 fold 
in 4-5 year olds and 2 fold in 6-11 year olds196.  
Although, both fasting and non-fasting triglyceride levels have been shown to increase with age 
in healthy children468,469, there was no significant association between age and change in 
fasting triglyceride levels. Prospective population-based studies in non-HIV infected children 
and adolescents have shown that cholesterol levels increase towards puberty, followed by a fall 
at puberty, and finally return to pubertal levels in late adolescence470-475. While multilevel 
multivariable models showed that older age was associated with decreases in all cholesterol 
levels, these were relatively small and included decreases in the anti-atherosclerotic HDL-
cholesterol.  Older age (12-18 years) at recruitment was also associated with non-significant 
changes in triglyceride levels.   
The reduced risk of metabolic abnormality with increasing age may be partly attributable to 
worse adherence to ART in adolescents, since there is some evidence to suggest that younger 
children show better adherence than older adolescents149. Within this study, age was a 
significant risk factor for metabolic abnormality in subjects with poor adherence (using 
detectable viral load as a proxy measure) and age only remained statistically significant in 
multivariable models restricted to subjects with undetectable viral load, whilst remaining non-
significant in most models in subjects with detectable viral load. However, detectable viral load 
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may be a problematic proxy for adherence in this population, and further investigation is 
required to understand the effects of age on metabolic abnormality. 
 
Sex 
Both paediatric 209 and adult476 studies have reported that females may be more likely to have 
body fat alterations, with some studies only finding an increased risk associated with 
lipohypertrophy447. Female gender was associated with a significant (unadjusted) 76% 
increased risk of lipohypertrophy in the current study, but no other significant associations 
between sex and body fat abnormality outcomes were found. When specific body sites were 
investigated, girls had increased probability of lipohypertrophy in the trunk or neck compared 
with boys.  
With respect to metabolic abnormalities, female sex was associated with a non-significant 
reduction in risk of dyslipidemia in unadjusted analyses, and was not significant in multivariable 
models. This is consistent with previous prospective adult studies which have reported non-
significant elevated triglyceride to be associated with male sex407,477. However, female sex was 
associated with a modest, but significant, increase in levels of HDL- cholesterol (4.94 mg/dL, 
95% CI: 1.56, 8.32) in multilevel models here. Differences between cholesterol levels between 
males and females may be explained by the negative regulatory role of androgenic hormones, 
and the positive regulatory role of estradiol on apolipoprotein A1478 which plays a critical role in 
removal of cholesterol from peripheral cells479,480.  
Sex hormones have been hypothesized to have specific effects on lipid levels in non-HIV-
infected children. Free testosterone was associated with increased triglyceride and LDL-
cholesterol, and decreased HDL-cholesterol; while increased estradiol was associated with 
increased HDL-cholesterol, and decreased triglyceride and LDL cholesterol in boys aged 10-15 
years old481.  Furthermore, differences seen in hormone levels between boys of Black ethnicity 
and White ethnicity in the same study population illustrate the more atherogenic lipid profile in 
White boys following puberty482. Longitudinal studies in non-HIV infected populations have 
shown that girls have higher mean cholesterol compared to boys of a similar age418,483. .   
Pharmacokinetic differences between sexes may be implicated in pathogenesis of LS. Indeed, 
the greater incidence of ART-associated toxicity in females has been attributed to increased 
intracellular concentrations due to reduced clearance compared to males. Women on NRTIs 
have higher intracellular concentrations of NRTI tri-phosphates (a proxy measure of the drug) 
and achieve viral suppression twice as fast as men, which may explain the greater NRTI-
associated toxicities seen in women484. Higher incidence of NNRTI-related toxicities in women 
have also been reported, and attributed to reduced clearance rates compared to men485.  
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Furthermore, while increased intracellular concentration of PI has been identified in women 
compared to men,  this statistically significant difference has not been seen in the absence of 
ritonavir boosting486: this may explain why associations with LS were found with ritonavir 
booster in this study and not for other specific PIs. Continued follow-up of the cohort will enable 
analyses exploring the interaction between gender and specific ART category/drug with 
sufficient statistical power.   
 
Ethnicity 
The majority of subjects were of White ethnicity (69.7%), with 26.2% of Black ethnicity. Results 
of the current investigation show White ethnicity to be associated with body fat alterations and 
lipoatrophy specifically. Furthermore, in the final multivariable model for concurrent lipoatrophy 
and lipohypertrophy using classes of ART, White ethnicity was a significant risk factor (AOR: 
4.28, 95% CI: 1.09, 16.79), compared to Black ethnicity.  Studies in HIV-infected adults have 
demonstrated White ethnicity to be an independent and significant risk factor for lipoatrophy or 
any body fat alterations, but not lipohypertrophy215,403. Previous paediatric studies have either 
not addressed ethnicity as a risk factor for body fat alterations, or found no significant 
association. 
An unexpected finding in this investigation was the significant reduced risk of incident LS with 
White ethnicity compared to Black ethnicity (AHR: 0.15, 95% CI: 0.05, 0.38, p <0.001). In 
previous cross-sectional analyses, White ethnicity had been a positive risk factor for any body 
fat alterations, lipoatrophy and LS. Furthermore the Western Australian Cohort of HIV-infected 
adults also reported a significant increased risk of emerging lipoatrophy associated with White 
ethnicity235. Interaction between ethnicity and age was significantly associated with incidence of 
LS (AHR: 8.47. 95% CI: 1.33, 53.94), suggesting that puberty and post-pubertal development 
across White and Black ethnic groups may have a different impact on LS emergence.  
White ethnicity was associated with a non-significant increased risk of both metabolic 
abnormality and fasting hypertriglyceridemia in cross-sectional multivariable logistic models in 
the current study. The lack of a significant association between ethnicity and metabolic 
outcomes in this study may be due to the incorporation of clinical site in the multivariable 
models: ethnicity was significantly associated with clinical site with 15% of Italian residency 
subjects of Black ethnicity and 63% of Belgian residency: all subjects residing in Poland were of 
White ethnicity. Thus the effects of ethnicity may be diminished by the random effect included 
for hospital of treatment.  
Previous paediatric and adult487 studies have found White ethnicity to be a significant risk factor 
for poor metabolic status. In the PACTG 219C White ethnicity was a significant risk factor 
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compared to Black ethnicity (AOR: 2.2, 95% CI: 1.4, 3.3)196, and African ethnicity was 
associated with a reduced risk (AOR: 0.34, 95% CI: 0.14, 0.80) of low HDL in the French 
multicentre prospective study of 130 HIV-infected children211. Indeed, analysis of Project 
Heartbeat data (on non-HIV infected children) demonstrated that sex and age-dependent 
trajectories of total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride differed by 
ethnicity, with Black children tending to have lower LDL-cholesterol and triglycerides, and higher 
HDL-cholesterol488. Furthermore, the Metabolic Syndrome has been shown to occur less 
frequently in individuals of Black compared with White ethnicity in non-HIV infected 
populations489. These previous studies are consistent with the finding here that White ethnicity 
was associated with significant decreases in HDL-cholesterol (and thus total cholesterol) 
compared to Black ethnicity. 
White ethnicity was also associated with significant and independent increases in fasting 
triglyceride in multilevel models explored in the current study. Lower triglyceride levels in people 
of Black ethnicity compared to those of White ethnicity have been reported in healthy 
subjects490, with the comparatively better lipoprotein profile in Afro-Caribbean men living in the 
UK attributed to secretion of large proportions of their VLDL as small, triglyceride-poor 
particles491. Thus underlying genetic differences (either independent of, or synergistic with HIV 
or ART pathways) are likely to effect the risk and manifestation of LS between Black and While 
populations. 
 
8.2.3 Relationship between body fat alterations and metabolic abnormality 
In order to establish whether metabolic abnormality precedes body fat alterations, or vice versa, 
a series of analyses investigating the relationship between both aspects of LS seen in this 
cohort were conducted: the aim of this was to gain further insight into the pathogenic process of 
LS.  
Within this cohort, overweight BMI at any time was associated with significant increased risk of 
incidence of metabolic abnormality. Although a prospective adult study reported a significant 
positive association between BMI and lipoatrophy400, a previous paediatric prospective 
paediatric study did not find an association between BMI and body fat alterations204. Significant 
increases in non-HDL cholesterol, and significant decreases in HDL cholesterol have been seen 
with increased BMI in both non-HIV infected children492 Association have also been reported 
between  adiposity and other biomarkers (increased blood pressure, apolipoprotein B, C-
reactive protein and IL-6, and decreased apolipoprotein A), suggesting that adiposity may foster 
an adverse cardiovascular and metabolic profile from early childhood492. However, BMI may be 
an inappropriate measure of body fat alterations in children. For example a subject who 
develops both lipoatrophy and lipohypertrophy may have similar BMI both before and after the 
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development of body fat alterations. Furthermore, either lipoatrophy occurring both in the trunk 
and the legs, or lipohypertrophy occurring in both these locations, would give a similar waist/hip 
ratio to a subject with no body fat alterations in these locations. Indeed, it has been argued that 
it may be a problematic to use BMI to identify overweight and obese children, given normal 
body development and localized fat accumulation493,494.   
Subjects here with incident body fat alterations had higher levels of fasting triglyceride, total 
cholesterol, LDL-cholesterol, and non-HDL cholesterol at the end of follow-up compared to 
recruitment, but this did not reach statistical significance. Furthermore, metabolic abnormality at 
recruitment was associated with a statistically significant 5-fold increased risk for incident body 
fat alterations. However, body fat alterations were not a significant risk factor for incident 
metabolic abnormality. These results indicate that while there are alterations in body habitus 
and metabolic profile that occur concurrently, there is evidence to suggest that metabolic 
abnormality does precede body fat alterations. Indeed, the observation that metabolic 
abnormality at recruitment was a statistically significant risk for incident body fat alterations, but 
time-updated metabolic abnormality was not, indicates that any pathogenic process for 
metabolic changes resulting in effects on adiposity may be slow-acting.  
Previous studies investigating the relationship between metabolic abnormality and body fat 
alterations in LS have been restricted to HIV-infected adults. Findings from the FRAM study 
suggest that specific metabolic abnormalities are associated with increases in specific fat 
alterations460,495: however, the cross-sectional nature of the data limit the strength of the 
evidence for this to be a causative association. Similarly, other studies have reported an 
association between body fat alterations and metabolic abnormality, but lacked a temporal 
component496-498. In a prospective study in South Africa, subjects developing body fat alterations 
had significantly higher levels of circulating insulin at baseline224, indicating that metabolic 
disturbances precede adipose tissue changes. Furthermore, analysis of 5-year data from the 
French Aquitaine Cohort showed hyperlipidemia to be significantly associated with a 2-fold 
increase in risk for body fat alterations241.  In a prospective study of 58 subjects, metabolic 
abnormality was seen to precede body fat alterations: significant increases in triglyceride, total 
cholesterol and both LDL and HDL cholesterol were seen at 12 months of follow-up, while 
significant changes in fat distribution (limb lipoatrophy) were not seen until 24 months499: Further 
evidence for metabolic abnormality preceding body fat alterations was seen in a 1-year 
prospective study of 31 HIV-infected adults: subjects who developed lipoatrophy had higher 
levels of triglyceride, and lower levels of HDL cholesterol, with decreased insulin sensitivity at 
recruitment compared to those who did not develop lipoatrophy500. Moreover, significant 
reductions were seen in expression of genes involved in adipocyte differentiation, lipid uptake, 
and local cortisol production in thigh adipocytes in lipoatrophy patients in the same study from 2 
months of follow-up500.  
Discussion  Chapter 8
   
310 
 
The evidence for a role of body fat alterations as a risk factor for the emergence of metabolic 
abnormality is more mixed, as few studies have had a longitudinal approach. Within the current 
study, no significant association was found between body fat alterations and incidence 
metabolic abnormality in either univariable or multivariable models. It is possible that this study 
was underpowered to detect a significant effect size on incident metabolic abnormality by 
recruitment body fat alterations.  
Advances in the understanding of pro-atherosclerotic pathways of metabolic changes have 
been made by investigating triglyceride and cholesterol levels in relation to abdominal 
obesity501,502 , subcutaneous and visceral adipose tissue503. Indeed, adipokines (seen to be 
over-secreted from abdominal adipose tissue in obesity504)  have a role in inflammation and 
postulated role in the metabolic syndrome505.  
 
8.2.4 Progression and regression of symptoms 
All 228 subjects who had LS at recruitment experienced both progression and regression of 
symptoms: this most commonly manifested itself as progression of metabolic abnormality 
accompanied by regression of body fat alterations, although regression of both body fat 
alterations and metabolic abnormality was also common. Among 201 subjects with body fat 
alterations at recruitment, almost three-quarters experienced regression of symptoms without 
worsening of any symptoms; the remainder experienced both progression and regression. 
However, among 214 subjects with metabolic abnormality at recruitment (some of whom had 
concurrent body alterations) the distribution of change in symptoms was more heterogeneous: 
approximately one-quarter experienced regression only, one-quarter experienced progression 
only, and approximately one-quarter experienced both. 
These results demonstrate the dynamic nature of LS in children. Furthermore, they illustrate the 
difficulty in monitoring patients with the syndrome. Although thresholds for hyperlipidemia were 
based on age and sex (with cut-off points for regression and progression of symptoms set at 
20% above and below the standard thresholds for hypercholesterolemia and 
hypertriglyceridemia), the identification of regression of body fat abnormality symptoms was 
dependent on clinician assessment as to the level of and change in severity of symptoms.  
Thus, it is possible that the changes seen in body fat severity were more arbitrary. Furthermore, 
it may be that the regression seen in fat alterations may be due to expected changes seen 
during puberty. Other studies in HIV-infected children with LS have focused on the 
disappearance of body fat alterations as an endpoint506 rather than looking at graded regression 
of symptoms, and therefore have not looked at the dynamism of LS-symptoms.   
Various methods of assessing morphological changes in HIV-infected adults have been 
employed507. Paediatric studies have assessed body fat alterations by using measures of 
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skinfold thickness compared to standards508,509, or using specific anthropometric measures, 
such as weight and height, to compile z-scores from distributions compiled from the underlying 
population510. Population-specific standards of waist-hip ratio have been shown to be suitable 
for detection of increased abdominal mass by using cut-off points based on standard deviations 
from the mean511. This approach was not suitable in this study given the mixed ethnic make-up 
of the cohort.  Adult studies have used computerized tomography (CT) scans to estimate 
visceral adipose tissue and total adipose tissue by examination of cross-sectional imaging512. 
Although this approach has been used to describe body fat in a case review of HIV-infected 
adolescents513, it has not been used in larger paediatric studies, due to the expense and 
requirement for specialist interpretation. DEXA are a straightforward method of assessing 
adiposity over time as (both total and specific compartmental) body fat can be estimated as both 
weight and as a proportion of body weight512. Paediatric studies have used DEXA to assess 
adiposity over time in HIV-infected children over time, but the study size has been relatively 
small (n ≤ 24)233,514,515. However, as with CT, issues of expense and inconvenience may be 
problematic in routine DEXA use. The current study was an epidemiological observational study 
and thus relied on routinely collected data and did not collect data from specialized testing 
outside routine hospital visits.   
No statistically significant associations were seen between any patient characteristics and 
change in symptom severity of either body fat alterations or metabolic abnormality symptoms. 
Thus other factors, possibly occurring over follow-up may be responsible for these changes. It is 
also feasible that the pathogenesis of LS may be reflected in the dynamic progression and 
regression of symptoms. LS is a multifactorial condition with both ART and ART-independent 
pathways of causation and multiple metabolic and physical manifestations: thus disease 
processes underlying lipoatrophy and lipohypertrophy may differ and might have critical periods 
of development as well as latent periods.   Periods of progression lipohypertrophy may be 
followed by regression of lipohypertrophy, but this regression may be accompanied by a spike 
in lipid levels: in such a situation the child would be recorded as having regression of symptoms 
of body fat alterations, progression of symptoms of metabolic abnormality, and no change in the 
symptoms of LS. In these circumstances it may be that the interval between monitoring specific 
symptoms is too long to detect multiple changes in symptom severity over the period, or that the 
thresholds for detection of such symptoms are not sensitive enough. The possibility that 
changes in body fat alterations and changes in metabolic abnormality, although associated, are 
occurring at different rates makes it difficult to accurately assess the change in symptoms of the 
syndrome over time. This has important implications in the management of LS and evaluation of 
effectiveness of interventions. 
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 8.2.5 Management of lipodystrophy syndrome 
This study was not designed to investigate effectiveness of management strategies, but instead 
allowed description of the range and combination of strategies used. The most common LS 
management strategy in this study was a combination of dietary and physical activity, used in a 
quarter of LS cases, followed by dietary intervention alone in 20% and physical activity in 
12.5%. However, for over half of children with LS, no dietary, physical activity, surgical or 
pharmaceutical intervention to manage LS symptoms was used.  
No specific guidelines exist for the identification or treatment of LS in HIV-infected children and 
adolescents. However, various guidelines for the management of elevated lipid levels in 
children in order to reduce development of CVD risk factors exist 516,517 518 519. As cholesterol 
levels in early childhood are associated with levels in adolescence and adulthood520,521, 
management of hyperlipidemia associated with LS in HIV-infected children may be an important 
strategy in reducing CVD risk later in life. 
Physical activity was one of the most common management strategies in this study, reflecting 
the literature demonstrating that increased physical activity and reduced sedentary behaviour is 
associated with a healthy weight or reduced subcutaneous fat168,169522-526. It has also been 
shown that increased physical activity in leisure time among male adolescents aged 15-21 was 
associated with increased HDL-cholesterol in the general population527. Lifestyle interventions 
encompassing modifications to physical activity and nutrition have been shown to be successful 
in positively impacting on weight528,529: A recent Cochrane systematic review concluded that 
combined behavioural lifestyle interventions compared to standard care or self-help may 
produce a significant and clinically important reduction in overweight in children and 
adolescents530. Thus increasing physical activity  and modifying diet may result in changes in 
body fat, but the regularity of,  and degree of effort  involved in, physical activity required to 
either prevent weight gain or lose weight may vary in different populations and at different 
stages of physical development531. Although sedentary lifestyle has been associated with the 
occurrence of concurrent lipoatrophy and lipohypertrophy in a cross-sectional study of 150 HIV-
infected adults532, and a case-review in HIV-infected adults with LS showed diet and exercise 
changes to be linked to reduced abdominal lipohypertrophy533, the body fat alterations seen in 
HIV-associated LS are unlikely to be physiologically analogous to changes in body habitus seen 
in overweight or obese children. Thus any interventions traditionally used to combat overweight 
BMI in children may not be appropriate for management for fat abnormalities associated with 
LS. This does not exclude the possibility that interventions (including lifestyle modification) 
designed to combat hyperlipidemia527 may have secondary effects on body shape.  
Dietary intervention had been recommended to 31 subjects with metabolic abnormality at 
recruitment, of whom 70% had hypercholesterolemia and one-third hypertriglyceridemia. There 
is abundant evidence that modification of diet can improve lipid profile. Both adult534 and 
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paediatric studies535-537 in non-HIV infected populations have shown that reducing dietary 
saturated fat can result in decreases in levels of total and LDL-cholesterol, including among 
children with hyperlipidemia538. Furthermore, increased dietary fibre has been associated with 
decreases in non-HDL-cholesterol539 (and smaller decreases in triglyceride540) in pre-pubescent 
children.  Although it has been suggested that vitamin supplements may reduce mitochondrial 
toxicity, and thus have beneficial effects on HIV-associated LS, inclusion of thiamine, riboflavin, 
ubiquinone and acetyl-carnitine in mitochondrial support therapy has shown mixed results281. 
Only 14 children with LS received pharmacological intervention during follow-up. This may 
reflect both the lack of clinical thresholds to diagnose LS in HV-infected children, and the 
absence of specific clinical guidelines for management of LS, and of evidence-based 
recommendations for management of dyslipidemia in the general paediatric population315. 
However, guidelines for identifying hyperlipidemia in children as part of cardiovascular risk 
factors in moderate/high risk groups have been proposed541. It is also possible that clinicians 
may have refrained from treating LS symptoms in order to avoid adding to an already complex 
pill burden in relation to ART. Such increased burden may have knock-on effects on adherence, 
especially where LS management drugs are known to be associated with paediatric adherence 
problems themselves, e.g. fibrates542,543.  Another possibility is the desire to avoid toxicity in 
relation to combining ART and LS management drugs, e.g. specific statins have been linked to 
liver and muscle toxicity if used in conjunction with PIs544  
The pharmacological interventions used in this study were growth hormone, steroids, 
testosterone, Omega 3 fatty acid, and statins. These were most commonly used where the child 
had body fat alterations. Most previous studies have focused on management of metabolic 
symptoms. Within the PAGTG 219C study, fewer than one in ten (8.1%) of the 624 HIV-infected 
children subjects with hypercholesterolemia (total cholesterol >200mg/dL) received 
pharmacological intervention, most commonly statins545. Within the current cohort, the 
proportion of subjects with prevalent or incident hypercholesterolemia and who were treated 
with pharmaceutical intervention (where data was known) was similar to the PACTG study: 
9.2% (n/N = 6/65).  A more recent UK-based prospective study (mean follow-up: 4.5 years) 
estimated the number (n = 3) of patients in their cohort (n = 445) who were eligible for 
pharmaceutical intervention (defined as LDL-cholesterol >190mg/dL with children with no CVD 
risk factors, or LDL-cholesterol >160mg/dL for children with ≥2 risk factors), but did not specify 
what interventions were then used (if any), and their effectiveness361.  
Within this cohort, 5 subjects, all with initial body fat alterations were being treated with growth 
hormone. Reduced total and abdominal visceral fat has been associated with growth hormone 
therapy in pre-pubertal children without HIV who were deficient in the hormone546. Growth 
hormone deficiency in HIV-infected adults in the pre-HAART era was associated with loss of 
lean and fat mass: however, HAART treated patients with body fat abnormalities have also 
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been seen to have growth hormone deficiency547. Reduced growth hormone secretion is 
associated with dyslipidemia and increased glucose concentrations in HIV-infected adults548 and 
adolescents549 with abdominal lipohypertrophy. In a double-blind randomized trial of 404 HIV-
infected adults, the growth hormone releasing factor tesamorelin was associated with significant 
decreases in visceral adipose tissue compared to placebo: this was also accompanied by 
improvements in body image distress in patients with abdominal lipohypertrophy550. Moreover, 
in a recent review of 10 randomized controlled trials of growth hormone treatment in patients 
with HIV-associated body fat alterations (n = 1511), treatment was associated significant 
decreased visceral adipose tissue and lean body mass compared to placebo551.  Growth 
hormone has also been shown to improve weight and height in pre-pubertal HIV-infected 
children552. 
There were 4 subjects treated with steroids, and a further 2 treated with testosterone, within this 
cohort: all 6 had body fat alterations at the beginning of treatment (1 also with metabolic 
abnormality), but only 1 had no symptoms at the end of follow-up. Treatment with steroids may 
restore the balance of lipolysis and lipogenesis regulated by cortisol and dehydoepiandristerone 
(levels of which are seen to change in HIV-infected adults with LS553), resulting in normalization 
of body fat changes. Androgenic anabolic steroids in tandem with progressive resistance 
exercise and physiologic doses of testosterone improved lean body mass in adult males with 
HIV-wasting554.  Indeed, steroid treatment has been shown to increase weight in HIV infected 
adult men and women with wasting, albeit associated with some liver toxicity555. A Cochrane 
review demonstrated an average increase in lean body mass of 1.3kg (95% CI: 0.6, 2.0), and of 
total body weight of 1.1kg (95% CI: 0.3, 2.0) in 13 randomized clinical trials of HIV-infected 
adults where anabolic steroids were used to treat weight loss556.  However no paediatric studies 
have investigated the efficacy of steroid therapy for treatment of body fat alterations. 
In a recent meta-analysis of 6 studies which investigated the effects of omega-3 fatty acid in 
HIV-infected adults, the overall reduction in weighted mean difference triglycerides following 8-
16 weeks of treatment was -80.34 mg/dL (95% CI: -129.08, -31.60)557. The American Heart 
Association (AHA) recommends that at least 5% of dietary intake should be omega-6 fatty acid, 
as this reduces risk of coronary heart disease compared to lower intakes through reduction of 
cholesterol558. Two children, both with initial metabolic abnormality, were treated with omega-3-
fatty acids in this study. Although both fibrates167,247 and bile acid binding resins166,167 have been 
shown to improve lipid profile in children209,249, neither of these approaches were used in the 
management of LS in this study population. This may be due to adverse reactions reported with 
fibrates542, and adherence issues with bile acid binding resins543.  
Given the association between specific ART and LS, switching regimen may sometimes be 
used in the management of symptoms of LS (while maintaining viral suppression). It may also 
be used to try to improve adherence by use of a less toxic drug. Improvements in lipoatrophy 
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were seen in adult patients after cessation of treatment with stavudine184,395. Switching from 
stavudine to tenofovir improved both lipoatrophy and lipid profile in a prospective study of 62 
adult patients559. In addition to switching from stavudine-containing regimens, moving from other 
ART regimens has been associated with improvements in LS-associated symptoms, including 
switching from PI-based regimens560,561. Paediatric studies have not specifically investigating 
switching of ART regimen in relation to management of LS: the PACTG 219C study described 
ART switching amongst HIV-infected children with LS, but did not relate it to symptoms545. Both 
adult and paediatric studies often have limited follow-up, with heterogeneity in LS measures, 
and inability to account for the impact of prior therapy562. Within this investigation, the 
examination of management of LS has been limited to non-ART based interventions. Given the 
rich data collected on past ART use in participants, and the continued follow-up, management 
of LS by switching of ART regimens may be investigated in future analyses.  
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8.3 Strengths and weaknesses of this investigation 
8.3.1 Data 
This study has several advantages over previous paediatric studies which have investigated LS. 
As discussed in Chapter 1, these were limited by small sample size, being cross-sectional in 
design, or being nested within a study which was not primarily dedicated to investigate LS. In 
contrast, the European Paediatric Lipodystrophy Cohort is a prospective study of 426 subjects 
attending specialist paediatric HIV centres across 3 European countries. The data collection 
tools were designed with the specific aim of capturing information on metabolic abnormality and 
body fat alterations associated with LS, and also on potential determinants of LS. Thus this 
research has the advantage of using specific LS definitions, with results being generalizable to 
a wide range of HIV-infected children and adolescents. In contrast to many previous studies, 
inference between the causal relationship between a given risk factor could be made from the 
longitudinal design. Furthermore, because of the range of data collected, the effects of LS on 
lipid levels could be modelled. 
 
Possible sources of bias 
While the multicentre structure of the cohort facilitated a large sample size and improved the 
potential applicability of findings to a greater population, there is the possibility that there may 
be systematic differences between study sites. These may take the form of different 
populations, differing ART regimens, or strategies in managing patients as they move through 
adolescence (for example in the number of routine hospital visits, or responsibility in taking on 
HIV treatment management). In order to address the possibility of these possible systematic 
biases effecting analyses, random effects for hospital were included in statistical modelling 
(logistic regression, Cox survival regression, and multilevel modelling).  
Given the wide range of metabolic changes identified during LS187, use of questionnaires to 
collect data provides a convenient approach to collecting data. Serum levels of triglyceride and 
cholesterol are specific continuous measures which can be interpreted within a suitable 
framework, e.g. threshold values dependent on sex and age. However, assessment on body fat 
alterations by examining changing in body habitus is less objective. Several recent studies have 
used DEXA scanning as a way of assessing body fat density to investigate LS563-565, although 
sonography has also been suggested as a useful alternative method566. Indeed DEXA has been 
seen as a gold standard in the assessment of lipoatrophy and lipohypertrophy286. The 
observational nature of this study made it impossible to collect DEXA scans for each child as 
these are not part of routine hospital visits. However, body fat alterations were assessed 
according to strictly defined criteria using a scale of severity by the subject’s established 
clinician. Clinical knowledge of adolescent body development, the independent effects of HIV on 
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growth, and body habitus changes associated with LS, alongside familiarity with the patient may 
reduce some subjectivity in observations of body fat alterations. Indeed, significant correlation 
between clinician-assessed body fat alterations, and results from DEXA scan has been 
reported567. Some earlier investigations have relied on self-reported changes which have been 
shown to over-reporting of body shape changes346: similar over-reporting is likely to occur when 
assessments are made by the care-givers to children and adolescents. While clinician 
assessments may avoid such over-estimation, they do not entirely remove the problem of 
reduced objectivity. Indeed, treating clinicians by their very nature are not blinded to the ART 
history of the patient, and thus this possible source of bias in assessments of body fat 
alterations cannot be excluded from consideration of the results in this investigation.  
Within this study, 28% of children with body fat alterations at recruitment were affected in a 
single body site, with a slight increase to 30% at the end of follow-up. Furthermore, 30 subjects 
at recruitment were defined as having body fat alterations by trunk lipohypertrophy alone, with 
this number rising to 33 at the end of follow-up. This may indicate that a conservative approach 
was taken by clinicians in assigning a child as having body fat alterations.  The collection of fat 
alteration by severity allowed sensitivity analyses to be conducted in cross-sectional logistic 
modelling: these reinforced results from the original models. It is still possible that the clinician 
may be more inclined to categorize a “borderline” patient as having body fat alterations where 
(s)he knows that the subjects is being treated with drugs previously shown to have an 
association: such assessments may lead to over estimation of both prevalence and risk 
associated with specific drug use.  
While previous studies investigating hyperlipidemia in HIV-infected children and adolescents 
have used adult thresholds in defining cases, this study has used specific age and gender 
defined thresholds568. Thus there is greater validity in the classification of subjects with 
metabolic abnormality: almost one in five (19.4% n/N = 43/222) of subjects with LS at 
recruitment were defined by either hypercholesterolemia or fasting hypertriglyceridemia (at the 
end of follow-up this had increased to 21.4%, n/N= 54/257). However, up to one quarter of our 
study population was missing fasting measures for serum total cholesterol, HDL/LDL-
cholesterol, triglyceride, glucose and insulin. Missing information on fasting triglyceride may 
have led to inaccuracy in estimates of prevalence and incidence of metabolic abnormality, and 
reduce power in statistical models. Indeed, numbers of subjects missing data on non-HDL 
cholesterol may have led to biases on the effects of risk factors associated with this clinically 
important group of lipids. Imputation was used to investigate the effect of missing values of 
cholesterol and fasting triglyceride on the multivariable models for hypercholesterolemia and 
fasting hypertriglyceridemia at recruitment (Chapter 5). The imputed multivariable models 
estimates of AORs were similar to the values of the models without imputed values (Chapter 5:), 
indicate that the missing values may not be influential on the results.  However, the models with 
imputed values for hyperlipidemia were not able to incorporate the random effect for clinical site 
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because this was unsupported by the statistical analysis software (STATA v11). Thus the effect 
of bias due to missing values of cholesterol and triglyceride cannot be excluded.   However, 
given the relatively small numbers of missing data, and the problems associated with using 
imputation in conjunction with incorporation of random effects in statistical models, it was 
decided not to use methods to address missing values within analyses.  
Within this investigation, metabolic profiles between ethnic groups have been shown to vary: 
hyperlipidemia thresholds for children which take into account age, sex and gender are not yet 
available. Given the ethnic diversity in this study population it is possible some bias may have 
been retained with respect to assessment of hypercholesterolemia and fasting 
hypertriglyceridemia.  
 
8.3.2 Analytical Methods 
Locally weighted smoothing and fractional polynomial models were used in the description of 
metabolic and anthropometric measures in subjects with/without LS. Outcomes, for example 
HDL-cholesterol, BMI etc., were modelled with age-at-recruitment as an explanatory variable: 
these fractional polynomial methods were used to explore the different phenotypes of LS, and 
were not designed to imply a causal relationship between age and these outcomes.  
Logistic regression models were performed using cross-sectional data collected at recruitment 
to investigate postulated risk factors associated with LS outcomes. Several factors were found 
to have an association with LS outcomes including PI and NNRTI use. These models can be 
interpreted to infer a causal relationship. However, statistical significance doesn’t necessarily 
prove a causal association. Furthermore logistic regression models do not   show a temporal 
relationship, e.g. PI use occurred before hypercholesterolemia occurred and thus caused it to 
occur. A temporal component (over the duration of follow-up) was provided by Cox proportional 
hazards modelling where an association between a given explanatory variable with incidence of 
a given outcome was investigated. Results from these models added to the argument of 
causality between LS and identified risk factors by calculating effect size and significance on the 
basis that the explanatory variable occurred before the outcome. Thus, for example, the 
argument for a causal relationship between PI use and LS in strengthened by the positive 
association between PI use at recruitment and the incidence of metabolic abnormality. 
Furthermore, the multilevel models also used longitudinal data and provide a temporal 
component in their exploration of the association between explanatory variables and serum lipid 
levels. These models also provide additional information on the degree to which an explanatory 
variable affects the cholesterol and triglyceride outcomes. For example a very significant 
association may result in the covariate only changing lipid levels over time, with this change not 
having clinical implications for the patient. However, a non-significant association may result in 
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the covariate causing a large change in lipid levels which may have a clinical implication. In the 
current study, PI use was shown to have a relatively large, and possibly clinically important, 
effect on serum cholesterol levels. 
Explanatory variables such as clinical status and degree of immunosuppression were ordinal, 
but did not show linear relationships in terms of risk associated with a given outcome. It has 
been argued that the relationship between cause and effect should be strong, in terms of 
magnitude of risk: a weak relationship may occur due to confounding and/or bias569. 
Explanatory variables such as stavudine, PI and White ethnicity were associated with a 
relatively high 4-fold increased risk of various LS outcomes, adding to the argument for a causal 
association.  
A benefit of logistic regression, Cox proportional hazards, and multilevel modelling is that all 
approaches can incorporate covariates to control for the effects of confounding. All models were 
adjusted for known confounders including age at recruitment, duration of ART use, and clinical 
site (hospital). Later models, which explored relationships between specific covariates and an 
outcome were adjusted by covariates that had been shown to have an association with the 
outcome in earlier models. However, this confounding will persist in models investigating the 
possible causal role of ART. Specific ART drugs were explanatory variables in several statistical 
models in the analyses. The distribution of these drugs in the study population would not be 
random (independent of LS status): treatment would be dependent on several clinical factors 
including disease state, immunosuppression, and adverse effects not excluding LS. It is 
therefore possible that residual confounding between ART and outcomes may remain even 
after controlling for clinical factors. 
In the cross-sectional investigation of factors associated with either body fat alterations or 
metabolic abnormality, three sets of logistic regression models were used: (i) incorporating 
categories of ART and other covariates chosen by stepwise selection, (ii) incorporating specific 
ART drugs and other covariates chosen by stepwise regression, and (iii) including ART regimen 
with specifically chosen covariates chosen intuitively. The first models allowed for ART 
categories to be investigated with maximum statistical power in order to verify the relationship 
between specific categories and manifestations were as seen in the published  literature. Given 
that different mechanisms of actions for each ART have been postulated , it was important to 
investigate each category separately within this thesis. Indeed this was shown to be occur: 
NNRTI was seen to be associated with body fat alterations (Table 8-3), and PI was seen to be 
associated with metabolic alterations (Table 8-4). The second set of models allowed more 
practical inferences to be made as they allowed distinctions to be made between drugs in the 
same ART category. For example, ritonavir booster was seen to be a consistent risk factor for 
metabolic abnormality outcomes while other PI drugs were not (Table 8-4). Indeed, newewr 
drugs have been developed which are designed to have less LS-associated adverse effects, 
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e.g. the newer PI atazanavir which was shown not to be a risk factor for metabolic abnormality 
in this investigation. Moreover, because all but two subjects who were currently on ART at 
recruitment were on NRTI, the first set of models was not able to investigate any relationship 
between LS outcomes and NRTI. However, because not all subjects were on the same specific 
NRTI drugs, the second set of models was able to establish a significant relationship between 
stavudine and specific body fat alteration outcomes (Table 8-3). The final set of models 
provided further practical results given that cART is the recommended method of treatment: 
these models were intuitively adjusted so that each body fat alteration model was comparable, 
and each metabolic abnormality model was comparable. The first two sets of models were not 
established by stepwise covariate selection to reduce the number of assumptions made. 
Moreover, since comparatively few previous studies had been conducted in children, such 
assumptions will have been made based upon literature for adult studies that may not 
necessarily have be applicable to paediatric studies.  
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Table 8-3: Summary of multivariable logistic regression models investigating risk factors for body fat alterations at recruitment 
 
  Stepwise variable selection Intutively adjusted  
 
Specific ART drugs  ART categories ART regimen 
Body fat alterations 
Efavirenz: 1.93 (1.03, 3.62) NNRTI: 1.97 (1.11, 3.50)   
Stavudine: 5.40 (2.15, 13.56) 
  
  
Triple class therapy: 5.41 (1.21, 
24.13) 
  
Age: 1.41 (1.06, 1.23) 
White ethnicity 3.32 (1.49, 7.41) White ethnicity: 3.48 (1.59, 7.62) White ethnicity: 3.09 (1.47, 6.48) 
Maximum clinical status C: 2.34 (1.18, 4.65) 
Maximum clinical status B: 2.40 (1.17, 
4.91) 
 
BMI: 1.17 (1.06, 1.28) BMI: 1.17 (1.07, 1.29)   
Lipohypertrophy 
  NNRTI: 1.83 (1.03, 3.26)   
  
Triple class therapy: 4.06 (1.12, 
14.75) 
  
Age: 1.08 (1.00, 1.17) 
 
Female sex: 1.87 (1.08, 3.22) 
 Maximum clinical status B: 2.08 (1.07, 4.05), C: 2.24 (1.07, 
4.69) 
Maximum clinical status C: 2.40 (1.17, 
4.91) 
 
BMI: 1.46 (1.30, 1.63)     
Lipoatrophy 
  NNRTI: 1.85 (1.01, 3.42)   
Stavudine: 2.69 (1.12, 6.47) 
  
  
Triple class therapy: 8.32 (1.73, 
40.07) 
Age: 1.20 (1.09, 1.32) 
 
Age: 1.16 (1.06, 1.27) 
White ethnicity: 4.01 (1.55, 10.38) White ethnicity: 5.08 (1.95, 13.27) White ethnicity: 4.80 (1.84, 12.54) 
Nadir immune status 0.42 (0.21, 0.83) 
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  Stepwise variable selection Intutively adjusted  
 
Specific ART drugs  ART categories ART regimen 
 
Lipohypertrophy and lipohypertrophy occurring 
together 
  NNRTI: 7.82 (1.97, 31.04)   
 
PI: 5.81 (1.46, 23.20) 
 
  
Triple class therapy: 6.30 (1.36, 
29.11) 
Zidovudine: 0.33 (0.12, 0.91) 
  
Lamivudine: 0.46 (0.21, 0.99) 
  
  
Age: 1.16 (1.03, 1.30) 
Maximum duration of ART: 1.20 (1.06, 1.36) 
  
 
White ethnicity: 4.28 (1.09, 16.79) 
 
BMI: 1.20 (1.06, 1.36)     
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Table 8-4: Summary of multivariable models investigating risk factors for metabolic abnormality at recruitment 
  Stepwise variable selection Intutively adjusted  
  Specific ART drugs  ART categories ART regimen 
Any metabolic abnormality 
Ritonavir booster: 2.79 (1.56, 4.99) PI: 2.26 (1.25, 4.06)   
  
NNRTI-based HAART (compared to PI-HAART): 0.50 
(0.28, 0.92) 
  
NRTI monotherapy (compared to PI-HAART): 0.23 
(0.06, 0.83) 
Age (per year): 0.87 (0.81, 0.94) Age (per year): 0.87 (0.80, 0.94) Age (per year): 0.89 (0.82, 0.95) 
Fasting hypertriglyceridemia 
Ritonavir booster: 3.35 (1.60, 7.04) PI: 2.57 (1.22, 5.49) 
 
  
NNRTI-based HAART (compared to PI-HAART): 0.37
(0.17, 0.80) 
  
NRTI-monotherapy: 0.21 (0.05, 0.99) 
Age (per year): 0.88 (0.80, 0.96) Age (per year): 0.87 (0.80, 0.95) Age (per year): 0.89 (0.82, 0.97) 
Hypercholesterolemia 
Ritonavir booster: 2.82 (1.36, 5.83) PI: 2.21 (1.07, 4.56) 
 
Age (per year): 0.82 (0.75, 0.90) Age (per year): 0.82 (0.75, 090) Age (per years): 0.81 (0.74, 0.89) 
Detectable viral load: 0.39 (0.17, 0.86) Detectable viral load: 0.40 (0.18, 0.89)   
Both hypercholesterolmeia and fasting 
hypertriglyceridemia 
Ritonavir booster: 7.46 (1.66, 33.57) PI: 6.18 (1.37, 37.85) 
 
  
NNRTI-based HAART (compared to PI-HAART): 0.20
(0.04, 0.93) 
Maximum duration of ART (per year): 1.22
(1.01, 1.48) 
Maximum duration of ART (per year): 1.22
(1.01, 1.47) 
Maximum duration of ART (per year): 1.22 (1.01, 
1.48) 
Age (per year): 0.71 (0.59, 0.85) Age (per year): 0.70 (0.59, 0.84) Age (per year): 0.70 (0.59, 0.84) 
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Table 8-5: Summary of multivariable models investigating risk factors for lipodystrophy 
syndrome at recruitment 
  Stepwise variable selection Intuitively adjusted  
  Specific ART drugs  ART categories ART regimen 
Lipodystrophy 
syndrome 
  PI: 2.56 (1.20, 5.45)   
Efavirenz: 1.93 (1.03, 3.62) 
NNRTI: 2.78 (1.26, 
6.11) 
Stavudine: 5.40 (2.15, 
13.56) 
White ethnicity: 3.32 (1.49, 
7.41) 
White ethnicity: 3.65 
(2.06, 4.46) 
White ethnicity: 3.03 (1.69, 
5.45) 
BMI: 1.17 (1.06, 1.28) 
BMI: 1.09 (1.00, 
1.19) 
Maximum clinical status C: 
2.34 (1.18, 4.65)   
Maximum clinical status B: 
1.86 (1.06, 3.28) 
 
Although a statistical significant association between explanatory variables and outcomes were 
found, it is possible that models may have been under-powered to show such an association, 
i.e. the role of chance cannot be discounted. Although no ART covariate was significant in 
multivariable Cox models for incident body fat alterations, several ART covariates were 
statistically significant in cross-sectional logistic regression analyses at recruitment. However, 
the Cox models may have been underpowered to detect a statistically significant effect size. It is 
possible that the significant results seen in the metabolic abnormality models may be examples 
of type I errors i.e. falsely statistically significant. However, the observed results from the Cox 
multivariable are consistent with results seen in other studies, thus diminishing (but not 
excluding) this possibility. 
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8.4 Summary and clinical implications 
This thesis has provided a body of evidence encompassing an assessment of the phenotype, 
identification of associated risk factors and description of management strategies related to LS 
in HIV-infected children and adolescents. Analyses were conducted on a large prospective 
cohort which allowed for appropriate measures to be taken to address bias and confounding. 
Moreover, the multi-centre structure of the cohort, with a diverse ethnic and age make-up 
means that the applicability of results is wider than previous paediatric studies. . A temporal 
relationship has been shown between postulated risk factors and LS.  Results were consistent 
with previous research. Furthermore, novel research was conducted: this is the first paediatric 
study to estimate incidence of several LS outcomes, to investigate the association between 
body fat alterations and metabolic abnormality in LS, and to model the longitudinal effects of LS 
on specific cholesterols. However, the clinical implications must be interpreted with 
consideration of the underlying study population. Indeed, participants have accumulated a 
specific ART history which will be different to subsequent cohorts of HIV infected children. As 
new therapy guidelines develop, and new drugs emerge, findings may not be as applicable to 
subsequent cohorts of children and adolescents. Although the multi-centre design of the nature 
has increased power of analyses and applicability of findings, patients had distinct backgrounds, 
for example all Poland-residents were of White ethnicity, and >20% of subjects in Italy and 
Belgium were of Black ethnicity. The unique nature of this cohort must be considered when 
considering the applicability of the results to other populations. 
This research has demonstrated that the prevalence of body fat alterations in HIV-infected 
children may be greater than previously thought, with 61% of subjects exhibiting LS symptoms 
at the end of follow-up. The most common presentation of body fat alterations occurred as 
lipohypertrophy in the abdomen and lipoatrophy in the limbs. In this cohort of predominantly 
vertically-infected children, with a wide experience of ART regimens, the incidence of body fat 
alterations was estimated as 8.01 per 100 person years. This is similar to estimates from adult 
populations. This investigation has used clinical assessments of adiposity which are practical 
and which not only can be used in further research, but also may be useful in detecting body fat 
alterations in clinical practice.  
Subjects with concurrent lipoatrophy and lipohypertrophy had a metabolic profile which showed 
aspects of characteristic of insulin resistance. All HIV-infected children treated with ART should 
be routinely and regularly monitored for LS: results from this thesis suggest that children with 
this concurrent lipoatrophy and lipohypertrophy should be subject to increased surveillance for 
adverse metabolic profile and be considered for immediate management for LS symptoms in 
order to either prevent the occurrence of a clinically poor metabolic status, or reduce the 
severity of symptoms when they do occur. Furthermore, this thesis has provided evidence that 
suggests that metabolic abnormality precedes body fat alterations: the period between 
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development of metabolic changes and before the emergence of body fat alterations may 
provide a therapeutic window during which LS management strategies can be applied to 
prevent lipoatrophy and/or lipohypertrophy Further studies are required to explore the temporal 
relationship between the two aspects of LS, and whether any such lag period represents an 
opportunity for management of symptoms.  
Estimates of the prevalence of hypercholesterolemia and fasting hypertriglyceridemia are 
similar to those reported in previous paediatric studies. Incidence of both hypercholesterolemia 
(4.6 cases per 100 person-years) and fasting hypertriglyceridemia (1.9 cases per 100 person 
years) during follow-up of children and adolescents in this study was higher than reported in 
previous adult investigations, which may be reflective of the larger proportion of subjects who 
were of Black ethnicity, (Black ethnicity having been shown to have higher lipid levels in healthy 
populations).  
This study has shown that risk factors for LS in children and adolescents are similar to 
previously established risk factors in adults. As in adults, PI use, NNRTI use, stavudine use, 
history of HIV-associated clinical disease, and White ethnicity (compared to Black ethnicity) 
were independent and significant risk factors for body fat alterations. A novel finding was that 
NNRTI use was associated with increased risk of concurrent lipoatrophy and lipohypertrophy: 
previous studies have not investigated risk factors for this particular presentation of LS.  
As with previous adult studies, PI use was a significant and independent risk factor for 
metabolic abnormality. Furthermore, PIs were associated with significant increases in total 
cholesterol, LDL-cholesterol and fasting triglycerides, in multilevel multivariable models: long 
term consequence of use may be a pro-atherosclerotic metabolic profile. NNRTI were 
associated with an independent and significant increase in HDL-cholesterol in multi-level 
models, indicating that a healthy metabolic profile, not conducive to atherosclerosis may be 
associated with use of these drugs. All children in this study who were on NNRTI-based therapy 
were on either efavirenz or nevirapine with a greater proportion on the former (70% vs. 30% 
respectively) These results suggest that switching children from PI-based HAART to NNRTI 
based HAART may limit the development of metabolic abnormality, while maintaining viral 
control (although other clinical considerations would be important in deciding on switching 
therapy in an individual patient). The most common PIs used in this cohort at the time of 
recruitment were ritonavir booster and nelfinavir. It is possible that future paediatric studies 
where participants have been exposed to newer PIs may have a better metabolic profile 
negating the need for switching. Indeed, given NNRTI was also associated with increased body 
fat alterations, the decision to switch is less clear. At the very least, these results underscore the 
importance of regular surveillance of body fat alterations and metabolic abnormality in tandem 
as different ART regimens can have opposing effects on both these aspects of LS.  
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Incidence of body fat alterations in this cohort was similar to that seen in previous adult studies, 
while the incidence of metabolic abnormality here was slightly higher: there is a need this to be 
validated in further paediatric studies. However, these results are reassuring in that they 
suggest that children and adolescents may not be at increased risk of developing LS compared 
to adults. However, the vast majority of children here have been vertically infected, and 
accumulated long durations of ART use. Adults in the previous studies will have accumulated 
durations of ART since, or at some point after, infection. Thus it is difficult to make a definitive 
conclusion about the emergence of LS in children and adolescents compared to adults. 
However, prospective analyses in this investigation have shown that ART is a risk factor for LS, 
and, crucially, is associated with increases in lipid levels in models containing LS as a covariate. 
Duration of follow-up was 4 years, but these results still add to the evidence of long-term toxicity 
of ART. Moreover, as treatment in life-long in HIV-infected children, this thesis reinforces the 
need to develop new therapies which address toxicities which develop over time. Moreover, 
studies with longer follow-up are required to address whether switching of ART (occurring as a 
result of treatment failure, short or long term toxicities, adherence problems, etc.) may itself 
have an effect on long-term toxicity.    
History of CDC clinical stage B disease was significantly associated with increases in total 
cholesterol, LDL-cholesterol, and fasting triglyceride. Furthermore, previous serious clinical 
condition was also, in common with previous paediatric and adult studies, a significant and 
independent risk factor for lipohypertrophy.  It is possible that symptomatic HIV disease history 
may also act as a proxy measure for complex ART history as its occurrence may have resulted 
in changes in ART regimen. It is therefore feasible that previous HIV-related clinical symptoms 
may either directly (through pathogenic processes related to HIV disease) or indirectly (through 
ART) lead to LS.  This further underscores the need for prospective studies to investigate the 
association between switching therapies and long-term toxicities in children and adolescents.  
Female sex was significantly associated with increased HDL-cholesterol level in multivariable 
multilevel models, whilst White ethnicity was associated with an independent and significant 
decrease in HDL-cholesterol levels, and increase in fasting triglyceride. Thus White male 
children may be a group at increased risk of developing LS, and perhaps be identified as a 
group which warrants increased surveillance when treated with ART. 
The dynamic nature of LS was demonstrated by the observation that all subjects with the 
syndrome at recruitment experienced progression and/or regression of symptoms over follow-
up.  However, investigation of change in severity of symptoms highlighted the difficulties in 
assessing changes in degree of fat alterations during adolescence. While CT and DEXA 
scanning may provide more accurate determination of changes in body fat alterations, such 
approaches are expensive and unfeasible for assessment in routine hospital appointments. 
Discussion  Chapter 8
   
328 
 
At the end of follow-up, over 40% of subjects with LS (and where LS-management data was 
available) had received an intervention to treat their symptoms Dietary and physical activity 
lifestyle modification was the most common strategy used for management of LS-related 
symptoms during follow-up of the cohort. However, information on the specific approaches of 
implementation was not collected. Several studies have demonstrated benefits in reducing 
cholesterol associated with changes in diet in non-HIV infected adults and children, and thus 
dietary modification may be a suitable approach in the management of LS-related 
hypercholesterolemia. Although several physical activity interventions have resulted in weight 
loss in obese and overweight children and adults, it is unknown whether such approaches are 
applicable to HIV-infected children with LS, given that body fat alterations are likely to have a 
unique pathogenesis.  
Numbers of subjects who were recommended a supplement or pharmaceutical intervention in 
the study were very small. This may be because of a lack of guidelines outlining (i) recognition 
of symptoms of LS, (ii) recommendations on when to commence treatment, and (iii) options for 
treatment.  It was likely (without specific indicators for treatment data) that statins were most 
commonly used to manage cholesterol levels within this study population. However, statin use 
for the management of cholesterol in HIV-infected children must be considered carefully 
because of the possible adverse effects seen with PIs.  
Significant associations of cardiovascular disease with both increased LDL-cholesterol, and 
decreased HDL-cholesterol are well established in the general population570, with clear 
pathways of cholesterol metabolism to atherosclerotic plaque formation proposed571. The direct 
or indirect effect of triglycerides in the pathogenesis of heart disease is a matter of debate572,573. 
Both having HIV and having elevated triglycerides have been shown to be significantly 
associated with increased carotid intima media thickness in adolescents574, with an association 
between elevated triglycerides and myocardial infarction (following adjustment for total and 
HDL-cholesterol) being shown in adult studies 575l576. Hypertriglyceridemia has been associated 
with an independent and significant increased risk of HIV sensory neuropathy in adults577. Thus 
the clinical importance of understanding factors affecting cholesterol and triglyceride levels in 
children with HIV remains an important issue. Furthermore, both hypertension578 and 
psychological well-being579 in HIV-infected individuals may be associated with lipoatrophy and 
lipohypertrophy, underscoring the importance of understanding factors associated with body fat 
alterations. Thus LS remains an important issue in public health in relation to HIV, particularly in 
ART-treated children who, as treatment is life-long, accumulate longer durations of exposure to 
multiple drugs as they survive into adolescence, young adulthood and beyond.   
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8.5 Future work 
While this study has provided compelling evidence for risk factors for LS in children, caveats on 
this must be applied since some of the analyses may have been statistically under-powered. 
Continuing prospective surveillance of this cohort will allow future analyses to confirm findings in 
this thesis with added statistical power. Continued follow-up of this cohort would also allow any 
association between newer ART drugs and LS to be investigated. Furthermore, the results of 
this investigation should be replicated in other studies: given the increasing availability of ART 
to populations outside Europe, there is a need to conduct this kind of investigation in African 
and Asian populations. 
Changes in lipid levels over time were modelled in this study, but further analyses on the effect 
of body fat alterations on anthropometric measures were beyond the scope of this thesis. Future 
analyses should encompass modelling anthropometric measures, such as BMI and waist/hip 
ratio, by LS status: this may help to establish an additional framework for recognising LS in the 
context of routine measures. In a prospective 48 week observational study of 97 pre-pubertal 
(aged between 1 month and 13 years) HIV-infected children, both anthropometric and skinfold 
thickness measures were collected, with mid-arm and thigh muscle circumferences used to 
calculate lean body mass, and several of these measures used to calculate free fat mass using 
standard equations. Commencing or switching ART was associated with improved growth and 
lean body mass, and with levels of immunosuppression over time, and furthermore central 
adiposity was associated with detectable viral load but not ART510. In a more recent cross-
sectional study of 369 children, DEXA scans were used to compare percentage body fat 
between HIV-infected children and HIV-exposed but uninfected children: specific ART and 
stunting was associated with specific body fat alterations580. Future studies may use similar 
assessments of lipoatrophy and lipohypertrophy to routinely identify body fat alterations, but 
these assessments can be validated by using DEXA scans on a sub-population of the study 
(thus reducing the complexity and expense of using these methods on the whole study 
population). Furthermore, the association between postulated risk factor and specific body fat 
alterations can be investigated: such studies would be important in deciphering the 
pathogenesis of LS if concurrent metabolic measures are taken.   
As the cohort ages, new opportunities will arise to investigate social risk factors for CVD (e.g. 
smoking status, alcohol intake, etc.) and their role in metabolic and body fat changes. 
Furthermore, as participants progress through adolescence and enter adulthood, the 
relationship between LS-status in childhood and LS-status in adulthood can be investigated. 
Moreover, as all subjects reach adulthood, a complete record of anthropometric and metabolic 
trajectories before, during, and following puberty will be available for a substantial proportion of 
this cohort: a thorough investigation of LS during puberty can then be conducted.  
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A.2 Abstracts arising from this thesis accepted to conferences 
A.2.1 18th International AIDS Conference 2010 
 
Risk factors for metabolic abnormality in a European cohort of HIV-
infected children and adolescents 
NM Alam1, M Cortina-Borja1, T Goetghebuer2, A Vigano3, M Marczynska4 and C. Thorne1 
for the European Paediatric HIV and Lipodystrophy Study 
1UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK 
2Hospital St. Pierre, Brussels, Belgium 
3Hospital L’Sacco, University of Milan, Italy 
4 Medical University Warsaw, Poland 
 
Background 
Antiretroviral therapy (ART) in HIV-infected children is associated with metabolic complications 
including dyslipidemia and disturbed glucose homeostasis.  
 
Methods 
HIV-infected children and adolescents were recruited to an active surveillance cohort from 14 
sites in Italy, Belgium and Poland. We present baseline data on prevalence of and risk factors 
for metabolic abnormality (MA), defined as ≥1 of: hypercholesterolemia (HC), 
hypertriglyceridemia (HT), both identified according to gender/age-determined thresholds, and 
impaired glucose tolerance.  
 
Results 
Among 468 participants (51% female), median age was 13.5 years (IQR 9.9-17.0) with 129 
(28%) at Tanner puberty stage (TAN) I and 160 (34%) at stage V. Most subjects (320, 68%) 
were white and 104 (22%) were of black African origin. Most (445, 95%) had ART for a median 
8.8 years, with 259 (57%) currently taking protease inhibitors (PI). Fat redistribution was present 
in 201 children (43%).  MA was present in 129 (28%) subjects: 21 (5%) had HC-only, 75 (16%) 
had HT-only, 4 had glucose intolerance (GI) only, 28 (6%) had both HC and HT, and one had 
combined GI, HC and HT. In unadjusted analyses, the following factors were associated with 
these outcomes: current PI use (MA, HC, HT), white ethnicity (MA, HT), advanced CDC clinical 
stage (MA), current NNRTI use (MA), past severe immunosuppression (HC), current 
undetectable viral load (<200 copies/ml) (HC), female gender (HT), TAN (HT) and country of 
residence (MA, HT, HC). In adjusted analyses, current PI use was significantly associated with 
MA, HC and HT (respective AORs [95% confidence intervals], 4.41 [2.55-7.63], 2.17 [1.03-
4.59], 5.71 [3.16-10.03]); detectable VL (AOR=0.16) remained associated with reduced 
likelihood of HC (p<0.05)  
 
Discussion 
Over one quarter of subjects had MA, with HT the most common manifestation. Current PI use 
was consistently associated with increased risk of MA. The reduced risk of HC associated with 
detectable VL probably reflects poorer adherence to ART.   
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A.2.2 54th Society of Social Medicine Scientific Conference 2010 
 
PATTERNS OF ANTIRETROVIRAL THERAPY IN A EUROPEAN STUDY OF 
HIV-INFECTED CHILDREN AND ADOLESCENTS  
 
Background 
Antiretroviral therapy (ART) has resulted in increasing median survival times in HIV-infected 
individuals by sustaining viral load suppression. Since children and adolescents are likely to 
have long-term exposure to ART, it is important to understand patterns of drug use to 
investigate the emergence of unintended sequelae.   
 
Aim 
To investigate patterns of ART in children and adolescents 
 
Study design 
Cross sectional analysis of HIV-infected subjects aged 2-22 years across 15 clinical sites in 
Belgium, Italy and Poland. 
 
Method 
Prevalence of both “ever-use” and “current-use” (at recruitment) of ART drug classes: 
Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs); Non-Nucleoside Analogue 
Reverse Transcriptase Inhibitors (NNRTIs) and; Protease Inhibitors (PIs), and individual drugs 
were investigated.  
 
Results 
Among 468 participants (51% female) the median age was 13.5 years (IQR 9.9-17.0) with 
320(68%) of white ethnicity and 104(22%) Black African.  Overall, 291(62%) were virologically 
suppressed (HIV-RNA ≤50copies/ml) at enrolment and 35(7%) had severe immuno-suppression 
(age-stratified CD4%). 
 
Only 25(5%) subjects were ART-naïve (median age=10.0 years, IQR; 3.6-11.0); 16 had 
experienced severe immuno-suppression or severe HIV-disease, with all having detectable viral 
load at recruitment.  
 
Of the ever-treated subjects, >98% (n=436) had received zidovudine and lamivudine in the past 
and 74%(n=350) currently; 82%(n=368) and 72%(n=323) had been ever-exposed to PIs and 
NNRTIs respectively. Median and modal lifetime number of drugs was 6. Over their lifetime, 128 
(27%) subjects had been exposed to ≥8 drugs (median age= 5.7 years, IQR; 12.3-18.0). Age 
was associated with duration of total drug use (p<0.001), with median age of ART initiation of 
3.6 years (IQR: 1.0-7.3) Median total duration of drug use was 8.7 years (IQR= 5.7-11 years) 
 
Nine percent of currently-treated subjects (n=38) had suboptimal management, defined as 
NRTIs-only (24 showing evidence of incomplete viral suppression), and 89% (n=379) had 
treatment with combination ART (cART).The most common PI in current-use was kaletra 
(n=170, 40%), possibly reflecting its availability as the only combination PI accessible in 
tablet/liquid form 
 
Current-use of PIs was associated (p<0.001) with hypercholesterolemia in adjusted analyses 
indicating a long-term consequence of specific ART   
 
Conclusions 
The majority of subjects had been managed with ART, with first exposure occurring at an early 
age. At least a quarter of participants had been treated with multiple individual drugs suggesting 
cumulative exposure and switching between regimens. The most prevalent treatment approach 
at recruitment was cART. However, there is evidence of continued use of suboptimal 
management strategies, and hypercholesterolemia being associated with PI use.   
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A.2.3 11th Annual Workshop on Adverse Drug Reactions & Co-morbidities 
 
Risk factors for body fat redistribution in a European cohort of HIV-
infected children and adolescents 
NM Alam,   M Cortina-Borja, T Goetghebuer, A Vigano and C. Thorne for the European 
Paediatric HIV and Lipodystrophy Study 
 
Objective 
Lipodystrophy is still poorly understood in HIV-infected children and adolescents. In order to 
characterize lipodystrophy in this population, we established an active surveillance cohort in 
three European countries (Belgium, Poland and Italy).  
 
Methods 
Participants (minimum age three years) were recruited over a three month period across 14 
paediatric sites by their clinicians who completed a screening questionnaire. Data collected 
included socio-demographic characteristics, clinical status, blood chemistry, anthropometric 
measures, treatment and family history. Standardized assessments were performed to assess 
fat redistribution in specific body areas (face, limbs, buttocks, breasts, neck and trunk). First 
round surveillance results are presented here. Logistic regression models were fitted to test 
associations between variables and different fat redistribution outcomes. 
 
Results 
Among 473 participants enrolled, 425 (89.9%) were vertically infected, and 240 (50.7%) were 
female. Median age was 13.5 years (IQR 9.9-17.0) with 131 (27.7%) at Tanner puberty (TAN) 
stage I and 161 (34.0%) at stage V. Most subjects (322, 68.1%) were white and 106 (22.4) were 
of black African origin. Most (419, 88.6%) had received antiretroviral therapy (ART) with a 
median duration of 8.8 years. Median CD4% was 31.4% (IQR 24-38.2) and 303 (64.1%) were 
currently asymptomatic. 
 
At least one clinically determined sign of fat redistribution was present in 200 children (43.2%, 
95%CI; 38.7-47.7): 64 (13.5%) had lipohypertrophy alone, 70 (15%) lipoatrophy alone and 66 
(14%) the combined sub-type. Lipohypertrophy occurred most frequently in the trunk, with 14 
cases classed as severe. Severe lipoatrophy was more frequently reported in the face. Eleven 
cases had both severe lipoatrophy with severe lipohypertrophy.  
 
In univariate analyses, factors significantly associated with increased risk of any fat 
redistribution included white ethnicity (OR=3.31), severe HIV disease (ever) (OR 4.46 vs. never 
symptomatic), TAN stage V (OR 3.10 vs. TAN stage 1), maternal lipodystrophy (OR=3.15) and 
any exposure to “D” drugs (OR 3.73), to indinavir (OR=3.50) or to efavirenz (OR=2.62). These 
factors were additionally significantly associated with lipoatrophy, lipohypertrophy, lipoatrophy-
without-lipohypertrophy and lipoatrophy-with-lipohypertrophy individually. Female gender was 
the only factor significantly associated with lipohypertrophy-without-lipoatrophy (OR=2.12).  
 
After controlling for total duration of ART, ethnicity, stavudine, efavirenz, indinavir and the “D” 
drugs remained significantly associated with increased risk of all the outcomes listed above.  
Furthermore, white ethnicity (AOR=3.11) and use of stavudine (AOR=4.37), efavirenz 
(AOR=2.80), indinavir (AOR=3.23) and the “D” drugs (AOR=3.47) remained significantly 
associated with increased risk of the combined sub-type after adjusting for treatment duration.  
 
Conclusion 
Body fat changes were prevalent in almost 50% of this cohort, which had accumulated relatively 
long durations of treatment. Increased risk of fat redistribution was associated with specific 
drugs as well as clinical and other variables. On-going follow-up will allow further description of 
the lipodystrophy phenotype and investigation of its emergence, progression and management.  
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A.2.4 16th Conference on Retroviruses and Opportunistic Infections 
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Appendix B Appendix to Chapter 2 
B.1 Centres for Disease Control (CDC) clinical categories for children with 
human immunodeficiency virus (HIV) infection (reproduced from581,582) 
 
Category N: Not symptomatic 
No signs or symptoms considered to the result of HIV infection or not to have any of the 
conditions listed in category A.  
 
Category A: Mildly symptomatic 
Two or more of the following conditions, but none of the conditions listed in categories B and C. 
• Lymphadenopathy (≥0.5 cm at more than two sites; bilateral = one site) 
• Hepatomegaly  
• Splenomegaly 
• Dermatitis 
• Parotitis 
• Recurrent or persistent upper respiratory infection, sinusitis, or otitis media 
 
Category B: moderately symptomatic 
Symptomatic conditions other than those listed for categories A or C that are attributable to HIV 
infection, e.g: 
• Anaemia (<8 mg/dL), neutropenia (< 1000mm3), or thrombocytopenia (<100000mm3) 
persisting ≥30 days 
• Bacterial meningitis, pneumonia, or sepsis (single episode) 
• Candidiasis, oropharyngeal (thrush), persisting (>2 months) in children >6 months of 
age 
• Cardiomyopathy 
• Cytomegalovirus infection, with onset before 1 month of age 
• Diarrheal, recurrent or chronic 
• Hepatitis 
• Herpes simplex virus (HSV) stomatitis, recurrent (more than two episodes within 1 year) 
• HSV bronchitis, pneumonitis, or esophagitis with onset before 1 month of age 
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• Herpes zoster (shingles) involving at least two distinct episodes or more than one 
dermatome 
• Leiomyosarcoma 
• Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia complex 
• Nephropathy 
• Norcardiosis 
• Persistent fever (lasting >1 month) 
• Toxoplasmosis, onset before 1 month of age 
• Varicella, disseminated (complicated chickenpox) 
 
Category C: severely symptomatic 
Any of the following: 
• Serious bacterial infections, multiple or recurrent (i.e., any combination of at least 
two culture-confirmed infections within a 2-year period), of the following types: 
septicaemia, pneumonia, meningitis, bone or joint infection, or abscess of an 
internal organ or body cavity (excluding otitis media, superficial skin or mucosal 
abscesses, and indwelling catheter-related infections) 
• Candidiasis, oesophageal or pulmonary (bronchi, trachea, lungs) 
• Coccidiodomycosis, disseminated (at site other than or in addition to lungs or 
cervical or hilar lymph nodes) 
• Cryptoococcosis, extrapulmonary 
• Cryptosporidiosis or isosporiasis with diarrhoea persisting >1 month 
• Cytomegalovirus disease with onset of the symptoms at age >1 month (at a site 
other than liver, spleen, or lymph nodes) 
• Encephalopathy (at least one of the following progressive findings present for at 
least 2 months in the absence of a concurrent illness other than HIV infection that 
could explain the findings): (a) failure to attain or loss of developmental milestones 
or loss of intellectual ability, verified by standard developmental scale or 
neuropsychological tests; (b) impaired brain growth or acquired microcephaly 
demonstrated by head circumference measurements or brain atrophy demonstrated 
by computerized tomography or magnetic resonance imaging (serial imaging is 
required for children <2 years of age; (c) acquired symmetric motor deficit 
manifested by two or more of the following: paresis, pathologic reflexes, ataxia, or 
gait disturbance 
  Appendix B 
377 
 
• Herpes simplex virus infection causing a mucocutaneous ulcer that persists for >1 
month: or bronchitis, pneumonitis, or esophagitis for any duration affecting a child 
>1 month of age 
• Histoplasmosis, disseminated (at a site other than or in addition to lungs or cervical 
or hilar lymph nodes) 
• Kaposi’s sarcoma 
• Lymphoma, primary, in brain 
• Lymphoma, small, non-cleaved cell (Burkett’s), or immunoblastic or large cell 
lymphoma of a B-cell or unknown immunologic phenotype 
• Mycobacterium tuberculosis, disseminated or extra pulmonary 
• Mycobacterium, other species or unidentified species, disseminated (at a site other 
than or in addition to lungs, skin or cervical or hilar lymph nodes) 
• Pneumocystis carinii pneumonia 
• Progressive multifocal leukoencephalopathy 
• Salmonella (no typhoid) septicaemia, recurrent 
• Toxoplasmosis of the brain with onset at >1 month of age 
• Wasting syndrome in the absence of a concurrent illness other than HIV infection 
that could explain the following findings: (a) persistent weight loss >10% of baseline 
OR (b) downward crossing of at least two of the following percentile lines on the 
weight-for-age chart (e.g., 95th, 7th, 50th, 25th, 5th) in a child ≥1 year of age OR (c) 
<5th percentile on weight-for-height chart on two consecutive measurements, ≥30 
days apart PLUS (a) chronic diarrhoea (i.e., at least two loose stools per day for 
≥30 days) OR (b) documented fever (for >30 days intermittent or constant).  
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B.2 Thresholds for hypercholesterolemia and fasting hypertriglyceridemia 
 
Table B-1: Age and gender defined thresholds for hypercholesterolemia 
Age 
(years) 
Male 
(mg/dL) 
Female 
(mg/dL) 
Any Moderate/ 
Severe 
Any Moderate/ 
Severe 
2-11 ≥200 ≥240 ≥200 ≥240 
12 ≥233 ≥280 ≥212 ≥254 
13 ≥225 ≥270 ≥209 ≥251 
14 ≥220 ≥264 ≥208 ≥250 
15 ≥220 ≥264 ≥211 ≥253 
16 ≥223 ≥268 ≥217 ≥260 
17 ≥227 ≥272 ≥225 ≥270 
18 ≥233 ≥280 ≥233 ≥280 
19 ≥238 ≥286 ≥239 ≥287 
20 ≥240 ≥288 ≥240 ≥288 
 
 
Table B-2: Age and gender defined thresholds for fasting hypertriglyceridemia 
Age  
(years) 
Male 
(mg/dL) 
Female 
(mg/dL) 
Any Moderate/ 
Severe 
Any Moderate/ 
Severe 
2-9 ≥100 ≥120 ≥100 ≥120 
10-11 ≥130 ≥156 ≥130 ≥156 
12 ≥163 ≥196 ≥180 ≥216 
13 ≥171 ≥205 ≥171 ≥205 
14 ≥179 ≥215 ≥161 ≥193 
15 ≥186 ≥223 ≥158 ≥190 
16 ≥191 ≥229 ≥162 ≥194 
17 ≥195 ≥234 ≥172 ≥206 
18 ≥198 ≥238 ≥185 ≥222 
19 ≥200 ≥240 ≥196 ≥235 
20 ≥200 ≥240 ≥200 ≥240 
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B.3 Thresholds for immuno-suppression 
 
Table B-3: Centres for disease control (CDC) defined categories of immunosuppression by age-specific CD4 T-lymphocyte counts and percentage 
of total lymphocytes (reproduced from581,582 ) 
 Age of child 
 <12 months 1-5 years 6-12 years 
 µL % µL % µL % 
No evidence of immuno-suppression ≥1 500 ≥25 ≥1 000 ≥25 ≥500 ≥25 
Moderate immuno-suppression 750 - 1 499 15-24 500 - 999 15-24 200 - 499 15-24 
Severe immuno-suppression <750 <15 <500 <15 <200 <15 
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B.4 Data collection form A 
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B.5 Original data collection form B 
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B.6 Revised data collection form B 
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B.7 Original data collection form C 
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B.8 Revised data collection form C 
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Appendix C Appendix to chapter 3 
 
Note on box plots 
There may not be agreement in the total number of data points when the same data is being displayed in box-plots (for medians) and scatter plots (for locally 
weighted smoothing and fractional polynomial models). This is because STATA automatically excludes “outside values” in box plots, i.e. box the length of the 
whiskers is restricted to 1.5 x the interquartile range.  However, these exclusions only occur in the visual representations: no values are excluded in tests 
investigating statistical differences in medians.  
C.1 Missing data 
Table C-1:  Missing physical and metabolic data by lipodystrophy outcome   
  Total cholesterol LDL cholesterol Non-HDL cholesterol HDL cholesterol Waist/hip ratio 
  % n/N p-
value 
% n/N p- 
value 
% n/N p- 
value 
% n/N p- 
value 
% n/N p-
value 
Ethnicity Black 1.0 1/107 0.624 13.1 14/107  13.1 14/107  13.1 14/107 0.696 18.7 20/107 0.044 
 White 2.1 6/285  19.6 56/285  16.1 46/285  16.1 46/285  29.1 83/285  
 Other 0.0 0/17  11.8 2/17  11.8 2/17  11.8 2/17  11.8 2/17  
Country Belgium 1.2 1/84 0.430 2.4 2/84 <0.001 15.9 44/276 <0.001 15.9 44/276 <0.001 39.1 108/276 <0.001 
 Italy 2.2 6/276  19.2 53/276  3.6 3/84  3.6 3/84  0.0 0/84  
 Poland 0.0 0/66  33.3 22/66  28.8 19/66  28.8 19/66  1.5 1/66  
Hospital Bambin Gesu 2.1 1/47 0.405 2.1 1/47 <0.001 2.1 1/47 <0.001 2.1 1/47 <0.001 97.9 46/47 <0.001 
 Como 0.0 0/3  0.0 0/3  0.0 0/3  0.0 0/3  33.3 1/3  
 Frederico II Napoli 0.0 0/34  11.8 4/34  11.8 4/34  11.8 4/34  5.9 2/34  
 Genova 0.0 0/27  0.0 0/27  0.0 0/27  0.0 0/27  3.7 1/27  
 Meyer 0.0 0/16  18.8 3/16  18.8 3/16  18.8 3/16  0.0 0/16  
 Padova 6.9 2/29  79.3 23/29  75.9 22/29  75.9 22/29  96.6 28/29  
 S. Matteo Pavia 0.0 0/6  8.3 5/6  16.7 1/6  16.7 1/6  0.0 0/6  
 Sacco 5.7 3/53  7.5 4/53  5.7 3/53  5.7 3/53  9.4 5/53  
 Torino 0.0 0/25  12.0 3/25  0.0 0/25  0.0 0/25  0.0 0/25  
 Civili Brescia 0.0 0/25  40.0 10/25  40.0 10/25  40.0 10/25  96.0 24/25  
 S. Paolo 0.0 0/11  0.0 0/11  0.0 0/11  0.0 0/11  9.1 1/11  
 St. Pierre 2.2 1/45  4.4 2/45  4.4 2/45  4.4 2/45  0.0 0/45  
 Liege 0.0 0/25  0.0 0/25  4.0 1/25  4.0 1/25  0.0 0/25  
 St. Luc 0.0 0/14  0.0 0/14  0.0 0/14  0.0 0/14  0.0 0/14  
 Warsaw 0.0 0/66  33.3 22/66  28.8 19/66  28.8 19/66  1.5 1/66  
Associations tested with χ2  test 
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C.2 Birth length and birth weight regression analysis 
 
Table C-2: Regression of birth length on body weight in subjects with birth gestation ≥ 37 
weeks 
 
No body fat alterations Body fat alterations 
 
n = 65 n = 59 
 
Estimate p - value Estimate p - value 
Slope 0.10 <0.001 0.10 <0.001 
Intercept -1.78 0.011 -1.74 0.196 
Mean square of 
residuals 
0.29  0.48  
 
 
C.3 Use of specific antiretroviral drugs at recruitment 
 
Table C-3: Distribution of ever-use and current-use (at recruitment) of specific 
antiretroviral drugs 
ART class Drug Ever use Never use Current use Not current 
use 
NRTI Lamivudine 376 49 247 146 
Zidovudine 308 117 102 291 
Stavudine 218 207 44 349 
Didanosine 197 228 47 346 
Abacavir 176 249 118 275 
Tenofovir 126 299 103 290 
Emtricitabine 48 377 42 351 
Zalcitabine 30 395 0 393 
Kivexa 6 419 5 388 
Trizivir 2 423 1 392 
NNRTI Efavirenz 159 266 94 299 
Nevirapine 105 320 39 354 
PI Ritonavir/kaletra 257 168 197 196 
Nelfinavir 204 221 1 392 
Fosamprenavir 33 393 20 373 
Atazanavir 27 398 17 376 
Indinavir 26 399 1 392 
Saquinavir 19 406 0 393 
Tipranavir 4 421 3 390 
FI Enfuviritide 3 422 1 392 
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C.4 Fractional polynomial models stratified by sex 
Table C-4: Fractional polynomial models fitting anthropometric and metabolic outcomes as a function of age at recruitment stratified by sex 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
Body mass 
index 
Male  =	  +	!" ln(%) +	! &'()  
 
195 α 18.41 (17.91, 18.91) <0.001 
  
 
β1 -7.20 (-15.65, 1.26) 0.095 
  
 
β2 23.63 (5.90, 41.36) 0.009 
 Female  =	  +	!" % +	!*(%) 
 
213 α 19.55 (19.08, 20.01) <0.001 
  
 
β1 0.91 (5.80, 9.98) <0.001 
  
 
β2 19.55 (19.08, 20.02) <0.001 
Wait/hip ratio Male  =		  +	!"% +	!%  
 
146 α 0.95 (0.93, 0.98) <0.001 
  
  
β1 0.09 (-0.14, 0.10) 0.272 
  
  
β2 -0.13 (-0.35, 0.10) 0.272 
 Female  =		  +		!"% +	!%	 
 
164 α 0.90 (0.88, 0.91) <0.001 
  
 
β1 -0.09 (-0.25, 0.07) 0.250 
  
 
β2 0.02 (-0.25, 0.07) 0.609 
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Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
Total 
cholesterol 
Male  =	  +	!" % +	!%

 
 
197 α 167.12 (159.83, 174.41) <0.001 
  
 
β1 4.96 (0.63, 9.30) 0.025 
  
 
β2 -2.67 (-7.20, 1.85) 0.245 
 Female  =	  +	!"% +	!%*	(%) 
 
211 α 170.95 (164.00, 177.91) <0.001 
  
  
β1 26.90 (-43.41, 97.22) 0.284 
  
  
β2 -35.57 (-100.88, 29.74) 0.284 
Low density 
lipoprotein 
(LDL) 
cholesterol 
Male  =	  +	!" % +	!% 
 
158 α 90.23 (84.99, 95.47) <0.001 
 
 
β1 4.79 (0.53, 9.04) 0.851 
  
 
β2 -1.82 (84.99, 95.47) <0.001 
 Female  =	  +	!" % 	+	!% 
 
183 α 95.16 (90.7, 99.66) <0.001 
  
 
β1 -77.29 (-132.70, -21.89) 0.007 
  
 
β2 190.99 (60.83, 321.45) 0.004 
Non-high 
density 
lipoprotein 
(HDL) 
Male  =	  +	+,('() 	+ 	
+)(
'()
(*(%)) 163 α 113.76 (107.87, 119.64) <0.001 
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Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
cholesterol 
  
  
β1 -2.49 (-19.93, 14.69) 0.775 
  
  
β2 -7.18 (-22.93, 8.56) 0.369 
 Female 
=	  +		!"%
+	!*(%)*(%) 
 
 
α 116.04 (109.49, 122.60) <0.001 
  
 
β1 -9.54 (-25.28, 6.20) 0.233 
  
 
β2 -19.08 (-46.06, 7.91) 0.165 
High density 
lipoprotein 
(HDL) 
cholesterol 
Male  =	  +	!" % +	!%
-
 
 
163 α 50.66 (47.82, 53.51) <0.001 
  
 
β1 0.62 (-1.02, 2.25) 0.457 
  
 
β2 -1.96 (-3.72, -0.19) 0.030 
 Female  =	  +	!" % +	!%
-
 
 
188 α 54.42 (51.73, 57.10) <0.001 
  
 
β1 0.45 (-1.09, 1.98) 0.568 
  
 
β2 -0.62 (-2.22, 0.97) 0.440 
Fasting 
triglyceride 
Male   =	  +	!" % +	!% 
139 α 114.5 (98.60, 130.3) <0.001 
  
 β1 15.03 (1.01, 29.0) 0.036 
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Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
  
  β2 93.3 (33.3, 153.3) 0.003 
 Female  =	  +	!"% +	!%- 
 
166 α 104.03 (90.30, 117.8) <0.001 
  
 β1 94.17 (16.39, 171.94) 0.018 
  
 β2 -49.70 (-91.05, -8.34) 0.019 
Fasting insulin Male 
=	  +	!"% +	!%(*(%)) 
 
93 α 9.77 (7.57, 11.97) <0.001 
  
 β1 8.60 (2.97, 14.23) 0.003 
  
 β2 10.49 (-0.32, 21.29) 0.057 
 Female 
=	  +	!" %
+	!(ln(%)) %  
 
103 α 12.29 (10.95, 13.63) <0.001 
  
 β1 -12.23 (-16.75, -5.87) <0.001 
  
 β2 -11.31 (-16.75, -5.87) <0.001 
Fasting glucose Male 
=	  +	!"% +	!%(ln(%)) 
 
139 α 84.28 (82.09, 86.47) <0.001 
  
 β1 13.55 (5.06, 22.04) 0.002 
  
 β2 -18.70 (-30.80, -6.59) 0.003 
Fasting glucose Females  =	  +	!"% +	!% 160 α 82.14 (80.44, 83.84) <0.001 
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Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
  
  β1 26.73 (9.12, 44.34) 0.003 
  
 β2 -11.20 (-18.97, -3.44) <0.001 
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C.5 Body mass index analysis 
Figure C-1: Modelling body mass index as a function of age at recruitment in: males estimated by (a) locally weighted smoothing (b) fractional polynomial model: and, in females 
estimated by (c) locally weighted smoothing, and (d) fractional polynomial model 
 
 
Both fractional polynomial models are of 2 orders, estimated over 44 models. Fractional polynomial model for males: =	. +	/ 01(2) +	 &2 :	 (n = 195). Fractional polynomial model for females:  =	. +	
/ 2 +	45(2) :  (n  = 213). 
Shaded area in (b) and (d) denote 95% confidence interval.  
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Table C-5: Fractional polynomial models fitting body mass index as a function of age at recruitment, stratified by sex and lipodystrophy syndrome 
status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
Male  =	  +	!"&%" +	!%- 86 α 18.35 17.65, 19.05 <0.001 
  
 
β1 3.16 -0.23, 12.34 0.051 
  
 
β2 0.35 -0.42, 1.12 0.368 
 Female  =	  +	!" % +	!ln	(%) 
89 α 18.86 18.25, 19.46 <0.001 
  
 
β1 1.09 0.59, 1.59 <0.001 
  
 
β2 8.10 5.65, 10.56) <0.001 
Lipodystrophy Male  
=	  +	!"%- +	!%-(*(%)) 
106 α 18.47 17.56, 19.39 <0.001 
  
 
β1 2.21 0.40, 4.02 0.017 
  
 
β2 -2.01 -4.99, 0.97 0.184 
 Female 
=	  +	!"%- +	!%-(*(%)) 
119 α 19.92 19.03, 20.78 <0.001 
  
 
β1 3.52 1.55, 5.48 0.001 
  
 
β2 -3.91 -7.14, -0.67 0.018 
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Figure C-2: Relationship between age and body mass index (m/kg2) in: (a) males without lipodystrophy (n = 86), (b) males with lipodystrophy (n = 
106), (c) females without lipodystrophy (n =89), and (d) female with lipodystrophy (n =119) 
 
 
Equations: (a)  =	  +	!"√%" +	!%- (b)  =	  +	!"%- +	!%-(*(%)) (c)  =	  +	!" % +	! ln(%)nd (d) =	  +	!"%
- +	!%-7*(%)8 Fractional 
polynomial models were of 2 orders, estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C5 for details of models. 
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Figure C-3: Modelling body mass index (m/kg2) as a function of age at recruitment in: (a) males without body fat disorder (n = 120), (b) males with 
body fat disorder (n = 75), (c) females without body fat disorder (n = 119), and (d) female with body fat disorder (n = 92) 
 
 
Equations: (a) " =	  +	!"(*(%) +	!%   (b)	 =	 +		!1 %2 +	
!2(*(%)) %2  (c)	 =	 +	
!1 % +	!2(*(%)) and (d)   =	  +		
!" % =	
!(*(%)) %  
Fractional polynomial models are of 2 orders, estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C-6 for details of model. 
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Table C-6: Fractional polynomial models fitting body mass index as a function of age at recruitment, stratified by sex and body fat disorder status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No fat disorder Male " =	  +	!"(*(%) +	!% 120 α 17.93 17.38, 18.48 <0.001 
  
 
β1 -2.22 -6.45, 2.00 0.300 
  
 
β2 6.88 2.21, 11.56 0.004 
 Female  =	  +	!" %; +	!(*(%)) 119 α 18.45 17.94, 18.97 <0.001 
  
 
β1 1.02 0.59, 1.45 <0.001 
  
 
β2 8.49 6.39, 10.59 <0.001 
Fat disorder Male   =	  +		!" %
=	!(*(%)) %  
75 α 19.18 18.32, 20.04 <0.001 
  
 
β1 -7.57 -11.92, -3.22) 0.001 
  
 
β2 -8.76 -14.65, -2.88 0.004 
 Female  =	  +		!" %
=	!(*(%)) %  
92 α 20.81 20.01, 21.61 <0.001 
  
 
β1 -6.14 -9.67, -2.62 0.001 
  
 
β2 -6.45 -10.66, -2.24 0.003 
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C.6 Waist/hip ratio 
Figure C-4: Modelling waist/hip ratio as a function of age at recruitment in: males estimated by (a) locally weighted smoothing, (b) fractional polynomial model: and, in females 
estimated by (c) locally weighted smoothing, and (d) fractional polynomial model 
 
 
Both fractional polynomial models are of 2 orders, estimated over 44 models.  Fractional polynomial for males:  =		. +	/2 +	2.: (n = 146). Fractional polynomial model for 
females: =		. +		/2 +	2:	: (n = 164). Shaded area in (b) and (d) denote 95% confidence interval.  
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Table C-7: Fractional polynomial models fitting waist/hip ratio as a function of age at recruitment, stratified by sex and lipodystrophy syndrome 
status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
Male  =	  +	!"% +	!%(*(%)) 63 α 0.94 0.91, 0.98 <0.001 
  
 
β1 0.19 -0.18, 0.56 0.308 
  
 
β2 -0.26 -0.62, 0.10 0.158 
 Female  =	  +	!" %; +	!%- 68 α 0.89 0.87, 0.91 <0.001 
  
 
β1 0.01 -0.02, 0.07 0.136 
  
 
β2 -0.01 -0.03, 0.00 0.136 
Lipodystrophy Male   =	  +	!"% +	!%(*(%)) 80 α 0.96 0.93, 0.99 <0.001 
  
 
β1 0.02 -0.29, 0.32 0.907 
  
 
β2 -0.03 -0.31, 0.26 0.861 
 Female 
=	  +	!"%- +	!%-(*(%)) 
94 α 0.90 0.88, 0.92 <0.001 
  
 
β1 -0.04 -0.08, 0.00 0.080 
  
 
β2 0.05 -0.02, 0.12 0.128 
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Figure C-5:   Relationship between age and waist/hip ratio in: (a) males without lipodystrophy (n = 63), (b) males with lipodystrophy (n = 80), (c) 
females without lipodystrophy (n = 68), and (d) female with lipodystrophy (n = 94) 
 
 
Equations: (a) <= = 	>= +	?/=@= +	?=@=(01(@=)) (b)  <= =	>= +	?/=@= +	?=@=(01(@=))(c)<= =	>= +	?/= @=; +	?=@= and (d)<= =	>= +	?/=@= +	?=@=(01(@=)). Fractional polynomial models were of 2 
orders, estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C-7 for details of model. 
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Table C-8: Fractional polynomial models fitting waist/hip ratio as a function of age at recruitment, stratified by sex and body fat disorder status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No fat disorder Male 
=	  +	!"% +	!%(*(%)) 
93 α 0.95 0.92, 0.97 <0.001 
  
 
β1 0.09 -0.17, 0.34 0.490 
  
 
β2 -0.16 -0.41, 0.09 <0.001 
 Female  =	  +	!" %; +	!%" 93 α 0.90 0.88, 0.92 <0.001 
  
 
β1 0.01 0.00, 0.01 0.225 
  
 
β2 -0.01 -0.02, 0.00 0.010 
Fat disorder Male  
=	  + 	!"(*(%))
+	!((*	%)) 
53 α 0.97 0.93, 1.01 <0.001 
  
 
β1 0.01 -0.09, 0.11 0.808 
  
 
β2 -0.12 -0.39, 0.15 0.395 
 Female 
=	  +	!"%- +	!%-(*(%)) 
71 α 0.90 0.88, 0.93 <0.001 
  
 
β1 -0.04 -0.10, 0.02 0.150 
  
 
β2 0.06 -0.03, 0.15 0.192 
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C.7 Total cholesterol 
Figure C-6: Modelling total cholesterol as a function of age at recruitment: in males estimated by (a) locally weighted smoothing and (b) fractional 
polynomial model: and, in females estimated by (c) locally weighted smoothing, and (d) fractional polynomial model 
 
 
Fractional polynomial models are of 2 orders, estimated over 44 models. Fractional polynomial model or males:  =	. +	/ 2 +	2
	(n = 197). Fractional polynomial model for 
females:  =	. +	/2 +	245	(2):: (n  = 211). Shaded area in (b) and (d) denote 95% confidence interval.  
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Table C-9: Fractional polynomial models fitting total cholesterol as a function of age at recruitment, stratified by sex and lipodystrophy syndrome 
status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
Male  =	  +	!" % 	+	!"%
-
  
88 α 151.89 143.29, 160.48 <0.001 
  
 
β1 2.15 -3.14, 7.45 0.553 
  
 
β2 -1.68 -7.28, 3.93 <0.001 
 Female  =	  +	!"%- +
	!%-(*(%)) 
89 α 151.93 143.85, 160.00 <0.001 
  
 
β1 -8.56 -24.02, 6.91 0.274 
  
 
β2 12.05 -13.32, 37.42 0.348 
Lipodystrophy Male   =	  +	!" % + !%
-
 
107 α 180.5 170.2, 190.7 <0.001 
  
 
β1 6.77 0.89, 12.66 0.025 
  
 
β2 -3.76 -9.87, 2.35 0.225 
 Female  =	  +	!" % + !%
-
 
119 α 180.84 171.57, 190.10 <0.001 
  
 
β1 1.27 -5.63, 8.17 0.716 
  
 
β2 -2.34 -8.39, 3.69 0.443 
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Figure C-7: Relationship between age and total cholesterol in: (a) males without lipodystrophy syndrome (n = 88), (b) males with lipodystrophy 
syndrome (n = 107), (c) females without lipodystrophy syndrome (n =89), and (d) female with lipodystrophy syndrome (n =119) 
 
 
Equations: (a) =	  +	!" % 	+	!"%
-
 (b) =	  +	!" % + !%
-		(c)	 =	  +	!"%- +	!%-(*(%)) and (d)  =	  +	!" % + !%
-
 Fractional polynomial 
models were of 2 orders, estimated over 44 models. Shaded area denotes 95% confidence interval. See appendix for details of models. See Table C-9 for details of models. 
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Table C-10: Fractional polynomial models fitting total cholesterol as a function of age at recruitment, stratified by sex and metabolic abnormality 
status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No metabolic 
abnormality 
Male  =	  +	!"%- +	!%-(*(%)) 141 α 156.24 148.64, 163.83 <0.001 
  
 
β1 -7.95 -23.99, 8.09 0.329 
  
 
β2 10.21 -15.89, 36.30 0.441 
 Female  =	  +	!"% +	!% 159 α 160.26 153.02, 167.51 <0.001 
  
 
β1 21.31 -54.01, 96.64 0.577 
  
 
β2 -9.82 -42.70, 23.06 0.556 
Metabolic 
abnormality 
Male   =	  +	!" %; +	!%- 54 α 197.71 179.75, 215.67 <0.001 
  
 
β1 4.44 -3.14, 12.03 0.245 
  
 
β2 -5.72 -16.53, 5.10 0.294 
 Female  =	  +	!"%- +	!%-(*(%)) 49 α 199.33 185.41, 213.26 <0.001 
  
 
β1 -6.93 -39.72, 25.85 0.672 
  
 
β2 12.70 -44.33, 69.74 0.656 
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Figure C-8: Comparison of median total cholesterol across age groups between subjects 
with/without (a) lipodystrophy syndrome (n = 403), (b) fat disorder (n = 407), and (c) 
metabolic abnormality (n = 403) 
 
 
 
Bars indicate 25th and 75th percentiles of the distribution within each age band. No significant differences were 
seen in median total cholesterol between subjects with fat disorder and those without (p > 0.05) 
50
10
0
15
0
20
0
25
0
30
0
To
ta
l b
lo
o
d 
ch
o
le
st
e
ro
l
2-3
 
ye
ar
s
4-5
 
ye
ar
s
6-7
 
ye
ar
s
8-9
 
ye
ar
s
10
-
11
 
ye
ar
s
12
-
13
 
ye
ar
s
14
-
15
 
ye
ar
s
16
-
18
 
ye
ar
s
excludes outside values
No lipodystrophy syndrome Lipodystrophy syndrome
50
10
0
15
0
20
0
25
0
30
0
To
ta
l b
lo
o
d 
ch
o
le
st
e
ro
l
2-3
 
ye
ar
s
4-5
 
ye
ar
s
6-7
 
ye
ar
s
8-9
 
ye
ar
s
10
-
11
 
ye
ar
s
12
-
13
 
ye
ar
s
14
-
15
 
ye
ar
s
16
-
18
 
ye
ar
s
excludes outside values
No fat disorder Fat disorder
50
10
0
15
0
20
0
25
0
30
0
To
ta
l b
lo
od
 
ch
o
le
st
e
ro
l
2-3
 
ye
ar
s
4-5
 
ye
ar
s
6-7
 
ye
ar
s
8-9
 
ye
ar
s
10
-
11
 
ye
ar
s
12
-
13
 
ye
ar
s
14
-
15
 
ye
ar
s
16
-
18
 
ye
ar
s
excludes outside values
No metabolic abnormality Any metabolic abnormality
(a) 
(b) 
(c) 
  
  Appendix C 
421 
 
C.8 Low density lipoprotein cholesterol 
Figure C-9: Low density lipoprotein cholesterol across age groups: (a) median LDL cholesterol, and (b) median 
standardized LDL cholesterol 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. n =349 for LDL cholesterol, and n = 341 for standardized LDL 
cholesterol. Comparison of median standardized LDL-cholesterol between males and females: p > 0.05 for all 
groups. 
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Figure C-10: Modelling LDL cholesterol as a function of age at recruitment in: males estimated by (a) locally weighted smoothing, (b) fractional 
polynomial model: and, in females estimated by (c) locally weighted smoothing, and (d) fractional polynomial model. 
 
 
Both fractional polynomial models are of 2 orders, estimated over 44 models. Fractional polynomial model for males:  =	. +	/ 2 +	2: :	(n = 158). Fractional polynomial model 
for females:  =	. +	/ 2 	+	2: (n = 183). Shaded area in (b) and (d) denote 95% confidence interval. 
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Table C-11: Fractional polynomial models fitting LDL-cholesterol as a function of age at recruitment, stratified by sex and lipodystrophy syndrome 
status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
syndrome 
Male 	 =	  +	!" % +	!%
-	
 
72 α 85.03 77.74, 92.32 <0.001 
  
 
β1 0.97 -3.65, 5.58 0.678 
  
 
β2 -0.97 -5.82, 3.88 0.692 
 Female  =	  +	!" %; +	
!
&%)  
80 α 84.78 79.62, 89.94 <0.001 
  
 
β1 -46.78 -101.77, 8.22 0.094 
  
 
β2 111.34 -22.52, 245.20 0.102 
Lipodystrophy 
syndrome 
Male  =	  +	!" %; +	!%- 86 α 93.97 85.29, 102.65 <0.001 
  
  
β1 27.50 10.53, 44.47 0.002 
  
  
β2 1.90 -3.94, 7.73 0.520 
 Female  =   +	!"%- +
	!%-(*(%)). 
101 α 100.72 92.16, 109.27 <0.001 
  
 
β1 -15.00 -34.01, 4.00 0.120 
  
 
β2 19.41 -11.53, 50.34 0.216 
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Figure C-11: Modelling LDL cholesterol as a function of age at recruitment in: (a) males without lipodystrophy syndrome (n = 72), (b) males with 
lipodystrophy syndrome (n = 86), (c) females without lipodystrophy syndrome (n = 80), and (d) female with lipodystrophy syndrome (n = 101) 
 
 
Equations: (a)	 =	  +	!" % +	!%
-	(b)	 =	  +	!" %; +	!%-			(c)   =	  +	
!" %; +	
!
&%)   and (d)   =   +	!"%
- +	!%-(*(%)). Fractional polynomial of two orders, estimated 
over 44 models. Shaded area denotes 95% confidence interval. See Table C-11 for details of models. 
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Table C-12: Fractional polynomial models fitting LDL-cholesterol as a function of age at recruitment, stratified by sex and metabolic abnormality 
status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No metabolic 
abnormality 
Male  =	  +	!"&%) +	!%- 116 α 86.44 80.03, 92.84 <0.001 
  
 
β1 -23.68 -89.61. 42.26 0.591 
  
 
β2 2.04 -5.45, 9.52 0.591 
 Female  =	  +	!" % +	
!" %;  136 α 85.36 81.44, 89.27 <0.001 
  
 
β1 -5.52 -12.69, 1.65 0.130 
  
 
β2 17.37 -7.60, 42.35 0.171 
Metabolic 
abnormality 
Male  =	  +	!" % +	!% 
42 α 103.30 90.01, 116.59 <0.001 
  
  
β1 4.21 -3.14, 11.56 0.254 
  
  
β2 -16.62 -59.14, 25.90 0.434 
 Female 
=	  +	!"%-
+	!%-(*(%) 
45 α 118.43 106.79, 130.07 <0.001 
  
 
β1 -9.78 -38.13, 18.57 0.490 
  
 
β2 18.61 -30.07, -67.29 0.445 
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Figure C-12: Comparison of median standardized LDL-cholesterol, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat disorder, and (c) 
metabolic abnormality  
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized LDL-cholesterol ratio 
between subjects with outcome and without outcome: *p < 0.01, **p < 0.01, ***p < 0.001  
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Figure C-13: Comparison of median low density lipoprotein (LDL) cholesterol across age 
groups between subjects with/without (a) lipodystrophy syndrome (n = 339), (b) fat 
disorder (n = 340), and (c) metabolic abnormality (n = 339) 
 
 
 
Bars indicate 25th and 75th percentile of the distribution within each age band. No significant differences were 
seen in median LDL cholesterol between subjects with fat disorder and those without (p > 0.05) 
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C.9 Non-high density lipoprotein cholesterol 
 
Figure C-14: Non high density lipoprotein cholesterol across age groups: (a) median non-HDL cholesterol, and 
(b) median standardized non-HDL cholesterol 
 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. n =360 for non-HDL cholesterol, and n = 351 for standardized non-
HDL cholesterol. Comparison of median standardized non- HDL-cholesterol between males and females: p > 
0.05 for all groups. 
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Figure C-15: Comparison of median non-HDL cholesterol across age groups between 
subjects with/without (a) lipodystrophy syndrome (n = 341), (b) fat disorder (n = 343), and 
(c) metabolic abnormality (n = 341) 
 
 
 
Bars indicate 25th and 75th percentiles of the distribution with each age band. No significant differences were 
seen in median non-HDL cholesterol between subjects with fat disorder and those without (p > 0.05)
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Figure C-16: Modelling non high density lipoprotein (HDL) cholesterol as a function of age at recruitment: in males estimated by (a) locally 
weighted smoothing, (b) fractional polynomial model: and, in females estimated by (c) locally weighted smoothing, and (d) fractional polynomial 
model.  
 
 
Both fractional polynomial models are order 2, estimated over 44 models. Fractional polynomial model for males:  =	. +	/ 2 +	2
: (n = 163). Fractional polynomial model for 
females:  =	. +	/ 2 +	2

 : (n = 188).  
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Table C-13: Fractional polynomial models fitting non-HDL-cholesterol as a function of age at recruitment, stratified by sex and lipodystrophy 
syndrome status 
 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
syndrome 
Male 	 =	  +	!" % +	!%
-		 73 α 51.97 47.68, 56.26 <0.001 
  
 
β1 0.75 -1.98, 3.48 0.587 
  
 
β2 -2.16 -4.98, 0.65 0.130 
 Female 	 =	  +	!"%- +	!%-(*(%)) 81 α 56.69 51.61, 61.77 <0.001 
  
 
β1 0.88 -8.91, 10.67 0.859 
  
 
β2 -3.32 -19.20, 12.55 0.678 
Lipodystrophy 
syndrome 
Male  =	  +	!" % +	!%
-
 
89 α 49.26 45.38, 53.14 <0.001 
  
  
β1 0.65 -1.41, 2.72 0.529 
  
  
β2 -1.81 -4.11, 0.49 0.122 
 Female  =	  +	!" % +	
!(*(%)) %  
105 α 53.21 49.94, 56.48 <0.001 
  
 
β1 -1.01 -10.65, 8.62 0.835 
  
 
β2 -2.64 -11.81, 6.53 0.570 
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Figure C-17: Modelling non-HDL cholesterol as a function of age at recruitment in: (a) males without lipodystrophy syndrome (n = 72), (b) males 
with lipodystrophy syndrome (n = 88), (c) females without lipodystrophy syndrome (n = 80), and (d) female with lipodystrophy syndrome (n = 101) 
 
 
Equations: (a)  =	  +	!" % +	!%
-	(b)		 =	  +	!"%- +	!%-(*(%)) (c)  =	  +	!" % +	!%
-
  and (d)   =	  +	!" % +	
!(*(%)) % 	
. Fractional polynomial models are of order 2, estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C-13 for details of models.   
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Table C-14: Fractional polynomial models fitting non-HDL-cholesterol as a function of age at recruitment, stratified by sex and metabolic 
abnormality status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No metabolic 
abnormality 
Male  =	!" % +	!%
-
 
119 α 52.17 49.02, 55.32 <0.001 
  
 
β1 0.78 -1.66, 3.23 0.527 
  
 
β2 -1.84 -3.91, 0.22 0.080 
 Female 
=	  +	!"%- +	!%-*(	%) 
139 α 56.84 52.92, 60.76 <0.001 
  
 
β1 2.24 -5.39, 10.67 0.517 
  
 
β2 -6.04 -18.87, 6.79 0.354 
Metabolic 
abnormality 
Male  =	!" % +	!%
-
 
43 α 45.92 40.08, 51.76 <0.001 
  
  
β1 0.98 -1.25, 3.21 0.380 
  
  
β2 -3.33 -6.70, 0.04 0.052 
 Female 
=	  +	!"%- +	!%-*(	%)	 
47 α 49.44 44.12, 54.77 <0.001 
  
 
β1 -16.47 -29.39, -3.54 0.014 
  
 
β2 27.89 5.62, 50.17 0.015 
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Figure C-18: Comparison of median standardized non HDL-cholesterol, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat disorder, and (c) 
metabolic abnormality 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized non-HDL cholesterol ratio 
between subjects with outcome and without outcome: *p < 0.01, **p < 0.01, ***p < 0.001.  
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C.10 High density lipoprotein cholesterol  
 
Figure C-19: High density lipoprotein (HDL) cholesterol across age groups: (a) median 
HDL cholesterol, and (b) median standardized HDL cholesterol 
 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. No significant difference in standardized HDL-cholesterol was 
seen between males and females in 2-3, 4-5, 8-9, 10-11, 12-13, 14-15, 16-18 year olds (p < 0.05): significant 
difference seen in 6-7 year olds (p = 0.019).  
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Figure C-20: Comparison of median high density lipoprotein (HDL) cholesterol across 
age groups between subjects with/without (a) lipodystrophy syndrome, (b) fat disorder, 
and (c) metabolic abnormality  
 
 
 
Bars indicate 25th and 75th percentiles of the distribution within each age band. No significant differences were 
seen in median HDL cholesterol between subjects with fat disorder and those without (p > 0.05) 
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Figure C-21: Modelling HDL-cholesterol as a function of age at recruitment in: males estimated by (a) locally weighted smoothing (b) fractional 
polynomial model: and, in females estimated by (c) locally weighted smoothing, and (d) fractional polynomial model 
 
 
Both fractional polynomial models are order 2, estimated over 44 models. Fractional polynomial model for males:  =	. +	/2 	+	

2
(01(2)):	(n  = 163). Fractional polynomial model for 
females:  =	. +		/2 +	45(2)45(2): (n  =188).  
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Table C-15: Fractional polynomial models fitting HDL-cholesterol as a function of age at recruitment, stratified by sex and lipodystrophy syndrome 
status 
Outcome Sex Model N Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
syndrome 
Male 
=   +		!" &%)
+	!*(%)	 
73 α 99.30 91.71, 106.88 <0.001 
  
 
β1 108.22 -147.63, 364.06 0.402 
  
 
β2 55.82 -85.55, 197.20 0.434 
 Female 
=	  +	!"%-
+	!%-*(%) 
81 α 94.17 86.49, 101.84 <0.001 
  
 
β1 -10.20 -24.98, 4.57 0.173 
  
 
β2 16.87 -7.09, 40.84 0.165 
Lipodystrophy 
syndrome 
Male 
=	  +	!" %
+ !(*(%)) %  
89 α 125.27 116.94, 133.59 <0.001 
  
 
β1 1.30 -21.21, 23.81 0.909 
  
 
β2 -5.19 -25.32, 14.94 0.610 
 Female 
=   +	!"&%)
+	!% 
105 α 129.18 118.08, 140.27 
 
<0.001 
  
 
β1 155.80 -335.12, 646.73 0.530 
  
 
β2 -84.69 -323.32, 153.95 0.483 
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Figure C-22: Modelling HDL cholesterol as a function of age in recruitment in: (a) males without lipodystrophy syndrome (n = 73), (b) males with 
lipodystrophy syndrome (n=89), (c) females without lipodystrophy syndrome (n = 81), (d) female with lipodystrophy syndrome (n=105) 
 
Equations: (a)	 =	  +	!" % +	!%
-		(b)		 =	  +	!" % +	!%
-			(c)	 =	  +	!"%- +	!%-(*(%)) and (d)  =	  +	!" % +	
!(*(%)) %  Fractional polynomial models are of order 2, 
estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C-15 for details of models.  
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Table C-16: Fractional polynomial models fitting HDL-cholesterol as a function of age at recruitment, stratified by sex and metabolic abnormality 
status 
 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No metabolic 
abnormality 
Male  =	  +	!"&%) +	!%- 119 α 103.83 96.79, 110.87 <0.001 
  
 
β1 -30.41 -101.53, 40.72 0.399 
  
 
β2 3.55 -4.55, 11.66 0.387 
 Female 
=	  +	!"%- +	!%-(*(%)) 
139 α 100.86 92.61, 109.11 <0.001 
  
 
β1 -2.39 -19.29, 14.50 0.780 
  
 
β2 5.39 -21.60, 32.39 0.693 
Metabolic 
abnormality 
Male 
=	  +	!" %
+	!(*(%)) %  
43 α 141.50 127.57, 155.43 <0.001 
  
 
β1 -7.31 -40.92, 26.31 0.663 
  
 
β2 -10.64 -39.74, 18.46 0.464 
 Female 
=	  +	!"&%)
+	!&%) 	(*(%)) 
47 α 151.78 138.86, 164.70 <0.001 
  
 
β1 226.89 -267.68, 721.46 0.360 
  
 
β2 -106.78 -361.07, 148.71 0.360 
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Figure C-23: Comparison of median standardized HDL-cholesterol, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat disorder, and (c) 
metabolic abnormality  
 
Boxes demark 25th and 75th percentiles (1st and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized HDL-cholesterol ratio 
between subjects with outcome and without outcome: *p < 0.01, **p < 0.01, ***p < 0.001.  
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Figure C-24: Non high density lipoprotein cholesterol across age groups: (a) median non-
HDL cholesterol, and (b) median standardized non-HDL cholesterol 
 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity.. n =360 for non-HDL cholesterol, and n = 351 for standardized non-
HDL cholesterol. Comparison of median standardized non- HDL-cholesterol between males and females: p > 
0.05 for all groups. 
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Figure C-25: Comparison of median non-HDL cholesterol across age groups between 
subjects with/without (a) lipodystrophy syndrome (n = 357), (b) fat disorder (n = 359), and 
(c) metabolic abnormality (n = 357) 
 
 
 
Bars indicate 25th and 75th percentiles of the distribution with each age band. No significant differences were 
seen in median non-HDL cholesterol between subjects with fat disorder and those without (p > 0.05) 
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C.11 Fasting triglyceride 
Figure C-26: Modelling fasting triglyceride as a function of age at recruitment in: males estimated by (a) locally weighted smoothing, (b) fractional 
polynomial model: and in females estimated by (c) locally weighted smoothing, and (d) fractional polynomial model.  
 
 
Both fractional polynomial models are order 2, estimated over 44 models. Fractional polynomial for males:  =	. +	/ 2 +	2:	 (n = 139). Fractional polynomial model for females: 
 =	. +	/2 +	2:: (n = 166). Shaded area in (b) and (d) denote 95% confidence interval. 
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Table C-17: Fractional polynomial models fitting fasting triglyceride as a function of age at recruitment, stratified by sex and lipodystrophy 
syndrome status 
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
Male  =	  +	!" %; +	!%- 66 α 71.81 60.49, 83.14 <0.001 
  
 
β1 8.88 -22.13, 39.89 0.569 
  
 
β2 12.58 3.28, 21.9 0.009 
 Female  =	  +	!%- +	!%-(*(%")) 74 α 65.35 57.04, 73.65 <0.001 
  
 
β1 -1.46 -17.40, 14.48 0.856 
  
 
β2 8.11 -17.85, 34.07 0.535 
Lipodystrophy Male   =	  +	!" %
+	!*(%) %  
73 α 162.07 137.77, 186.37 <0.001 
  
 
β1 -62.03 -134.80, 10.74 0.094 
  
 
β2 -54.23 -118.27, 9.84 0.096 
 Female  =	  +	!%- +	!%-(*(%")) 91 α 130.48 108.80, 152.16 <0.001 
  
 
β1 56.54 8.04, 105.04 0.023 
  
 
β2 -98.23 -178.19, -18.27 0.017 
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Figure C-27: Relationship between age and fasting triglyceride in: (a) males without lipodystrophy syndrome (n = 66), (b) males with lipodystrophy 
syndrome (n =73), (c) females without lipodystrophy syndrome (n = 74), and (d) female with lipodystrophy syndrome (n =91) 
 
 
Equations: (a)  =	  +	!" %; +	!%- (b)  =	  +	
!" % +	
!*(%) % 	 (c)  =	  +	!%
- +	!%-(*(%")) and (d) =	  +	!%- +	!%-(*(%")). Fractional 
polynomial models includes age raised to two powers, estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C-17 for details of models.  
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Table C-18: Fractional polynomial models fitting fasting triglyceride as a function of age at recruitment, stratified by sex and metabolic 
abnormality status  
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No metabolic 
abnormality 
Male  =	  +	!" %; +	!% 94 α 80.86 71.45, 90.27 <0.001 
  
 
β1 30.27 -19.27, 79.81 0.228 
  
 
β2 76.23 19.79, 132.67 0.009 
 Female 
=	  +	!"%- +	!%-(*(%)) 
119 α 68.65 62.04, 75.27 <0.001 
  
 
β1 2.45 -11.36, 16.26 0.726 
  
 
β2 2.88 -19.33, 25.09 0.797 
Metabolic 
abnormality  
Male   =	  +	!" %; +	!% 45 α 185.20 154.44, 215.96 <0.001 
  
 
β1 19.32 0.39, 38.26 0.046 
  
 
β2 204 101.70, 307.11 <0.001 
 Female 
=	  +	!"%- +	!%-(*(%)) 
45 α 174.15 67.72, 206.57 <0.001 
  
 
β1 137.15 67.75, 206.57 <0.001 
  
 
β2 -224.20 -344.59, -103.82 0.001 
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C.12 Fasting insulin 
 
Figure C-28: Fasting insulin across age groups: (a) median fasting insulin, and (b) 
median standardized fasting insulin  
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. n =199 for fasting insulin, and n = 196 for standardized fasting 
insulin respectively. Comparison of median standardized fasting insulin between males and females: p > 0.05 
for all groups 
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Figure C-29: Modelling fasting insulin as a function of age at recruitment estimated: in males by (a) locally weighted smoothing, (b) fractional 
polynomial model: and in females by (c) locally weighted smoothing and (d) fractional polynomial model 
 
 
Both fractional polynomial models are order 2, estimated over 44 models. Fractional polynomial for males:   = 	. +	/2 +	2(45(2)):  (n = 93). Fractional polynomial model for 
females:  =	. +	/ 2 +	
(01(2)) 2 : (n = 103). Shaded area in (b) and (d) denote 95% confidence interval.  
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Table C-19:  Fractional polynomial models fitting fasting insulin as a function of age at recruitment, stratified by sex and lipodystrophy syndrome 
status  
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
Male 
=	  +	!%- +	!%-(*(%")) 
45 α 9.47 7.54, 8.84 <0.001 
  
 
β1 3.78 -1.28, 8.84 0.191 
  
 
β2 -5.31 -13.38, 2.76 0.191 
 Female 
=	  +	!%- +	!%-(*(%")) 
45 α 11.69 9.41, 13.97 <0.001 
  
 
β1 7.65 2.67, 12.64 0.003 
  
 
β2 -11.55 -19.80, -3.29 0.007 
Lipodystrophy Male  
=	  +	!"√%) 
+	!&%) (*(%)	 
46 α 9.97 5.41, 14.53 <0.001 
  
 
β1 -108.77 -289.48, 71.94 0.231 
  
 
β2 62.98 -26.11, 152.08 0.161 
 Female 
=	  +	!" % +	
!*(%) %  
58 α 13.86 11.94, 15.76 <0.001 
  
 
β1 -17.21 -24.82, -9.59 <0.001 
  
 
β2 -16.71 -25, 60, -7.83 <0.001 
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Figure C-30: Modelling fasting insulin as a function of age at recruitment in: (a) males without lipodystrophy syndrome, (n = 45) (b) males with 
lipodystrophy syndrome (n = 46), (c) females without lipodystrophy syndrome (n =45), and (d) female with lipodystrophy syndrome (n = 58) 
 
Equations: (a) =	  +	!%- +	!%-(*(%"))(b)	 =	  +	!"√%)  +	!&%) (*(%)	(c) =	  +	!%- +	!%-(*(%"))and (d) =	  +	!" % +	
!*(%) %  Fractional polynomial models are of 
2 orders, estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C-19 for details of model. 
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Table C-20:  Fractional polynomial models fitting fasting insulin as a function of age at recruitment, stratified by sex and body metabolic 
abnormality status  
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No metabolic 
abnormality 
Male  =	  +	!"&%) +
	!%    
64 α 9.71 6.73, 12.69 <0.001 
  
 
β1 -46.68 -194.93, 101.57 0.531 
  
 
β2 29.84 -41.39, 101.08 0.405 
 Female  =	  +		!" %
=	!(*(%)) %  
75 α 12.65 11.11, 14.19 <0.001 
  
 
β1 -11.00 -17.09, -4.91 0.001 
  
 
β2 -9.88 -16.44, -3.31 0.004 
Metabolic 
abnormality 
Male  
=	!" &%)
+	! 	(*(%)) &%)  
27 α 9.50 6.66, 12.34 <0.001 
  
 
β1 -126.80 -219.64, -33.96 0.010 
  
 
β2 -52.57 -94.38, -10.77 0.016 
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Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
 Female  =	  +		!" %
=	!(*(%)) %  
28 α 10.84 7.94, 13.75 <0.001 
  
 
β1 -17.82 -28.52, -7.12 0.002 
  
 
β2 -17.32 -29.00, -5.64 0.005 
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Figure C-31: Comparison of median standardized fasting insulin, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat disorder, and (c) 
metabolic abnormality  
 
Boxes demark 25th and 75th percentiles (1st and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized insulin between subjects with 
outcome and without outcome: p ≥  0.057.  
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Figure C-32: Comparison of median fasting insulin across age groups between subjects 
with/without (a) lipodystrophy syndrome, (b) fat disorder, and (c) metabolic abnormality 
 
 
 
Bars indicate 25th and 75th percentiles of the distribution within each age band. No significant differences were 
seen in median fasting insulin between subjects with fat disorder and those without (p > 0.05) 
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C.13 Fasting glucose 
Figure C-33: Fasting glucose across age groups: (a) median fasting glucose, and (b) 
median standardized fasting glucose  
 
 
Boxes demark 25th and 75th percentiles (2nd and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. No significant difference in standardized fasting glucose was seen 
between males and females in 2-3, 4-5, 6-7, 8-9, 12-13, 14-15 and 16-18 year olds (p < 0.05): significant 
difference seen in 10-11 year olds (p = 0.041)  
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Figure C-34: Modelling fasting glucose as a function of age at recruitment estimated: in males by (a) locally weighted smoothing, and (b) fractional 
polynomial model: and, in females by (locally weighted smoothing and fractional polynomial model 
 
Fractional polynomial models are of order 2, estimated over 44 models. Fractional polynomial model for males: <= =	>= +	?/=@= +	?=@=(01(@=)) : (n = 139). Fractional polynomial model 
for females:  =	. +	/2 +	2: (n = 160 ). Shaded area in (b) and (d) denote 95% confidence interval.  
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Table C-21: Fractional polynomial models fitting fasting glucose as a function of age at recruitment, stratified by sex and lipodystrophy syndrome 
status  
Outcome Sex Model n Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No 
lipodystrophy 
Male  =	  +	!"% +	!%(ln	(%)) 66 α 86.34 83.04, 89.65 <0.001 
  
 
β1 47.44 6.13, 88.76 0.025 
  
 
β2 -41.29 -79.73, -2.84 0.036 
 Female  =	  +	!"% +	!%- 72 α 83.14 80.41, 85.86 <0.001 
  
 
β1 25.83 11.46, 40.19 0.001 
  
 
β2 -13.20 -20.78, -5.62 0.001 
Lipodystrophy Male   =	  +	!%- +	!%-(*(%")) 71 α 82.07 79.26, 84.88 <0.001 
  
 
β1 6.76 0.83, 12.69 0.026 
  88 β2 -10.68 -20.29, -1.06 0.030 
 Female  =	  +	!" %
+	!*(%) %  
 
α 81.16 79.40, 82.92 <0.001 
  
 
β1 2.84 -2.42, 8.11 0.286 
  
 
β2 3.11 -1.68, 7.90 0.200 
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Figure C-35: Modelling fasting glucose as a function of age at recruitment in: (a) males without lipodystrophy syndrome (n = 66), (b) males with 
lipodystrophy syndrome (n =71), (c) females without lipodystrophy syndrome (n = 72), and (d) female with lipodystrophy syndrome (n = 88) 
 
 
Equations: (a)	 =	  +	!"% +	!%(ln	(%)) (b)  =	  +	!%- +	!%-(*(%"))	(c)  =	  +	!"% +	!%-and (d) =	  +	!" % +	
!*(%) %  Fractional 
polynomial models of 2 orders, estimated over 44 models. Shaded area denotes 95% confidence interval. See Table C-21 for details of models.
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Table C-22: Fractional polynomial models fitting fasting glucose by age at recruitment, stratified by sex metabolic abnormality status  
Outcome Sex Model N Coefficients 
    Parameter Estimate 95% confidence 
interval 
p-value 
No metabolic 
abnormality 
Male 
=	  +	!"&%)
+	!% 
94 α 85.33 82.59, 88.06 <0.001 
  
 
β1 65.48 15.95, 115.01 0.010 
  
 
β2 -13.41 -23.70, -3.13 0.011 
 Female 
=	  +	!"%
+	!%(*(%)) 
116 α 83.13 81.12, 85.15 <0.01 
  
 
β1 12.85 5.25, 20.45 0.001 
  
 
β2 -17.77 -28.31, -7.23 0.001 
Metabolic 
abnormality 
Male  
=	  +	!"%-
+	!%-(*(%)) 
43 α 80.81 77.93, 83.68 <0.001 
  
 
β1 5.42 -0.49, 11.33 0.071 
  
 
β2 -7.95 -17.83, 1.93 0.112 
 Female  =	  +		!" %
=	!(*(%)) %  
44 α 79.93 77.23, 82.63 <0.001 
  
 
β1 3.24 -4.10, 10.60 0.378 
  
 
β2 3.31 -3.07, 9.70 0.301 
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Figure C-36: Comparison of median standardized fasting glucose, stratified by sex, 
between subjects with/without (a) lipodystrophy syndrome, (b) fat disorder, and (c) 
metabolic abnormality  
 
Boxes demark 25th and 75th percentiles (1st and 3rd quartile) and lines indicate adjacent values (most extreme 
values within 1.5 interquartile range of the nearest quartile) of the distribution within each age band. Values 
outside adjacent values excluded for clarity. Comparison of median standardized fasting glucose between 
subjects with outcome and without outcome: p ≥  0.157.  
-
3
-
2
-
1
0
1
2
St
a
n
da
rd
ize
d 
fa
st
in
g 
gl
u
co
se
Male Female
excludes outside values
No lipodystrophy syndrome Lipodystrophy syndrome
-
3
-
2
-
1
0
1
2
St
a
n
da
rd
ize
d 
fa
st
in
g 
gl
u
co
se
Male Female
excludes outside values
No fat disorder Fat disorder
-
3
-
2
-
1
0
1
2
St
a
n
da
rd
ize
d 
fa
st
in
g 
gl
u
co
se
Male Female
excludes outside values
No metabolic abnormality Any metabolic abnormality
(a) 
(b) 
(c) 
  Appendix C 
462 
 
Figure C-37: Comparison of median fasting glucose across age groups between subjects 
with/without (a) lipodystrophy syndrome, (b) fat disorder, and (c) metabolic abnormality 
 
 
 
Bars indicate 25th and 75th percentiles of the distribution within each age band. No significant differences were 
seen in median fasting glucose between subjects with fat disorder and those without (p > 0.05) 
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Appendix D Appendix to chapter 4  
 
D.1 Prevalence of body fat alterations outcomes by categories of antiretroviral therapy 
 
Table D-1: Prevalence of fat alteration outcomes by categories of antiretroviral therapy: exclusion of ART-naïve/ART status missing subjects 
 
 Body fat alterations Lipohypertrophy Lipoatrophy Both lipohypertrophy and 
lipoatrophy 
 
 Prevalence n/N p-value Prevalence n/N p-value Prevalence n/N p-value Prevalence n/N p-value 
NRTI Not current 50.00 1/2 0.868 50.00 1/2 0.487 50.00 1/2 0.549 50.00 1/2 0.143 
 Current  44.17 159/360  27.86 100/359  30.45 109/358  13.89 50/360  
NNRTI Not current 41.56 96/231 0.179 25.65 59/230 0.192 27.95 64/229 0.156 11.69 27/231 0.081 
 Current  48.85 64/131  32.06 42/131  35.11 46/131  18.32 24/131  
PI Not current 44.83 65/145 0.844 26.90 39/145 0.708 30.34 44/145 0.943 15.21 18/145 0.454 
 Current  43.78 95/217   62/216  30.74 66/215  14.09 51/362  
Association investigated using χ2 test   
        Appendix D 
464 
 
 
D.2 Univariable analyses for body fat alterations 
 
 
Table D-2:  Univariable analysis for fat alterations outcomes by participant characteristic at recruitment 
  
Body fat alterations Lipohypertrophy Lipoatrophy Combined lipohypertrophy 
and lipoatrophy 
  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Demographic 
factors 
             
Gender Male 1   1   1   1   
 Female 1.24 (0.84, 
1.84) 
0.287 1.76 (1.13, 
2.75) 
0.012 0.87 (0.56, 
1.35) 
0.537 1.31 (0.74, 
2.34) 
0.359 
Age (years) 2-6 1   1   1   1   
 7-11 2.92 (1.19, 
7.13) 
0.019 2.53 (0.91, 
7.04) 
0.075 3.75 (1.07, 
13.13) 
0.039 4.85  (0.61, 
38.45) 
0.135 
 12-18 4.80 (2.06, 
11.18) 
<0.001 3.40 (1.29, 
8.96) 
0.013 6.82 (2.05, 
22.66) 
0.002 8.21 (1.10, 
61.26) 
0.040 
Ethnicity Black 1   1   1   1   
 White 3.29 (1.97, 
5.48) 
<0.001 2.34 (1.33, 
4.12) 
0.003 4.93 (2.46, 
9.89) 
<0.001 5.30 (1.86, 
15.10) 
0.002 
 Other 1.44 (0.46, 
4.50) 
0.529 1.52 (0.44, 
5.20) 
0.504 1.28 (0.26, 
6.42) 
0.764 1.61 (0.17, 
15.33) 
0.679 
Country of 
residence 
Italy 1   1   1      
Belgium 0.46 (0.27, 
0.80) 
0.005 0.61 (0.34, 
1.13) 
0.116 0.42 (0.21, 
0.84) 
0.014 0.55 (0.21, 
1.48) 
0.236 
Poland 1.57 (0.91, 
2.69) 
0.104 1.49 (0.85, 
2.63) 
0.166 3.16 (1.82, 
5.51) 
<0.001 4.66 (2.46, 
8.84) 
<0.001 
Infection 
factors 
             
CDC immune 
stage at 
recruitment 
Stage 1 1   1   1   1   
Stage 2 0.51 (0.31, 
0.86) 
0.012 0.66 (0.37, 
1.16) 
0.150 0.44 (0.24, 
0.83) 
0.010 0.52 (0.22, 
1.19) 
0.120 
Stage 3 0.66 (0.24, 0.428 0.52 (0.14, 0.306 0.68 (0.22, 0.515 0.36 (0.05, 0.321 
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Body fat alterations Lipohypertrophy Lipoatrophy Combined lipohypertrophy 
and lipoatrophy 
  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
1.83) 1.83) 2.15) 2.74) 
Nadir CDC 
immune 
stage 
Stage 1 1   1   1   1   
Stage 2 0.80 (0.52, 
1.24) 
0.314 1.28 (0.79, 
2.08) 
0.313 0.63 (0.39, 
1.03) 
0.063 1.13 (0.60, 
2.12) 
0.710 
Stage 3 1.21 (0.71, 
2.04) 
0.487 1.10 (0.61, 
2.01) 
0.745 1.15 (0.66, 
2.02) 
0.621 1.01 (0.46, 
2.22) 
0.976 
CDC clinical 
stage at 
recruitment 
N+A 1   1   1   1   
B 1.32 (0.55, 
3.20) 
0.533 1.11 (0.42, 
2.94) 
0.837 1.73 (0.69, 
4.31) 
0.239 1.74 (0.56, 
5.42) 
0.340 
C 0.55 (0.14, 
2.10) 
0.378 1.04 (0.27, 
4.00) 
0.956 0.62 (0.13, 
2.95) 
0.552 1.64 (0.34, 
7.87) 
0.535 
Maximum 
CDC clinical 
stage  
N+A 1   1   1   1   
B 2.35 (1.48, 
3.73) 
<0.001 2.09 (1.25, 
3.49) 
0.005 2.15 (1.28, 
3.61) 
0.004 2.18 (1.10, 
4.31) 
0.026 
C 2.48 (1.45, 
4.23) 
0.001 2.09 (1.17, 
3.73) 
0.013 2.16 (1.20, 
3.90) 
0.010 1.96 (0.90, 
4.29) 
0.089 
Viral load 
(copies/ml) 
≤50 1   1   1   1   
>50 0.98 (0.56, 
1.72) 
0.942 0.86 (0.47, 
1.59) 
0.633 0.97 (0.52, 
1.80) 
0.917 0.79 (0..37, 
1.72) 
0.558 
Maximum 
duration of 
ART use 
Per year 1.04 (0.98, 
1.10) 
0.187 1.01 (0.96, 
1.08) 
0.620 1.04 (0.98, 
1.10) 
0.239 1.01 (0.94, 
1.09) 
0.782 
Other factors              
Hepatitis C 
co-infection 
Uninfected 1   1   1   1   
Infected 2.96 (1.24, 
7.07) 
0.015 2.80 (1.22, 
6.44) 
0.015 1.59 (0.68, 
3.74) 
0.288 1.74 (0.62, 
4.88) 
0.389 
Tanner score 
for puberty 
I 1   1   1   1   
II-IV 2.43 (1.47, 
4.01) 
0.001 1.75 (1.00, 
3.08) 
0.052 2.54 (1.44, 
4.47) 
0.001 1.93 (0.92, 
4.06) 
0.082 
V 2.75 (1.58, 
4.79) 
<0.001 2.49 (1.36, 
4.56) 
0.003 2.05 (1.09, 
3.84) 
0.026 1.95 (0.87, 
4.37) 
0.107 
BMI Kg/m2 1.14 (1.08, 
1.21) 
<0.001 1.28 (1.19, 
1.37) 
<0.001 0.97 (0.91, 
1.03) 
0.323 - - - 
NRTI              
Any NRTI Not current 1   1   1   1   
 Current 2.60 (1.09, 0.032 1.54 (0.61, 0.356 3.94 (1.17, 0.027 2.26 (0.52, 0.276 
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Body fat alterations Lipohypertrophy Lipoatrophy Combined lipohypertrophy 
and lipoatrophy 
  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
6.21) 3.89) 13.26) 9.77) 
Didanosine Not current 1   1   1   1   
 Current  1.00 (0.54, 
1.85) 
0.999 1.06 (0.53, 
2.10) 
0.870 1.05 (0.54, 
2.05) 
0.882 1.16 (0.49, 
2.74) 
0.737 
Lamivudine Not current 1   1   1   1   
 Current 0.86 (0.56, 
1.28) 
0.432 0.73 (0.46, 
1.15) 
0.175 0.75 (0.48, 
1.17) 
0.208 0.49 (0.27, 
0.88) 
0.018 
Tenofovir Not current 1   1   1   1   
 Current 1.55 (0.98, 
2.43) 
0.059 1.56 (0.96, 
2.54) 
0.075 1.57 (0.97, 
2.54) 
0.066 1.92 (1.04, 
3.54) 
0.036 
Stavudine Not current 1   1   1   1   
 Current 3.31 (1.69, 
6.47) 
<0.001 1.81 (0.94, 
3.48) 
0.075 2.66 (1.40, 
5.07) 
0.003 1.53 (0.67, 
3.49) 
0.318 
Zidovudine Not current 1   1   1   1   
 Current 0.60 (0.38, 
0.97) 
0.036 0.58 (0.33, 
1.00) 
0.052 0.53 (0.31, 
0.92) 
0.025 0.33 (0.14, 
0.81) 
0.015 
NNRTI              
Any NNRTI Not current 1   1   1   1   
 Current 1.47 (0.96, 
2.25) 
0.075 1.43 (0.90, 
2.27) 
0.130 1.57 (0.99, 
2.47) 
0.053 1.85 (1.02, 
3.34) 
0.041 
Efavirenz Not current 1   1   1   1   
 Current 1.71 (1.07, 
2.74) 
0.024 1.68 (1.02, 
2.77) 
0.042 1.82 (1.11, 
2.98) 
0.017 2.27 (1.23, 
4.20) 
0.009 
  
            
PI              
Any PI Not current 1   1   1   1   
 
Current 1.12 (0.75, 
1.68) 
0.587 1.18 (0.75, 
1.85) 
0.472 1.22 (0.78, 
1.91) 
0.375 1.45 (0.79, 
2.66) 
0.225 
 
 
            
Type of drug 
therapy at 
recruitment 
PI-based 
HAART 
1   1   1   1   
NRTI mono-
therapy 
0.84 (0.38, 
1.87) 
0.666 0.56 (0.20, 
1.54) 
0.262 0.79 (0.32, 
1.95) 
0.609 0.23 (0.03, 
1.79) 
0.162 
NNRTI-based 
HAART 
 
1.20 (0.76, 
1.89) 
0.446 1.12 (0.67, 
1.85) 
0.671 1.16 (0.71, 
1.91) 
0.551 1.13 (0.58, 
2.17) 
0.723 
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Body fat alterations Lipohypertrophy Lipoatrophy Combined lipohypertrophy 
and lipoatrophy 
  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Triple class 3.09 (0.92, 
10.35) 
0.068 3.14 (1.01, 
9.75) 
0.048 3.97 (1.25, 
12.65) 
0.020 5.62 (1.76, 
17.98) 
0.004 
  
            
Odds ratios (OR) and accompanying 95% confidence interval (95% CI) for fat alterations by participant characteristic. CDC-defined immune status - stage 1: no immunosuppression, 
stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe 
symptoms. 
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Table D-3: Univariable analysis for body fat alterations outcomes by ever use of antiretroviral therapy 
    
Body fat alterations  Lipohypertrophy Lipoatrophy 
Both lipoatrophy  
and lipohypertrophy  
n=422 n=421 n=420 n=422 
    
OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  
Ever use of ART No 1 1 1 1 
 
Yes 2.78 (1.10, 7.01) 0.03 1.79 (0.66, 4.82) 0.251 5.4 (1.26, 23.11) 0.023 4.38 (0.58, 32.90) 0.151 
Any NRTI No 1 1 1 1 
 
Yes 2.78 (1.10, 7.01) 0.03 1.79 (0.66, 4.82) 0.251 5.4 (1.26, 23.11) 0.023 4.38 (0.58, 32.90) 0.151 
Didanosine No 1 1 1 1 
 
Yes 2.74 (1.83, 4.07) <0.001 2.49 (1.60, 3.87) <0.001 2.69 (1.73, 4.18) <0.001 3.37 (1.82, 6.23) <0.001 
Lamivudine No 1 1 1 1 
 
Yes 1.60 (0.84, 3.06) 0.151 1.26 (0.62, 2.57) 0.524 1.49 (0.71, 3.10) 0.288 1.05 (0.42, 2.60) 0.914 
Stavudine No 1 1 1 1 
 
Yes 3.92 (2.59, 5.93) <0.001 2.43 (1.55, 3.81) <0.001 4.98 (3.05, 8.15) <0.001 4.09 (2.09, 8.00) <0.001 
Zidovudine No 1 1 1 1 
 
Yes 1.16 (0.75, 1.79) 0.511 1.03 (0.63, 1.66) 0.919 1.13 (0.70, 1.84) 0.619 0.93 (0.50, 1.73) 0.812 
Tenofovir No 1 1 1 1 
 
Yes 1.62 (1.06, 2.47) 0.025 1.52 (0.96, 2.40) 0.071 2.01 (1.28, 3.15) 0.002 2.51 (1.42, 4.45) 0.002 
Any NNRTI No 1 1 1 1 
 
Yes 1.81 (1.21, 2.70) 0.004 1.56 (1.00, 2.43) 0.05 1.96 (1.25, 3.08) 0.004 2.01 (1.08, 3.71) 0.026 
Efavirenz No 1 1 1 1 
 
Yes 2.51 (1.68, 3.77) <0.001 2.02 (1.31, 3.13) 0.002 2.55 (1.65, 3.95) <0.001 2.54 (1.43, 4.50) 0.001 
Nevirapine No 1 1 1 1 
 
Yes 0.93 (0.59, 1.46) 0.753 1.11 (0.68, 1.81) 0.687 0.88 (0.53, 1.45) 0.619 1.14 (0.60, 2.15) 0.690 
Any PI No 1 1 1 1 
 
Yes 2.11 (1.28, 3.46) 0.003 2.15 (1.20, 3.87) 0.01 2.23 (1.24, 4.00) 0.007 3.33 (1.29, 8.59) 0.013 
Ritonavir booster No 1 1 1 1 
 
Yes 1.59 (1.06, 2.38) 0.024 1.81 (1.14, 2.86) 0.012 1.76 (1.12, 2.78) 0.015 3.01 (1.51, 6.00) 0.002 
Indinavir No 1 1 1 1 
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Body fat alterations  Lipohypertrophy Lipoatrophy 
Both lipoatrophy  
and lipohypertrophy  
n=422 n=421 n=420 n=422 
    
OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  
 
Yes 4.13 (1.70, 10.06) 0.002 2.87 (1.29, 6.40) 0.010 3.3 (1.48, 7.36) 0.004 3.22 (1.33, 7.81) 0.010 
Nelfinavir  No 1 1 1 1 
 
Yes 1.83 (1.24, 2.70) 0.003 1.51 (0.98, 2.32) 0.062 1.39 (0.91, 2.14) 0.128 1.01 (0.57, 1.76) 0.986 
Saquinavir No 1 1 1 1 
  Yes 2.5 (0.96, 6.48) 0.06 3.94 (1.54, 10.06) 0.004 1.54 (0.59, 4.02) 0.375 3.26 (1.18, 8.96) 0.022 
 
 
 
 
 
D.3 Multivariable analyses for body fat alterations 
 
See next page.
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Table D-4: Final multivariable models for body fat alteration outcomes with ever-use of specific antiretroviral drugs as explanatory variables 
  
Body fat alterations Any lipohypertrophy 
 
Any lipoatrophy  
 
Combined lipohypertrophy  
and lipoatrophy  
  
n=342 n=354 n=344 n=359 
    n  AOR 
(95% CI) 
P n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p 
Age per year 342 1.03 
(0.95, 1.12) 
0.491 354 0.93 
(0.85, 1.02) 
0.137 344 1.17 
(1.06, 1.28) 
0.001 359 1.13 
(1.00, 1.27) 
0.045 
Duration of ART per year 342 0.98 
(0.91, 1.05) 
0.608 354 0.97 
(0.90, 1.05) 
0.496 344 0.98 
(0.91, 1.06) 
0.65 359 0.95 
(0.86, 1.04) 
0.270 
Ethnicity Black 93 1      
  
  92 1      
  
  
 White 232 2.56 
(1.25, 5.23) 
0.01     
  
  235 3.87 
(1.50, 10.01) 
0.005     
  
  
 Other 17 1.08 
(0.28, 4.19) 
0.913     
  
  17 0.97 
(0.16, 6.03) 
0.978     
  
  
BMI (kg/m2) per unit 342 1.2 
(1.09, 1.31) 
<0.001 354 1.46 
(1.30, 1.64) 
<0.001     
  
      
  
  
Stavudine Never 156 1  161 1  157 1      
  
  
 Ever 186 3.56 
(2.08, 6.09) 
<0.001 193 2.53 
(1.38, 4.63) 
0.003 187 4.98 
(2.58, 9.61) 
<0.001     
  
  
Efavirenz Never 212 1      
  
  212 1  222 1  
 Ever 130 1.86 
(1.10, 3.16) 
0.022     
  
  132 1.87 
(1.05, 3.35) 
0.034 137 2.38 
(1.11, 5.12) 
0.026 
Didanosine  Never 
    
  
      
  
      
  
  179 1  
 Ever 
    
  
      
  
      
  
  180 3.44 
(1.47, 8.07) 
0.004 
Ritonavir booster Never 
    
  
      
  
      
  
  128 1  
 Ever 
    
  
      
  
      
  
  231 2.92 
(1.16, 7.33) 
0.023 
Indinavir Never 
    
  
      
  
      
  
  338 1  
  Ever 
    
  
      
  
      
  
  21 4 
(1.04, 15.41) 
0.044 
Models constructed using reverse stepwise logistic regression. CDC-defined immune status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe 
immunosuppression. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
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Table D-5: Sensitivity analysis: Multivariable models for moderate/severe body fat alteration outcomes  
  
Body fat alteration Any lipohypertrophy 
 
Any lipoatrophy  
 
Combined lipohypertrophy  
and lipoatrophy  
  
n=302 n=338 n=305 n=97 
    n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p 
Age per year 302 1.09 (0.97, 1.22) 0.158 338 0.99 (0.86, 1.14) 0.895 305 1.24 (1.09, 1.42) 0.001 97 0.85 (0.60, 1.21) 0.371 
Duration of ART per year 302 1.05 (0.96, 1.15) 0.280 338 1.03 (0.92, 1.14) 0.634 305 1.07 (0.97, 1.18) 0.191 97 1.15 (0.89, 1.49) 0.275 
Ethnicity Black 73 1     73 1  50 1  
 White 215 3.17 (1.09, 9.28) 0.035    218 3.17 (0.89, 11.39) 0.076 44 20.19 (1.40, 291.36) 0.027 
 Other 14 3.81 (0.64, 22.87) 0.143    14 - 0.997 3 - 1.00 
Maximum CDC  
clinical status 
N+A 121 1  139 1  121 1     
B 110 0.88 (0.40, 1.92) 0.747 122 0.81 (0.32, 2.08) 0.663 111 1.11 (0.46, 2.68) 0.808    
C 71 1.54 (0.68, 3.48) 0.300 77 1.22 (0.43, 3.43) 0.707 73 1.53 (0.57, 4.06) 0.398    
Nadir CDC 
Immune status 
Stage 1 
      111 1     
Stage 2 
      123 0.32 (0.14, 0.76) 0.010    
Stage 3 
      71 0.40 (0.14, 1.08) 0.071    
BMI (kg/m2) per unit 302 1.21 (1.09, 1.35) <0.001 338 1.51 (1.29, 1.75) <0.001    97 1.16 (0.83, 1.61) 0.397 
Efavirenz Never 226 1           
 Ever 41 0.82 (0.31, 2.18) 0.698          
Didanosine  Never 261 1           
 Ever 41 0.82 (0.31, 2.18) 0.698          
Lamivudine Never 
         25 1  
 Ever 
         72 0.06 (0.01, 0.58) 0.015 
Stavudine Never 266 1     269 1     
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Body fat alteration Any lipohypertrophy 
 
Any lipoatrophy  
 
Combined lipohypertrophy  
and lipoatrophy  
  
n=302 n=338 n=305 n=97 
    n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p 
 Ever 36 1.71 (0.65, 4.55) 0.279    36 2.18 (0.77, 6.15) 0.141    
Zidovudine Never 
         53 1  
  Ever 
         44 - 1.00 
Model structure defined by backward stepwise regression using fat disorder outcomes as outcome variables: optimal models then repeated using moderate/severe fat disorder as the 
outcome variables. CDC-defined immune status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical 
status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
  
         Appendix D 
473 
 
 
 
 
Table D-6: Final multivariable models for body fat alteration outcome adjusted by Tanner score for puberty 
  
Body fat alteration  Any lipohypertrophy 
 
Any lipoatrophy  
 
Combined lipohypertrophy  
and lipoatrophy  
  
n=268 n=300 n=2667 n=283 
    n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p 
Age per year 268 1.03 (0.89, 1.20) 0.656 300 0.95 (0.82, 1.10) 0.491 267 1.14 (0.97, 1.33) 0.114 283 1.01 (0.82, 1.24) 0.922 
Duration of ART per year 268 1.07 (0.98, 1.17) 0.115 300 1.00 (0.92, 1.09) 0.987 267 1.05 (0.96, 1.16) 0.263 283 1.02 (0.91, 1.15) 0.721 
Tanner score for 
puberty  
I 97 1  111 1  96 1  101 1  
II-IV 106 1.37 (0.51, 3.71) 0.531 114 0.95 (0.34, 2.69) 0.922 106 1.81 (0.62, 5.33) 0.280 114 1.39 (0.35, 5.56) 0.646 
V 65 1.36 (0.34, 5.37) 0.663 75 0.75 (0.18, 3.06) 0.685 65 1.82 (0.41, 7.98) 0.429 68 1.44 (0.22, 9.31) 0.701 
Ethnicity Black 64 1     63 1  73 1  
 White 190 2.89 (1.21, 6.91) 0.017    190 4.18 (1.43, 12.26) 0.009 195 3.15 (0.71, 14.00) 0.132 
 Other 14 1.72 (0.38, 7.85) 0.484    14 1.37 (0.21, 9.06) 0.743 15 0.82 (0.06, 10.87) 0.879 
Maximum CDC  
clinical status 
N+A 111 1  128 1  110 1     
B 94 1.72 (0.86, 3.42) 0.125 104 2.17 (1.07, 4.43) 0.033 94 1.98 (0.94, 4.16) 0.073    
C 63 2.72 (1.29, 5.72) 0.009 68 2.50 (1.13, 5.51) 0.023 63 1.87 (0.80, 4.36) 0.146    
Nadir CDC 
Immune status 
Stage 1 
      99 1     
Stage 2 
      109 0.44 (0.21, 0.93) 0.030    
Stage 3 
      59 0.69 (0.29, 1.68) 0.414    
BMI (kg/m2) per unit 268 1.17 (1.06, 1.30) 0.003 300 1.46 (1.29, 1.65) <0.001    283 1.20 (1.05, 1.37) 0.006 
Efavirenz Never 200 1           
 Ever 68 2.39 (1.19, 4.79) 0.014          
Didanosine  Never 231 1           
 Ever 37 0.46 (0.18, 1.18) 0.105          
Lamivudine Never 
         88 1  
 Ever 
         195 0.52 (0.23, 1.19) 0.120 
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Body fat alteration  Any lipohypertrophy 
 
Any lipoatrophy  
 
Combined lipohypertrophy  
and lipoatrophy  
  
n=268 n=300 n=2667 n=283 
    n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p 
Stavudine Never 234 1     234 1     
 Ever 34 5.01 (1.92, 13.05) 0.001    33 2.19 (0.87, 5.53) 0.098    
Zidovudine Never 
         202 1  
  Ever 
         81 0.32 (0.10, 0.98) 0.045 
Model structure defined by backward stepwise regression using fat disorder outcomes as outcome variables , with addition of Tanner score for puberty as an additional variable. CDC-
defined immune status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
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Table D-7: Final multivariable models for body fat alteration outcome with the addition of an interaction between sex and age 
  
Body fat alteration Any lipohypertrophy 
 
Any lipoatrophy  
 
Combined lipohypertrophy  
and lipoatrophy  
  
n=296 n=330 n=297 n=310 
    n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p 
Age per year 296 1.07 (0.95, 1.20) 0.241 330 0.93 (0.83, 1.05) 0.237 297 1.21 (1.06, 1.38) 0.004 310 1.08 (0.90, 1.30) 0.400 
Duration of ART per year 296 1.05 (0.97, 1.13) 0.257 330 0.99 (0.92, 1.07) 0.817 297 1.04 (0.96, 1.13) 0.361 310 1.03 (0.92, 1.14) 0.645 
Sex Male 153 1  168 1  155 1  160 1  
Female 143 1.34 (0.20, 9.12) 0.766 162 1.18 (0.17, 8.03) 0.863 142 2.19 (0.25, 19.17) 0.478 150 4.57 (0.23, 90.24) 0.318 
Age*Female Interaction 143 1.02 (0.87, 1.18) 0.845 162 1.01 (0.87, 1.18) 0.856 142 0.98 (0.83, 1.15) 0.780 150 0.94 (0.75, 1.17) 0.563 
Ethnicity Black 73 1     72 1  81 1  
 White 209 3.17 (1.43, 7.02) 0.004    211 4.05 (1.56, 10.52) 0.004 214 4.16 (0.99, 17.57) 0.052 
 Other 14 1.98 (0.47, 8.37) 0.354    14 1.34 (0.21, 8.30) 0.756 15 0.77 (0.06, 10.34) 0.845 
Maximum CDC  
clinical status 
N+A 121 1  139 1  120 1     
B 108 1.85 (0.98, 3.49) 0.059 118 2.16 (1.11, 4.20) 0.024 109 1.95 (0.98, 3.87) 0.056    
C 67 2.34 (1.16, 4.71) 0.018 73 2.17 (1.03, 4.59) 0.043 68 1.70 (0.76, 3.79) 0.197    
Nadir CDC 
Immune status 
Stage 1 
      109 1     
Stage 2 
      120 0.37 (0.18, 0.74) 0.005    
Stage 3 
      68 0.62 (0.27, 1.39) 0.243    
BMI (kg/m2) per unit 296 1.15 (1.05, 1.27) 0.004 330 1.43 (1.28, 1.61) <0.001    310 1.20 (1.06, 1.37) 0.005 
Efavirenz Never 222 1           
 Ever 74 1.87 (0.99, 3.52) 0.053          
Didanosine  Never 255 1           
 Ever 41 0.46 (0.19, 1.10) <0.001          
Lamivudine Never 
         97 1  
 Ever 
         213 0.36 (0.15, 0.83) 0.017 
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Body fat alteration Any lipohypertrophy 
 
Any lipoatrophy  
 
Combined lipohypertrophy  
and lipoatrophy  
  
n=296 n=330 n=297 n=310 
    n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p n  AOR 
(95% CI) 
p 
Stavudine Never 260 1     262 1     
 Ever 36 5.66 (2.25, 14.28) <0.001    35 2.78 (1.15, 6.70) 0.023    
Zidovudine Never 
         217 1  
  Ever 
         93 0.38 (0.14, 1.08) 0.070 
Model structure defined by backward stepwise regression using fat disorder outcomes as outcome variables , with addition of an interaction for sex and age. CDC-defined immune 
status - stage 1: no immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no 
symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms. 
 
Table D-8: Multivariable logistic regressions for body fat alterations including categories of ART as explanatory variables: threshold for stepwise 
covariate selection set at 10% significance 
  Body fat alterations Lipohypertrophy Lipoatrophy Both lipohypertrophy 
and lipoatrophy 
  n = 302 n = 301 n = 303 n = 320 
Age  Per year 1.06 (0.97, 1.16) 0.93 (0.84, 1.03) 1.16 (1.06, 1.27)*** 1.17 (1.04, 1.31)** 
Ethnicity Black 1 1 1 1 
White 3,58 (1.59, 7.62)** 2.17 (0.88, 5.36) † 5.08 (1.95, 13.27)*** 5.22 (1.36, 20.03)*** 
Other 1.82 (0.44, 7.55) 1.44 (0.27, 7.71) 1.62 (0.27, 9.72) 0.72 (0.05, 9.91) 
Body mass index Per kg/m2 1.17 (1.07, 1.29)*** 1.45 (1.28, 1.63)***   
Maximum CDC 
clinical status 
N/A 1 1 1  
B 1.94 (1.05, 3.56)* 2.06 (1.00, 4.26)† 1.78 (0.92, 3.45)†  
C 2.59 (1.32, 5.11)** 2.86 (1.31, 6.25)** 1.71 (0.82, 3.57)  
Duration of ART  Per year 1.06 (0.97, 1.16) 1.02 (0.94, 1.11) 1.03 (0.95, 1.11) 1.01 (0.91, 1.11) 
NNRTI use at 
recruitment 
No 1 1 1 1 
Yes 1.97 (1.11, 3.50)* 1.77 (0.92, 3.41)† 1.85 (1.01, 3.42)* 8.18 (2.18, 30.63)** 
PI use at recruitment No 
   1 
Yes 
   6.55 (1.73, 24.74)** 
†0.10 > p ≥ 0.05, *0.05 > p ≥> 0.01, **0.01 > p ≥ 0.001, ***0.001< p 
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Table D-9: Multivariable logistic regressions for body fat alterations including specific ART drugs  as explanatory variables: threshold for stepwise 
covariate selection set at 10% significance 
  Body fat alterations Lipohypertrophy Lipoatrophy Both lipohypertrophy 
and lipoatrophy 
  n = 302 n = 337 n = 318 n = 305 
Age  Per year 1.08 (0.99, 1.18) 0.93 (0.85, 1.02) 1.20 (1.10, 1.31)*** 1.14 (1.02, 1.28)* 
Ethnicity Black 1  1 1 
White 2.90 (1.36, 6.17)**  4.81 )1.90, 12.16)*** 3.45 (0.87, 13.62)† 
Other 1.73 (0.42, 7.12)  1.47 (0.25, 8.69) 1.25 (0.11, 14.68) 
Body mass index Kg/m2 1.16 (1.05, 1.27)** 1.46 (1.30, 1.63)***   
Maximum CDC-
defined clinical 
symptoms 
N/A 1 1  1 
B 1.81 (0.97, 3.38)† 2.08 (1.07, 4.05)*  2.29 (0.93, 5.61)† 
C 2.36 (1.20, 4.66)* 2.24 (1.07, 4.69)*  1.80 (0.68, 4.77) 
Duration of ART  Per year 1.04 (0.96, 1.12) 0.99 (0.91, 1.07) 1.03 (0.96, 1.12) 0.99 (0.89, 1.09) 
Zidovudine at 
recruitment 
No 
   1 
Yes 
   0.28 (0.10, 0.78)* 
Stavudine at 
recruitment 
No 1  1  
Yes 4.59 (1.88, 11.25)***  3.19 (1.36, 7.47)**  
Efavirenz at 
recruitment 
No 1  1  
Yes 1.99 (1.07, 3.68)*  1.73 (0.91, 3.27)†  
†0.10 > p ≥ 0.05, *0.05 > p ≥> 0.01, **0.01 > p ≥ 0.001, ***0.001< p 
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Appendix E Appendix to Chapter 5 
 
 
E.1 Prevalence of metabolic abnormality outcomes by categories of antiretroviral therapy 
 
Table E-1: Prevalence of metabolic abnormality outcomes by categories of antiretroviral therapy: exclusion of ART-naïve/ART status missing 
subjects 
 
 Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Hypercholesterolemia and 
fasting 
hypertriglyceridemia 
 
 Prevalence n/N p-
value 
Prevalence n/N p-
value 
Prevalence n/N p-
value 
Prevalence n/N p-
value 
NRTI Not 
current 
100.00 1/1 0.101 100.00 1/1 0.032 50.00 1/2 0.130 50.00 1/2 0.005 
 Current  26.97 96/356  17.60 63/359  13.30 48/361  5.03 18/358  
NNRTI Not 
current 
29.39 67/228 0.211 20.52 47/229 0.076 14.72 34/231 0.368 6.55 15/229 0.153 
 Current  23.26 30/129  13.08 17/130  11.36 15/132  3.05 4/131  
PI Not 
current 
18.06 26.144 0.001 9.66 14/145 0.001 8.90 13/146 0.036 1.38 2/145 0.007 
 Current  33.33 71/2130  23.36 50/214  16.59 36/217  7.91 17/215  
Association investigated using χ2 test   
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E.2 Univariable analyses for metabolic abnormality 
 
Table E-2: Univariable analyses for metabolic abnormality outcomes at recruitment 
  
Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Combined fasting 
hypertriglyceridemia, and 
hypercholesterolemia 
  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Demographic 
factors 
             
Sex Male 1   1   1   1   
 Female 0.82 (0.53, 
1.28) 
0.387 0.67 (0.40, 
1.12) 
0.130 0.93 (0.52, 
1.65) 
0.793 0.64 (0.27, 
1.53) 
0.312 
Age (years) 2-6 1   1   1   1   
 7-11 0.97 (0.47, 
2.01) 
0.936 0.85 (0.38, 
1.92) 
0.695 0.93 (0.41, 
2.07) 
0.851 0.71 (0.25, 
2.03) 
0.525 
 12-18 0.41 (0.20, 
0.81) 
0.011 0.44 (0.20, 
0.95) 
0.036 0.20 (0.09, 
0.47) 
<0.001 0.10 (0.03, 
0.36) 
<0.001 
Ethnicity Black 1   1   1   1   
 White 1.98 (1.12, 
3.49) 
0.019 2.49 (1.22, 
5.09) 
0.012 1.70 (0.82. 
3.52) 
0.155 2.27 (0.66, 
7.88) 
0.196 
 Other 1.00 (0.26, 
3.85) 
1.000 1.27 (0.25, 
6.36) 
0.774 - - - - - - 
Country of 
residence 
Italy 1   1   1   1   
Belgium 0.71 (0.39, 
1.32) 
0.281 0.43 (0.20, 
0.96) 
0.038 1.09 (0.49, 
2.43) 
0. 826 0.93 (0.25, 
3.41) 
0.910 
Poland 1.46 (0.82, 
2.61) 
0.201 0.73 (0.35, 
1.52) 
0.398 3.96 (2.05, 
7.65) 
<0.001 3.29 (1.27, 
8.53) 
0.015 
Infection 
factors 
             
CDC immune 
stage at 
recruitment 
Stage 1 1   1   1   1   
Stage 2 0.60 (0.33, 
1.09) 
0.093 0.95 (0.50, 
1.81) 
0.874 0.52 (0.23, 
1.19) 
0.122 1.14 (0.41, 
3.19) 
0.799 
Stage 3 0.36 (0.08, 
1.61) 
0.181 0.29 (0.04, 
2.25) 
0.238 0.36 (0.05, 
2.75) 
0.323 - - - 
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Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Combined fasting 
hypertriglyceridemia, and 
hypercholesterolemia 
  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
Nadir CDC 
immune 
stage 
Stage 1 1   1   1   1   
Stage 2 0.68 (0.42, 
1.12) 
0.128 0.92 (0.52, 
1.62) 
0.773 0.49 (0.26, 
0.94) 
0.032 0.55 (0.21, 
1.46) 
0.229 
Stage 3 0.73 (0.40, 
1.33) 
0.304 0.73 (0.35, 
1.52) 
0.402 0.69 (0.32, 
1.46) 
0.327 0.67 (0.21, 
2.17) 
0.502 
CDC clinical 
stage at 
recruitment 
N+A 1   1   1   1   
B 0.72 (0.23, 
2.20) 
0.559 0.85 (0.24, 
2.98) 
0.795 0.34 (0.04, 
2.60) 
0.300 - - - 
C 0.82 (0.17, 
4.01) 
0.805 0.60 (0.07, 
4.88) 
0.633 1.52 (0.32, 
7.24) 
0.603 - - - 
Maximum 
CDC clinical 
stage  
N+A 1   1   1   1   
B 1.12 (0.68, 
1.86) 
0.655 0.95 (0.53, 
1.72) 
0.866 0.86 (0.44, 
1.69) 
0.665 0.43 (0.13, 
1.37) 
0.151 
C 0.91 (0.49, 
1.67) 
0.758 0.91 (0.46, 
1.83) 
0.799 1.02 (0.48, 
2.17) 
0.953 1.08 (0.39, 
3.04) 
0.878 
Viral load 
(copies/ml) 
≤50 1   1   1   1   
>50 0.38 (0.21, 
0.68) 
0.001 0.64 (0.32, 
1.26) 
0.197 0.25 (0.13, 
0.48) 
<0.001 0.31 (0.12, 
0.80) 
0.015 
Maximum 
duration of 
ART use 
Per year 0.92 (0.87, 
0.99) 
0.017 0.97 (0.90, 
1.04) 
0.373 0.90 (0.83, 
0.98) 
0.017 0.98 (0.87, 
1.11) 
0.707 
Other factors              
Hepatitis C 
co-infection 
Uninfected 1   1   1   -   
Infected 0.36 (0.11, 
1.24) 
0.106 0.40 (0.09, 
1.75) 
0.227 0.26 (0.03, 
1.95) 
0.189 - - - 
Tanner score 
for puberty 
I 1   1   1   1   
II-IV 0.36 (0.21, 
0.62) 
<0.001 0.44 (0.24, 
0.82) 
0.009 0.21 (0.10, 
0.45) 
<0.001 0.15 (0.04, 
0.52) 
0.003 
V 0.38 (0.20, 
0.70) 
0.002 0.30 (0.14, 
0.66) 
0.003 0.27 (0.12, 
0.60) 
0.002 0.08 (0.01, 
0.58) 
0.013 
BMI Kg/m2 0.94 (0.88, 
1.00) 
 
 
 
0.052 0.95 (0.88, 
1.02) 
0.175 0.87 (0.79, 
0.95) 
0.002 0.86 (0.75, 
0.99) 
0.037 
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Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Combined fasting 
hypertriglyceridemia, and 
hypercholesterolemia 
  
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value 
NRTI              
Any NRTI Not current 1   1   1   1   
 Current 1.05 (0.43, 
2.57) 
0.906 0.98 (0.36, 
2.68) 
0.972 0.77 (0.28, 
2.10) 
0.605 0.48 (0.13, 
1.72) 
0.258 
NNRTI              
Any NNRTI Not current 1   1   1   1   
 Current 0.75 (0.46, 
1.23) 
0.253 0.60 (0.33, 
1.10) 
0.098 0.75 (0.39, 
1.41) 
0.367 0.44 (0.15, 
1.35) 
0.152 
PI              
Any PI Not current 1   1   1   1   
 
Current 2.16 (1.34, 
3.48) 
0.002 2.61 (1.46, 
4.67) 
0.001 1.84 (0.99, 
3.40) 
0.053 3.63 (1.20, 
10.99) 
0.023 
Ritonavir 
booster 
Not current 1   1   1   1   
Current 2.67  (1.66, 
4.30) 
<0.001 3.08 (1.73, 
5.46) 
<0.001 2.36 (1.27, 
4.36) 
0.006 4.51 (1.49, 
13.67) 
0.008 
Type of drug 
therapy at 
recruitment 
PI-based 
HAART 
1   1   1   1   
NRTI 
immunotherapy 
0.24 (0.07, 
0.82) 
0.023 0.25 (0.06, 
1.09) 
0.065 0.18 (0.02, 
1.36) 
0.096 - - - 
NNRTI-based 
HAART 
0.52 (0.30, 
0.89) 
0.018 0.39 (0.20, 
0.77) 
0.007 0.57 (0.28, 
1.15) 
0.118 - - - 
Triple class 1.78 (0.58, 
5.51) 
0.317 1.50 (0.44, 
5.09) 
0.517 0.91 (0.19, 
4.29) 
0.904 0.20 (0.05, 
0.90) 
0.036 
Odds ratio (OR) and accompanying 95% confidence interval (95% CI) for metabolic abnormality by participant characteristic. CDC-defined immune status - stage 1: no 
immunosuppression, stage 2: moderate immunosuppression, stage 3: severe immunosuppression. CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate 
symptoms, C: severe symptoms.  
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Table E-3: Univariable analyses for metabolic outcomes by ever-use of antiretroviral therapy 
    
Metabolic abnormality  Fasting hypertriglyceridemia Hypercholesterolemia 
Combined hypercholesterolemia and 
Fasting hypertriglyceridemia  
n= 415 n= 418 n=423 n= 419 
    
OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  
Ever use of ART No 1   1   1   1   
 
Yes 1.18 (0.46, 3.03) 0.724 1.19 (0.40, 3.55) 0.756 0.91 (0.30, 2.73) 0.866 0.70 (0.16, 3.16) 0.644 
Any NRTI No 1   1   1   1   
 
Yes 1.18 (0.46, 3.03) 0.724 1.19 (0.40, 3.55) 0.756 0.91 (0.30, 2.73) 0.866 0.70 (0.16, 3.16) 0.644 
Didanosine No 1   1   1   1   
 
Yes 1.25 (0.81, 1.95) 0.312 1.30 (0.78, 2.17) 0.312 0.78 (0.44, 1.38) 0.397 0.65 (0.27, 1.58) 0.340 
Lamivudine No 1   1   1   1   
 
Yes 1.26 (0.60, 2.64) 0.539 1.41 (0.57, 3.47) 0.452 0.86 (0.36, 2.02) 0.723 0.79 (0.22, 2.78) 0.712 
Stavudine No 1   1   1   1   
 
Yes 1.27 (0.82, 1.98) 0.284 1.44 (0.86, 2.42) 0.168 1.02 (0.58, 1.80) 0.938 0.95 (0.40, 2.23) 0.899 
Zidovudine No 1   1   1   1   
 
Yes 1.03 (0.63, 1.68) 0.918 1.65 (0.88, 3.09) 0.119 0.63 (0.35, 1.14) 0.126 1.01 (0.38, 2.65) 0.985 
Tenofovir No 1   1   1   1   
 
Yes 0.98 (0.61, 1.59) 0.947 1.17 (0.67, 2.02) 0.581 0.68 (0.35, 1.31) 0.250 0.88 (0.33, 2.29) 0.788 
Any NNRTI No 1   1   1   1   
 
Yes 0.89 (0.57, 1.39) 0.619 0.83 (0.49, 1.38) 0.467 0.59 (0.34, 1.04) 0.069 0.32 (0.13, 0.81) 0.016 
Efavirenz No 1   1   1   1   
 
Yes 0.86 (0.54, 1.35) 0.510 0.83 (0.49, 1.42) 0.502 0.57 (0.31, 1.07) 0.082 0.35 (0.12, 1.06) 0.062 
Nevirapine No 1   1   1   1   
 
Yes 1.07 (0.64, 1.78) 0.799 1.06 (0.59, 1.92) 0.838 0.71 (0.35, 1.43) 0.337 0.47 (0.14, 1.62) 0.231 
Any PI No 1   1   1   1   
 
Yes 1.93 (1.07, 3.47) 0.030 1.55  (0.79, 3.01) 0.201 2.24 (0.98, 5.12) 0.056 1.91 (0.55, 6.60) 0.306 
Ritonavir booster No 1   1   1   1   
 
Yes 2.08 (1.29, 3.37) 0.003 1.96 (1.11, 3.46) 0.020 2.14 (1.13, 4.07) 0.019 3.10 (1.03, 9.34) 0.044 
Indinavir No 1   1   1   1   
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Metabolic abnormality  Fasting hypertriglyceridemia Hypercholesterolemia 
Combined hypercholesterolemia and 
Fasting hypertriglyceridemia  
n= 415 n= 418 n=423 n= 419 
    
OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  OR (95% CI) p  
 
Yes 0.84 (0.33, 2.16) 0.724 1.18 (0.43, 3.23) 0.753 0.25 (0.03, 1.87) 0.177 - - - 
Nelfinavir  No 1   1   1   1   
 
Yes 1.40 (0.90, 2.17) 0.135 1.20 (0.72, 2.00) 0.484 1.19 (0.68, 2.09) 0.542 0.90 (0.38, 2.13) 0.808 
Saquinavir No 1   1   1   1   
  Yes 1.86 (0.70, 4.94) 0.210 2.37 (0.87, 6.47) 0.092 0.35 (0.05, 2.69) 0.315 - - - 
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E.3 Multivariable analyses for metabolic abnormality 
 
Table E-4: Final multivariable models for metabolic outcomes with ever-use of specific antiretroviral drugs as explanatory variables 
    
Any metabolic abnormality Any fasting 
hypertriglyceridemia 
Any hypercholesterolemia Combined 
hypercholesterolemia, and 
fasting 
hypertriglyceridemia 
    
n = 341 n = 356 n = 358 n = 356 
  n AOR  
(95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
n AOR 
 (95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
Age Per year 341 0.87  
(0.81, 0.94) 
<0.001 356 0.89  
(0.82, 0.97) 
0.008 358 0.82  
(0.75, 0.90) 
<0.001 356 0.71  
(0.60, 0.84) 
<0.001 
ART 
duration 
Per Year  341 0.96  
(0.89, 1.04) 
0.298 356 1.00  
(0.92, 1.09) 
0.962 358 0.99  
(0.90, 1.10) 
0.891 356 1.20  
(1.00, 1.43) 
0.049 
Sex Male 
            
Female 
            
Ethnicity Black 88 1           
White 236 2.08  
(1.01, 4.29) 
0.048          
Other 17 0.86  
(0.21, 3.59) 
0.836          
Viral load 
(HIV-RNA) 
<50 
copies/ml 
      128 1     
≥50 
copies/ml 
      230 2.77 
 (1.26, 6.10) 
0.011    
Ritonavir 
booster 
Never 122 1  127 1  128 1  128 1  
Ever 219 2.11  
(1.15, 3.87) 
0.016 229 2.08  
(1.04, 4.18) 
0.038 230 2.77  
(1.26, 6.10) 
0.011 228 5.49  
(1.22, 24.62) 
0.026 
Models constructed using backwards stepwise logistic regression.  
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Table E-5: Sensitivity analyses: Multivariable models for moderate/severe metabolic abnormality outcomes  
    
Any metabolic abnormality Any fasting 
hypertriglyceridemia 
Any hypercholesterolemia Combined 
hypercholesterolemia, and 
fasting 
hypertriglyceridemia 
    
n = 315 n = 309 n = 321 n = 321 
  n AOR  
(95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
n AOR 
 (95% CI) 
p-
value 
Age Per year 315 0.90  
(0.82, 0.98) 
0.019 309 0.95 
 (0.86, 1.05) 
0.362 321 0.76 
 (0.64, 0.90) 
0.001 321 0.76  
(0.63, 0.91) 
0.003 
ART 
duration 
Per Year  315 1.01 
 (0.91, 1.11) 
0.866 309 1.00  
(0.90, 1.11) 
0.943 321 1.11  
(0.93, 1.34) 
0.248 321 1.07  
(0.88, 1.32) 
0.491 
Sex Male 
   161 1        
Female 
   148 0.44  
(0.20, 0.96) 
0.040       
Ethnicity Black 77 1  79 1        
White 223 2.12  
 
(0.77, 5.87) 
0.148 215 2.53  
(0.80, 8.05) 
0.115       
Other 15 0.69  
(0.07, 6.62) 
0.748 15 1.01 
 (0.10, 
10.32) 
0.992       
Viral load 
(HIV-RNA) 
<50 
copies/ml 
   195 1  203 1     
≥50 
copies/ml 
   114 1.18  
(0.54, 2.60) 
0.679 118 0.80 
 (0.24, 2.63) 
0.716    
Ritonavir 
booster 
Not current 144 1  141 1  147 1  147 1  
Current 171 4.65 
(1.97, 10.99) 
<0.001 168 4.35  
(1.72, 11.03) 
0.002 174 4.04  
(1.09, 14.96) 
0.037 174 4.68  
(0.98, 22.42) 
0.054 
Models constructed using backwards stepwise logistic regression. 
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Table E-6: Final multivariable models for metabolic outcomes adjusted by Tanner score for puberty 
    
Any metabolic abnormality Any fasting 
hypertriglyceridemia 
Any hypercholesterolemia Combined 
hypercholesterolemia, and 
fasting 
hypertriglyceridemia 
    
n = 278 n = 272 n = 293 n = 292 
  n AOR  
(95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
Age Per year 278 0.98 
 (0.85, 1.11) 
0.712 272 0.96  
(0.82, 1.13) 
0.623 293 0.86  
(0.74, 1.01) 
0.062 292 0.73 
 (0.55, 0.95) 
0.021 
ART 
duration 
Per Year  278 0.95 
 (0.87, 1.04) 
0.278 272 0.97  
(0.87, 1.08) 
0.564 293 1.02  
(0.91, 1.14) 
0.777 292 1.28  
(1.04, 1.59) 
0.022 
Tanner 
score 
puberty 
I 101 1  98 1  107 1  107 1  
II-IV 111 0.37  
(0.15, 0.94) 
0.036 106 0.40  
(0.13, 1.24) 
0.113 115 0.47  
(0.15, 1.46) 
0.190 116 0.34 
 (0.05, 2.43) 
0.282 
V 66 0.32 
 (0.09, 1.22) 
0.095 68 0.30  
(0.06, 1.50) 
0.143 71 0.89  
(0.19, 4.17) 
0.884 69 0.71  
(0.04, 12.65) 
0.817 
Sex Male 
   136 1        
Female 
   136 0.80  
(0.39, 1.60) 
0.522       
Ethnicity Black 69 1  70 1        
White 194 2.00  
(0.90, 4.47) 
0.090 187 2.46  
(0.83, 7.27) 
0.103       
Other 15 0.85  
(0.19, 3.80) 
0.827 15 0.92  
(0.14, 6.23) 
0.936       
Viral load 
(HIV-RNA) 
<50 
copies/ml 
   169 1  181 1     
≥50 
copies/ml 
   103 1.51  
(0.69, 3.30) 
0.304 112 0.41  
(0.18, 0.93) 
0.033    
Ritonavir 
booster 
Not current 124 1  121 1  132 1  131 1  
Current 154 2.25  
(1.22, 4.16) 
0.009 151 2.87  
(1.29, 6.39) 
0.010 161 2.65  
(1.24, 5.67) 
0.012 161 13.19  
(1.69, 103.1) 
0.014 
Original models constructed using backward stepwise logistic regression: additional adjustment with Tanner score for puberty 
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Table E-7: Final multivariable models for fat disorder outcome with the addition of an interaction between sex and age 
    
Any metabolic abnormality Any fasting 
hypertriglyceridemia 
Any hypercholesterolemia Combined 
hypercholesterolemia, and 
fasting hypertriglyceridemia 
    
n = 308 n = 309 n = 324 n = 322 
  n AOR  
(95% CI) 
p-
value 
n AOR 
 (95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
n AOR  
(95% CI) 
p-
value 
Age Per year 308 0.91 
 (0.82, 1.00) 
0.047 309 0.93 
(0.83, 1.04) 
0.192 324 0.76 
(0.66, 0.87) 
<0.001 322 0.65 
(0.52, 0.82) 
<0.001 
ART 
duration 
Per Year  308 0.97  
(0.089, 1.05) 
0.447 309 0.98  
(0.89, 1.08) 
0.740 324 1.02 
(0.91, 1.14) 
0.752 322 1.25 
(1.02, 1.52) 
0.028 
Sex Male 161 1  161 1  167 1  167 1  
Female 147 2.39 
(0.41,13.96) 
0.333 148 3.74 
(0.50, 27.46) 
0.199 157 0.22 
(0.03, 1.55) 
0.129 155 0.16 
(0.01, 2.35) 
0.182 
Age*Female Interaction 147 0.93  
(0.08, 1.08) 
0.319 309 0.93 
(0.83, 1.04) 
0.192 157 1.18 
(0.98, 1.41) 
0.083 155 1.18 
(0.90, 1.55) 
0.221 
Ethnicity Black 76 1  79 1        
White 217 1.61  
(0.74, 3.48) 
0.230 215 2.33 
(0.85, 6.34) 
0.099       
Other 15 0.597  
(0.15, 2.98) 
0.597 15 0.81 
(0.13, 5.07) 
0.820       
Viral load 
(HIV-RNA) 
<50 
copies/ml 
   195 1  204 1     
≥50 
copies/ml 
   114 1.30 
(0.63, 2.70) 
0.476 120 0.35 
(0.15, 0.81) 
0.015    
Ritonavir 
booster 
Not current 140 1  141 1  148 1  147 1  
Current 168 2.91  
(1.59, 5.34) 
0.001 168 3.69 
(1.73, 7.87) 
0.001 176 2.76 
(1.29, 5.89) 
0.009 175 7.18 
(1.58, 32.62) 
0.011 
Original models constructed using backward stepwise logistic regression: additional adjustment with interaction between sex and age 
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Table E-8: Multivariable logistic regressions for metabolic abnormality outcomes   including categories of ART as explanatory variables: threshold 
for stepwise covariate selection set at 10% significance 
  
Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Both 
hypercholesterolemia 
and fasting 
hyoertriglyceridemia 
  
n = 326 n = 317 n = 331 n =328 
Age Per year 0.89 (0.82, 0.95)*** 0.88 (0.80, 0.96)** 0.82 (0.75, 0.90)*** 0.71 (0.59, 0.85)*** 
Ethnicity Black 
 1   
White 
 2.44 (0.92, 6.49)†   
Other 
 0.94 (0.15, 5.75)   
Detectable viral load ≤50 copies/ml 
  1 1 
>50 copies/ml 
  0.40 (0.18, 0.89)* 0.33 (0.09, 1.23)† 
Duration of ART  Per year 0.97 (0.90, 1.05) 0.99 (0.91, 1.09) 1.00 (0.90, 1.11) 1.24 (1.02, 1.50)* 
NNRTI at recruitment No 1    
Yes 2.11 (0.87, 5.11)†    
PI at recruitment No 1 1 1 1 
Yes 4.17 (1.72, 10.15)** 2.79 (1.35, 5.77)** 2.21 (1.07, 4.56)* 6.31 (1.39, 28.68)* 
†0.10 > p ≥ 0.05, *0.05 > p ≥> 0.01, **0.01 > p ≥ 0.001, ***0.001< p 
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Table E-9: Multivariable logistic regressions for metabolic abnormality outcomes   including specific ART drugs  as explanatory variables: 
threshold for stepwise covariate selection set at 10% significance 
  
Metabolic abnormality Fasting 
hypertriglyceridemia 
Hypercholesterolemia Both 
hypercholesterolemia 
and fasting 
hypertriglyceridemia 
  
n = 315 n = 328 n = 331 n = 328 
Age Per year 0.87 (0.81, 0.94)*** 0.88 (0.81, 0.97)** 0.82 (0.75, 0.90)*** 0.71 (0.60, 0.86)*** 
Ethnicity Black 1    
 White 1.64 (0.77, 3.49)    
 Other 0.75 (0.17, 3.25)    
Detectable viral load ≤50 copies/ml 
  1 1 
>50 copies/ml 
  0.39 (0.17, 0.86)* 0.30 (0.08, 1.12)† 
Duration of ART Per Year 0.97 (0.90, 1.05) 1.01 (0.92, 1.11) 1.01 (0.91, 1.12) 1.25 (1.03, 1.53)* 
Ritonavir-booster at 
recruitment 
No 1 1 1 1 
Yes 2.79 (1.56, 4.99)*** 6.17 (2.32, 16.40)*** 2.82 (1.36, 5.83)** 8.06 (1.76, 36.81)** 
Efavirenz at 
recruitment 
No 
 1   
Yes 
 2.57 (0.88, 7.47)†   
†0.10 > p ≥ 0.05, *0.05 > p ≥> 0.01, **0.01 > p ≥ 0.001, ***0.001< p 
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E.4 Prevalence of lipodystrophy syndrome by categories of antiretroviral 
therapy 
 
Table E-10: Prevalence of lipodystrophy syndrome by categories of antiretroviral 
therapy: exclusion of ART-naïve/ART status missing subjects 
  
Prevalence n/N p-value 
NRTI Not current 100.00 2/2 0.245 
 Current 59.55 212/356  
NNRTI Not current 58.95 135/229 0.672 
 Current 61.24 79/129  
PI Not current 54.55 78/143 0.100 
 Current 63.26 136/215  
Association investigated using χ2 test 
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E.5 Univariable analyses for lipodystrophy syndrome 
 
Table E-11: Univariable analyses for lipodystrophy syndrome by ever-use of antiretroviral 
therapy 
    
Lipodystrophy syndrome  
n= 416 
    
OR (95% CI) p  
Ever use of ART No 1   
 
Yes 2.60 (1.13, 5.98) 0.024 
Any NRTI No 1   
 
Yes 2.60 (1.13, 5.98) 0.024 
Didanosine No 1   
 
Yes 2.46 (1.65, 3.67) <0.001 
Lamivudine No 1   
 
Yes 1.72 (0.92, 3.21) 0.087 
Stavudine No 1   
 
Yes 2.95 (1.97, 4.41) <0.001 
Zidovudine No 1   
 
Yes 1.27 (0.82, 1.96) 0.283 
Tenofovir No 1   
 
Yes 1.32 (0.86, 2.03) 0.199 
Any NNRTI No 1   
 
Yes 1.43 (0.97, 2.12) 0.073 
Efavirenz No 1   
 
Yes 1.61 (1.07, 2.42) 0.021 
Nevirapine No 1   
 
Yes 1.08 (0.69, 1.71) 0.727 
Any PI No 1   
 
Yes 2.20 (1.38, 3.53) 0.001 
Ritonavir booster No 1   
 
Yes 2.01 (1.35, 3.01) 0.001 
Indinavir No 1   
 
Yes 4.57 (1.55, 13.51) 0.006 
Nelfinavir  No 1   
 
Yes 1.84 (1.24, 2.73) 0.002 
Saquinavir No 1   
  Yes 6.54 (1.48, 28.82) 0.013 
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E.6 Multivariable analyses for lipodystrophy syndrome 
 
Table E-12: Final multivariable model for lipodystrophy syndrome with ever-use of 
specific antiretroviral drugs as explanatory variables (n = 338) 
  n AOR (95% CI) p – value 
Age Per year 338 0.90 (0.83, 0.98) 0.018 
Duration of ART use Per year 338 0.93 (0.87, 1.00) 0.052 
Ethnicity Black 90 1  
White 231 3.09 (1.77, 5.39) <0.001 
Other 17 0.72 (0.23, 2.27) 0.573 
BMI Per kg/m2 338 1.11 (1.02, 1.21) 0.021 
Abacavir Never use 188 1  
 Ever use 150 0.57 (0.35, 0.93) 0.023 
Stavudine Never use 153 1  
 Ever use 185 2.24 (1.29, 3.88) 0.004 
Didanosine Never use 167 1  
 Ever use 171 1.95 (1.09, 3.49) 0.024 
Indinavir Never use 318 1  
 Ever use 20 4.20 (1.08, 16.37) 0.038 
Models constructed using backward stepwise logistic regression. 
 
Table E-13: Final multivariable models for lipodystrophy syndrome adjusted by Tanner 
score for puberty (n = 279) 
  n AOR (95% CI) p – value 
Age Per year 279 0.94 (0.83, 1.07) 0.333 
Duration of ART use Per year 279 1.04 (0.96, 1.12) 0.385 
Tanner score for 
puberty 
I 101 1  
II-IV 112 0.75 (0.31, 1.80) 0.521 
V 66 1.10 (0.32, 3.75) 0.881 
Ethnicity Black 70 1  
White 194 3.54 (1.85, 6.77) <0.001 
Other 15 0.70 (0.20, 2.49) 0.579 
Body mass index (BMI) Per m/kg2 279 1.10 (1.00, 1.21) 0.046 
Efavirenz Not current 209 1  
 Current 70 4.64 (1.94, 11.11) 0.001 
Nevirapine Not current 248 1  
 Current 31 3.80 (1.31, 11.0) 0.014 
Ritonavir booster Not current 124 1  
 Current 155 4.03 (1.84, 8.85) 0.001 
Original model constructed using backward stepwise logistic regression: additional adjustment with Tanner 
score for puberty
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Table E-14: Final multivariable models for lipodystrophy syndrome with the addition of 
an interaction between sex and age (n = 306) 
  n AOR (95% CI) p – value 
Age Per year 306 0.96 (0.87, 1.05) 0.363 
Duration of ART use Per year 306 1.02 (0.95, 1.10) 0.648 
Gender Male 159 1  
Female 147 1.84 (0.35, 9.74) 0.474 
Gender * Age interaction 147 0.97 (0.85, 1.11) 0.648 
Ethnicity Black 78 1  
White 213 3.42 (1.87, 6.26) <0.001 
Other 15 0.70 (0.20, 2.47) 0.579 
Body mass index   Per m/kg2 306 1.11 (1.01, 1.21) 0.025 
Efavirenz Not current 231 1  
Current 75 2.79 (1.29, 6.07) 0.009 
Nevirapine Not current 274 1  
Current 32 2.95 (1.11, 7.86) 0.030 
Ritonavir booster Not current 139 1  
Current 167 3.08 (1.54, 6.15) 0.001 
Original model constructed using backward  stepwise logistic regression: additional adjustment with 
interaction between sex and age 
 
 
Table E-15: Multivariable logistic regressions for lipodystrophy syndrome   including 
categories of ART as explanatory variables: threshold for stepwise covariate selection 
set at 10% significance 
  
Lipodystrophy syndrome 
  
n = 298 
Age Per year 
 0.93 (0.86, 1.01)† 
Ethnicity Black 1 
 White 3.24 (1.78, 5.88)*** 
 Other 0.90 (0.26, 3.19) 
Body mass index Kg/m2 1.09 (1.00, 1.19)† 
Maximum CDC-defined 
clinical condition 
N/A 1 
B 1.89 (1.07, 3.36)* 
C 1.65 (0.86, 3.16) 
Duration of ART Per year 1.01 (0.94, 1.09) 
PI at recruitment No 1 
Yes 2.40 (1.14, 5.05)* 
NNRTI at recruitment No 1 
Yes 2.76 (1.27, 6.00)* 
†0.10 > p ≥ 0.05, *0.05 > p ≥> 0.01, **0.01 > p ≥ 0.001, ***0.001< p 
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Table E-16: Multivariable logistic regressions for lipodystrophy syndrome   including 
categories of ART as explanatory variables: threshold for stepwise covariate selection 
set at 10% significance 
  Lipodystrophy syndrome 
  
n = 298 
Age Per year 0.93 (0.86, 1.02) 
Ethnicity Black 1 
 White 2.72 (1.50, 4.92)*** 
 Other 0.88 (0.25, 3.13) 
Body mass index Kg/m2 1.10 (1.01, 1.20)* 
Maximum CDC-defined 
clinical status 
N/A 1 
B 1.79 (1.00, 3.19)* 
C 1.56 (0.82, 2.98) 
Duration of ART use Per year 1.02 (0.95, 1.10) 
Stavudine at recruitment No 1 
 Yes 2.48 (1.01, 6.08)* 
Efavirenz at recruitment No 1 
 Yes 2.27 (1.11, 4.65)* 
Ritonavir booster at 
recruitment 
No 1 
Yes 2.14 (1.14, 3.99)* 
†0.10 > p ≥ 0.05, *0.05 > p ≥> 0.01, **0.01 > p ≥ 0.001, ***0.001< p 
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Appendix F Appendix to chapter 6 
 
F.1 Classification of body mass index 
 
Table F-1: International classification of adult underweight, overweight and obesity 
according to body mass index 
 BMI range (kg/m2) 
Severely underweight <16.00 
Underweight 16.0 – 18.5 
Healthy weight 18.5 – 25.0 
Overweight 25.0 – 30.0 
Obese >30.0 
 
 
F.2 Assumptions of LS status over follow-up 
 
Specific data was collected for 416 subjects regarding LS status at recruitment. Following this, 
308 subjects had data collected in a second questionnaire, 292 in a third questionnaire, and 88 
subjects in a fourth questionnaire. Despite, the diminishing number of subjects at each follow-up 
point, specific assumptions could be made regarding a proportion of subjects at each follow-up. 
Figure F-1 illustrates the number of questionnaires collected with specific LS data during active 
surveillance of the cohort. The number of subjects where assumptions could be made at each 
time point is also illustrated. Assumptions were made regarding the presence or absence of LS 
symptoms dependent on data collected at the previous time point: where this was not possible, 
no assumptions were made and LS status was classed as “missing”. The minimum number of 
subjects where assumptions were possible is illustrated as LS status does not remain constant 
in a given subject over time (i.e. new cases can occur and complete reversal of symptoms can 
occur).  
Similar assumptions regarding other LS symptoms (e.g. specific body fat alterations and 
metabolic abnormality) with continuing surveillance were made.  
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Figure F-1: Assumptions regarding lipodystrophy syndrome symptoms with follow-up 
 
 
These assumptions were investigated by calculating the prevalence of LS as estimated from the 
first, second and third follow-up study visit questionnaires collected for each variable. 
  
308 subjects 
195 with LS, 113 without LS 
292 subjects 
196 with LS, 96 without LS 
88 subjects 
49 with LS, 39 without LS 
416 subjects 
235 with LS, 181 without LS 
394 subjects 
240 with LS, 154 without LS 
413 subjects 
264 with LS, 149 without LS 
414 subjects 
263 with LS, 151 without LS 
Assumptions 
>86 subjects 
Assumptions 
>121 subjects 
Assumptions 
>326 subjects 
Dataset for analysis 
Collected data 
First follow-up 
Second follow-up 
Third follow-up 
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Table F-2: Prevalence of lipodystrophy outcomes as estimated from follow-up questionnaires 
 First follow-up Second follow-up Third follow-up Data at the end of follow-
up (with assumptions) 
 n = 308 n = 292 n = 88 n = 414 
 n/N % n/N % n/N % n/N % 
Lipodystrophy syndrome 195/308 63.3 196/292 67.1 49/88 55.7 253/414 61.1 
Body fat alterations only 91/308 29.5 110/292 37.7 20/88 22.7 120/414 29.0 
Metabolic abnormality only 54/308 17.5 39/292 13.4 20/88 22.7 72/414 17.4 
Both body fat alterations and 
metabolic abnormality 
50/308 16.2 47/292 16.1 9/88 10.2 61/414 14.7 
Lipoatrophy only 53/308 17.2 56/292 19.2 12/88 13.6 63/414 15.2 
Lipohypertrophy only 39/308 12.7 56/292 19.2 10/88 11.4 54/414 13.0 
Both lipoatrophy and 
lipohypertrophy 
53/308 17.2 56/292 19.2 12/88 13.6 64/414 15.5 
Fasting hypertriglyceridemia only 34/208 11.0 26/292 8.9 1/88 1.1 39/414 9.4 
Hypercholesterolemia only 58/208 18.8 51/292 17.5 26/88 29.5 60/414 14.5 
Both hypercholesterolemia and 
fasting hypertriglyceridemia 
12/308 3.9 9/292 3.1 2/88 2.3 15/414 3.6 
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F.3 Hospital visits 
 
Table F-3: Median interval between hospital visits (years) 
 
Hospital visit 
 
1st and 2nd visit* 2nd and 3rd visit* 3rd and 4th visit* 
Belgium 0.54 (0.46, 0.61) 0.63 (0.48, 0.92) 0.61 (0.50, 0.99) 
Italy 1.21 (1.04, 1.50) 2.10 (1.87, 2.30) 0 
Poland 0.50 (0.48, 0.52) 0.51 (0.49, 0.53) 0.51 (0.50, 0.53) 
TOTAL 1.00 (0.54, 1.28) 1.71 (0.56, 2.16) 0.53 (0.50, 0.68) 
No 4th visit data was collected for subjects resident in Italy. * Mann-Whitney-U test for medians between 
countries: p < 0.001 
 
F.3 Characteristics of participants at end of follow-up 
 
Figure F-2: Prevalence of detectable viral load at the end of follow-up (n = 416) 
 
Detectable viral load defined as >50 copies HIV-RNA per mL.  
  
46.88%
53.13%
Undetectable Detectable viral load
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Figure F-3:  Prevalence of CDC-defined clinical condition at the end of follow-up (n = 410) 
  
CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms 
Figure F-4: Prevalence of CDC-defined immunosuppression at the end of follow-up (n = 
416) 
 
  
71.95%
14.88%
13.17%
N/A B
C
No immunosuppression Moderate immunosuppression
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F.4 Follow-up of subjects who were ART-naïve at recruitment 
 
Figure F-5: Flow chart of subjects whose antiretroviral therapy status was unknown at 
recruitment 
 
*Italian cases: no fourth visit 
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F.5 Kaplan-Meier survival plots 
Figure F-6: Kaplan-Meir estimates for incidence lipodystrophy syndrome by (a) age at 
recruitment, and (b) and BMI at recruitment  
 
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of incidence/complete reversal of LS over follow-up. Log rank test: (a) p = 0.036, and (b) p = 0.476.    
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Figure F-7: Kaplan-Meier plots for emergence of (a) body fat alterations and (b) metabolic 
abnormality, by age at recruitment 
 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up, (b). Log-rank test: (a) 0.069, and (b) 0.581.   
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Figure F-8: Kaplan-Meier plots for emergence of (a) body fat alterations and (b) metabolic 
abnormality, by BMI at recruitment 
 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up, (b). Log-rank test: (a) 0.179, and (b) 0.099.   
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Figure F-9: Kaplan-Meir estimates for incidence lipodystrophy syndrome by (a) maximum 
CDC-defined clinical condition (b) nadir CDC immune status 
 
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of emergence/complete reversal of LS over follow-up.  Log rank test: (a) p = 0.284, and (b) p = 0.770.  
CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms.  
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Figure F-10: Kaplan-Meier plots for emergence of (a) body fat alterations and (b) 
metabolic abnormality, by maximum CDC-defined clinical condition  
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up, (b). Log-rank test: (a)  0.0337, and (b)  0.280.   
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Figure F-11: Kaplan-Meir estimates for incidence lipodystrophy syndrome by recruitment 
CDC-defined (a) clinical status, and (b) degree of immunosuppression 
 
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of incidence/complete reversal of LS over follow-up.  Log rank test: (a) p = 0.365, and (b) p = 0.620.  
CDC-defined clinical status - N + A: no symptoms/asymptomatic, B: moderate symptoms, C: severe symptoms.  
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Figure F-12: Kaplan-Meier plots for emergence of (a) body fat alterations, and (b) 
metabolic abnormality, by nadir CDC-defined immune status  
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up (b).  Log-rank test: (a) p = 0.183, and (b) p = 0.507.   
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Figure F-13: Kaplan-Meier plots for emergence of (a) fat alterations, and (b) metabolic 
abnormality, by recruitment CDC-defined clinical condition at recruitment 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up (b). Log-rank test: (a) - p = 0.00161, and (b) – p = 0.0845.   
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Figure F-14: Kaplan-Meier plots for emergence of (a) body fat alterations, and metabolic 
abnormality, by recruitment CDC-defined immune status  
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up (b). Log-rank test: (a) -  p < 0.117, and (b) – p = 0.297.   
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Figure F-15: Kaplan-Meir estimates for incidence lipodystrophy syndrome by (a) Tanner 
score for puberty at recruitment, and (b) use of non-nucleoside reverse transcriptase 
inhibitor use at recruitment 
  
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of incidence/complete reversal of LS over follow-up. Log rank test: (a) p = 0.0114, and (b) p = 0.974.   
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Figure F-16: Kaplan-Meier plots for emergence of (a) body fat alterations, and (b) 
metabolic abnormality, by Tanner score for puberty at recruitment 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up (b).  Log-rank test: (a) - p = 0.974, and (b) - p  = 0.634.   
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Figure F-17: Kaplan-Meier plots for emergence of (a) body fat alterations, and (b) 
metabolic abnormality, by use of non-nucleoside reverse transcriptase at recruitment 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up (b). Log-rank test: (a) - p = 0.0115, and (b) p = 0.155.   
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Figure F-18: Kaplan-Meir estimates for incidence lipodystrophy syndrome by use at 
recruitment of (a) protease inhibitors, and (b) highly active antiretroviral therapy 
 
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of incidence/complete reversal of LS over follow-up.  Log rank test: (a) p < 0.732, and (b) p = 0.621.   
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Figure F-19: Kaplan-Meier plots for emergence of fat alterations, and metabolic 
abnormality, by use of protease inhibitor at recruitment 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up, (b).  Log-rank test: (a) p = 0.837, and (b) p = 0.975.   
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Figure F-20: Kaplan-Meier plots for emergence of fat alterations, and metabolic 
abnormality by use of highly active anti-retroviral therapy at recruitment 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up, (b).  Log-rank test:  (a) p = 0.00309, and (b) p = 0.0543.   
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Figure F-21: Kaplan-Meir estimates for incidence lipodystrophy syndrome by (a) 
antiretroviral therapy regimen at recruitment and (b) duration of ART use at recruitment 
  
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of incidence/complete reversal of LS over follow-up. Log rank test: (a)  p = 0.821, and (b) p = 0.635.    
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Figure F-22: Kaplan-Meier plots for emergence of fat alterations, and metabolic 
abnormality, by use specific antiretroviral therapy regiment at recruitment 
 
  
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up.  (b). Log-rank test: (a) p = 0.00335, and (b) p = 0.118.  
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Figure F-23: Kaplan-Meier plots for emergence of fat alterations, and metabolic 
abnormality, by duration of ART use 
 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up.  (b). Log-rank test: (a) p < 0.638, and (b) p = 0.698.  
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Figure F-24: Kaplan Meir plots for incidence lipodystrophy syndrome by (a) detectable 
viral load during follow-up, and (b) and CDC-defined clinical symptoms during follow-up  
 
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of incidence/complete reversal of LS over follow-up. Log rank test: (a) p = 0.040, and (b) p = 0.576.    
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Figure F-25: Kaplan-Meir estimates for incidence lipodystrophy syndrome by CDC-
defined immunosuppression during follow-up  
 
Excludes 205 subjects with continuous lipodystrophy syndrome over follow-up and17 subjects with >1 
occasion of incidence/complete reversal of LS over follow-up. Log rank test p = 0.046  
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Figure F-26: Kaplan-Meier plots for emergence of fat alterations, and metabolic 
abnormality, by any detectable viral load during follow-up 
 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up.  (b). Log-rank test: (a) p < 0.001, and (b) p = 0.143.  
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Figure F-27: Kaplan-Meier plots for emergence of fat alterations, and metabolic 
abnormality, by any CDC-defined clinical symptoms during follow-up 
 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up.  (b). Log-rank test: (a) p < 0.001, and (b) p = 0.040.  
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Figure F-28: Kaplan-Meier plots for emergence of fat alterations, and metabolic 
abnormality, by any CDC-defined immunosuppression during follow-up 
 
 
Estimates exclude 122 subjects with continuous fat alterations over follow-up and 19 subjects with >1 occasion 
of emergence/complete regression  of fat alterations over follow-up (a), and 106 subjects with continuous 
metabolic abnormality over follow-up and 20 subjects with >1 occasion of emergence/complete regression  of 
fat alterations over follow-up.  (b). Log-rank test: (a) p = 0.964, and (b) p = 0.939.  
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F.6 Cox proportional hazards models with antiretroviral regimen at recruitment 
 
Table F-4: Cox proportional hazards using ART regimen at recruitment and clinical site as a random effect 
  
Body fat alterations Metabolic abnormality Lipodystrophy syndrome 
  
(n = 376 ) (n = 406) (n = 248) 
  
Adjusted hazard 
ratio (95% CI) 
p-value Adjusted hazard 
ratio (95% CI) 
p-value Adjusted hazard 
ratio (95% CI) 
p-value 
Age 
(years)*  
2-11 1  1  1  
12-18 1.59 (0.76, 3.31) 0.218 1.32 (0.52, 3.32) 0.558 2.01(0.89, 4.68) 0.091 
Duration 
of ART 
(years)* 
 
<2.5 1  1  1  
2.5-4.9 0.71 (0.25, 1.96) 0.503 0.77 (0.22, 2.67) 0.686 0.96 (0.33, 2.83) 0.944 
5.0-7.4 1.25 (0.40, 3.89) 0.696 0.56 (0.15, 2.17) 0.403 0.52 (0.13, 2.12) 0.364 
7.5-9.9 1.28 (0.48, 3.43) 0.625 0.64 (0.19, 2.18) 0.472 1.00 (0.34, 2.96) 0.997 
≥10.0 0.35 (0.07, 1.77) 0.206 0.84 (0.23, 3.04) 0.785 - - 
ART 
regimen 
PI-based HAART 1  1  1  
NRTI-mono-therapy 0.40 (0.13, 1.24) 0.113 0.26 (0.03, 2.05) 0.199 0.87 (0.25, 2.99) 0.829 
NNRTI-based HAART 1.13 (0.49, 2.61) 0.30 0.27 (0.08, 0.95) 0.041 0.82 (0.32, 2.09) 0.677 
 Triple therapy - - 1.21 (0.26, 5.52) 0.807 1.46 (0.17, 12.68) 0.731 
Models contain random effect for clinical site of treatment. *Status at recruitment. GLOBAL test for proportional hazards: Body fat alterations p = 0.7011, metabolic abnormality p = 
0.3529, lipodystrophy syndrome p = 0.8976
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F.7 Testing proportional hazards assumptions of multivariable Cox 
survival models 
 
Table F-5: Testing proportional hazards for emerging body fat alterations: recruitment 
factors
 
  χ
2
 statistic p – value 
Age (years)* 2-11 Ref. Ref. 
 12-18 0.35** 0.553 
Duration of ART 
(years)* 
<2.5 Ref. Ref. 
2.5-4.9 0.06** 0.808 
5.0-7.4 0.02** 0.875 
7.5-9.9 0.00** 0.989 
 ≥10.0 1.32** 0.250 
GLOBAL  1.74*** 0.884 
*Status at recruitment. **1 degree of freedom. ***5degrees of freedom  
 
Table F-6: Testing proportional hazards for emerging body fat alterations: follow-up 
factors 
  χ
2
 statistic p – value 
Age (years)* 2-11 Ref. Ref. 
 12-18 0.57** 0.452 
Duration of ART 
(years)* 
<2.5 Ref. Ref. 
 2.5-4.9 0.08** 0.780 
 5.0-7.4 0.00** 0.964 
 7.5-9.9 0.04** 0.850 
 ≥10.0 1.35** 0.245 
Immunosuppression 
during follow-up 
No 
immunosuppression 
Ref. Ref. 
Immunosuppression 2.29** 0.130 
GLOBAL  4.03*** 0.673 
*Status at recruitment. **1 degree of freedom. ***6 degrees of freedom 
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Table F-7: Testing proportional hazards for emerging metabolic abnormality: recruitment 
factors 
  χ
2
 statistic p – value 
Age (years)* 2-11 Ref. Ref. 
 12-18 0.63** 0.428 
Duration of ART 
(years)* 
<2.5 0.00** 0.970 
 2.5-4.9 Ref. Ref. 
 5.0-7.4 0.09** 0.769 
 7.5-9.9 0.09** 0.769 
 ≥10.0 0.01** 0.936 
Body Mass index* Severely 
underweight 
Ref. Ref. 
 Underweight 1.36** 0.244 
 Health weight 2.53** 0.111 
 Overweight 0.13** 0.721 
 Obese - - 
PI* No use Ref. Ref. 
 Use 0.61** 0.434 
GLOBAL  6.70*** 0.668 
*Status at recruitment.** 1 degree of freedom. ***9 degrees of freedom  
 
 
 
Table F-8: Testing proportional hazards for emerging metabolic abnormality: follow-up 
factors 
  χ
2
 statistic p – value 
Age (years)* 2-11 Ref. Ref. 
 12-18 0.55** 0.451 
Duration of ART 
(years)* 
<2.5 Ref. Ref. 
2.5-4.9 0.03** 0.852 
 5.0-7.4 0.35** 0.555 
 7.5-9.9 0.10** 0.747 
 ≥10.0 0.02** 0.899 
Body Mass index* Severely underweight Ref. Ref. 
 Underweight 1.02** 0.313 
 Health weight 2.17** 0.141 
 Overweight 0.01** 0.913 
 Obese 0.00** 1.00 
PI* No use Ref. Ref. 
 Use 0.04** 0.846 
Immuno-suppression 
during follow-up 
No immunosuppression Ref. Ref. 
Immunosuppression 1.31** 0.253 
GLOBAL  6.27*** 0.855 
*Status at recruitment. **1 degree of freedom. ***11 degrees of freedom  
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Table F-9: Testing proportional hazards for emerging lipodystrophy syndrome: 
recruitment factors 
  χ
2
 statistic p – value 
Age( years)*  2-11 Ref. Ref. 
 12-18 1.45** 0.229 
Duration of ART (years)* <2.5 Ref. Ref. 
2.5-4.9 0.05** 0.829 
5.0-7.4 0.22** 0.638 
7.5-9.9 0.78** 0.377 
 ≥10.0 0.13** 0.723 
Ethnicity Black Ref. Ref. 
 White 0.15** 0.697 
 Other 0.01** 0.927 
Maximum CDC-defined 
clinical status 
N/A Ref. Ref. 
B 0.80** 0.372 
C 0.13** 0.717 
GLOBAL  4.90*** 0.843 
*Status at recruitment. **1 degree of freedom.** *9 degrees of freedom 
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Table F-10: Testing proportional hazards for emerging lipodystrophy syndrome: recruitment ART regimen 
  
Body fat alterations Metabolic abnormality Lipodystrophy syndrome 
  χ
2
 statistic p-value χ2 statistic p-value χ2 statistic p-value 
Age (years)*  2-11 
      
12-18 0.00** 0.995 1.09** 0.297 1.14** 0.286 
Duration of 
ART (years)* 
 
<2.5 
      
2.5-4.9 0.05** 0.825 0.33** 0.567 0.73** 0.391 
5.0-7.4 0.02** 0.882 0.97** 0.325 0.03** 0.859 
7.5-9.9 0.19** 0.661 0.51** 0.474 0.84** 0.360 
≥10.0 1.26** 0.261 0.26** 0.611 0.02** 0.894 
ART regimen PI-based HAART Ref. Ref. Ref. Ref. Ref. Ref. 
NRTI-mono-therapy 0.59** 0.441 3.27** 0.070 0.32** 0.572 
NNRTI-based HAART 2.00** 0.158 0.09** 0.760 0.01** 0.905 
 Triple therapy - - 3.09** 0.079 0.00**  
GLOBAL  4.66*** 0.701 8.88# 0.8352 3.52# 0.8976 
*Status at recruitment. **1 degree of freedom. *** 7degrees of freedom. #8 degrees of freedom 
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Appendix G Appendix to Chapter 7 
 
G.1 Median lipid concentrations in subjects with incident body fat alterations 
 
Table G-1: Comparison of median serum concentrations of lipids in subjects with incident body fat alterations at recruitment and end of follow-up 
by sex and age (n = 62) 
  
Male Female 
  
Recruitment End of follow-up p -value Recruitment End of follow-up p -value 
Fasting triglyceride 
(mg/dL) 
2-11 years 65 (41, 122) 125 (50, 289) 1.000 64 (55, 97) 93 (51, 164) 1.000 
12-18 years 179 (83, 253) 107 (58, 133) 0.006 87 (54, 111) 122 (79, 173) 0.180 
Total cholesterol 
(mg/dL) 
2-11 years 186 (165, 217) 189 (167, 206) 1.000 178 (166, 198) 190 (155, 203) 0.648 
12-18 years 172 (131, 197) 162 (118, 197) 0.791 170 (121, 197) 166 (122, 166) 0.629 
LDL cholesterol  
(mg/dL) 
2-11 years 83 (78, 112) 67 (57, 110) 1.00 99 (82, 120) 99 (85, 126) 1.000 
12-18 years 90 (73, 109) 92 (67, 122) 0.581 80 (69, 100) 89 (70, 111) 0.454 
Non-HDL 
cholesterol (mg/dL) 
2-11 years 112 (89, 131) 136 (134, 151) 0.453 115 (98, 159) 114 (89, 150) 0.648 
12-18 years 131 (105, 152) 109 (87, 148) 0.607 98 (85, 140) 126 (98, 147) 0.607 
HDL cholesterol 
(mg/dL) 
2-11 years 59 (46, 63) 48 (37, 73) 0.453 64 (51, 67) 61 (52, 72) 1.000 
12-18 years 39 (35, 52) 38 (30, 61) 0.607 50 (38, 71) 40 (39, 58) 0.454 
Interquartile range in brackets. Males 2-11 years old: n = 10. Males 12-18 years old:  n =16. Females 2-11 years old: n = 19. Females 12-18 years old: n = 17 
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Table G-2: Univariable 3-level multilevel models of serum concentrations  
    Total cholesterol LDL-cholesterol Non-HDL cholesterol HDL cholesterol Fasting triglyceride 
    Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Recruitment 
lipodystrophy 
Absent Comparison  Comparison  Comparison  Comparison  Comparison  
Present 26.33 
(17.78, 34.88) 
<0.001 18.47 
(11.90, 25.03) 
<0.001 26.14 
(18.09, 34.19) 
<0.001 -0.05 
(-3.78, 3.68) 
0.979 41.40 
(26.00, 56.80) 
<0.001 
Any LS over 
follow-up 
Never Comparison  Comparison  Comparison  Comparison  Comparison  
Any 28.77 
(18.80, 38.75) 
<0.001 20.50 
(12.76, 28.25) 
<0.001 28.17 
(18.88, 37.46) 
<0.001 -0.20 
(-4.49, 4.10) 
0.928 45.89 
(27.52, 64.27) 
<0.001 
Age at 
recruitment 
<12 years Comparison  Comparison  Comparison  Comparison  Comparison  
12-18 years -17.20 
(-23.98, -10.41) 
<0.001 -10.90 
(-16.24, -5.56) 
<0.001 -10.15 
(-16.72, -3.59) 
0.002 -5.71 
(-8.59, -2.83) 
<0.001 6.43 
(-6.50, 19.35) 
0.330 
Ethnicity Black Comparison  Comparison  Comparison  Comparison  Comparison  
White 1.72 
(-7.44, 10.88) 
0.713 1.94 
(-5.07, 8.94) 
0.588 8.97 
(0.31, 17.63) 
0.042 -7.45 
(-11.49, -3.42) 
<0.001 44.68 
(29.28, 60.07) 
<0.001 
Other -5.17 
(-23.37, 13.03 
0.578 -4.06 
(-18.24, 10.11) 
0.574 -0.51 
(-17.32, 16.29) 
0.952 -5.11 
(-12.86, 2.64) 
0.196 22.92 
(-9.28, 55.13) 
0.163 
Sex Male Comparison  Comparison  Comparison  Comparison  Comparison  
Female 3.20 
(-3.84, 10.24) 
0.373 2.07 
(-3.43, 7.60) 
0.461 -1.14 
(-7.73, 5.44) 
0.733 3.91 
(1.01, 6.81) 
0.008 -17.12 
(-29.86, -4.36) 
0.009 
Detectable viral 
load at 
recruitment* 
<50 copies/ml Comparison  Comparison  Comparison  Comparison  Comparison  
≥50 copies/ml -21.45 
(-31.74, -11.16) 
<0.001 -14.82 
(-22.75, -6.88) 
<0.001 -19.09 
(-29.52, -8.65) 
<0.001 -5.24 
(-10.14, -0.33) 
0.037 -18.02 
(-39.24, 3.20) 
0.096 
Any detectable 
viral load over 
follow-up** 
Never Comparison  Comparison  Comparison  Comparison  Comparison  
Any -25.52 
(-36.46, -14.57) 
<0.001 -16.83 
(-25.30, -8.35) 
<0.001 -21.25 
(-32.24, -10.26) 
<0.001 -6.59 
(-11.71, -1.47) 
0.012 -13.36 
(-35.88, 9.17) 
0.245 
Recruitment 
immuno-
suppression 
None Comparison  Comparison  Comparison  Comparison  Comparison  
Moderate -12.08 
(-20.86, -3.30) 
0.007 -7.01 
(-13.84, -0.17) 
0.044 -7.20 
(-15.40, 1.10) 
0.086 -4.19 
(-7.83, -0.56) 
0.024 -5.49 
(-21.51, 10.53) 
0.502 
Severe -9.55 
(-28.30, 9.20) 
0.318 0.65 
(-14.40, 15.71) 
0.932 5.81 
(-12.25, 23.88) 
0.528 -6.80 
(-14.80, 1.20) 
0.096 16.53 
(-18.36, 51.42) 
0.353 
Immuno-
suppression 
during follow-up 
None Comparison  Comparison  Comparison  Comparison  Comparison  
Any -14.48 
(-21.49, -7.46) 
<0.001 -8.67 
(-14.17, -3.16) 
0.002 -11.22 
(-17.82, -4.62) 
0.001 -3.06 
(-6.03, -0.10) 
0.043 -11.93 
(-24.97, 1.11) 
0.073 
Nadir immuno-
suppression 
None Comparison  Comparison  Comparison  Comparison  Comparison  
Moderate -4.43 
(-12.44, 3.57) 
0.278 -2.12 
(-8.35, 4.11) 
0.505 -1.67 
(-9.12, 5.78) 
0.661 -1.46 
(-4.77, 1.86) 
0.389 5.90 
(-8.67, 20.47) 
0.427 
Severe 0.74 
(-8.41, 9.88) 
0.875 -0.88 
(-8.04, 6.28) 
0.809 3.24 
(-5.33, 11.82) 
0.459 -2.46 
(-6.27, 1.35) 
0.206 14.19 
(-2.67, 31.05) 
0.099 
Clinical 
condition at 
recruitment 
N+A Comparison  Comparison  Comparison  Comparison  Comparison  
B 3.24 
(-13.81, 20.30) 
0.709 3.22 
(-9.82, 16.28) 
0.628 5.18 
(-10.52, 20.88) 
0.518 -1.72 
(-8.58, 5.15) 
0.624 0.65 
(-30.04, 31.33) 
0.967 
C -4.28 
(-25.13, 16.56) 
 
 
0.687 3.41 
(-14.06, 20.89) 
0.702 5.83 
(-15.02, 26.67) 
0.584 0.86 
(-8.75, 10.52) 
0.857 27.29 
(-13.81, 68.38) 
0.193 
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    Total cholesterol LDL-cholesterol Non-HDL cholesterol HDL cholesterol Fasting triglyceride 
    Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Any clinical 
symptoms over 
follow-up 
None Comparison  Comparison  Comparison  Comparison  Comparison  
Any -4.69 
(-14.08, 4.71) 
0.328 0.80 
(-6.48, 8.07) 
0.830 -3.16 
(-12.06, 5.74) 
0.486 -0.14 
(-4.13, 3.85) 
0.945 -9.69 
(-27.01, 7.64) 
0.273 
Maximum 
clinical status 
N+A Comparison  Comparison  Comparison  Comparison  Comparison  
B 6.68 
(-1.55, 14.92) 
0.111 3.72 
(-2.66, 10.10) 
0.253 6.24 
(-1.38, 13.87) 
0.108 0.24 
(-3.10, 3.58) 
0.888 16.54 
(1.32, 31.75) 
0.033 
C 6.97 
(-2.52, 16.47) 
0.150 7.42 
(0.06, 14.77) 
0.048 9.22 
(0.43, 18.02) 
0.040 -1.53 
(-5.39, 2.33) 
0.437 20.12 
(2.31, 37.92) 
0.027 
Body mass 
index at 
recruitment  
Healthy Comparison  Comparison  Comparison  Comparison  Comparison  
Severely 
underweight 
13.25 
(3.83, 22.66) 
0.006 10.63 
(3.34, 17.92) 
0.004 6.39 
(-2.45, 15.24) 
0.157 5.17 
(1.28, 9.06) 
<0.001 -9.90 
(-27.29, 7.48) 
0.264 
Underweight 0.98 
(-7.34, 9.29) 
0.818 -0.70 
(-7.24, 5.83) 
0.833 -1.80 
(-9.69, 6.09) 
0.654 2.29 
(-1.16, 5.74) 
0.193 -4.47 
(-19.60, 10.66) 
0.563 
Overweight -7.74 
(-22.80, 7.31) 
0.313 -6.31 
(-17.88, 5.25) 
0.285 -7.08 
(-21.00, 6.83) 
0.318 -1.39 
(-7.48, 4.71) 
0.656 6.86 
(-20.44, 34.16) 
0.622 
Obese -20.04 
(-68.24, 28.15) 
0.415 -8.47 
(-45.18, 28.24) 
-0.651 -13.82 
(-58.21, 30.56) 
0.542 -5.97 
(-25.44, 13.50) 
0.548 -29.22 
(-114.01, 55.57) 
0.499 
Duration of ART 
use at 
recruitment  
<2.5 years Comparison  Comparison  Comparison  Comparison  Comparison  
2.5 - 4.9 years -4.63 
(-15.35, 6.10) 
0.398 -4.15 
(-12.36, 4.06) 
0.322 -10.82 
(-20.91, -0.73) 
0.036 5.36 
(0.75, 9.96) 
0.023 -25.35 
(-46.16, -4.54) 
0.017 
5.0 – 7.4 years 2.15 
(-9.03, 13.33) 
0.706 -0.19 
(-8.82, 8.43) 
0.965 -4.24 
(-14.77, 6.29) 
0.430 6.79 
(1.98, 11.60) 
0.006 -16.74 
(-38.52, 5.04) 
0.132 
7.5 – 9.9 years -4.76 
(-15.77, 6.25) 
0.397 -6.46 
(-14.92, 1.99) 
0.134 -8.62 
(-19.00, 1.75) 
0.103 0.64 
(-4.09, 5.38) 
0.789 8.10 
(-13.21, 29.41) 
0.456 
≥10 years -24.35 
(-36.17, -12.53) 
<0.001 -22.20 
(-31.22, -13.18) 
<0.001 -26.60 
(-37.66, -15.54) 
<0.001 1.55 
(-3.50, 6.60) 
0.548 -12.43 
(-35.12, 10.26) 
0.283 
Recruitment 
protease 
inhibitor 
No use Comparison  Comparison  Comparison  Comparison  Comparison  
Use 14.93 
(7.66, 22.20) 
<0.001 12.35 
(6.73, 17.98) 
<0.001 21.77 
(15.16, 28.39) 
<0.001 -5.72 
(-8.78, -2.67) 
<0.001 49.05 
(36.36, 61.75) 
<0.001 
Any protease 
inhibitor use 
over follow-up 
Never use Comparison  Comparison  Comparison  Comparison  Comparison  
Ever use 14.51 
(7.20, 21.81) 
<0.001 13.30 
(7.67, 18.93) 
<0.001 23.36 
(16.77, 29.96) 
<0.001 -6.50 
(-9.56, -3.45) 
<0.001 51.86 
(39.22, 64.49) 
<0.001 
Recruitment 
nucleoside 
reverse 
transcriptase 
inhibitor 
No use Comparison  Comparison  Comparison  Comparison  Comparison  
Use 13.76 
(-0.33, 27.84) 
0.056 8.30 
(-2.73, 19.33) 
0.140 8.96 
(-4.37, 22.28) 
0.188 4.42 
(-1.49, 10.33) 
0.143 11.75 
(-14.04, 37.54) 
0.372 
Any nucleoside 
reverse 
transcriptase 
inhibitor use 
over follow-up 
Never use Comparison  Comparison  Comparison  Comparison  Comparison  
Ever use -10.80 
(-89.71, 68.11) 
 
 
 
 
 
0.789 -6.51 
(-65.52, 52.50) 
0.829 -29.69 
(-100.43, 41.06) 
0.411 18.77 
(-12.65, 50.18) 
0.242 -115.84 
(-255.22, 23.54) 
0.103 
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    Total cholesterol LDL-cholesterol Non-HDL cholesterol HDL cholesterol Fasting triglyceride 
    Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Beta 
(95% CI) 
p-
value 
Recruitment 
reverse non-
nucleoside 
reverse 
transcriptase 
inhibitor 
No use Comparison  Comparison  Comparison  Comparison  Comparison  
Use -3.53 
(-11.46, 4.40) 
0.383 -5.57 
(-11.71, 0.57) 
0.075 -13.06 
(-20.45, -5.67) 
0.001 7.91 
(4.66, 11.15) 
<0.001 -35.70 
(-50.24,-21.17) 
<0.001 
Any non-
nucleoside 
reverse 
transcriptase 
inhibitor use 
over follow-up 
Never use Comparison  Comparison  Comparison  Comparison  Comparison  
Ever use 21.79 
(10.34, 33.24) 
<0.001 11.27 
(2.29, 20.25) 
0.014 17.62 
(6.72, 28.52) 
0.002 3.24 
(-1.65, 8.13) 
0.194 30.80 
(9.83, 51.77) 
0.004 
ART regimen at 
recruitment 
PI-based HAART Comparison  Comparison  Comparison  Comparison  Comparison  
NRTI mono-
therapy 
-22.01 
(-36.08, -7.94) 
0.002 -16.77 
(-27.48, -6.05) 
0.002 -26.98 
(-39.84, -14.13) 
<0.001 4.87 
(-1.01, 10.75) 
0.104 -51.78 
(-76.62, -26.95) 
<0.001 
NNRTI-based 
HAART 
-10.07 
(-18.35, -1.79) 
0.017 -10.05 
(-16.51, -3.59) 
0.002 -20.25 
(-27.85, -12.65) 
<0.001 8.34 
(4.90, 11.79) 
<0.001 -49.84 
(-64.66, -35.02) 
<0.001 
Triple class 
therapy 
9.42 
(-9.37, 28.22) 
0.326 0.76 
(-13.65, 15.16) 
0.918 -0.82 
(-17.67, 16.02) 
0.924 7.03 
(-0.60, 14.67) 
0.071 4.16 
(-28.44, 36.77) 
0.802 
Time-updated 
ART regiment 
PI-based HAART Comparison  Comparison  Comparison  Comparison  Comparison  
NRTI mono-
therapy 
-16.59 
(-25.78, -7.40) 
<0.001 -12.90 
(-19.91, -5.89) 
<0.001 -19.08 
(-27.45, -10.70) 
<0.001 1.04 
(-2.71, 4.80) 
0.585 -40.21 
(-57.43, -23.00) 
<0.001 
NNRTI-based 
HAART 
-9.75 
(-17.29, -2.20) 
0.001 -10.48 
(-16.40, -4.56) 
0.001 -20.61 
(-27.59, -13.64) 
<0.001 8.08 
(4.92, 11.23) 
<0.001 -48.18 
(-61.71, -34.65) 
<0.001 
Triple class 
therapy 
1.66 
(-6.61, .93) 
0.694 -2.81 
(-8.87, 3.24) 
0.362 -4.25 
(-11.58, 3.08) 
0.256 2.97 
(-0.26, 6.20) 
0.071 2.45 
(-15.03, 19.93) 
0.784 
 3-level models include repeated measures of individuals who are clustered into hospital in the random intercept  
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G.2 Multivariable multilevel models for cholesterol and fasting triglyceride 
 
Table G-3: Multivariable multilevel model for cholesterol and fasting triglyceride including recruitment explanatory variables 
  Total cholesterol LDL-cholesterol Non-HDL cholesterol HDL cholesterol Fasting triglyceride 
  n = 212 
observations = 602 
n = 209 
observations = 559 
n = 208 
observations = 560 
n = 208 
observations = 561 
n = 210 
observations = 522 
  Estimate p – value Estimate p - value Estimate p - value Estimate p - value Estimate p - value 
Age at recruitment <12 years Comparison  Comparison  Comparison  Comparison  Comparison  
12-18 years -15.0 
(-25.5, -4.4) 
0.006 -7.2 
(-15.4, 1.0) 
0.086 -9.7 
(-19.2, -0.2) 
0.045 -2.9 
(-7.0, 1.2) 
0.170 -4.2 
(-22.8, 14.5) 
0.663 
Sex Male Comparison  Comparison  Comparison  Comparison  Comparison  
Female 2.4 
(-6.8, 11.6) 
0.613 3.8 
(-3.4, 10.9) 
0.301 -1.9 
(-10.1, 13.3) 
0.655 5.3 
(1.7, 8.8) 
0.004 -23.9 
(-40.3, -7.5) 
0.004 
Ethnicity Black Comparison  Comparison  Comparison  Comparison  Comparison  
White -13.9 
(-25.6, -2.2 
0.019 -7.1 
(-16.0, 1.7) 
0.112 -5.1 
(-15.3, 5.0) 
0.320 -7.3 
(-12.1, -2.6) 
0.003 18.1 
(-1.8, 38.0) 
0.075 
Other -20.5 
(-44.1, 3.1) 
0.089 -11.1 
(-29.3, 7.1) 
0.232 -7.6 
(-28.6, 13.3) 
0.475 -10.2 
(-19.4, -0.9) 
0.031 12.9 
(-28.7, 54.4) 
0.544 
Body mass index at 
recruitment 
Healthy weight Comparison  Comparison  Comparison  Comparison  Comparison  
Severely 
underweight 
5.4 
(-8.9, 19.7) 
0.462 10.5 
(-0.5, 21.6) 
0.062 2.2 
(-10.5, 14.9) 
0.734 3.4 
(-2.2, 9.0) 
0.238 -27.0 
(-52.4, -1.6) 
0.038 
Underweight -0.5 
(-11.5, 10.6) 
0.934 -2.4 
(-11.0, 6.2) 
0.587 -2.7 
(-12.7, 7.2) 
0.589 0.6 
(-3.7, 5.0) 
0.773 0.7 
(-19.0, 20.4) 
0.942 
Overweight 1.2 
(-17.3, 19.6) 
0.899 -1.4 
(-15.7, 12.9) 
0.847 -3.5 
(-20.0, 13.0) 
0.677 2.4 
(-4.7, 9.6) 
0.503 -3.0 
(-35.9, 29.8) 
0.856 
Obese -35.7 
(-99.6, 28.2) 
0.273 -26.7 
(-75.6, 22.3) 
0.286 -43.6 
(-100.2, 13.0) 
0.131 3.7 
(-21.0, 28.3) 
0.769 -89.7 
(-199.9, 20.5) 
0.111 
Lipodystrophy 
syndrome at 
recruitment 
Absent Comparison  Comparison  Comparison  Comparison  Comparison  
Present 20.5 
(10.0, 31.0) 
<0.001 11.1 
(2.9, 19.2) 
0.008 19.7 
(10.3, 29.1) 
<0.001 0.8 
(-3.3, 4.9) 
0.710 37.0 
(18.5, 55.5) 
<0.001 
Maximum clinical 
condition 
N/A Comparison  Comparison  Comparison  Comparison  Comparison  
B 11.6 
(0.8, 22.4) 
0.036 9.6 
(1.2, 18.0) 
0.024 11.0 
(1.3, 20.8) 
0.026 1.1 
(-3.1, 5.3) 
0.617 11.0 
(-8.2, 30.2) 
0.262 
C 6.0 
(-6.3, 18.3) 
0.340 6.4 
(-3.1, 16.0) 
0.189 5.6 
(-5.4, 16.6) 
0.318 0.3 
(-4.5, 5.1) 
0.890 -6.2 
(-28.3, 15.9) 
0.581 
Immuno-
suppression at 
recruitment 
None Comparison  Comparison  Comparison  Comparison  Comparison  
Moderate -8.9 
(-21.3, 3.6) 
0.162 -4.1 
(-13.7, 5.5) 
0.402 -4.3 
(-15.4, 6.8) 
0.451 -4.1 
(-8.9, 0.8) 
0.101 -6.2 
(-28.2, 15.9) 
0.584 
Severe -9.2 
(-42.6, 24.1) 
 
 
0.587 -12.3 
(-38.1, 13.5) 
0.250 -7.8 
(-37.6, 22.0) 
0.609 -4.5 
(-17.5, 8.5) 
0.500 35.1 
(-23.4, 93.6) 
0.240 
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  Total cholesterol LDL-cholesterol Non-HDL cholesterol HDL cholesterol Fasting triglyceride 
  n = 212 
observations = 602 
n = 209 
observations = 559 
n = 208 
observations = 560 
n = 208 
observations = 561 
n = 210 
observations = 522 
  Estimate p – value Estimate p - value Estimate p - value Estimate p - value Estimate p - value 
Detectable viral load <50 copies/ml Comparison  Comparison  Comparison  Comparison  Comparison  
≥50 copies/ml -13.9 
(-27.5, -0.3) 
0.045 -3.4 
(-13.9, 7.0) 
0.518 -7.2 
(-19.3, 5.0) 
0.247 -6.1 
(-11.8, -0.5) 
0.034 -11.2 
(-34.9, 12.4) 
0.352 
ART regimen at 
recruitment 
PI-based HAART Comparison  Comparison  Comparison  Comparison  Comparison  
NRTI mono -
therapy 
-13.9 
(-30.7, 2.9) 
0.105 -12.5 
(-25.3, 0.4) 
0.057 -17.6 
(-32.4, -2.9) 
0.019 4.7 
(-1.9, 11.2) 
0.164 -37.4 
(-67.1, -7.8) 
0.014 
NNRTI-based 
HAART 
-9.2 
(-19.7, 1.3) 
0.087 -6.6 
(-14.8, 1.6) 
0.116 -16.2 
(-25.7, -6.6) 
<0.001 7.3 
(3.1, 11.4) 
0.001 -45.4 
(-64.0, -26.8) 
<0.001 
Triple-class 
therapy 
3.1 
(-17.2, 23.4) 
0.764 -4.7 
(-20.3, 10.9) 
0.558 -6.6 
(-24.6, 11.5) 
0.476 6.6 
(-1.3, 14.5) 
0.100 -3.2 
(-39.0, 32.5) 
0.860 
Duration of ART use 
at recruitment 
<2.5 years Comparison  Comparison  Comparison  Comparison  Comparison  
2.5 - 4.9 years -5.1 
(-18.7, 8.5) 
0.461 -4.2 
(-14.7, 6.2) 
0.426 -11.3 
(-23.4, 0.8) 
0.066 5.6 
(0.2, 10.9) 
0.041 -22.3 
(-46.4, 1.7) 
0.069 
5.0 – 7.4 years -5.5 
(-20.0, 8.9) 
0.453 -1.5 
(-12.7, 9.7) 
0.795 -8.5 
(-21.5, 4.5) 
0.200 4.3 
(-1.4, 9.9) 
0.139 -18.0 
(-43.7, 7.6) 
0.168 
7.5 – 9.9 years -6.9 
(-20.6, 6.9) 
0.328 -4.3 
(-15.0, 6.3) 
0.426 -8.3 
(-20.7, 4.0) 
0.187 -0.8 
(-6.2, 4.6) 
0.784 2.4 
(-22.2, 26.9) 
0.849 
≥10 years -10.3 
(-26.3, 5.6) 
0.205 -12.8 
(-25.2, -0.5) 
0.041 -16.2 
(-30.5, -2.0) 
0.025 5.5 
(-0.8, 11.8) 
0.085 -5.5 
(-33.7, 22.7) 
0.702 
Intercept  195.1 
(173.3, 
217.1) 
<0.001 105.8 
(89.2, 122.5) 
<0.001 137.1 
(118.0, 
156.2) 
<0.001 55.5 
(46.7, 64.4) 
<0.001 127.5 
(89.8, 165.3) 
<0.001 
Random effect statistics provided in Table  
 
Table G-4: Estimates of random effects’ standard deviations for multivariable multilevel models with recruitment explanatory variables  
   Clinical site Individual Residual 
 
Est. 95% CI Est. 95% CI Est. 95% CI 
Total cholesterol 3.62 (0.40, 32.41) 28.68 (25.36, 32.43) 23.20 (21.63, 24.88) 
LDL cholesterol 1.30 (0, 54286.70) 21.88 (19.20, 24.92) 18.21 (16.92, 19.60) 
Non-HDL cholesterol 0.00 (0.00, 41.93) 25.66 (22.68, 29.03) 19.92 (18.43, 21.53) 
HDL cholesterol 2.50 (0.68, 9.24) 11.03 (9.73, 12.52) 8.70 (8.08, 9.36) 
Fasting triglyceride 0.00 (0.00, 0.17) 46.18 (36.95, 57.71) 50.86 (46.79, 55.29) 
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Table G-5: Multivariable multilevel model for cholesterol and fasting triglyceride including time-updated explanatory variables 
  Total cholesterol LDL-cholesterol Non-HDL cholesterol HDL cholesterol Fasting triglyceride 
  n = 253 
observations = 668 
n = 250 
observations = 619 
n = 249 
observations = 621 
n = 249 
observations = 622 
n = 250 
observations = 574 
  Estimate p – value Estimate p - value Estimate p - value Estimate p - value Estimate p - value 
Age at recruitment <12 years Comparison  Comparison  Comparison  Comparison  Comparison  
12-18 years -12.4 
(-21.5, -3.3) 
0.007 -5.7 
(-12.8, 1.4) 
0.118 -7.5 
(-15.6, 0.7) 
0.073 -2.9 
(-6.6, 0.8) 
0.123 -4.4 
(-21.8, 13.0) 
0.621 
Sex Male Comparison  Comparison  Comparison  Comparison  Comparison  
Female 3.0 
(-4.9, 11.0) 
0.455 2.9 
(-3.3, 9.1) 
0.357 -1.9 
(-9.0, 5.2) 
0.601 5.2 
(1.9, 8.4) 
0.002 -20.0 
(-34.8, -4.5) 
0.011 
Ethnicity Black Comparison  Comparison  Comparison  Comparison  Comparison  
White -6.9 
(-16.7, 2.9) 
0.168 -3.5 
(-11.2, 4.2) 
0.371 0.7 
(-8.1, 9.6) 
0.868 -7.3 
(-11.3, -3.3) 
<0.001 27.4 
(8.9, 45.9) 
0.004 
Other -19.1 
(-39.3, 1.2) 
0.065 12.6 
(-28.4, 3.1) 
0.116 -9.0 
(-26.9, 9.0) 
0.326 -8.4 
(-16.6, -0.3) 
0.043 14.3 
(-23.4, 51.9) 
0.458 
Body mass index 
over follow-up 
Healthy weight Comparison  Comparison  Comparison  Comparison  Comparison  
Severely 
underweight 
10.9 
(1.5, 20.4) 
0.023 8.8 
(1.2, 16.4) 
0.023 6.7 
(-1.7, 15.1) 
0.118 4.1 
(0.3, 7.9) 
0.035 -17.1 
(-37.5, 3.3) 
0.101 
Underweight -0.6 
(-7.3, 6.1) 
0.863 -2.0 
(-7.5, 3.5) 
0.468 -4.3 
(-10.3, 1.7) 
0.162 1.8 
(-0.9, 4.5) 
0.189 3.5 
(-11.5, 18.4) 
0.650 
Overweight 7.6 
(-3.1, 18.2) 
0.163 1.0 
(-7.7, 9.6) 
0.829 5.2 
(-4.4, 14.8) 
0.287 -0.4 
(-4.8, 3.9) 
0.842 8.8 
(-13.8, 31.5) 
0.445 
Obese -33.5 
(-105.4, 38.3) 
0.361 -25.1 
(-80.7, 30.5) 
0.376 -49.0 
(-111.7, 13.7) 
0.126 12.0 
(-16.5, 40.5) 
0.410 -114.2 
(-252.7, 24.3) 
0.106 
Lipodystrophy 
syndrome over 
follow-up 
Absent Comparison  Comparison  Comparison  Comparison  Comparison  
Present 19.4 
(8.2, 30.6) 
0.001 12.6 
(3.8, 21.3) 
0.005 19.3 
(9.3, 29.4) 
<0.001 0.5 
(-4.1, 5.1) 
0.824 37.3 
(16.3, 58.2) 
<0.001 
Maximum clinical 
condition 
N/A Comparison  Comparison  Comparison  Comparison  Comparison  
B 6.7 
(-2.8, 16.2) 
0.169 4.6 
(-2.8, 12.0) 
0.224 5.8 
(-2.8, 14.3) 
0.185 0.55 
(-3.3, 4.4) 
0.782 8.6 
(-9.3, 26.4) 
0.348 
C 4.7 
(-5.7, 15.2) 
0.376 3.9 
(-4.3, 12.1) 
0.349 3.2 
(-6.2, 12.5) 
0.505 0.5 
(-3.7, 4.8) 
0.814 -7.6 
(-27.8, 12.5) 
0.457 
Immuno-
suppression over 
follow-up 
None Comparison  Comparison  Comparison  Comparison  Comparison  
Any -8.9 
(-17.3, -0.4) 
0.400 -4.2 
(-10.8, 2.4) 
0.211 -6.9 
(-14.4, 0.7) 
0.075 -2.3 
(-5.7, 1.2) 
0.198 -9.5 
(-25.5, 6.5) 
0.246 
Detectable viral load 
over follow-up 
None Comparison  Comparison  Comparison  Comparison  Comparison  
Any -15.6 
(-27.5, -3.7) 
0.010 -6.4 
(-15.8, 2.9) 
0.178 -10.6 
(-21.4, 0.2) 
0.055 -5.5 
(-10.4, -0.5) 
0.030 -9.9 
(-32.7, 12.9) 
0.396 
ART regimen over 
follow-up 
PI-based HAART Comparison  Comparison  Comparison  Comparison  Comparison  
NRTI mono -
therapy 
-13.4 
(-24.4, -2.4) 
0.017 -12.5 
(-21.0, -3.9) 
0.023 -17.3 
(-27.0, -7.7) 
<0.001 3.0 
(-1.3, 7.4) 
0.172 -33.5 
(-55.5, -11.6) 
0.003 
NNRTI-based 
HAART 
-4.7 
(-13.5, 4.2) 
 
0.163 -5.9 
(-13.0, 1.2) 
0.104 -14.7 
(-22.7, -6.6) 
<0.001 8.4 
(4.7, 12.1) 
<0.001 -47.1 
(-64.4, -29.8) 
<0.001 
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  Total cholesterol LDL-cholesterol Non-HDL cholesterol HDL cholesterol Fasting triglyceride 
  n = 253 
observations = 668 
n = 250 
observations = 619 
n = 249 
observations = 621 
n = 249 
observations = 622 
n = 250 
observations = 574 
  Estimate p – value Estimate p - value Estimate p - value Estimate p - value Estimate p - value 
Triple-class 
therapy 
1.7 
(-7.1, 10.6) 
0.702 -3.5 
(-10.5, 3.6) 
0.332 -4.8 
(-12.5, 2.9) 
0.223 4.2 
(0.7, 7.7) 
0.018 0.3 
(-20.8, 21.4) 
0.980 
Duration of ART use 
at recruitment 
<2.5 years Comparison  Comparison  Comparison  Comparison  Comparison  
2.5 - 4.9 years -7.2 
(-19.0, 4.5) 
0.229 -6.0 
(-15.2, 3.2) 
0.199 -13.9 
(-24.4, -3.3) 
0.010 5.7 
(0.9, 10.4) 
0.021 -26.4 
(-48.9, -4.0) 
0.021 
5.0 – 7.4 years -4.0 
(-16.6, 8.6) 
0.535 -2.9 
(-12.7, 7.0) 
0.571 -10.1 
(-21.4, 1.2) 
0.079 6.8 
(1.6, 11.9) 
0.010 -18.9 
(-42.6, 4.8) 
0.118 
7.5 – 9.9 years -9.1 
(-20.8, 2.6) 
0.129 -6.8 
(-16.0, 2.4) 
0.149 -11.3 
(-21.9, -0.8) 
0.035 0.2 
(-4.6, 5.0) 
0.824 -0.7 
(-23.0, 21.6) 
0.950 
≥10 years -9.1 
(-22.7, 4.5) 
0.190 -12.1 
(-22.8, -1.5) 
0.026 -15.5 
(-27.7, -3.3) 
0.013 6.0 
(0.4, 11.5) 
0.035 -7.8 
(-33.6, 18.0) 
0.552 
Intercept  189.4 
(169.6, 
209.1) 
<0.001 106.6 
(91.1, 122.2) 
0.005 136.2 
(118.4, 
154.0) 
<0.001 54.4 
(46.4, 62.5) 
<0.001 115.9 
(78.4, 153.4) 
<0.001 
Random effect statistics provided in Table G-6 
 
Table G-6: Estimates of random effects’ standard deviations for multivariable multilevel models with time-updated explanatory variables  
   Clinical site Individual Residual 
 
Est. 95% CI Est. 95% CI Est. 95% CI 
Total cholesterol 0.00 (0.00, 0.00) 27.34 (24.36, 30.69) 23.60 (22.06, 25.25) 
LDL cholesterol 0.00 (0.00, 9.05) 20.96 (18.25, 24.08) 18.43 (16.73, 20.30) 
Non-HDL cholesterol 0.00 (0.00, 18.59) 24.47 (21.76, 27.52) 19.84 (18.40, 21.39) 
HDL cholesterol 0.00 (0.00, -) 11.17 (9.95, 12.53) 8.93 (8.31, 9.60) 
Fasting triglyceride 0.00 (0.00, 0.00) 47.01 (40.51, 54.55) 51.37 (47.52, 55.53) 
3-level model includes individuals clustered into clinical site in the random intercept. 2-level model includes subjects in the random intercept 
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Table G-7: Comparison of 3-level and 2-level models with log ratio tests 
  Models adjusted by categories of 
ART 
Models adjusted by ART 
regimen 
  Recruitment 
explanatory 
factors 
Time-updated 
explanatory 
factors 
Recruitment 
explanatory 
factors 
Time-updated 
explanatory 
factors 
 χ
2
 
p- 
value 
χ
2
 
p-
value 
χ
2
 
p-
value 
χ
2
 
p-
value 
Total cholesterol 0.598 0.493 26.480 <0.001 0.259 0.611 17.644 <0.001 
LDL cholesterol 0.000 1.000 24.920 <0.001 0.006 0.938 16.837 <0.001 
Non-HDL 
cholesterol 
0.000 1.000 26.637 <0.001 0.000 1.000 0.001 1.000 
HDL cholesterol 0.144 0.704 21.630 <0.001 1.024 0.311 14.853 <0.001 
Fasting triglyceride 0.000 1.000 31.196 <0.001 0.000 1.000 20.781 <0.001 
 
 
Table G-8: Comparison of 3-level and null models with log ratio tests 
  Models adjusted by categories of 
ART 
Models adjusted by ART regimen 
  Recruitment 
explanatory 
factors 
Time-updated 
explanatory 
factors 
Recruitment 
explanatory 
factors 
Time-updated 
explanatory 
factors 
 χ
2
 
p- 
value 
χ
2
 
p-
value 
χ
2
 
p-
value 
χ
2
 
p-
value 
Total 
cholesterol 
155.847 <0.001 241.941 <0.001 103.624 <0.001 117.505 <0.001 
LDL cholesterol 164.877 <0.001 231.483 <0.001 87.972 <0.001 108.069 <0.001 
Non-HDL 
cholesterol 
199.742 <0.001 258.453 <0.001 108.103 <0.001 133.956 <0.001 
HDL cholesterol 213.074 <0.001 213.525 <0.001 128.832 <0.001 151.586 <0.001 
Fasting 
triglyceride 
10.664 <0.005 31.196 <0.001 67.252 <0.001 32.208 <0.001 
3-level model includes individuals clustered into clinical site in the random intercept. null model includes no  
random intercept 
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Appendix H Appendix to Chapter 8 
H.1 Observational adult studies investigating lipodystrophy syndrome 
 
Table H-1: Methods of lipodystrophy assessment in observational adult studies cited in this thesis 
Study Study type Location Number 
of 
subjects 
Age Assessment of outcomes 
Andany et al (2011) 
Ontario Cohort Study 
Multi-centre 
cross-sectional 
Canada 778 48 (median) Self-assessed lipoatrophy and/or lipohypertrophy 
Bonfanti et al  
(2003)404 
Coordinamento 
Italiano Studio 
Allergia e Infezione 
da HIV (CISAI) 
Group 
Multi-centre, 22-
month 
prospective 
Italy 1480 Adults (not 
specified) 
Clinician-assessed lipoatrophy and/or lipohypertrophy 
Bongiovanni et al 
(2006)402 
3-month 
prospective  
Italy 382 38 (median) Non-HDL cholesterol ≥190mg/dL 
Triglyceride ≥200mg/dL 
Bogner et al 
(2001)403 
101-week 
prospective 
Germany 115 38 (mean) Lipoatrophy and/or lipohypertrophy  by >2 of:  assessed by patient, 
assessed by clinician, or  by treatment-blinded physician 
Calza et al (2003)410 1-year 
prospective  
Italy 212 38 (mean) Cholesterol ≥200mg/dL (severe ≥300mg/dL) 
HDL-cholesterol ≤35mg/dL 
LDL-cholesterol ≥160mg/dL 
Triglyceride ≥200mg/dL (severe ≥750 mg/dL) 
Carr et al (1999)226 <27 week 
prospective 
United States 113 40 (mean) Self-assessed body fat alterations 
Cholesterol >213 mg/dL 
HDL-cholesterol <35mg/dL 
Triglyceride >177 mg/dL 
Carter et al (2001)411 Cross-sectional Australia 159 males Not specified Self-reported lipoatrophy and/or lipohypertrophy 
Body fat alterations: total body fat  by DEXA<20%, or waist 
circumference >90cm 
Fasting cholesterol >213mg/dL 
Fasting triglyceride >177 mg/dL 
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Dong et al (1999)583 Cross-sectional  United States 21 
females 
39 (mean) Abdominal lipohypertrophy: increased belt/dressed size 
Breast lipohypertrophy: increased bra size 
Peripheral lipoatrophy: visual definition of muscle group and 
increased prominence of veins 
Friis-Moller et al 
(2004)394 
Data collection on 
Adverse events of 
anti-HIV Drugs (DAD) 
study 
Multi-centre 
cross-sectional 
Multi-country 17,852 39 (median) Clinician-assessed body fat alterations 
Dyslipidemia: total cholesterol ≥240mg/dL and/or HDL-cholesterol 
≤35mg/dL and/or triglycerides ≥200mg/dL 
FRAM (2005)584 
The Study of Fat 
Redistribution and 
Metabolic Change in 
HIV Infection 
Multi-centre 
cross-sectional 
United States 425 males 40 (median) Self-assessed and researcher-validated lipoatrophy and/or 
lipohypertrophy, magnetic resonance imagining to measure 
compartmental percentage fat 
FRAM (2006)434 
The Study of Fat 
Redistribution and 
Metabolic Change in 
HIV Infection 
Multi-centre 
cross-sectional 
United States 183 
females 
39 (median) Self-assessed and researcher-validated lipoatrophy and/or 
lipohypertrophy, magnetic resonance imagining to measure 
compartmental percentage fat 
Galli et al  (2002)407 25-week 
prospective study 
Italy 335 34 (median) Self and clinician assessed lipoatrophy and lipohypertrophy : 
subset  validated by DEXA 
Cholesterol ≥250mg/dL 
Triglyceride ≥200mg/dL 
Galli et al (2002)421 
LipoICoNa (Lipo-
Italian Cohort of 
Antiretroviral-Naïve 
patients) 
Multi-centre 86-
week prospective 
Italy 655 35 (median) Physician-assessed lipoatrophy and/or lipohypertrophy 
George et al 
(2009)224 
2-year 
prospective  
South Africa 42 34 (mean) Self and clinician-assessed lipoatrophy and lipohypertrophy 
Cholesterol ≥193mg/dL 
LDL-cholesterol ≥116mg/dL 
HDL-cholesterol <39mg/dL 
Triglyceride ≥151mg/dL 
Gervasoni et al 
(1999)228 
Cross-sectional Italy 306 34 (median) Clinical observations to observe changes in body habitus from 
previous hospital appointment. 
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Patients with body fat alterations underwent DEXA to measure 
percentages body fat and lean body mass 
Heath et al (2002)406 1-year 
prospective 
Canada 745 41 (mean) Self-assessed lipoatrophy and/or lipohypertrophy 
Total cholesterol >201 mg/dL 
Fasting triglyceride 204mg/dL 
Heath et al (2002)422 1-year 
prospective 
Canada 366 Adult (not 
specified)  
Self-assessed lipoatrophy and/or lipohypertrophy 
Total cholesterol >201 mg/dL 
Fasting triglyceride >204mg/dL 
Jacobson et al 
(2005)413 
Nutrition for Healthy 
Living longitudinal 
study of HIV-infected 
adults 
1-year 
prospective 
United States 452 44 (mean men) 
41 (mean women) 
Lipoatrophy by triceps skin fold measurement < 10% NHANTES by 
sex and gender 
Lipohypertrophy by waist/hip ratio (>0.95 men, >0.85 women) 
Jacobson et al 
(2006)408 
Nutrition for Healthy 
Living longitudinal 
study of HIV-infected 
adults 
Cross-sectional United States 477 43 (median) Abdominal obesity: waist circumference >102cm (men)/88cm 
(women) 
HDL-cholesterol <40mg/dL 
Triglyceride >150mg/dL 
Jevtovic et al 
(2009)412 
Cross-sectional Serbia 582 45 (mean) Self and clinician-assessed lipoatrophy and/or lipohypertrophy 
Cholesterol ≥240 mg/dL 
HDL-cholesterol ≤166 mg/dL L 
LDL-cholesterol ≥159 mg/dL 
Triglycerides ≥159 mg/dL 
Lichtenstein et al 
(2001)215 
HIV Outpatient Study 
(HOPS) 
Multi-centre 
cross-sectional 
United States 1077 41 (median) Clinician assessed lipoatrophy and lipohypertrophy 
Miller et al (2003)405 Multi-centre 
cross-sectional 
Australia 1348 39.8 (mean) Clinician-assessed lipoatrophy and/or lipohypertrophy : subset 
examined by DEXA and CAT scans 
Martinez et al  
(2001)199 
18-month 
prospective 
Spain 494 Adults (not 
specified) 
Clinician-assessed lipoatrophy and/or lipohypertrophy 
Mallal et al (2000)235 
Western Australian 
Study HIV Cohort 
30-month 
prospective 
Australia 277 41 (mean) Patient and clinical assessment of lipoatrophy 
Percentage of fat assessed by DEXA scans 
Mauss et al (2002) 36-month multi- Germany 221 38 (median) Clinician-assessed lipoatrophy and/or lipohypertrophy with use of 
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DAGNAE LipART centre 
prospective 
visual analogue scales 
Mutimura et al 
(2007)193 
Cross-sectional Rwanda 571 38 (mean) Body fat alterations confirmed by physician 
Cholesterol >240mg/dL 
HDL-cholesterol <39mg/dL 
Triglyceride >195mg/dL 
Narciso et al 
(2001)420 
1-year 
prospective 
Italy 41 31 (mean) Self-assessed body fat alterations 
Cholesterol >200mg/dL 
Triglyceride >220 
 
Paton et al (2002)401 Cross-sectional Singapore  410 40 (mean) Self-assessed body fat alterations 
Pujari et al (2005)227 Cross-sectional  India 306 37 (mean) Self-assessed lipoatrophy and lipohypertrophy confirmed by 
physician 
Cholesterol ≥200 mg/dL 
LDL-cholesterol ≥130mg/dL 
Triglycerides ≥150mg/dL 
HDL-cholesterol <40mg/dL 
Total cholesterol: HDL-cholesterol ratio ≥6.5 
Tien et al (2003)423 30-month 
prospective 
United States 605  
women 
41 (median) Examiner-assessed lipoatrophy and/or lipohypertrophy (self-
assessed changes confirmed by anthropometric measures) 
Saves et al (2002)225 
Antiproteases 
Cohorte (APROCO) 
Multi-centre 
cross-sectional 
France 614 Adults (not 
specified) 
Clinician-assessed lipoatrophy and/or lipohypertrophy 
Cholesterol ≥193mg/dL 
HDL-cholesterol <35mg/dL 
LDL-cholesterol ≥131mg/dL 
Triglyceride ≥195mg/dL 
Saint-Marc et al  
(2000)184 
LIPOCO Study 
Multi-centre 
cross-sectional 
France 154 
male 
40 (mean) Regional fat distribution measured by computed tomography (CT): 
intra-abdominal visceral and subcutaneous adipose 
Seminari et al 
(2002)463 
Cross-sectional Italy 504 38 (mean) Clinician-assessed lipoatrophy and/or lipohypertrophy 
Graded cholesterol: grade 1 (200-239mg/dL), grade 2 (240-
300mg/dL), and grade 3 (≥300mg/dL) 
Graded triglyceride: grade 1 (200-399mg/dL), grade 2 (400-
1000mg/dL), and grade 3 (>1000mg/dL) 
Shlay et al (2009)236 
The Metabolic Study 
Cross-sectional United States 416 38 (mean) Measures of subcutaneous and non-subcutaneous  tissue 
estimated from calculation of recorded circumferences (arm, thigh, 
waist) and skinfold thickness (subscapular, suprascapular, thigh, 
triceps and abdomen) 
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 Thiebaut et al 
(2000)216 
Multi-centre 
cross-sectional 
France 581 39 (med) Lipoatrophy and/or lipohypertrophy assessed by physician 
Cholesterol > 213mg/dL 
Fasting triglyceride >531mg/dL 
Thiebaut et al 
(2001)409 
French Aquitaine 
Cohort 
Multi-centre 25-
month 
prospective 
France 925 36 (median) Triglyceride >531mm/L 
Hypercholesterolemia (threshold not specified)  
Tsiodras et al 
(2000)398 
French Aquitaine 
Cohort 
5-year 
retrospective 
cohort 
United States 221 37 Cholesterol >240mg/dL 
Triglyceride > 500mg/dL 
Van Griensven et al 
(2007)399 
Cross-sectional Rwanda 409 38 (median) Self-reported and clinical assessment of lipoatrophy 
 
 
Walmsley et al 
(2008)499 
36-month 
prospective 
Canada 68 39 (median) Self and clinician-assessed lipoatrophy and/or lipohypertrophy 
(with photography, regional DEXA scan) 
Young et al (2005)447 
Swiss HIV Cohort 
Study 
20-month 
prospective 
Switzerland 925 Adults (not 
specified) 
Lipoatrophy and/or lipohypertrophy assessment by clinician and 
patient 
Zannou et al 
(2009)400 
23.2 month 
prospective 
Benin 88 38 (mean) Physician-assessed lipoatrophy and/or lipoatrophy 
Metabolic syndrome (thresholds of waist circumference,/elevated 
triglyceride/elevated blood pressure/elevated glucose/reduced 
HDL-cholesterol 
Lipoatrophy and/or lipohypertrophy denotes fat alterations in specific body locations, however these locations may not be consistent between all studies 
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